

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/00	A2	(11) International Publication Number: WO 99/66028 (43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: PCT/EP99/04171 (22) International Filing Date: 16 June 1999 (16.06.99) (30) Priority Data: 09/099,504 18 June 1998 (18.06.98) US 60/101,631 24 September 1998 (24.09.98) US 60/118,906 5 February 1999 (05.02.99) US (71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT). (72) Inventors; and (75) Inventors/Applicants (for US only): SCHUPP, Thomas [CH/CH]; Fröschmattweg 5, CH-4313 Möhlin (CH). LIGON, James, Madison [US/US]; 3616 South Pointe Drive, Apex, NC 27502 (US). MOLNAR, Istvan [HU/US]; 4004 Branchwood Drive, Durham, NC 27705 (US). ZIRKLE, Ross [US/US]; 6532 Wynbrook Way, Raleigh, NC 27612 (US). GÖRLACH, Jörn [DE/US]; 3907 King Charles Road, Durham, NC 27707 (US). CYR, Devon		[US/US]; 413 Vuncannon Drive, Fuquay-Varina, NC 27526 (US). (74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: GENES FOR THE BIOSYNTHESIS OF EPOTHILONES (57) Abstract Nucleic acid molecules are isolated from <i>Sorangium cellulosum</i> that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENES FOR THE BIOSYNTHESIS OF EPOTHILONES

FIELD OF THE INVENTION

The present invention relates generally to polyketides and genes for their synthesis. In particular, the present invention relates to the isolation and characterization of novel polyketide synthase and nonribosomal peptide synthetase genes from *Sorangium cellulosum* that are necessary for the biosynthesis of epothilones A and B.

BACKGROUND OF THE INVENTION

Polyketides are compounds synthesized from two-carbon building blocks, the β -carbon of which always carries a keto group, thus the name polyketide. These compounds include many important antibiotics, immunosuppressants, cancer chemotherapeutic agents, and other compounds possessing a broad range of biological properties. The tremendous structural diversity derives from the different lengths of the polyketide chain, the different side-chains introduced (either as part of the two-carbon building blocks or after the polyketide backbone is formed), and the stereochemistry of such groups. The keto groups may also be reduced to hydroxyls, enoys, or removed altogether. Each round of two-carbon addition is carried out by a complex of enzymes called the polyketide synthase (PKS) in a manner similar to fatty acid biosynthesis.

The biosynthetic genes for an increasing number of polyketides have been isolated and sequenced. For example, see U.S. Patent Nos. 5,639,949, 5,693,774, and 5,716,849, all of which are incorporated herein by reference, which describe genes for the biosynthesis of soraphen. See also, Schupp *et al.*, *FEMS Microbiology Letters* 159: 201-207 (1998) and WO 98/07868, which describe genes for the biosynthesis of rifamycin, and U.S. Patent No. 5,876,991, which describes genes for the biosynthesis of tylactone, all of which are incorporated herein by reference. The encoded proteins generally fall into two types: type I and type II. Type I proteins are polyfunctional, with several catalytic domains carrying out different enzymatic steps covalently linked together (e.g. PKS for erythromycin, soraphen, rifamycin, and avermectin (MacNeil *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C.


pp. 245-256 (1993)); whereas type II proteins are monofunctional (Hutchinson *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C. pp. 203-216 (1993)).

For the simpler polyketides such as actinorhodin (produced by *Streptomyces coelicolor*), the several rounds of two-carbon additions are carried out iteratively on PKS enzymes encoded by one set of PKS genes. In contrast, synthesis of the more complicated compounds such as erythromycin and soraphen involves PKS enzymes that are organized into modules, whereby each module carries out one round of two-carbon addition (for review, see Hopwood *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C., pp. 267-275 (1993)).

Complex polyketides and secondary metabolites in general may contain substructures that are derived from amino acids instead of simple carboxylic acids. Incorporations of these building blocks are accomplished by non-ribosomal polypeptide synthetases (NRPSs). NRPSs are multienzymes that are organized in modules. Each module is responsible for the addition (and the additional processing, if required) of one amino acid building block. NRPSs activate amino acids by forming aminoacyl-adenylates, and capture the activated amino acids on thiol groups of phosphopantetheinyl prosthetic groups on peptidyl carrier protein domains. Further, NRPSs modify the amino acids by epimerization, N-methylation, or cyclization if necessary, and catalyse the formation of peptide bonds between the enzyme-bound amino acids. NRPSs are responsible for the biosynthesis of peptide secondary metabolites like cyclosporin, could provide polyketide chain terminator units as in rapamycin, or form mixed systems with PKSs as in yersiniabactin biosynthesis.

Epothilones A and B are 16-membered macrocyclic polyketides with an acylcysteine-derived starter unit that are produced by the bacterium *Sorangium cellulosum* strain So ce90 (Gerth *et al.*, *J. Antibiotics* 49: 560-563 (1996), incorporated herein by reference). The structure of epothilone A and B wherein R signifies hydrogen (epothilone A) or methyl (epothilone B) is:

- 3 -



The epothilones have a narrow antifungal spectrum and especially show a high cytotoxicity in animal cell cultures (*see*, Höfle *et al.*, Patent DE 4138042 (1993), incorporated herein by reference). Of significant importance, epothilones mimic the biological effects of taxol, both *in vivo* and in cultured cells (Bollag *et al.*, *Cancer Research* 55: 2325-2333 (1995), incorporated herein by reference). Taxol and taxotere, which stabilize cellular microtubules, are cancer chemotherapeutic agents with significant activity against various human solid tumors (Rowinsky *et al.*, *J. Natl. Cancer Inst.* 83: 1778-1781 (1991)). Competition studies have revealed that epothilones act as competitive inhibitors of taxol binding to microtubules, consistent with the interpretation that they share the same microtubule-binding site and possess a similar microtubule affinity as taxol. However, epothilones enjoy a significant advantage over taxol in that epothilones exhibit a much lower drop in potency compared to taxol against a multiple drug-resistant cell line (Bollag *et al.* (1995)). Furthermore, epothilones are considerably less efficiently exported from the cells by P-glycoprotein than is taxol (Gerth *et al.* (1996)). In addition, several epothilone analogs have been synthesized that have a superior cytotoxic activity as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules (WO 98/25929, incorporated herein by reference).

Despite the promise shown by the epothilones as anticancer agents, problems pertaining to the production of these compounds presently limit their commercial potential. The compounds are too complex for industrial-scale chemical synthesis and so must be produced by fermentation. Techniques for the genetic manipulation of myxobacteria such as *Sorangium cellulosum* are described in U.S. Patent No. 5,686,295, incorporated herein by reference. However, *Sorangium cellulosum* is notoriously difficult to ferment and production levels of epothilones are therefore low. Recombinant production of epothilones in heterologous hosts that are more amenable to fermentation could solve current production problems. However, the genes that encode the polypeptides responsible for epothilone bio-

- 4 -

synthesis have heretofore not been isolated. Furthermore, the strain that produces epothilones, i.e. So ce90, also produces at least one additional polyketide, spirangien, which would be expected to greatly complicate the isolation of the genes particularly responsible for epothilone biosynthesis.

Therefore, in view of the foregoing, one object of the present invention is to isolate the genes that are involved in the synthesis of epothilones, particularly the genes that are involved in the synthesis of epothilones A and B in myxobacteria of the Sorangium/-Polyangium group, i.e., *Sorangium cellulosum* strain So ce90. A further object of the invention is to provide a method for the recombinant production of epothilones for application in anticancer formulations.

SUMMARY OF THE INVENTION

In furtherance of the aforementioned and other objects, the present invention unexpectedly overcomes the difficulties set forth above to provide for the first time a nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone. In a preferred embodiment, the nucleotide sequence is isolated from a species belonging to *Myxobacteria*, most preferably *Sorangium cellulosum*.

In another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID

- 5 -

NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

In a more preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684

of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

In yet another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1,

- 7 -

nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

In an especially preferred embodiment, the present invention provides a nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence is selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of

SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

In yet another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID

NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

The present invention also provides a chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule of the invention. Further, the present invention provides a recombinant vector comprising such a chimeric gene, wherein the vector is capable of being stably transformed into a host cell. Still further, the present invention provides a recombinant host cell comprising such a chimeric gene, wherein the host cell is capable of expressing the nucleotide sequence that encodes at least one polypeptide necessary for the biosynthesis of an epothilone. In a preferred embodiment, the recombinant host cell is a bacterium belonging to the order *Actinomycetales*, and in a more preferred embodiment the recombinant host cell is a strain of *Streptomyces*. In other embodiments, the recombinant host cell is any other bacterium amenable to fermentation, such as a pseudomonad or *E. coli*. Even further, the present invention provides a Bac clone comprising a nucleic acid molecule of the invention, preferably Bac clone pEPO15.

In another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes an epothilone synthase domain.

According to one embodiment, the epothilone synthase domain is a β -ketoacyl-synthase (KS) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. According to this embodiment, said KS domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids

- 11 -

3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is an acyltransferase (AT) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. According to this embodiment, said AT domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino

acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

According to still another embodiment, the epothilone synthase domain is an enoyl reductase (ER) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. According to this embodiment, said ER domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of

SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is an acyl carrier protein (ACP) domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. According to this embodiment, said ACP domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40,

- 14 -

45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is a dehydratase (DH) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. According to this embodiment, said DH domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1,

nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

According to yet another embodiment, the epothilone synthase domain is a β -keto-reductase (KR) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. According to this embodiment, said KR domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

According to an additional embodiment, the epothilone synthase domain is a methyltransferase (MT) domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6. According to this embodiment, said MT domain preferably comprises amino acids 2671-3045 of SEQ ID NO:6. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to nucleotides 51534-52657 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of nucleotides 51534-52657 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is nucleotides 51534-52657 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is a thioesterase (TE) domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7. According to this embodiment, said TE domain preferably comprises amino acids 2165-2439 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to nucleotides 61427-62254 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of nucleotides 61427-62254 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is nucleotides 61427-62254 of SEQ ID NO:1.

In still another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a non-ribosomal peptide synthetase, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3. According to this

embodiment, said non-ribosomal peptide synthetase preferably comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-

12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

The present invention further provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:2-23.

In accordance with another aspect, the present invention also provides methods for the recombinant production of polyketides such as epothilones in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer. A specific advantage of these production methods is the chirality of the molecules produced; production in transgenic organisms avoids the generation of populations of racemic mixtures, within which some enantiomers may have reduced activity. In particular, the present invention provides a method for heterologous expression of epothilone in a recombinant host, comprising: (a) introducing into a host a chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule of the invention that comprises a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone; and (b) growing the host in conditions that allow biosynthesis of epothilone in the host. The present invention also provides a method for producing epothilone, comprising: (a) expressing epothilone in a recombinant host by the aforementioned method; and (b) extracting epothilone from the recombinant host.

According to still another aspect, the present invention provides an isolated polypeptide comprising an amino acid sequence that consists of an epothilone synthase domain.

According to one embodiment, the epothilone synthase domain is a β -ketoacyl-synthase (KS) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. According to this embodiment,

said KS domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is an acyltransferase (AT) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. According to this embodiment, said AT domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

According to still another embodiment, the epothilone synthase domain is an enoyl reductase (ER) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. According to this embodiment, said ER domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is an acyl carrier protein (ACP) domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of

SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. According to this embodiment, said ACP domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is a dehydratase (DH) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. According to this embodiment, said DH domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

According to yet another embodiment, the epothilone synthase domain is a β -keto-reductase (KR) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. According to this embodiment, said KR domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

According to an additional embodiment, the epothilone synthase domain is a methyl-transferase (MT) domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6. According to this embodiment, said MT domain preferably comprises amino acids 2671-3045 of SEQ ID NO:6.

According to another embodiment, the epothilone synthase domain is a thioesterase (TE) domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7. According to this embodiment, said TE domain preferably comprises amino acids 2165-2439 of SEQ ID NO:7.

Other aspects and advantages of the present invention will become apparent to those skilled in the art from a study of the following description of the invention and non-limiting examples.

DEFINITIONS

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

Associated With / Operatively Linked: Refers to two DNA sequences that are related physically or functionally. For example, a promoter or regulatory DNA sequence is said to be "associated with" a DNA sequence that codes for an RNA or a protein if the two sequences are operatively linked, or situated such that the regulator DNA sequence will affect the expression level of the coding or structural DNA sequence.

Chimeric Gene: A recombinant DNA sequence in which a promoter or regulatory DNA sequence is operatively linked to, or associated with, a DNA sequence that codes for an mRNA or which is expressed as a protein, such that the regulator DNA sequence is able to regulate transcription or expression of the associated DNA sequence. The regulator DNA sequence of the chimeric gene is not normally operatively linked to the associated DNA sequence as found in nature.

Coding DNA Sequence: A DNA sequence that is translated in an organism to produce a protein.

Domain: That part of a polyketide synthase necessary for a given distinct activity. Examples include acyl carrier protein (ACP), β -ketosynthase (KS), acyltransferase (AT), β -ketoreductase (KR), dehydratase (DH), enoylreductase (ER), and thioesterase (TE) domains.

Epothilones: 16-membered macrocyclic polyketides naturally produced by the bacterium *Sorangium cellulosum* strain So ce90, which mimic the biological effects of taxol. In this application, "epothilone" refers to the class of polyketides that includes epothilone A and epothilone B, as well as analogs thereof such as those described in WO 98/25929.

Epothilone Synthase: A polyketide synthase responsible for the biosynthesis of epothilone.

Gene: A defined region that is located within a genome and that, besides the aforementioned coding DNA sequence, comprises other, primarily regulatory, DNA sequences responsible for the control of the expression, that is to say the transcription and translation, of the coding portion.

Heterologous DNA Sequence: A DNA sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring DNA sequence.

Homologous DNA Sequence: A DNA sequence naturally associated with a host cell into which it is introduced.

Homologous Recombination: Reciprocal exchange of DNA fragments between homologous DNA molecules.

Isolated: In the context of the present invention, an isolated nucleic acid molecule or an isolated enzyme is a nucleic acid molecule or enzyme that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule or enzyme may exist in a purified form or may exist in a non-native environment such as, for example, a recombinant host cell.

Module: A genetic element encoding all of the distinct activities required in a single round of polyketide biosynthesis, i.e., one condensation step and all the β -carbonyl processing steps associated therewith. Each module encodes an ACP, a KS, and an AT activity to accomplish the condensation portion of the biosynthesis, and selected post-condensation activities to effect the β -carbonyl processing.

NRPS: A non-ribosomal polypeptide synthetase, which is a complex of enzymatic activities responsible for the incorporation of amino acids into secondary metabolites including, for example, amino acid adenylation, epimerization, N-methylation, cyclization, peptidyl carrier protein, and condensation domains. A functional NRPS is one that catalyzes the incorporation of an amino acid into a secondary metabolite.

NRPS gene: One or more genes encoding NRPSs for producing functional secondary metabolites, e.g., epothilones A and B, when under the direction of one or more compatible control elements.

Nucleic Acid Molecule: A linear segment of single- or double-stranded DNA or RNA that can be isolated from any source. In the context of the present invention, the nucleic acid molecule is preferably a segment of DNA.

ORF: Open Reading Frame.

PKS: A polyketide synthase, which is a complex of enzymatic activities (domains) responsible for the biosynthesis of polyketides including, for example, ketoreductase, dehydratase, acyl carrier protein, enoylreductase, ketoacyl ACP synthase, and acyltransferase. A functional PKS is one that catalyzes the synthesis of a polyketide.

PKS Genes: One or more genes encoding various polypeptides required for producing functional polyketides, e.g., epothilones A and B, when under the direction of one or more compatible control elements.

Substantially Similar: With respect to nucleic acids, a nucleic acid molecule that has at least 60 percent sequence identity with a reference nucleic acid molecule. In a preferred embodiment, a substantially similar DNA sequence is at least 80% identical to a reference DNA sequence; in a more preferred embodiment, a substantially similar DNA sequence is at least 90% identical to a reference DNA sequence; and in a most preferred embodiment, a substantially similar DNA sequence is at least 95% identical to a reference DNA sequence. A substantially similar DNA sequence preferably encodes a protein or peptide having substantially the same activity as the protein or peptide encoded by the reference DNA sequence. A substantially similar nucleotide sequence typically hybridizes to a reference nucleic acid molecule, or fragments thereof, under the following conditions: hybridization at 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄ pH 7.0, 1 mM EDTA at 50°C; wash with 2X SSC, 1% SDS, at 50°C. With respect to proteins or peptides, a substantially similar amino acid sequence is an amino acid sequence that is at least 90% identical to the amino acid sequence of a reference protein or peptide and has substantially the same activity as the reference protein or peptide.

Transformation: A process for introducing heterologous nucleic acid into a host cell or organism.

Transformed / Transgenic / Recombinant: Refers to a host organism such as a bacterium into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can be auto-replicating. Transformed cells, tissues, or plants are understood to

encompass not only the end product of a transformation process, but also transgenic progeny thereof. A "non-transformed", "non-transgenic", or "non-recombinant" host refers to a wild-type organism, i.e., a bacterium, which does not contain the heterologous nucleic acid molecule.

Nucleotides are indicated by their bases by the following standard abbreviations: adenine (A), cytosine (C), thymine (T), and guanine (G). Amino acids are likewise indicated by the following standard abbreviations: alanine (ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C), glutamine (Gln; Q), glutamic acid (Glu; E), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V). Furthermore, (Xaa; X) represents any amino acid.

DESCRIPTION OF THE SEQUENCES IN THE SEQUENCE LISTING

SEQ ID NO:1 is the nucleotide sequence of a 68750 bp contig containing 22 open reading frames (ORFs), which comprises the epothilone biosynthesis genes.

SEQ ID NO:2 is the protein sequence of a type I polyketide synthase (EPOS A) encoded by *epoA* (nucleotides 7610-11875 of SEQ ID NO:1).

SEQ ID NO:3 is the protein sequence of a non-ribosomal peptide synthetase (EPOS P) encoded by *epoP* (nucleotides 11872-16104 of SEQ ID NO:1).

SEQ ID NO:4 is the protein sequence of a type I polyketide synthase (EPOS B) encoded by *epoB* (nucleotides 16251-21749 of SEQ ID NO:1).

SEQ ID NO:5 is the protein sequence of a type I polyketide synthase (EPOS C) encoded by *epoC* (nucleotides 21746-43519 of SEQ ID NO:1).

SEQ ID NO:6 is the protein sequence of a type I polyketide synthase (EPOS D) encoded by *epoD* (nucleotides 43524-54920 of SEQ ID NO:1).

SEQ ID NO:7 is the protein sequence of a type I polyketide synthase (EPOS E) encoded by *epoE* (nucleotides 54935-62254 of SEQ ID NO:1).

SEQ ID NO:8 is the protein sequence of a cytochrome P450 oxygenase homologue (EPOS F) encoded by *epoF* (nucleotides 62369-63628 of SEQ ID NO:1).

SEQ ID NO:9 is a partial protein sequence (partial Orf 1) encoded by *orf1* (nucleotides 1-1826 of SEQ ID NO:1).

SEQ ID NO:10 is a protein sequence (Orf 2) encoded by *orf2* (nucleotides 3171-1900 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:11 is a protein sequence (Orf 3) encoded by *orf3* (nucleotides 3415-5556 of SEQ ID NO:1).

SEQ ID NO:12 is a protein sequence (Orf 4) encoded by *orf4* (nucleotides 5992-5612 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:13 is a protein sequence (Orf 5) encoded by *orf5* (nucleotides 6226-6675 of SEQ ID NO:1).

SEQ ID NO:14 is a protein sequence (Orf 6) encoded by *orf6* (nucleotides 63779-64333 of SEQ ID NO:1).

SEQ ID NO:15 is a protein sequence (Orf 7) encoded by *orf7* (nucleotides 64290-63853 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:16 is a protein sequence (Orf 8) encoded by *orf8* (nucleotides 64363-64920 of SEQ ID NO:1).

SEQ ID NO:17 is a protein sequence (Orf 9) encoded by *orf9* (nucleotides 64727-64287 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:18 is a protein sequence (Orf 10) encoded by *orf10* (nucleotides 65063-65767 of SEQ ID NO:1).

SEQ ID NO:19 is a protein sequence (Orf 11) encoded by *orf11* (nucleotides 65874-65008 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:20 is a protein sequence (Orf 12) encoded by *orf12* (nucleotides 66338-65871 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:21 is a protein sequence (Orf 13) encoded by *orf13* (nucleotides 66667-67137 of SEQ ID NO:1).

SEQ ID NO:22 is a protein sequence (Orf 14) encoded by *orf14* (nucleotides 67334-68251 of SEQ ID NO:1).

SEQ ID NO:23 is a partial protein sequence (partial Orf 15) encoded by *orf15* (nucleotides 68346-68750 of SEQ ID NO:1).

SEQ ID NO:24 is the universal reverse PCR primer sequence.

SEQ ID NO:25 is the universal forward PCR primer sequence.

SEQ ID NO:26 is the NH24 end "B" PCR primer sequence.

SEQ ID NO:27 is the NH2 end "A" PCR primer sequence.

SEQ ID NO:28 is the NH2 end "B" PCR primer sequence.

- 26 -

SEQ ID NO:29 is the pEPO15-NH6 end "B" PCR primer sequence.

SEQ ID NO:30 is the pEPO15-H2.7 end "A" PCR primer sequence.

DEPOSIT INFORMATION

The following material has been deposited with the Agricultural Research Service, Patent Culture Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604, under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. All restrictions on the availability of the deposited material will be irrevocably removed upon the granting of a patent.

<u>Deposited Material</u>	<u>Accession Number</u>	<u>Deposit Date</u>
pEPO15	NRRL B-30033	June 11, 1998
pEPO32	NRRL B-30119	April 16, 1999

DETAILED DESCRIPTION OF THE INVENTION

The genes involved in the biosynthesis of epothilones can be isolated using the techniques according to the present invention. The preferable procedure for the isolation of epothilone biosynthesis genes requires the isolation of genomic DNA from an organism identified as producing epothilones A and B, and the transfer of the isolated DNA on a suitable plasmid or vector to a host organism that does not normally produce the polyketide, followed by the identification of transformed host colonies to which the epothilone-producing ability has been conferred. Using a technique such as λ ::Tn5 transposon mutagenesis (de Bruijn & Lupski, *Gene* 27: 131-149 (1984)), the exact region of the transforming epothilone-conferring DNA can be more precisely defined. Alternatively or additionally, the transforming epothilone-conferring DNA can be cleaved into smaller fragments and the smallest that maintains the epothilone-conferring ability further characterized. Whereas the host organism lacking the ability to produce epothilone may be a different species from the organism from which the polyketide derives, a variation of this technique involves the transformation of host DNA into the same host that has had its epothilone-producing ability disrupted by mutagenesis. In this method, an epothilone-producing organism is mutated and non-epothilone-producing mutants are isolated. These are then complemented by genomic DNA isolated from the epothilone-producing parent strain.

A further example of a technique that can be used to isolate genes required for epothilone biosynthesis is the use of transposon mutagenesis to generate mutants of an epothilone-producing organism that, after mutagenesis, fails to produce the polyketide. Thus, the region of the host genome responsible for epothilone production is tagged by the transposon and can be recovered and used as a probe to isolate the native genes from the parent strain. PKS genes that are required for the synthesis of polyketides and that are similar to known PKS genes may be isolated by virtue of their sequence homology to the biosynthetic genes for which the sequence is known, such as those for the biosynthesis of rifamycin or soraphen. Techniques suitable for isolation by homology include standard library screening by DNA hybridization.

Preferred for use as a probe molecule is a DNA fragment that is obtainable from a gene or another DNA sequence that plays a part in the synthesis of a known polyketide. A preferred probe molecule comprises a 1.2 kb *Sma*I DNA fragment encoding the ketosynthase domain of the fourth module of the soraphen PKS (U.S. Patent No. 5,716,849), and a more preferred probe molecule comprises the β -ketoacyl synthase domains from the first and second modules of the rifamycin PKS (Schupp *et al.*, *FEMS Microbiology Letters* 159: 201-207 (1998)). These can be used to probe a gene library of an epothilone-producing microorganism to isolate the PKS genes responsible for epothilone biosynthesis.

Despite the well-known difficulties with PKS gene isolation in general and despite the difficulties expected to be encountered with the isolation of epothilone biosynthesis genes in particular, by using the methods described in the instant specification, biosynthetic genes for epothilones A and B can surprisingly be cloned from a microorganism that produces that polyketide. Using the methods of gene manipulation and recombinant production described in this specification, the cloned PKS genes can be modified and expressed in transgenic host organisms.

The isolated epothilone biosynthetic genes can be expressed in heterologous hosts to enable the production of the polyketide with greater efficiency than might be possible from native hosts. Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, heterologous genes can be expressed in *Streptomyces* and other actinomycetes using techniques such as those described in McDaniel *et al.*, *Science* 262: 1546-1550 (1993) and Kao *et al.*, *Science* 265: 509-512 (1994), both of which are incorporated herein by reference. See also, Rowe *et al.*, *Gene*

216: 215-223 (1998); Holmes *et al.*, *EMBO Journal* 12(8): 3183-3191 (1993) and Bibb *et al.*, *Gene* 38: 215-226 (1985), all of which are incorporated herein by reference.

Alternately, genes responsible for polyketide biosynthesis, i.e., epothilone biosynthetic genes, can also be expressed in other host organisms such as pseudomonads and *E. coli*. Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, PKS genes have been successfully expressed in *E. coli* using the pT7-7 vector, which uses the T7 promoter. See, Tabor *et al.*, *Proc. Natl. Acad. Sci. USA* 82: 1074-1078 (1985), incorporated herein by reference. In addition, the expression vectors pKK223-3 and pKK223-2 can be used to express heterologous genes in *E. coli*, either in transcriptional or translational fusion, behind the *tac* or *trc* promoter. For the expression of operons encoding multiple ORFs, the simplest procedure is to insert the operon into a vector such as pKK223-3 in transcriptional fusion, allowing the cognate ribosome binding site of the heterologous genes to be used. Techniques for overexpression in gram-positive species such as *Bacillus* are also known in the art and can be used in the context of this invention (Quax *et al.*, in: *Industrial Microorganisms: Basic and Applied Molecular Genetics*, Eds. Baltz *et al.*, American Society for Microbiology, Washington (1993)).

Other expression systems that may be used with the epothilone biosynthetic genes of the invention include yeast and baculovirus expression systems. See, for example, "The Expression of Recombinant Proteins in Yeasts," Sudbery, P. E., *Curr. Opin. Biotechnol.* 7(5): 517-524 (1996); "Methods for Expressing Recombinant Proteins in Yeast," Mackay, et al., Editor(s): Carey, Paul R., *Protein Eng. Des.* 105-153, Publisher: Academic, San Diego, Calif (1996); "Expression of heterologous gene products in yeast," Pichuanes, et al., Editor(s): Cleland, J. L., Craik, C. S., *Protein Eng.* 129-161, Publisher: Wiley-Liss, New York, N. Y (1996); WO 98/27203; Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998); "Insect Cell Culture: Recent Advances, Bioengineering Challenges And Implications In Protein Production," Palomares, et al., Editor(s): Galindo, Enrique; Ramirez, Octavio T., *Adv. Bioprocess Eng.* Vol. II, Invited Pap. Int. Symp., 2nd (1998) 25-52, Publisher: Kluwer, Dordrecht, Neth; "Baculovirus Expression Vectors," Jarvis, Donald L., Editor(s): Miller, Lois K., *Baculoviruses* 389-431, Publisher: Plenum, New York, N. Y. (1997); "Production Of Heterologous Proteins Using The Baculovirus/Insect Expression System," Grittiths, et al., *Methods Mol. Biol.* (Totowa, N. J.) 75 (Basic Cell Culture Protocols (2nd Edition)) 427-440 (1997); and "Insect Cell Expression Technology," Luckow, Verne A., *Protein Eng.* 183-218,

Publisher: Wiley-Liss, New York, N. Y. (1996); all of which are incorporated herein by reference.

Another consideration for expression of PKS genes in heterologous hosts is the requirement of enzymes for posttranslational modification of PKS enzymes by phosphopantetheinylation before they can synthesize polyketides. However, the enzymes responsible for this modification of type I PKS enzymes, phosphopantetheinyl (P-pant) transferases are not normally present in many hosts such as *E. coli*. This problem can be solved by coexpression of a P-pant transferase with the PKS genes in the heterologous host, as described by Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998), incorporated herein by reference.

Therefore, for the purposes of polyketide production, the significant criteria in the choice of host organism are its ease of manipulation, rapidity of growth (*i.e.* fermentation), possession or the proper molecular machinery for processes such as posttranslational modification, and its lack of susceptibility to the polyketide being overproduced. Most preferred host organisms are actinomycetes such as strains of *Streptomyces*. Other preferred host organisms are pseudomonads and *E. coli*. The above-described methods of polyketide production have significant advantages over the technology currently used in the preparation of the compounds. These advantages include the cheaper cost of production, the ability to produce greater quantities of the compounds, and the ability to produce compounds of a preferred biological enantiomer, as opposed to racemic mixtures inevitably generated by organic synthesis. Compounds produced by heterologous hosts can be used in medical (*e.g.* cancer treatment in the case of epothilones) as well as agricultural applications.

EXPERIMENTAL

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Ausubel (ed.), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc. (1994); T. Maniatis, E. F. Fritsch and J. Sambrook, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor laboratory, Cold Spring Harbor, NY (1989); and by T.J. Silhavy, M.L. Berman, and L.W. Enquist, *Experiments with Gene Fusions*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984).

Example 1: Cultivation of an Epothilone-Producing Strain of *Sorangium cellulosum*

Sorangium cellulosum strain 90 (DSM 6773, Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig) is streaked out and grown (30°C) on an agar plate of SolE medium (0.35% glucose, 0.05% tryptone, 0.15% $\text{MgSO}_4 \times 7\text{H}_2\text{O}$, 0.05% ammonium sulfate, 0.1% CaCl_2 , 0.006% K_2HPO_4 , 0.01% sodium dithionite, 0.0008% Fe-EDTA, 1.2% HEPES, 3.5% [vol/vol] supernatant of sterilized stationary *S. cellulosum* culture) pH ad. 7.4. Cells from about 1 square cm are picked and inoculated into 5 mls of G51t liquid medium (0.2% glucose, 0.5% starch, 0.2% tryptone, 0.1% probion S, 0.05% $\text{CaCl}_2 \times 2\text{H}_2\text{O}$, 0.05% $\text{MgSO}_4 \times 7\text{H}_2\text{O}$, 1.2% HEPES, pH ad. 7.4) and incubated at 30°C with shaking at 225 rpm. After 4 days, the culture is transferred into 50 mls of G51t and incubated as above for 5 days. This culture is used to inoculate 500 mls of G51t and incubated as above for 6 days. The culture is centrifuged for 10 minutes at 4000 rpm and the cell pellet is resuspended in 50 mls of G51t.

Example 2: Generation of a Bacterial Artificial Chromosome (Bac) Library

To generate a Bac library, *S. cellulosum* cells cultivated as described in Example 1 above are embedded into agarose blocks, lysed, and the liberated genomic DNA is partially digested by the restriction enzyme *HindIII*. The digested DNA is separated on an agarose gel by pulsed-field electrophoresis. Large (approximately 90-150 kb) DNA fragments are

isolated from the agarose gel and ligated into the vector pBelobacII. pBelobacII contains a gene encoding chloramphenicol resistance, a multiple cloning site in the *lacZ* gene providing for blue/white selection on appropriate medium, as well as the genes required for the replication and maintenance of the plasmid at one or two copies per cell. The ligation mixture is used to transform *Escherichia coli* DH10B electrocompetent cells using standard electroporation techniques. Chloramphenicol-resistant recombinant (white, *lacZ* mutant) colonies are transferred to a positively charged nylon membrane filter in 384 3X3 grid format. The clones are lysed and the DNA is cross-linked to the filters. The same clones are also preserved as liquid cultures at -80°C.

Example 3: Screening the Bac Library of *Sorangium cellulosum* 90 for the Presence of Type I Polyketide Synthase-Related Sequences

The Bac library filters are probed by standard Southern hybridization procedures. The DNA probes used encode β -ketoacyl synthase domains from the first and second modules of the rifamycin polyketide synthase (Schupp *et al.*, *FEMS Microbiology Letters* 159: 201-207 (1998)). The probe DNAs are generated by PCR with primers flanking each ketosynthase domain using the plasmid pNE95 as the template (pNE95 equals cosmid 2 described in Schupp *et al.* (1998)). 25 ng of PCR-amplified DNA is isolated from a 0.5% agarose gel and labeled with ^{32}P -dCTP using a random primer labeling kit (Gibco-BRL, Bethesda MD, USA) according to the manufacturer's instructions. Hybridization is at 65°C for 36 hours and membranes are washed at high stringency (3 times with 0.1x SSC and 0.5% SDS for 20 min at 65°C). The labeled blot is exposed on a phosphorescent screen and the signals are detected on a PhosphorImager 445SI (screen and 445SI from Molecular Dynamics). This results in strong hybridization of certain Bac clones to the probes. These clones are selected and cultured overnight in 5 ml of Luria broth (LB) at 37°C. Bac DNA from the Bac clones of interest is isolated by a typical miniprep procedure. The cells are resuspended in 200 μl lysozyme solution (50mM glucose, 10 mM EDTA, 25 mM Tris-HCl, 5mg/ml lysozyme), lysed in 400 μl lysis solution (0.2 N NaOH and 2% SDS), the proteins are precipitated (3.0 M potassium acetate, adjusted to pH5.2 with acetic acid), and the Bac DNA is precipitated with isopropanol. The DNA is resuspended in 20 μl of nuclease-free distilled water, restricted with *Bam*HI (New England Biolabs, Inc.) and separated on a 0.7% agarose gel. The gel is blotted by Southern hybridization as described above and probed

- 32 -

under conditions described above, with a 1.2 kb *Sma*I DNA fragment encoding the ketosynthase domain of the fourth module of the soraphen polyketide synthase as the probe (*see*, U.S. Patent No. 5,716,849). Five different hybridization patterns are observed. One clone representing each of the five patterns is selected and named pEPO15, pEPO20, pEPO30, pEPO31, and pEPO33, respectively.

Example 4: Subcloning of *Bam*HI Fragments from pEPO15, pEPO20, pEPO30, pEPO31, and pEPO33

The DNA of the five selected Bac clones is digested with *Bam*HI and random fragments are subcloned into pBluescript II SK+ (Stratagene) at the *Bam*HI site. Subclones carrying inserts between 2 and 10 kb in size are selected for sequencing of the flanking ends of the inserts and also probed with the 1.2 *Sma*I probe as described above. Subclones that show a high degree of sequence homology to known polyketide synthases and/or strong hybridization to the soraphen ketosynthase domain are used for gene disruption experiments.

Example 5: Preparation of Streptomycin-Resistant Spontaneous Mutants of *Sorangium cellulosum* strain So ce90

0.1 ml of a three day old culture of *Sorangium cellulosum* strain So ce90, which is raised in liquid medium G52-H (0.2% yeast extract, 0.2% soyameal defatted, 0.8% potato starch, 0.2% glucose, 0.1% MgSO₄ x7H₂O, 0.1% CaCl₂ x2H₂O, 0.008% Fe-EDTA, pH ad 7.4 with KOH), is plated out on agar plates with SolE medium supplemented with 100 µg/ml streptomycin. The plates are incubated at 30°C for 2 weeks. The colonies growing on this medium are streptomycin-resistant mutants, which are streaked out and cultivated once more on the same agar medium with streptomycin for purification. One of these streptomycin-resistant mutants is selected and is called BCE28/2.

Example 6: Gene Disruptions in *Sorangium cellulosum* BCE28/2 Using the Subcloned *Bam*HI Fragments

The *Bam*HI inserts of the subclones generated from the five selected Bac clones as described above are isolated and ligated into the unique *Bam*HI site of plasmid pCIB132 (see, U.S. Patent No. 5,716,849). The pCIB132 derivatives carrying the inserts are transformed into *Escherichia coli* ED8767 containing the helper plasmid pUZ8 (Hedges and Matthew, *Plasmid* 2: 269-278 (1979)). The transformants are used as donors in conjugation experiments with *Sorangium cellulosum* BCE28/2 as recipient. For the conjugation, 5-10 x 10⁹ cells of *Sorangium cellulosum* BCE28/2 from an early stationary phase culture (reaching about 5 x 10⁸ cells/ml) grown at 30°C in liquid medium G51b (G51b equals medium G51t with tryptone replaced by peptone) are mixed in a 1:1 cellular ratio with a late-log phase culture (in LB liquid medium) of *E. coli* ED8767 containing pCIB132 derivatives carrying the subcloned *Bam*HI fragments and the helper plasmid pUZ8. The mixed cells are then centrifuged at 4000 rpm for 10 minutes and resuspended in 0.5 ml G51b medium. This cell suspension is then plated as a drop in the center of a plate with So1E agar containing 50 mg/l kanamycin. The cells obtained after incubation for 24 hours at 30°C are harvested and resuspended in 0.8 ml of G51b medium, and 0.1 to 0.3 ml of this suspension is plated out on a selective So1E solid medium containing phleomycin (30 mg/l), streptomycin (300 mg/l), and kanamycin (50 mg/l). The counterselection of the donor *Escherichia coli* strain takes place with the aid of streptomycin. The colonies that grow on this selective medium after an incubation time of 8-12 days at a temperature of 30°C are isolated with a plastic loop and streaked out and cultivated on the same agar medium for a second round of selection and purification. The colony-derived cultures that grow on this selective agar medium after 7 days at a temperature of 30°C are transconjugants of *Sorangium cellulosum* BCE28/2 that have acquired phleomycin resistance by conjugative transfer of the pCIB132 derivatives carrying the subcloned *Bam*HI fragments.

Integration of the pCIB132-derived plasmids into the chromosome of *Sorangium cellulosum* BCE28/2 by homologous recombination is verified by Southern hybridization. For this experiment, complete DNA from 5-10 transconjugants per transferred *Bam*HI fragment is isolated (from 10 ml cultures grown in medium G52-H for three days) applying the method described by Pospiech and Neumann, *Trends Genet.* 11: 217 (1995). For the Southern blot, the DNA isolated as described above is cleaved either with the restriction

enzymes *Bgl*II, *Cla*I, or *Not*I, and the respective *Bam*HI inserts or pCIB132 are used as ³²P labelled probes.

Example 7: Analysis of the Effect of the Integrated *Bam*HI Fragments on Epothilone Production by *Sorangium cellulosum* After Gene Disruption

Transconjugant cells grown on about 1 square cm surface of the selective So1E plates of the second round of selection (see Example 6) are transferred by a sterile plastic loop into 10 ml of medium G52-H in an 50 ml Erlenmeyer flask. After incubation at 30°C and 180 rpm for 3 days, the culture is transferred into 50 ml of medium G52-H in an 200 ml Erlenmeyer flask. After incubation at 30°C and 180 rpm for 4-5 days, 10 ml of this culture is transferred into 50 ml of medium 23B3 (0.2 % glucose, 2 % potato starch, 1.6 % soya meal defatted, 0.0008 % Fe-EDTA Sodium salt, 0.5 % HEPES (4-(2-hydroxyethyl)-piperazine-1-ethane-sulfonic-acid), 2 % vol/vol polysterole resin XAD16 (Rohm & Haas), pH adjusted to 7.8 with NaOH) in an 200 ml Erlenmeyer flask.

Quantitative determination of the epothilone produced takes place after incubation of the cultures at 30°C and 180 rpm for 7 days. The complete culture broth is filtered by suction through a 150 µm nylon filter. The resin remaining on the filter is then resuspended in 10 ml isopropanol and extracted by shaking the suspension at 180 rpm for 1 hour. 1 ml is removed from this suspension and centrifuged at 12,000 rpm in an Eppendorff Microfuge. The amount of epothilones A and B therein is determined by means of an HPLC and detection at 250 nm with a UV_DAD detector (HPLC with Waters -Symetry C18 column and a gradient of 0.02 % phosphoric acid 60%-0% and acetonitril 40%-100%).

Transconjugants with three different integrated *Bam*HI fragments subcloned from pEPO15, namely transconjugants with the *Bam*HI fragment of plasmid pEPO15-21, transconjugants with the *Bam*HI fragment of plasmid pEPO15-4-5, and transconjugants with the *Bam*HI fragment of plasmid pEPO15-4-1, are tested in the manner described above. HPLC analysis reveals that all transconjugants no longer produce epothilone A or B. By contrast, epothilone A and B are detectable in a concentration of 2-4 mg/l in transconjugants with *Bam*HI fragments integrated that are derived from pEPO20, pEPO30, pEPO31, pEPO33, and in the parental strain BCE28/2.

**Example 8: Nucleotide Sequence Determination of the Cloned Fragments and
Construction of Contigs**

A. *Bam*HI Insert of Plasmid pEPO15-21

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-21], and the nucleotide sequence of the 2.3-kb *Bam*HI insert in pEPO15-21 is determined. Automated DNA sequencing is done on the double-stranded DNA template by the dideoxynucleotide chain termination method, using Applied Biosystems model 377 sequencers. The primers used are the universal reverse primer (5' GGA AAC AGC TAT GAC CAT G 3' (SEQ ID NO:24)) and the universal forward primer (5' GTA AAA CGA CGG CCA GT 3' (SEQ ID NO:25)). In subsequent rounds of sequencing reactions, custom-synthesized oligonucleotides, designed for the 3' ends of the previously determined sequences, are used to extend and join contigs. Both strands are entirely sequenced, and every nucleotide is sequenced at least two times. The nucleotide sequence is compiled using the program Sequencher vers. 3.0 (Gene Codes Corporation), and analyzed using the University of Wisconsin Genetics Computer Group programs. The nucleotide sequence of the 2213-bp insert corresponds to nucleotides 20779-22991 of SEQ ID NO:1.

B. *Bam*HI Insert of Plasmid pEPO15-4-1

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-4-1], and the nucleotide sequence of the 3.9-kb *Bam*HI insert in pEPO15-4-1 is determined as described in (A) above. The nucleotide sequence of the 3909-bp insert corresponds to nucleotides 16876-20784 of SEQ ID NO:1.

C. *Bam*HI Insert of Plasmid pEPO15-4-5

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-4-5], and the nucleotide sequence of the 2.3-kb *Bam*HI insert in pEPO15-4-5 is determined as described in (A) above. The nucleotide sequence of the 2233-bp insert corresponds to nucleotides 42528-44760 of SEQ ID NO:1.

Example 9: Subcloning and Ordering of DNA Fragments from pEPO15 Containing Epothilone Biosynthesis Genes

pEPO15 is digested to completion with the restriction enzyme *Hind*III and the resulting fragments are subcloned into pBluescript II SK- or pNEB193 (New England Biolabs) that has been cut with *Hind*III and dephosphorylated with calf intestinal alkaline phosphatase. Six different clones are generated and named pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24 (all based on pNEB193), and pEPO15-H2.7 and pEPO15-H3.0 (both based on pBluescript II SK-).

The *Bam*HI insert of pEPO15-21 is isolated and DIG-labeled (Non-radioactive DNA labeling and detection system, Boehringer Mannheim), and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signal is detected for pEPO15-NH24, indicating that pEPO15-21 is contained within pEPO15-NH24.

The *Bam*HI insert of pEPO15-4-1 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signals are detected for pEPO15-NH24 and pEPO15-H2.7. Nucleotide sequence data generated from one end each of pEPO15-NH24 and pEPO15-H2.7 are also in complete agreement with the previously determined sequence of the *Bam*HI insert of pEPO15-4-1. These experiments demonstrate that pEPO15-4-1 (which contains one internal *Hind*III site) overlaps pEPO15-H2.7 and pEPO15-NH24, and that pEPO15-H2.7 and pEPO15-NH24, in this order, are contiguous.

The *Bam*HI insert of pEPO15-4-5 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signal is detected for pEPO15-NH2, indicating that pEPO15-21 is contained within pEPO15-NH2.

Nucleotide sequence data is generated from both ends of pEPO15-NH2 and from the end of pEPO15-NH24 that does not overlap with pEPO15-4-1. PCR primers NH24 end "B": GTGACTGGCGCCTGGAATCTGCATGAGC (SEQ ID NO:26), NH2 end "A": AGCGGGAGCTTGCTAGACATTCTGTTTC (SEQ ID NO:27), and NH2 end "B": GACGCGCCTCGGGCAGCGCCCCAA (SEQ ID NO:28), pointing towards the *Hind*III sites,

- 37 -

are designed based on these sequences and used in amplification reactions with pEPO15 and, in separate experiments, with *Sorangium cellulosum* So ce90 genomic DNA as the templates. Specific amplification is found with primer pair NH24 end "B" and NH2 end "A" with both templates. The amplimers are cloned into pBluescript II SK- and completely sequenced. The sequences of the amplimers are identical, and also agree completely with the end sequences of pEPO15-NH24 and pEPO15-NH2, fused at the *HindIII* site, establishing that the *HindIII* fragments of pEPO15-NH2 and pEPO15-NH24 are, in this order, contiguous.

The *HindIII* insert of pEPO15-H2.7 is isolated and DIG-labeled as above, and used as a probe in a DNA hybridization experiment at high stringency against pEPO15 digested by *NotI*. A *NotI* fragment of about 9 kb in size shows a strong hybridization, and is further subcloned into pBluescript II SK- that has been digested with *NotI* and dephosphorylated with calf intestinal alkaline phosphatase, to yield pEPO15-N9-16. The *NotI* insert of pEPO15-N9-16 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signals are detected for pEPO15-NH6, and also for the expected clones pEPO15-H2.7 and pEPO15-NH24. Nucleotide sequence data is generated from both ends of pEPO15-NH6 and from the end of pEPO15-H2.7 that does not overlap with pEPO15-4-1. PCR primers are designed pointing towards the *HindIII* sites and used in amplification reactions with pEPO15 and, in separate experiments, with *Sorangium cellulosum* So ce90 genomic DNA as the templates. Specific amplification is found with primer pair pEPO15-NH6 end "B": CACCGAAGCGTCGATCTGGTCCATC (SEQ ID NO:29) and pEPO15-H2.7 end "A": CGGTCAGATCGACGACGGGCTTTCC (SEQ ID NO:30) with both templates. The amplimers are cloned into pBluescript II SK- and completely sequenced. The sequences of the amplimers are identical, and also agree completely with the end sequences of pEPO15-NH6 and pEPO15-H2.7, fused at the *HindIII* site, establishing that the *HindIII* fragments of pEPO15-NH6 and pEPO15-H2.7 are, in this order, contiguous.

All of these experiments, taken together, establish a contig of *HindIII* fragments covering a region of about 55 kb and consisting of the *HindIII* inserts of pEPO15-NH6, pEPO15-H2.7, pEPO15-NH24, and pEPO15-NH2, in this order. The inserts of the remaining two *HindIII* subclones, namely pEPO15-NH1 and pEPO15-H3.0, are not found to be parts of this contig.

Example 10: Further Extension of the Subclone Contig Covering the Epothilone
Biosynthesis Genes

An approximately 2.2 kb *Bam*HI – *Hind*III fragment derived from the downstream end of the insert of pEPO15-NH2 and thus representing the downstream end of the subclone contig described in Example 9 is isolated, DIG-labeled, and used in Southern hybridization experiments against pEPO15 and pEPO15-NH2 DNAs digested with several enzymes. The strongly hybridizing bands are always found to be the same in size between the two target DNAs indicating that the *Sorangium cellulosum* So ce90 genomic DNA fragment cloned into pEPO15 ends with the *Hind*III site at the downstream end of pEPO15-NH2.

A cosmid DNA library of *Sorangium cellulosum* So ce90 is generated, using established procedures, in pScosTriplex-II (Ji, *et al.*, *Genomics* 31: 185-192 (1996)). Briefly, high-molecular weight genomic DNA of *Sorangium cellulosum* So ce90 is partially digested with the restriction enzyme *Sau*3AI to provide fragments with average sizes of about 40 kb, and ligated to *Bam*HI and *Xba*I digested pScosTriplex-II. The ligation mix is packaged with Gigapack III XL (Stratagene) and used to transfect *E. coli* XL1 Blue MR cells.

The cosmid library is screened with the approximately 2.2 kb *Bam*HI – *Hind*III fragment, derived from the downstream end of the insert of pEPO15-NH2, used as a probe in colony hybridization. A strongly hybridizing clone, named pEPO4E7 is selected.

pEPO4E7 DNA is isolated, digested with several restriction endonucleases, and probed in Southern hybridization experiments with the 2.2 kb *Bam*HI – *Hind*III fragment. A strongly hybridizing *Not*I fragment of approximately 9 kb in size is selected and subcloned into pBluescript II SK- to yield pEPO4E7-N9-8. Further Southern hybridization experiments reveal that the approximately 9 kb *Not*I insert of pEPO4E7-N9-8 overlaps pEPO15-NH2 over 6 kb in a *Not*I – *Hind*III fragment, while the remaining approximately 3 kb *Hind*III – *Not*I fragment would extend the subclone contig described in Example 9. End sequencing reveals, however, that the downstream end of the insert of pEPO4E7-N9-8 contains the *Bam*HI – *Not*I polylinker of pScosTriplex-II, thereby indicating that the genomic DNA insert of pEPO4E7 ends at a *Sau*3AI site within the extending *Hind*III – *Not*I fragment and that the *Not*I site is derived from pScosTriplex-II.

An approximately 1.6 kb *Pst*I – *Sal*I fragment derived from the approximately 3 kb extending *Hind*III – *Not*I subfragment of pEPO4E7-N9-8, containing only *Sorangium*

cellulosum So ce90-derived sequences free of vector, is used as a probe against the bacterial artificial chromosome library described in Example 2. Besides the previously-isolated EPO15, a Bac clone, named EPO32, is found to strongly hybridize to the probe. pEPO32 is isolated, digested with several restriction endonucleases, and hybridized with the approximately 1.6 kb *Pst*I – *Sal*I probe. A *Hind*III – *Eco*RV fragment of about 13 kb in size is found to strongly hybridize to the probe, and is subcloned into pBluescript II SK-digested with *Hind*III and *Hinc*II to yield pEPO32-HEV15.

Oligonucleotide primers are designed based on the downstream end sequence of pEPO15-NH2 and on the upstream (*Hind*III) end sequence derived from pEPO32-HEV15, and used in sequencing reactions with pEPO4E7-N9-8 as the template. The sequences reveal the existence of a small *Hind*III fragment (EPO4E7-H0.02) of 24 bp, undetectable in standard restriction analysis, separating the *Hind*III site at the downstream end of pEPO15-NH2 from the *Hind*III site at the upstream end of pEPO32-HEV15.

Thus, the subclone contig described in Example 9 is extended to include the *Hind*III fragment EPO4E7-H0.02 and the insert of pEPO32-HEV15, and constitutes the inserts of: pEPO15-NH6, pEPO15-H2.7, pEPO15-NH24, pEPO15-NH2, EPO4E7-H0.02 and pEPO32-HEV15, in this order.

Example 11: Nucleotide Sequence Determination of the Subclone Contig Covering the Epothilone Biosynthesis Genes

The nucleotide sequence of the subclone contig described in Example 10 is determined as follows.

pEPO15-H2.7. Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-H2.7], and the nucleotide sequence of the 2.7-kb *Bam*HI insert in pEPO15-H2.7 is determined. Automated DNA sequencing is done on the double-stranded DNA template by the dideoxynucleotide chain termination method, using Applied Biosystems model 377 sequencers. The primers used are the universal reverse primer (5' GGA AAC AGC TAT GAC CAT G 3' (SEQ ID NO:24)) and the universal forward primer (5' GTA AAA CGA CGG CCA GT 3' (SEQ ID NO:25)). In subsequent rounds of sequencing reactions, custom-synthesized oligonucleotides, designed for the 3' ends of the previously determined sequences, are used to extend and join contigs.

pEPO15-NH6, pEPO15-NH24 and pEPO15-NH2. The *Hind*III inserts of these plasmids are isolated, and subjected to random fragmentation using a Hydroshear apparatus (Genomic Instrumentation Services, Inc.) to yield an average fragment size of 1-2 kb. The fragments are end-repaired using T4 DNA Polymerase and Klenow DNA Polymerase enzymes in the presence of desoxynucleotide triphosphates, and phosphorylated with T4 DNA Kinase in the presence of ribo-ATP. Fragments in the size range of 1.5-2.2 kb are isolated from agarose gels, and ligated into pBluescript II SK- that has been cut with *Eco*RV and dephosphorylated. Random subclones are sequenced using the universal reverse and the universal forward primers.

pEPO32-HEV15. pEPO32-HEV15 is digested with *Hind*III and *Ssp*I, the approximately 13.3 kb fragment containing the ~13 kb *Hind*III – *Eco*RV insert from *So. cellulosum* So ce90 and a 0.3 kb *Hinc*II – *Ssp*I fragment from pBluescript II SK- is isolated, and partially digested with *Hae*III to yield fragments with an average size of 1-2 kb. Fragments in the size range of 1.5-2.2 kb are isolated from agarose gels, and ligated into pBluescript II SK- that has been cut with *Eco*RV and dephosphorylated. Random subclones are sequenced using the universal reverse and the universal forward primers.

The chromatograms are analyzed and assembled into contigs with the Phred, Phrap and Consed programs (Ewing, *et al.*, *Genome Res.* 8(3): 175-185 (1998); Ewing, *et al.*, *Genome Res.* 8(3): 186-194 (1998); Gordon, *et al.*, *Genome Res.* 8(3): 195-202 (1998)). Contig gaps are filled, sequence discrepancies are resolved, and low-quality regions are resequenced using custom-designed oligonucleotide primers for sequencing on either the original subclones or selected clones from the random subclone libraries. Both strands are completely sequenced, and every basepair is covered with at least a minimum aggregated Phred score of 40 (confidence level of 99.99%).

The nucleotide sequence of the 68750 bp contig is shown as SEQ ID NO:1.

Example 12: Nucleotide Sequence Analysis of the Epothilone Biosynthesis Genes

SEQ ID NO:1 is found to contain 22 ORFs as detailed below in Table 1:

Table 1

ORF	Start codon	Stop codon	Homology of deduced protein	Proposed function of deduced protein
<i>orf1</i>	outside of sequenced range	1826		
<i>orf2</i> *	3171	1900	Hypothetical protein SP: Q11037; DD-peptidase SP:P15555	
<i>orf3</i>	3415	5556	<i>Na/H antiporter PID: D1017724</i>	<i>Transport</i>
<i>orf4</i> *	5992	5612		
<i>orf5</i>	6226	6675		
<i>epoA</i>	7610	11875	Type I polyketide synthase	Epothilone synthase: Thiazole ring formation
<i>epoP</i>	11872	16104	Non-ribosomal peptide synthetase	Epothilone synthase: Thiazole ring formation
<i>epoB</i>	16251	21749	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoC</i>	21746	43519	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoD</i>	43524	54920	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoE</i>	54935	62254	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoF</i>	62369	63628	Cytochrome P450	Epothilone macrolactone oxidase
<i>orf6</i>	63779	64333		
<i>orf7</i> *	64290	63853		
<i>orf8</i>	64363	64920		
<i>orf9</i> *	64727	64287		
<i>orf10</i>	65063	65767		
<i>orf11</i> *	65874	65008		
<i>orf12</i> *	66338	65871		
<i>orf13</i>	66667	67137		
<i>orf14</i>	67334	68251	Hypothetical protein GI:3293544; Cation efflux system protein GI:2623026	Transport
<i>orf15</i>	68346	outside of sequenced range		

* On the reverse complement strand. Numbering according to SEQ ID NO:1.

epoA (nucleotides 7610-11875 of SEQ ID NO:1) codes for EPOS A (SEQ ID NO:2), a type I polyketide synthase consisting of a single module, and harboring the following domains: β -ketoacyl-synthase (KS) (nucleotides 7643-8920 of SEQ ID NO:1, amino acids 11-

- 42 -

437 of SEQ ID NO:2); acyltransferase (AT) (nucleotides 9236-10201 of SEQ ID NO:1, amino acids 543-864 of SEQ ID NO:2); enoyl reductase (ER) (nucleotides 10529-11428 of SEQ ID NO:1, amino acids 974-1273 of SEQ ID NO:2); and acyl carrier protein homologous domain (ACP) (nucleotides 11549-11764 of SEQ ID NO:1, amino acids 1314-1385 of SEQ ID NO:2). Sequence comparisons and motif analysis (Haydock, et al. *FEBS Lett.* 374: 246-248 (1995); Tang, et al., *Gene* 216: 255-265 (1998)) reveal that the AT encoded by EPOS A is specific for malonyl-CoA. EPOS A should be involved in the initiation of epothilone biosynthesis by loading the acetate unit to the multienzyme complex that will eventually form part of the 2-methylthiazole ring (C26 and C20).

epoP (nucleotides 11872-16104 of SEQ ID NO:1) codes for EPOS P (SEQ ID NO:3), a non-ribosomal peptide synthetase containing one module. EPOS P harbors the following domains:

- peptide bond formation domain, as delineated by motif K (amino acids 72-81 [FPLTDIQESY] of SEQ ID NO:3, corresponding to nucleotide positions 12085-12114 of SEQ ID NO:1); motif L (amino acids 118-125 [VVARHDML] of SEQ ID NO:3, corresponding to nucleotide positions 12223-12246 of SEQ ID NO:1); motif M (amino acids 199-212 [SIDLINVDLGSLSI] of SEQ ID NO:3, corresponding to nucleotide positions 12466-12507 of SEQ ID NO:1); and motif O (amino acids 353-363 [GDFTSMVLLDI] of SEQ ID NO:3, corresponding to nucleotide positions 12928-12960 of SEQ ID NO:1);
- aminoacyl adenylate formation domain, as delineated by motif A (amino acids 549-565 [LYEELSRRSRRLGARL] of SEQ ID NO:3, corresponding to nucleotide positions 13516-13566 of SEQ ID NO:1); motif B (amino acids 588-603 [VAVLAVLESGAAYVPI] of SEQ ID NO:3, corresponding to nucleotide positions 13633-13680 of SEQ ID NO:1); motif C (amino acids 669-684 [AYVIYTSGSTGLPKGVI] of SEQ ID NO:3, corresponding to nucleotide positions 13876-13923 of SEQ ID NO:1); motif D (amino acids 815-821 [SLGGATE] of SEQ ID NO:3, corresponding to nucleotide positions 14313-14334 of SEQ ID NO:1); motif E (amino acids 868-892 [GQLYIGGVGLALGYWRDEEKTRKSF] of SEQ ID NO:3, corresponding to nucleotide positions 14473-14547 of SEQ ID NO:1); motif F (amino acids 903-912 [YKTGDLGRYL] of SEQ ID NO:3, corresponding to nucleotide positions 14578-14607 of SEQ ID NO:1); motif G (amino acids 918-940 [EFMGREDNQIKLRGYRVELGEIE] of SEQ ID NO:3, corresponding to nucleotide positions 14623-14692 of SEQ ID NO:1); motif H (amino acids 1268-1274 [LPEYMVP] of SEQ ID NO:3, corresponding to nucleotide positions 15673-15693 of SEQ ID NO:1); and

motif I (amino acids 1285-1297 [LTSNGKVDRKALR] of SEQ ID NO:3, corresponding to nucleotide positions 15724-15762 of SEQ ID NO:1);

- an unknown domain, inserted between motifs G and H of the aminoacyl adenylate formation domain (amino acids 973-1256 of SEQ ID NO:3, corresponding to nucleotide positions 14788-15639 of SEQ ID NO:1); and
- a peptidyl carrier protein homologous domain (PCP), delineated by motif J (amino acids 1344-1351 [GATSIHIV] of SEQ ID NO:3, corresponding to nucleotide positions 15901-15924 of SEQ ID NO:1).

It is proposed that EPOS P is involved in the activation of a cysteine by adenylation, binding the activated cysteine as an aminoacyl-S-PCP, forming a peptide bond between the enzyme-bound cysteine and the acetyl-S-ACP supplied by EPOS A, and the formation of the initial thiazoline ring by intramolecular heterocyclization. The unknown domain of EPOS P displays very weak homologies to NAD(P)H oxidases and reductases from *Bacillus* species. Thus, this unknown domain and/or the ER domain of EPOS A may be involved in the oxidation of the initial 2-methylthiazoline ring to a 2-methylthiazole.

epoB (nucleotides 16251-21749 of SEQ ID NO:1) codes for EPOS B (SEQ ID NO:4), a type I polyketide synthase consisting of a single module, and harboring the following domains: KS (nucleotides 16269-17546 of SEQ ID NO:1, amino acids 7-432 of SEQ ID NO:4); AT (nucleotides 17865-18827 of SEQ ID NO:1, amino acids 539-859 of SEQ ID NO:4); dehydratase (DH) (nucleotides 18855-19361 of SEQ ID NO:1, amino acids 869-1037 of SEQ ID NO:4); β -ketoreductase (KR) (nucleotides 20565-21302 of SEQ ID NO:1, amino acids 1439-1684 of SEQ ID NO:4); and ACP (nucleotides 21414-21626 of SEQ ID NO:1, amino acids 1722-1792 of SEQ ID NO:4). Sequence comparisons and motif analysis reveal that the AT encoded by EPOS B is specific for methylmalonyl-CoA. EPOS A should be involved in the first polyketide chain extension by catalysing the Claisen-like condensation of the 2-methyl-4-thiazolecarboxyl-S-PCP starter group with the methylmalonyl-S-ACP, and the concomitant reduction of the β -keto group of C17 to an enoyl.

epoC (nucleotides 21746-43519 of SEQ ID NO:1) codes for EPOS C (SEQ ID NO:5), a type I polyketide synthase consisting of 4 modules. The first module harbors a KS (nucleotides 21860-23116 of SEQ ID NO:1, amino acids 39-457 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 23431-24397 of SEQ ID NO:1, amino acids 563-884 of SEQ ID NO:5); a KR (nucleotides 25184-25942 of SEQ ID NO:1, amino acids 1147-1399 of SEQ ID NO:5); and an ACP (nucleotides 26045-26263 of SEQ ID NO:1, amino acids 1434-1506 of

SEQ ID NO:5). This module incorporates an acetate extender unit (C14-C13) and reduces the β -keto group at C15 to the hydroxyl group that takes part in the final lactonization of the epothilone macrolactone ring. The second module of EPOS C harbors a KS (nucleotides 26318-27595 of SEQ ID NO:1, amino acids 1524-1950 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 27911-28876 of SEQ ID NO:1, amino acids 2056-2377 of SEQ ID NO:5); a KR (nucleotides 29678-30429 of SEQ ID NO:1, amino acids 2645-2895 of SEQ ID NO:5); and an ACP (nucleotides 30539-30759 of SEQ ID NO:1, amino acids 2932-3005 of SEQ ID NO:5). This module incorporates an acetate extender unit (C12-C11) and reduces the β -keto group at C13 to a hydroxyl group. Thus, the nascent polyketide chain of epothilone corresponds to epothilone A, and the incorporation of the methyl side chain at C12 in epothilone B would require a post-PKS C-methyltransferase activity. The formation of the epoxi ring at C13-C12 would also require a post-PKS oxidation step. The third module of EPOS C harbors a KS (nucleotides 30815-32092 of SEQ ID NO:1, amino acids 3024-3449 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 32408-33373 of SEQ ID NO:1, amino acids 3555-3876 of SEQ ID NO:5); a DH (nucleotides 33401-33889 of SEQ ID NO:1, amino acids 3886-4048 of SEQ ID NO:5); an ER (nucleotides 35042-35902 of SEQ ID NO:1, amino acids 4433-4719 of SEQ ID NO:5); a KR (nucleotides 35930-36667 of SEQ ID NO:1, amino acids 4729-4974 of SEQ ID NO:5); and an ACP (nucleotides 36773-36991 of SEQ ID NO:1, amino acids 5010-5082 of SEQ ID NO:5). This module incorporates an acetate extender unit (C10-C9) and fully reduces the β -keto group at C11. The fourth module of EPOS C harbors a KS (nucleotides 37052-38320 of SEQ ID NO:1, amino acids 5103-5525 of SEQ ID NO:5); a methylmalonyl CoA-specific AT (nucleotides 38636-39598 of SEQ ID NO:1, amino acids 5631-5951 of SEQ ID NO:5); a DH (nucleotides 39635-40141 of SEQ ID NO:1, amino acids 5964-6132 of SEQ ID NO:5); an ER (nucleotides 41369-42256 of SEQ ID NO:1, amino acids 6542-6837 of SEQ ID NO:5); a KR (nucleotides 42314-43048 of SEQ ID NO:1, amino acids 6857-7101 of SEQ ID NO:5); and an ACP (nucleotides 43163-43378 of SEQ ID NO:1, amino acids 7140-7211 of SEQ ID NO:5). This module incorporates a propionate extender unit (C24 and C8-C7) and fully reduces the β -keto group at C9.

epoD (nucleotides 43524-54920 of SEQ ID NO:1) codes for EPOS D (SEQ ID NO:6), a type I polyketide synthase consisting of 2 modules. The first module harbors a KS (nucleotides 43626-44885 of SEQ ID NO:1, amino acids 35-454 of SEQ ID NO:6); a methylmalonyl CoA-specific AT (nucleotides 45204-46166 of SEQ ID NO:1, amino acids 561-881 of SEQ ID NO:6); a KR (nucleotides 46950-47702 of SEQ ID NO:1, amino acids

1143-1393 of SEQ ID NO:6); and an ACP (nucleotides 47811-48032 of SEQ ID NO:1, amino acids 1430-1503 of SEQ ID NO:6). This module incorporates a propionate extender unit (C23 and C6-C5) and reduces the β -keto group at C7 to a hydroxyl group. The second module harbors a KS (nucleotides 48087-49361 of SEQ ID NO:1, amino acids 1522-1946 of SEQ ID NO:6); a methylmalonyl CoA-specific AT (nucleotides 49680-50642 of SEQ ID NO:1, amino acids 2053-2373 of SEQ ID NO:6); a DH (nucleotides 50670-51176 of SEQ ID NO:1, amino acids 2383-2551 of SEQ ID NO:6); a methyltransferase (MT, nucleotides 51534-52657 of SEQ ID NO:1, amino acids 2671-3045 of SEQ ID NO:6); a KR (nucleotides 53697-54431 of SEQ ID NO:1, amino acids 3392-3636 of SEQ ID NO:6); and an ACP (nucleotides 54540-54758 of SEQ ID NO:1, amino acids 3673-3745 of SEQ ID NO:6). This module incorporates a propionate extender unit (C21 or C22 and C4-C3) and reduces the β -keto group at C5 to a hydroxyl group. This reduction is somewhat unexpected, since epothilones contain a keto group at C5. Discrepancies of this kind between the deduced reductive capabilities of PKS modules and the redox state of the corresponding positions in the final polyketide products have been, however, reported in the literature (see, for example, Schwecke, et al., *Proc. Natl. Acad. Sci. USA* 92: 7839-7843 (1995) and Schupp, et al., *FEMS Microbiology Letters* 159: 201-207 (1998)). An important feature of epothilones is the presence of gem-methyl side groups at C4 (C21 and C22). The second module of EPOS D is predicted to incorporate a propionate unit into the growing polyketide chain, providing one methyl side chain at C4. This module also contains a methyltransferase domain integrated into the PKS between the DH and the KR domains, in an arrangement similar to the one seen in the HMWP1 yersiniabactin synthase (Gehring, A.M., DeMoll, E., Fetherston, J.D., Mori, I., Mayhew, G.F., Blattner, F.R., Walsh, C.T., and Perry, R.D.: Iron acquisition in plague: modular logic in enzymatic biogenesis of yersiniabactin by *Yersinia pestis*. *Chem. Biol.* 5, 573-586, 1998). This MT domain in EPOS D is proposed to be responsible for the incorporation of the second methyl side group (C21 or C22) at C4.

epoE (nucleotides 54935-62254 of SEQ ID NO:1) codes for EPOS E (SEQ ID NO:7), a type I polyketide synthase consisting of one module, harboring a KS (nucleotides 55028-56284 of SEQ ID NO:1, amino acids 32-450 of SEQ ID NO:7); a malonyl CoA-specific AT (nucleotides 56600-57565 of SEQ ID NO:1, amino acids 556-877 of SEQ ID NO:7); a DH (nucleotides 57593-58087 of SEQ ID NO:1, amino acids 887-1051 of SEQ ID NO:7); a probably nonfunctional ER (nucleotides 59366-60304 of SEQ ID NO:1, amino acids 1478-1790 of SEQ ID NO:7); a KR (nucleotides 60362-61099 of SEQ ID NO:1, amino acids 1810-2055

of SEQ ID NO:7); an ACP (nucleotides 61211-61426 of SEQ ID NO:1, amino acids 2093-2164 of SEQ ID NO:7); and a thioesterase (TE) (nucleotides 61427-62254 of SEQ ID NO:1, amino acids 2165-2439 of SEQ ID NO:7). The ER domain in this module harbors an active site motif with some highly unusual amino acid substitutions that probably render this domain inactive. The module incorporates an acetate extender unit (C2-C1), and reduces the β -keto at C3 to an enoyl group. Epothilones contain a hydroxyl group at C3, so this reduction also appears to be excessive as discussed for the second module of EPOS D. The TE domain of EPOS E takes part in the release and cyclization of the grown polyketide chain via lactonization between the carboxyl group of C1 and the hydroxyl group of C15.

Five ORFs are detected upstream of *epoA* in the sequenced region. The partially sequenced *orf1* has no homologues in the sequence databanks. The deduced protein product (Orf 2, SEQ ID NO:10) of *orf2* (nucleotides 3171-1900 on the reverse complement strand of SEQ ID NO:1) shows strong similarities to hypothetical ORFs from *Mycobacterium* and *Streptomyces coelicolor*, and more distant similarities to carboxypeptidases and DD-peptidases of different bacteria. The deduced protein product of *orf3* (nucleotides 3415-5556 of SEQ ID NO:1), Orf 3 (SEQ ID NO:11), shows homologies to Na/H antiporters of different bacteria. Orf 3 might take part in the export of epothilones from the producer strain. *orf4* and *orf5* have no homologues in the sequence databanks.

Eleven ORFs are found downstream of *epoE* in the sequenced region. *epoF* (nucleotides 62369-63628 of SEQ ID NO:1) codes for EPOS F (SEQ ID NO:8), a deduced protein with strong sequence similarities to cytochrome P450 oxygenases. EPOS F may take part in the adjustment of the redox state of the carbons C12, C5, and/or C3. The deduced protein product of *orf14* (nucleotides 67334-68251 of SEQ ID NO:1), Orf 14 (SEQ ID NO:22) shows strong similarities to GI:3293544, a hypothetical protein with no proposed function from *Streptomyces coelicolor*, and also to GI:2654559, the human embryonic lung protein. It is also more distantly related to cation efflux system proteins like GI:2623026 from *Methanobacterium thermoautotrophicum*, so it might also take part in the export of epothilones from the producing cells. The remaining ORFs (*orf6-orf13* and *orf15*) show no homologies to entries in the sequence databanks.

Example 13: Recombinant Expression of Epothilone Biosynthesis Genes

Epothilone synthase genes according to the present invention are expressed in heterologous organisms for the purposes of epothilone production at greater quantities than can be accomplished by fermentation of *Sorangium cellulosum*. A preferable host for heterologous expression is *Streptomyces*, e.g. *Streptomyces coelicolor*, which natively produces the polyketide actinorhodin. Techniques for recombinant PKS gene expression in this host are described in McDaniel *et al.*, *Science* 262: 1546-1550 (1993) and Kao *et al.*, *Science* 265: 509-512 (1994). See also, Holmes *et al.*, *EMBO Journal* 12(8): 3183-3191 (1993) and Bibb *et al.*, *Gene* 38: 215-226 (1985), as well as U.S. Patent Nos. 5,521,077, 5,672,491, and 5,712,146, which are incorporated herein by reference.

According to one method, the heterologous host strain is engineered to contain a chromosomal deletion of the actinorhodin (*act*) gene cluster. Expression plasmids containing the epothilone synthase genes of the invention are constructed by transferring DNA from a temperature-sensitive donor plasmid to a recipient shuttle vector in *E. coli* (McDaniel *et al.* (1993) and Kao *et al.* (1994)), such that the synthase genes are built-up by homologous recombination within the vector. Alternatively, the epothilone synthase gene cluster is introduced into the vector by restriction fragment ligation. Following selection, e.g. as described in Kao *et al.* (1994), DNA from the vector is introduced into the *act*-minus *Streptomyces coelicolor* strain according to protocols set forth in Hopwood *et al.*, *Genetic Manipulation of Streptomyces. A Laboratory Manual* (John Innes Foundation, Norwich, United Kingdom, 1985), incorporated herein by reference. The recombinant *Streptomyces* strain is grown on R2YE medium (Hopwood *et al.* (1985)) and produces epothilones. Alternatively, the epothilone synthase genes according to the present invention are expressed in other host organisms such as pseudomonads, *Bacillus*, yeast, insect cells and/or *E. coli*. PKS and NRPS genes are preferably expressed in *E. coli* using the pT7-7 vector, which uses the T7 promoter. See, Tabor *et al.*, *Proc. Natl. Acad. Sci. USA* 82: 1074-1078 (1985). In another embodiment, the expression vectors pKK223-3 and pKK223-2 are used to express PKS and NRPS genes in *E. coli*, either in transcriptional or translational fusion, behind the *tac* or *trc* promoter. Expression of PKS and NRPS genes in heterologous hosts, which do not naturally have the phosphopantetheinyl (P-pant) transferases needed for post-translational modification of PKS enzymes, requires the coexpression in the host of a P-pant transferase, as described by Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998).

Example 14: Isolation of Epothilones from Producing Strains

Examples of cultivation, fermentation, and extraction procedures for polyketide isolation, which are useful for extracting epothilones from both native and recombinant hosts according to the present invention, are given in WO 93/10121, incorporated herein by reference, in Example 57 of U.S. Patent No. 5,639,949, in Gerth *et al.*, *J. Antibiotics* 49: 560-563 (1996), and in Swiss patent application no. 396/98, filed February 19, 1998, and U.S. patent application no. 09/248,910 (that discloses also preferred mutant strains of *Sorangium cellulosum*), both of which are incorporated herein by reference. The following are procedures that are useful for isolating epothilones from cultured *Sorangium cellulosum* strains such as So ce90, and may also be used for the isolation of epothilone from recombinant hosts.

A: Cultivation of epothilone-producing strains:

Strain: *Sorangium cellulosum* Soce-90 or a recombinant host strain according to the present invention.

Preservation of the strain: In liquid N₂.

Media: Precultures and intermediate cultures: G52
Main culture: 1B12

G52 Medium:

yeast extract, low in salt (BioSpringer, Maison Alfort, France)	2 g/l
MgSO ₄ (7 H ₂ O)	1 g/l
CaCl ₂ (2 H ₂ O)	1 g/l
soya meal defatted Soyamine 50T (Lucas Meyer, Hamburg, Germany)	2 g/l
potato starch Noredux A-150 (Blattmann, Waedenswil, Switzerland)	8 g/l
glucose anhydrous	2 g/l
EDTA-Fe(III)-Na salt (8 g/l)	1 ml/l

- 49 -

pH 7.4, corrected with KOH
Sterilisation: 20 mins. 120 °C

1B12 Medium:

potato starch Noredux A-150 (Blattmann, Waedenswil, Switzerland)	20 g/l
soya meal defatted Soyamine 50T (Lucas Meyer, Hamburg, Germany)	11 g/l
EDTA-Fe(III)-Na salt	8 mg/l

pH 7.8, corrected with KOH
Sterilisation: 20 mins. 120 °C

Addition of cyclodextrins and cyclodextrin derivatives:

Cyclodextrins (Fluka, Buchs, Switzerland, or Wacker Chemie,
Munich, Germany) in different concentrations are sterilised
separately and added to the 1B12 medium prior to seeding.

Cultivation: 1 ml of the suspension of *Sorangium cellulosum* Soce-90 from a liquid N₂ ampoule is transferred to 10 ml of G52 medium (in a 50 ml Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 25 mm displacement. 5 ml of this culture is added to 45 ml of G52 medium (in a 200 ml Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 25 mm displacement. 50 ml of this culture is then added to 450 ml of G52 medium (in a 2 litre Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Maintenance culture: The culture is overseeded every 3-4 days, by adding 50 ml of culture to 450 ml of G52 medium (in a 2 litre Erlenmeyer flask). All experiments and fermentations are carried out by starting with this maintenance culture.

Tests in a flask:

(I) Preculture in an agitating flask:

- 50 -

Starting with the 500 ml of maintenance culture, 1 x 450 ml of G52 medium are seeded with 50 ml of the maintenance culture and incubated for 4 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

(ii) Main culture in the agitating flask:

40 ml of 1B12 medium plus 5 g/l 4-morpholine-propane-sulfonic acid (= MOPS) powder (in a 200 ml Erlenmeyer flask) are mixed with 5 ml of a 10x concentrated cyclodextrin solution, seeded with 10 ml of preculture and incubated for 5 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Fermentation: Fermentations are carried out on a scale of 10 litres, 100 litres and 500 litres. 20 litre and 100 litre fermentations serve as an intermediate culture step. Whereas the pre-cultures and intermediate cultures are seeded as the maintenance culture 10% (v/v), the main cultures are seeded with 20% (v/v) of the intermediate culture. Important: In contrast to the agitating cultures, the ingredients of the media for the fermentation are calculated on the final culture volume including the inoculum. If, for example, 18 litres of medium + 2 litres of inoculum are combined, then substances for 20 litres are weighed in, but are only mixed with 18 litres.

Preculture in an agitating flask:

Starting with the 500 ml maintenance culture, 4 x 450 ml of G52 medium (in a 2 litre Erlenmeyer flask) are each seeded with 50 ml thereof, and incubated for 4 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Intermediate culture, 20 litres or 100 litres:


20 litres: 18 litres of G52 medium in a fermenter having a total volume of 30 litres are seeded with 2 litres of the preculture. Cultivation lasts for 3-4 days, and the conditions are: 30°C, 250 rpm, 0.5 litres of air per litre liquid per min, 0.5 bars excess pressure, no pH control.

100 litres: 90 litres of G52 medium in a fermenter having a total volume of 150 litres are seeded with 10 litres of the 20 litre intermediate culture. Cultivation lasts for 3-4 days, and the conditions are: 30°C, 150 rpm, 0.5 litres of air per litre liquid per min, 0.5 bars excess pressure, no pH control.

Main culture, 10 litres, 100 litres or 500 litres:

10 litres: The media substances for 10 litres of 1B12 medium are sterilised in 7 litres of water, then 1 litre of a sterile 10% 2-(hydroxypropyl) - β -cyclodextrin solution are added, and seeded with 2 litres of a 20 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 250 rpm, 0.5 litres of air per litre of liquid per min, 0.5 bars excess pressure, pH control with H₂SO₄/KOH to pH 7.6 +/- 0.5 (i.e. no control between pH 7.1 and 8.1).

100 litres: The media substances for 100 litres of 1B12 medium are sterilised in 70 litres of water, then 10 litres of a sterile 10% 2-(hydroxypropyl) - β -cyclodextrin solution are added, and seeded with 20 litres of a 20 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 200 rpm, 0.5 litres air per litre liquid per min., 0.5 bars excess pressure, pH control with H₂SO₄/KOH to pH 7.6 +/- 0.5. The chain of seeding for a 100 litre fermentation is shown schematically as follows:



500 litres: The media substances for 500 litres of 1B12 medium are sterilised in 350 litres of water, then 50 litres of a sterile 10% 2-(hydroxypropyl) - β -cyclodextrin solution are added, and seeded with 100 litres of a 100 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 120 rpm, 0.5 litres air per litre liquid per min., 0.5 bars excess pressure, pH control with H₂SO₄/KOH to pH 7.6 +/- 0.5.

Product analysis:Preparation of the sample:

50 ml samples are mixed with 2 ml of polystyrene resin Amberlite XAD16 (Rohm + Haas, Frankfurt, Germany) and shaken at 180 rpm for one hour at 30°C. The resin is subsequently filtered using a 150 µm nylon sieve, washed with a little water and then added together with the filter to a 15 ml Nunc tube.

Elution of the product from the resin:

10 ml of isopropanol (>99%) are added to the tube with the filter and the resin. Afterwards, the sealed tube is shaken for 30 minutes at room temperature on a Rota-Mixer (Labinco BV, Netherlands). Then, 2 ml of the liquid are centrifuged off and the supernatant is added using a pipette to HPLC tubes.

HPLC analysis:


Column:	Waters-Symetry C18, 100 x 4 mm, 3.5 µm WAT066220 + preliminary column 3.9 x 20 mm WAT054225
Solvents:	A: 0.02 % phosphoric acid B: Acetonitrile (HPLC-Quality)
Gradient:	41% B from 0 to 7 min. 100% B from 7.2 to 7.8 min. 41% B from 8 to 12 min.
Oven temp.:	30°C
Detection:	250 nm, UV-DAD detection
Injection vol.:	10 µl
Retention time:	Epo A: 4.30 min Epo B: 5.38 min

B: Effect of the addition of cyclodextrin and cyclodextrin derivatives to the epothilone concentrations attained.


Cyclodextrins are cyclic (α -1,4)-linked oligosaccharides of α -D-glucopyranose with a relatively hydrophobic central cavity and a hydrophilic external surface area.

The following are distinguished in particular (the figures in parenthesis give the number of glucose units per molecule): α -cyclodextrin (6), β -cyclodextrin (7), γ -cyclodextrin (8), δ -cyclodextrin (9), ϵ -cyclodextrin (10), ζ -cyclodextrin (11), η -cyclodextrin (12), and θ -cyclodextrin (13). Especially preferred are δ -cyclodextrin and in particular α -cyclodextrin, β -cyclodextrin or γ -cyclodextrin, or mixtures thereof.

Cyclodextrin derivatives are primarily derivatives of the above-mentioned cyclodextrins, especially of α -cyclodextrin, β -cyclodextrin or γ -cyclodextrin, primarily those in which one or more up to all of the hydroxy groups (3 per glucose radical) are etherified or esterified. Ethers are primarily alkyl ethers, especially lower alkyl, such as methyl or ethyl ether, also propyl or butyl ether; the aryl-hydroxyalkyl ethers, such as phenyl-hydroxy-lower-alkyl, especially phenyl-hydroxyethyl ether; the hydroxyalkyl ethers, in particular hydroxy-lower-alkyl ethers, especially 2-hydroxyethyl, hydroxypropyl such as 2-hydroxypropyl or hydroxybutyl such as 2-hydroxybutyl ether; the carboxyalkyl ethers, in particular carboxy-lower-alkyl ethers, especially carboxymethyl or carboxyethyl ether; derivatised carboxyalkyl ethers, in particular derivatised carboxy-lower-alkyl ether in which the derivatised carboxy is etherified or amidated carboxy (primarily aminocarbonyl, mono- or di-lower-alkyl-aminocarbonyl, morpholino-, piperidino-, pyrrolidino- or piperazino-carbonyl, or alkyloxycarbonyl), in particular lower alkyloxycarbonyl-lower-alkyl ether, for example methyloxycarbonylpropyl ether or ethyloxycarbonylpropyl ether; the sulfoalkyl ethers, in particular sulfo-lower-alkyl ethers, especially sulfobutyl ether; cyclodextrins in which one or more OH groups are etherified with a radical of formula



wherein alk is alkyl, especially lower alkyl, and n is a whole number from 2 to 12, especially 2 to 5, in particular 2 or 3; cyclodextrins in which one or more OH groups are etherified with a radical of formula



wherein R' is hydrogen, hydroxy, $-\text{O}(\text{alk-O})_z\text{-H}$, $-\text{O}(\text{alk}(-\text{R})\text{-O})_p\text{-H}$ or $-\text{O}(\text{alk}(-\text{R})\text{-O})_q\text{-alk-CO-Y}$; alk in all cases is alkyl, especially lower alkyl; m, n, p, q and z are a whole number from 1 to 12, preferably 1 to 5, in particular 1 to 3; and Y is OR_1 or NR_2R_3 , wherein R_1 , R_2 and R_3 independently of one another, are hydrogen or lower alkyl, or R_2 and R_3 combined together with the linking nitrogen signify morpholino, piperidino, pyrrolidino or piperazino; or branched cyclodextrins, in which etherifications or acetals with other sugar molecules are present, especially glucosyl-, diglucosyl- (G_2 - β -cyclodextrin), maltosyl- or dimaltosyl-cyclodextrin, or N-acetylglucosaminyl-, glucosaminyl-, N-acetylgalactosaminyl- or galactosaminyl-cyclodextrin.

Esters are primarily alkanoyl esters, in particular lower alkanoyl esters, such as acetyl esters of cyclodextrins.

It is also possible to have cyclodextrins in which two or more different said ether and ester groups are present at the same time.

Mixtures of two or more of the said cyclodextrins and/or cyclodextrin derivatives may also exist.

Preference is given in particular to α -, β - or γ -cyclodextrins or the lower alkyl ethers thereof, such as methyl- β -cyclodextrin or in particular 2,6-di-O-methyl- β -cyclodextrin, or in particular the hydroxy lower alkyl ethers thereof, such as 2-hydroxypropyl- α -, 2-hydroxypropyl- β - or 2-hydroxypropyl- γ -cyclodextrin.

The cyclodextrins or cyclodextrin derivatives are added to the culture medium preferably in a concentration of 0.02 to 10, preferably 0.05 to 5, especially 0.1 to 4, for example 0.1 to 2 percent by weight (w/v).

Cyclodextrins or cyclodextrin derivatives are known or may be produced by known processes (see for example US 3,459,731; US 4,383,992; US 4,535,152; US 4,659,696; EP 0 094 157; EP 0 149 197; EP 0 197 571; EP 0 300 526; EP 0 320 032; EP 0 499 322; EP 0 503 710; EP 0 818 469; WO 90/12035; WO 91/11200; WO 93/19061; WO 95/08993; WO 96/14090; GB 2,189,245; DE 3,118,218; DE 3,317,064 and the references mentioned therein, which also refer to the synthesis of cyclodextrins or cyclodextrin derivatives, or also: T. Loftsson and M.E. Brewster (1996): Pharmaceutical Applications of Cyclodextrins: Drug Solubilization and Stabilisation: Journal of Pharmaceutical Science 85 (10):1017-1025; R.A. Rajewski and V.J. Stella(1996): Pharmaceutical Applications of Cyclodextrins: In Vivo Drug Delivery: Journal of Pharmaceutical Science 85 (11): 1142-1169).

All the cyclodextrin derivatives tested here are obtainable from the company Fluka, Buchs, CH. The tests are carried out in 200 ml agitating flasks with 50 ml culture volume. As controls, flasks with adsorber resin Amberlite XAD-16 (Rohm & Haas, Frankfurt, Germany) and without any adsorber addition are used. After incubation for 5 days, the following epothilone titres can be determined by HPLC:

Table 2:

Addition	order No.	Conc [%w/v] [†]	Epo A [mg/l]	Epo B [mg/l]
Amberlite XAD-16 (v/v)		2.0 (%v/v)	9.2	3.8

- 55 -

Addition	order No.	Conc [%w/v] ¹	Epo A [mg/l]	Epo B [mg/l]
2-hydroxypropyl- β -cyclodextrin	56332	0.1	2.7	1.7
2-hydroxypropyl- β -cyclodextrin	"	0.5	4.7	3.3
2-hydroxypropyl- β -cyclodextrin	"	1.0	4.7	3.4
2-hydroxypropyl- β -cyclodextrin	"	2.0	4.7	4.1
2-hydroxypropyl- β -cyclodextrin	"	5.0	1.7	0.5
2-hydroxypropyl- α -cyclodextrin	56330	0.5	1.2	1.2
2-hydroxypropyl- α -cyclodextrin	"	1.0	1.2	1.2
2-hydroxypropyl- α -cyclodextrin	"	5.0	2.5	2.3
β -cyclodextrin	28707	0.1	1.6	1.3
β -cyclodextrin	"	0.5	3.6	2.5
β -cyclodextrin	"	1.0	4.8	3.7
β -cyclodextrin	"	2.0	4.8	2.9
β -cyclodextrin	"	5.0	1.1	0.4
methyl- β -cyclodextrin	66292	0.5	0.8	<0.3
methyl- β -cyclodextrin	"	1.0	<0.3	<0.3
methyl- β -cyclodextrin	"	2.0	<0.3	<0.3
2,6 di-o-methyl- β -cyclodextrin	39915	1.0	<0.3	<0.3
2-hydroxypropyl- γ -cyclodextrin	56334	0.1	0.3	<0.3
2-hydroxypropyl- γ -cyclodextrin	"	0.5	0.9	0.8
2-hydroxypropyl- γ -cyclodextrin	"	1.0	1.1	0.7
2-hydroxypropyl- γ -cyclodextrin	"	2.0	2.6	0.7
2-hydroxypropyl- γ -cyclodextrin	"	5.0	5.0	1.1
no addition			0.5	0.5

¹) Apart from Amberlite (%v/v), all percentages are by weight (%w/v).

Few of the cyclodextrins tested (2,6-di-o-methyl- β -cyclodextrin, methyl- β -cyclodextrin) display no effect or a negative effect on epothilone production at the concentrations used. 1-2% 2-hydroxy-propyl- β -cyclodextrin and β -cyclodextrin increase epothilone production in the examples by 6 to 8 times compared with production using no cyclodextrins.

C: 10 litre fermentation with 1% 2-(hydroxypropyl)- β -cyclodextrin):

Fermentation is carried out in a 15 litre glass fermenter. The medium contains 10 g/l of 2-(hydroxypropyl)- β -cyclodextrin from Wacker Chemie, Munich, Germany. The progress of fermentation is illustrated in Table 3. Fermentation is ended after 6 days and working up takes place.

Table 3: Progress of a 10 litre fermentation

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0.5	0.3
3	1.8	2.5
4	3.0	5.1
5	3.7	5.9
6	3.6	5.7

D: 100 litre fermentation with 1% 2-(hydroxypropyl)- β -cyclodextrin):

Fermentation is carried out in a 150 litre fermenter. The medium contains 10 g/l of 2-(Hydroxypropyl)- β -cyclodextrin. The progress of fermentation is illustrated in Table 4. The fermentation is harvested after 7 days and worked up.

Table 4: Progress of a 100 litre fermentation

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0.3	0

- 57 -

3	0.9	1.1
4	1.5	2.3
5	1.6	3.3
6	1.8	3.7
7	1.8	3.5

E: 500 litre fermentation with 1% 2-(hydroxypropyl)- β -cyclodextrin):

Fermentation is carried out in a 750 litre fermenter. The medium contains 10 g/l of 2-(Hydroxypropyl)- β -cyclodextrin. The progress of fermentation is illustrated in Table 5. The fermentation is harvested after 7 days and worked up.

Table 5: Progress of a 500 litre fermentation

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0	0
3	0.6	0.6
4	1.7	2.2
5	3.1	4.5
6	3.1	5.1

F: Comparison example 10 litre fermentation without adding an adsorber:

Fermentation is carried out in a 15 litre glass fermenter. The medium does not contain any cyclodextrin or other adsorber. The progress of fermentation is illustrated in Table 6. The fermentation is not harvested and worked up.

Table 6: Progress of a 10 litre fermentation without adsorber.

- 58 -

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0	0
3	0	0
4	0.7	0.7
5	0.7	1.0
6	0.8	1.3

G: Working up of the epothilones: Isolation from a 500 litre main culture:

The volume of harvest from the 500 litre main culture of example 2D is 450 litres and is separated using a Westfalia clarifying separator Type SA-20-06 (rpm = 6500) into the liquid phase (centrifugate + rinsing water = 650 litres) and solid phase (cells = ca. 15 kg). The main part of the epothilones are found in the centrifugate, The centrifuged cell pulp contains < 15% of the determined epothilone portion and is not further processed. The 650 litre centrifugate is then placed in a 4000 litre stirring vessel, mixed with 10 litres of Amberlite XAD-16 (centrifugate:resin volume = 65:1) and stirred. After a period of contact of ca. 2 hours, the resin is centrifuged away in a Heine overflow centrifuge (basket content 40 litres; rpm = 2800). The resin is discharged from the centrifuge and washed with 10-15 litres of deionised water. Desorption is effected by stirring the resin twice, each time in portions with 30 litres of isopropanol in 30 litre glass stirring vessels for 30 minutes. Separation of the isopropanol phase from the resin takes place using a suction filter. The isopropanol is then removed from the combined isopropanol phases by adding 15-20 litres of water in a vacuum-operated circulating evaporator (Schmid-Verdampfer) and the resulting water phase of ca. 10 litres is extracted 3x each time with 10 litres of ethyl acetate. Extraction is effected in 30 litre glass stirring vessels. The ethyl acetate extract is concentrated to 3-5 litres in a vacuum-operated circulating evaporator (Schmid-Verdampfer) and afterwards concentrated to dryness in a rotary evaporator (Büchi type) under vacuum. The result is an ethyl acetate extract of 50.2 g. The ethyl acetate extract is dissolved in

- 59 -

500 ml of methanol, the insoluble portions filtered off using a folded filter, and the solution added to a 10 kg Sephadex LH 20 column (Pharmacia, Uppsala, Sweden) (column diameter 20 cm, filling level ca. 1.2 m). Elution is effected with methanol as eluant. Epothilone A and B is present predominantly in fractions 21-23 (at a fraction size of 1 litre). These fractions are concentrated to dryness in a vacuum on a rotary evaporator (total weight 9.0 g). These Sephadex peak fractions (9.0 g) are thereafter dissolved in 92 ml of acetonitrile:water:methylene chloride = 50:40:2, the solution filtered through a folded filter and added to a RP column (equipment Prepbar 200, Merck; 2.0 kg LiChrospher RP-18 Merck, grain size 12 μ m, column diameter 10 cm, filling level 42 cm; Merck, Darmstadt, Germany). Elution is effected with acetonitrile:water = 3:7 (flow rate = 500 ml/min.; retention time of epothilone A = ca. 51-59 mins.; retention time of epothilone B = ca. 60-69 mins.). Fractionation is monitored with a UV detector at 250 nm. The fractions are concentrated to dryness under vacuum on a Büchi-Rotavapor rotary evaporator. The weight of the epothilone A peak fraction is 700 mg, and according to HPLC (external standard) it has a content of 75.1%. That of the epothilone B peak fraction is 1980 mg, and the content according to HPLC (external standard) is 86.6%. Finally, the epothilone A fraction (700 mg) is crystallised from 5 ml of ethyl acetate:toluene = 2:3, and yields 170 mg of epothilone A pure crystallisate [content according to HPLC (% of area) = 94.3%]. Crystallisation of the epothilone B fraction (1980 mg) is effected from 18 ml of methanol and yields 1440 mg of epothilone B pure crystallisate [content according to HPLC (% of area) = 99.2%]. m.p. (Epothilone B): e.g. 124-125 °C; ¹H-NMR data for Epothilone B: 500 MHz-NMR, solvent: DMSO-d₆. Chemical displacement δ in ppm relative to TMS. s = singlet; d = doublet; m = multiplet

δ (Multiplicity)	Integral (number of H)
7.34 (s)	1
6.50 (s)	1
5.28 (d)	1
5.08 (d)	1
4.46 (d)	1
4.08 (m)	1

- 60 -

3.47 (m)	1
3.11 (m)	1
2.83 (dd)	1
2.64 (s)	3
2.36 (m)	2
2.09 (s)	3
2.04 (m)	1
1.83 (m)	1
1.61 (m)	1
1.47 - 1.24 (m)	4
1.18 (s)	6
1.13 (m)	2
1.06 (d)	3
0.89 (d + s, overlapping)	6
	$\Sigma = 41$

Example 15: Medical Uses of Recombinantly Produced Epothilones

Pharmaceutical preparations or compositions comprising epothilones are used for example in the treatment of cancerous diseases, such as various human solid tumors. Such anticancer formulations comprise, for example, an active amount of an epothilone together with one or more organic or inorganic, liquid or solid, pharmaceutically suitable carrier materials. Such formulations are delivered, for example, enterally, nasally, rectally, orally, or parenterally, particularly intramuscularly or intravenously. The dosage of the active ingredient is dependent upon the weight, age, and physical and pharmacokinetical condition of the patient and is further dependent upon the method of delivery. Because epothilones mimic the biological effects of taxol, epothilones may be substituted for taxol in compositions and methods utilizing taxol in the treatment of cancer. *See*, for example, U.S.

Patent Nos. 5,496,804, 5,565,478, and 5,641,803, all of which are incorporated herein by reference.

For example, for treatments, epothilone B is supplied in individual 2 ml glass vials formulated as 1 mg/1 ml of clear, colorless intravenous concentrate. The substance is formulated in polyethylene glycol 300 (PEG 300) and diluted with 50 or 100 ml 0.9% Sodium Chloride Injection, USP, to achieve the desired final concentration of the drug for infusion. It is administered as a single 30-minute intravenous infusion every 21 days (treatment three-weekly) for six cycles, or as a single 30-minute intravenous infusion every 7 days (weekly treatment).

Preferably, for weekly treatment, the dose is between about 0.1 and about 6, preferably about 0.1 and about 5 mg/m², more preferably about 0.1 and about 3 mg/m², even more preferably 0.1 and 1.7 mg/m², most preferably about 0.3 and about 1 mg/m²; for three-weekly treatment (treatment every three weeks or every third week) the dose is between about 0.3 and about 18 mg/m², preferably about 0.3 and about 15 mg/m², more preferably about 0.3 and about 12 mg/m², even more preferably about 0.3 and about 7.5 mg/m², still more preferably about 0.3 and about 5 mg/m², most preferably about 1.0 and about 3.0 mg/m². This dose is preferably administered to the human by intravenous (i.v.) administration during 2 to 180 min, preferably 2 to 120 min, more preferably during about 5 to about 30 min, most preferably during about 10 to about 30 min, e.g. during about 30 min.

While the present invention has been described with reference to specific embodiments thereof, it will be appreciated that numerous variations, modifications, and embodiments are possible, and accordingly, all such variations, modifications and embodiments are to be regarded as being within the spirit and scope of the present invention.


**BUDAPEST TREATY N THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSE OF PATENT PROCEDURES**

INTERNATIONAL FORM

TO
Novartis AG
Novartis Corporation
Patent and Trademark Dept.
3054 Cornwallis Rd.
Research Triangle Park, NC 27709

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

**NAME AND ADDRESS
OF DEPOSITOR**

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> DH10B [pEP015]	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-30033
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by:	
<input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on June 11, 1998 (date of the original deposit) ¹	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I. above was received by this International Depositary Authority on _____ (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 7-21-98

¹ Where Rule 5.4(d) applies, such date is the date on which the status of international depositary authority was acquired.


BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORM

TO
Novartis AG
c/o Novartis Agricultural Biotechnology
Research, Inc.
Patent & Trademark Department
3054 Cornwallis Road
Research Triangle Park, NC 27709

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

NAME AND ADDRESS
OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: Escherichia coli DH10B [pEPO32]	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-30119
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by:	
<input type="checkbox"/> a scientific description	
<input checked="" type="checkbox"/> a proposed taxonomic designation	
(Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on April 16, 1999 (date of the original deposit) ¹	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I. above was received by this International Depositary Authority on _____ (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 5-24-99

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone.
2. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is isolated from a myxobacterium.
3. An isolated nucleic acid molecule according to claim 2, wherein said myxobacterium is *Sorangium cellulosum*.
4. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 1.
5. A recombinant vector comprising a chimeric gene according to claim 4.
6. A recombinant host cell comprising a chimeric gene according to claim 4.
7. The recombinant host cell of claim 6, which is a bacteria.
8. The recombinant host cell of claim 7, which is an Actinomycete.
9. The recombinant host cell of claim 8, which is *Streptomyces*.
10. A Bac clone comprising a nucleic acid molecule according to claim 1.
11. The Bac clone of claim 10, which is pEPO15.
12. An isolated nucleic acid molecule according to claim 1, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids

118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

13. An isolated nucleic acid molecule according to claim 12, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino

acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

14. An isolated nucleic acid molecule according to claim 12, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ

ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

15. A nucleic acid molecule according to claim 12, wherein said nucleotide sequence is selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID

NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

16. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 12.

17. A recombinant vector comprising a chimeric gene according to claim 16.

18. A recombinant host cell comprising a chimeric gene according to claim 16.

19. The recombinant host cell of claim 18, which is a bacteria.

20. The recombinant host cell of claim 19, which is an Actinomycete.

21. The recombinant host cell of claim 20, which is *Streptomyces*.

22. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID

NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

23. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 22.

24. A recombinant vector comprising a chimeric gene according to claim 23.

25. A recombinant host cell comprising a chimeric gene according to claim 23.

26. The recombinant host cell of claim 25, which is a bacteria.

27. The recombinant host cell of claim 26, which is an Actinomycete.

28. The recombinant host cell of claim 27, which is *Streptomyces*.

29. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one epothilone synthase domain.

30. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a β -ketoacyl-synthase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

31. An isolated nucleic acid molecule according to claim 30, wherein said β -ketoacyl-synthase domain comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

32. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

33. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

34. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

35. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a an acyltransferase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

36. An isolated nucleic acid molecule according to claim 35, wherein said acyltransferase domain comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

37. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

38. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

39. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

40. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is an enoyl reductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

41. An isolated nucleic acid molecule according to claim 40, wherein said enoyl reductase domain comprises an amino acid sequence selected from the group consisting

of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

42. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

43. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

44. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

45. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is an acyl carrier protein domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

46. An isolated nucleic acid molecule according to claim 45, wherein said acyl carrier protein domain comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID

NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

47. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

48. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

49. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

50. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a dehydratase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of:

amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

51. An isolated nucleic acid molecule according to claim 50, wherein said dehydratase domain comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

52. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

53. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

54. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

55. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a β -ketoreductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino

acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

56. An isolated nucleic acid molecule according to claim 55, wherein said β -ketoreductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

57. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

58. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

59. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID

NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

60. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a methyltransferase domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6.

61. An isolated nucleic acid molecule according to claim 60, wherein said methyltransferase domain comprises amino acids 2671-3045 of SEQ ID NO:6.

62. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence is substantially similar to nucleotides 51534-52657 of SEQ ID NO:1.

63. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of nucleotides 51534-52657 of SEQ ID NO:1.

64. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence is nucleotides 51534-52657 of SEQ ID NO:1.

65. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a thioesterase domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7.

66. An isolated nucleic acid molecule according to claim 65, wherein said thioesterase domain comprises amino acids 2165-2439 of SEQ ID NO:7.

67. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence is substantially similar to nucleotides 61427-62254 of SEQ ID NO:1.

68. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of nucleotides 61427-62254 of SEQ ID NO:1.

69. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence is nucleotides 61427-62254 of SEQ ID NO:1.

70. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a non-ribosomal peptide synthetase, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3.

71. An isolated nucleic acid molecule according to claim 70, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3.

72. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID

NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

73. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

74. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

75. A method for heterologous expression of epothilone in a recombinant host, comprising:

- (a) introducing a chimeric gene according to claim 4 into a host; and
- (b) growing the host in conditions that allow biosynthesis of epothilone in the host.

76. A method for producing epothilone, comprising:

- (a) expressing epothilone in a recombinant host by the method of claim 75; and
- (b) extracting epothilone from the recombinant host.

77. An isolated polypeptide comprising an amino acid sequence that consists of an epothilone synthase domain.

78. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a β -ketoacyl-synthase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

79. An isolated polypeptide according to claim 78, wherein said β -ketoacyl-synthase domain comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

80. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an acyltransferase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

81. An isolated polypeptide according to claim 80, wherein said acyltransferase domain comprises an amino acid sequence selected from the group consisting of: amino

acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

82. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an enoyl reductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

83. An isolated polypeptide according to claim 82, wherein said enoyl reductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

84. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an acyl carrier protein domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

85. An isolated polypeptide according to claim 84, wherein said acyl carrier protein domain comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

86. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a dehydratase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

87. An isolated polypeptide according to claim 86, wherein said dehydratase domain comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

88. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a β -ketoreductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

89. An isolated polypeptide according to claim 88, wherein said β -ketoreductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

90. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a methyltransferase domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6.

91. An isolated polypeptide according to claim 90, wherein said methyltransferase domain comprises amino acids 2671-3045 of SEQ ID NO:6.

92. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a thioesterase domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7.

93. An isolated polypeptide according to claim 77, wherein said thioesterase domain comprises amino acids 2165-2439 of SEQ ID NO:7.

- 1 -

SEQUENCE LISTING

<110> Novartis AG

<120> GENES FOR THE BIOSYNTHESIS OF EPOTHILONES

<130> 4-30582A

<140>

<141>

<160> 30

<170> PatentIn Ver. 2.0

<210> 1

<211> 68750

<212> DNA

<213> Sorangium cellulosum

<400> 1

```
aagcttcgct cgacgcccctc ttccgcccgc ccacctctgc ccgtgtgtctc gatgatggcc 60
acggcccgggc caccgagcgg catgtgtctcg ccgagggcgg cgggatcgag gacctccgcg 120
ccctccgaga gcacctccgc atccaggaag gggggccgctc ctttcactgc atgtgcctcg 180
gcgacctgac ggtggagctc ctccgcacac accagcccc cgcgtccatc agcttccacc 240
atgcccgcag cctgaggcac cccgactgga cctcggacgc gatgtctcgtc gacggccccg 300
cgctcgtccg gtggctcgcc gcgcgcggcg cgccgggtcc cctccgcgag tacgaagagg 360
agcgcgagcg agcccgaacc gcgcagggagg cgaggcgccct gtggctcgcg gccgcgcccgc 420
cctgcttcgc gcccgatctg ccccgcttcg aggcacgacgc caacgggctg ccgctcggcc 480
cgatgtcgcc tgaagtcgcc gaggccgagc ggcgcctccg cgcctcgtac gcgactcctg 540
agctcgcttg tgccgcgctg ctccgctggc tcgggacggg cgccgggtccc tggtcgggat 600
atcccgctta cgagatgctg ccagagaatc tgctcctcgg gtctggcctc ccgaccgcga 660
tcgcccgggc ctccgcgccc ggcacatcgg aggcgcctct ccgcggcgca gcgcggctgt 720
tcgctcctcg ggaggtcgta tcgagcaaga agagccagct cggcaacatc cccgaagccc 780
tgtgggagcg gctccggagc gcggcgaggg tgccgcgccc gcgcgcacag ccggcgccct 900
tcgagcgcgc cgaggcgatc gcggcgaggg tgccgcgccc gcgcgcacag ccggcgccct 960
tcgcgggcgg cgccggcctg gcgggtcgctg gggctctctc gagcgggccg ctctcggggc 1020
tcgtgaccga cggagacgca ttgtactccg gcgacggcaa cgacatcgtc atgttccaac 1080
ccggccggat ctccgcccgtc gtgtgtctcg ccggaaccga tcccctcttc gagctcgac 1140
cgccctcag ccagatgctc ttctgtcgcg acgccaacgc gggcaccatc tccaaggtcc 1200
tgacggaagg cagccccctc atcgtgatgg caagaaacca ggcgcgaccg atgagcctcg 1260
tccacgtctg cgggttcctg gcgtgggtca accaggccat ggtgcccgc cccgagcggg 1320
gcgcgcccct cgctgtccag cgctcgacca tcattggaatt cgagcaccac acgctcgtt 1380
gtctccacga gcccgccggc agcgttttct ccctcgcctg cgacgaggag cactctact 1440
gggtcgagct ttccggtggc cggtcgcgac tatggcgcca cccgcaccac cgccccggcg 1500
ccccgagccg cttcgcgtac ctccgcgagc accccattgc ggcgacctgg taccctcgc 1560
tcacctcaa tgcgaccac gtgtgtgggg ccgacctga tcgcaggggc atcttcgggg 1620
tcgacaagcg caccggcgta gagcccatcg tcctcgcgga gacgcgccat ccccgggcg 1680
acgtcgtgtc cgaggaccgg gacatcttcg cgtttaccgg acagcccgc tcccgcgact 1740
ggcacgtcga gcacatccgc tccggcgccct ccacgctcgt ggccgactac cagcgccagc 1800
tatgggaccg ccctgacatg gtgtcaatc ggcgcggcct cttcttcacg acgaacgacc 1860
gcacatcgtc gctcgcggcg agctgacatc gctcgacgcc gggccgctca tcgaggggcg 1920
ccggaccgag ctggcgaccc gccgctggcg ggccgcagct catgccgatt cgggtggcgac 1980
gtagacgctg cgccagaaac cctcgagagc ccccgagaac aggaagcccg cggatttgt 2040
catcacgata ccgatcagct cgcggcccg atcattgatc caggacgtcc cgaaccggc 2100
gtcccaccca tagcgcccg gcacctccga gaccgcgtcc ggcgcctgta ccacggccat 2160
cccataaccc cagccgtgctg tctcgaagaa gcccgggaaa aacgaggagc ccgcttctg 2220
ggccggcggt aggtgatcg ccgtcatctc gcgcaccgag gcggcgctca agagccggcg 2280
gccctcgtgc acaccggcgt tcgatgagc gcgcgcgaac agggagtagt cgtccaccgt 2340
cgacacgagc ccggcgggcg ccgaagggaa cgccggcggg ctggcatagg cgctctcggc 2400
cccgctcgca tccatgcgcy tcttctcccc cgtctgctcg tcgggtgaagt aaccgcagc 2460
cgcgaaaccga gcgagcttgt ccgcccggac gtgaaagtgc gtgtcccgca tcccagcg 2520
cgcgaggatg cgctcgcgca cgaacgcac gaagccctgg tcggccgcgc gccccacgag 2580
caccctctgc accaggctcc ccgtgtgtga catccactgc gccccggct gatgcagag 2640
cggcagcgtc ccgagccgac ggatccactc gtctggcccc tgccggcgta tcggcaccgg
```

- 2 -

ctgCGcgttg acgagccccga gctcgtcgat ggccccgttg atcgggcgacg atgCGtcgaa 2700
 cgagattccg aagccccatcg tgaacgtcat caggctcgcg accgtgatcg gccgctccgc 2760
 gggcaccgctc tcgctcgatcg gaccatcgat gcgCGccagc accttccggg tcgCGagctc 2820
 cggcaaccat cgtcgcgacgg gggagtcgag gtcgagcttg ccttccctcga cgagcatcat 2880
 caccgcccgtc gCGgtgaccg ccttcgtcat cgaggcgatc cggaagatcg tgtcccgcg 2940
 catggcgCG cgtcgcgcccga gctcgggtcac gccaccgCG tccacgtgca cgtcgtcgcc 3000
 gcgCGcgacc agccagaccg ctcccggcat ctgccccgc gccacctccg ccgCCatcac 3060
 ctCGcgcCG ggcgCCagcg cgcCGcccc cCGctcctgc cctggctgcc cctcctcctc 3120
 ggccccaccc aacCGgcacc cggCGccgc cactctccgag cgggggCGcc tgccccctgcc 3180
 ccttctcatg accgtcgatg cctctccgag cgggggCGcc tgccccctgcc gagagcactg 3240
 actgccccg cccgaaaaaa tcatcgggtgc cccgtcacga tcgCGcccg gcgtggctcc 3300
 gccCGcgCG cCGctcgggc gccCGcccc ggacgagcaa agctcgcCG cccCGctca 3360
 gcacgCGct tgccatgtc ggctcgacc cactcgacc agccaccac cctgatgcac 3420
 ggctcaccg agcgcgaggt cctgctctcg ctcgtcacc tcgCGctcat cctcgtgacc 3480
 gcgCGcgCG cCGggcgagct cgcCGcgCG ctcCGccagc cCGaggtgct cggggagctc 3540
 ttCGggCGc tcgtgctggg cccctcctgc gtcggcgCG tcgCGcccg gttccatcga 3600
 gccctcttcc aggagcCGg ggtcggggtc gtcgtctcgg gcactctcctg gatagcgCG 3660
 ctccctcctgc tgcgtgatgg gggcatcgag gtcgacgtgg gcactcctgc caaggaggcg 3720
 cgcCGcgCG cgtctcCGc gctcCGcgCG atcCGcccc cgtcCGcgCG gggcgCGcc 3780
 ttctcggCG tcgtgctcga tcggccccct cCGagcgCG tcttctcCG gatcgtgctc 3840
 tcggtgacg cggctcagcgt gatcCGgaag gtgctgatcg agcgcgagtc gatcgCGcc 3900
 agctatgCG aggtgacgct cgcCGcgCG gtggtcagcg aggtcgtgc ctcgggtgctc 3960
 gtcCGgatga cgtcgtcgag ctacggcgCG tcgccccgc tggcggtcgc cgggagcgCG 4020
 ctctggcga cgggattctt gctgttcatg gtgtccaaag gacaggtgct gctcgtcctc 4140
 gcgatgCG cgttggcCG gCGcagcCG cagcggtcCG gcctgcaccc gctgctcggc 4200
 gcttCGcCG tcggcggtgt gctcaacagc gctcctcga ccaaccgccc tctcctcga 4260
 ggCGtgCaga cgtcgtgCG gggcctcttc gCGctgtgt tctcgtcct cgcgggcatg 4320
 cgcgtcCagc tgtcCagct gCGcagcCG gCGcggtgg ggacggtcgc gttgctgctg 4380
 gcgaccgCG cggcgCGgaa ggtcgtcccc gCGcggtcCG gcCGcgCG cggcgggctc 4440
 agggcgagCG agggcgCGct cgtggcggtg ggctgaaca tgaaggcgCG caccgacctc 4500
 atcgtcCga tcgtcCGcgt cgaagtcCG cctctctcca acgaggtcta tacgatgtac 4560
 gccgtcgtc cgtggtcac ggtgacgCG tcacccgCG tctcatctg gctcagagaa 4620
 agggcgctc cGacgagga gtagtcggct cgcctcagc gcgagggagc cgcgagcgCG 4680
 gcgtacatc cgggggtcga gCGgactc gtcCGatcg tggcgCacgc cctgccccgg 4740
 ttCGccacg acatcgtgga gagcatcgt gccctcaagc gaaagctcgg cgagacggtc 4800
 gacatcacg agctctcgt ggagcagcag gcgccccg catcgcgCG cgcgggggag 4860
 gcgagcCG ggctcCGag gctcggcgCG cgcctcCG cggcatctg cgggcaaaag 4920
 cgcgagctgc gCGctcgt cagggcgatc ctgCGcgct cgcgggatca cgtctgctc 4980
 gtgatcCG cgcgatcCG ggcgCGcgCG cgcggaatgt cgttcggtc cctgcaggac 5040
 gcgatcgtc agcgggCGga gtccaacgt ctcgtcgtg tggcgCaccc tccggcgCG 5100
 gagcCGct cCGcgCGg gatcctcgt cCGatcatc gcctcagta ctcttCGc 5160
 gccCGcga cgtgCGcct cgtggcgCG gcgtgggag cCGagctcgt gctcgtcagc 5220
 agcCGcaga cCGatccgg cgcggtcgt tggcgCgac gcgagccatc cCGgtgCGc 5280
 gcggtgCG cggagcgtcgt cGacgagcg gcttctcggg ggcgCGgct cggcgtgCGc 5340
 gtctcgtCG gcgtgcacgt gggcgCGc cCGagcag agataacCG gtagctcCGc 5400
 cgcCGccgt acgatctgt cgtgctcGga tgctacgacc atggggcgt cggcCGctc 5460
 tacctcggca gcacggtcga gtcggtggt gtcCGgagc ggggtgCGgt cgcgttgc 5520
 gtcCGcgtg gagggactc agagcaggt aggtgaggt tccaccgCG tcgccccgta 5580
 ggaagcagc gcccggtct gccgacgac gtcactccc gtcgtgtag gcgatcgtc 5640
 tgagcagCG gttctccg gccagcaggt tgacgCaggt cGagccggg atgctgCag acgatgggg 5700
 cgtccgattc gatcacgct gcatagtcCG tatcgcgCG gatcggctc ggttcggta 5760
 gatcgttgaa cCGacgctg cgggtgCG cgtcggaa ggtcaccCG taaggcccg 5820
 cggggtcCG gtcgtgaag taaacggtg tggcgacct cCGtcccg tccgacgat 5880
 tcaacagga ggcgtctca tggctcgtc tctcgggtc aggtcgtt cctccgctg 5940
 ggatgtagc ctctgCgatt gcacagcCG tccgccccat cggcttgtc atgtgtcctc 6000
 cctcctggt cctcttggc agcctccctc tgtgtcCag gagcgtggc ctcttCGctc 6060
 gagcCGctc gggatccatg gctgaggat ctcgCGagc gctcctcgc gaccgCGcg 6120
 ccgagcCG acgggcttg aaagcCGc accggcagc cggagcCG gcccgagag 6180
 gacagtgggt cCGcgtgaa gcagagagg gatcaggtg gtgagatgaa acacgtcGac 6240
 acgggCGgac gattcggCG cgggatagg caccagctc gcttctcgc gagcatggc 6300
 ctCGcCGgt cgggCGgtc gagcgaGaa accgtgCag gcacgCGgt cgcgccccg 6360
 gccgatgCG gcgtcaccg cGacgtcGac cccgacCG cGaccacCG gctggcCGt 6420
 gacgtcgtc acctctcCG gcccgagCG ctcgagggc gacgagcG gttcgtcgtc 6480
 tggcagcgtc cGagccccga gtcCGcgtg cGacgggtc gagtgtcga ctacaatgct 6540

gacagccgaa gaggcaagct ggccgagacg accgtgccgt atgccaactt cgaagtgttc 6600
atcacccgag agaagcagag cagccctcag tcgccatcgt ctgccgccgt catcggggccg 6660
acgtctgtcg ggtgacatcg cgctatcagc agcgtgagc ccgccagcag gccccaggcg 6720
cctgcctcga tggccttccc catcacccct gcgcactcct ccagcgacgg ccgcgcagcg 6780
acggccgcgt ccaagcaacc gccgtgccgg cgccgctcca cgcgcgcgac aggcgagcgt 6840
cttggcgcg cctgcgcac gctggaagga tcggcgaggc atggatagag aatcagggat 6900
cgcgatcttt gttgccatcg cagccaacgt ggcgatcgcg gcggtcaagt tcacgcgccg 6960
cgccgtgacc ggcagctcgg cgaaggcgtt gccgacttcg gcggcgctccc gcgcgtgtcg 7020
ctctacgaca acctcaagag cgccgtcgtc gagcgccacg gcgacgcgat ccggttccac 7080
cccacgctgc tggctctgtc ggccattac cgcttcgagc cgcgccccgt cgccgtcgcc 7140
cgccgcaacg agaagggccg cgtccagcgc gccatcacgg cgtggagcag atggcgcgga 7200
aacgtcgtcg taaccgccc gcaatgtcat gggaatggcc ccttgaaatg gccctttag 7260
ggggctggcc ggggtcgacg atatcgcg atctccccgt caattcccga tggtaaaaga 7320
aaaatttgtc atagatcgta agctgtgata gtggtctgtc ttacgttgcg tcttccgcac 7380
ctcagcgagc ttctctcgga taactttcaa ttttcccgag gggggccttg tctctggttc 7440
ctcaggaagc ctgatcggga cgagctaatt cccatccatt tttttagagg tctgctcaa 7500
gggattagat cgagtgcgac agttcttttg cagtgcgcga agaaccctgg cctcgaccgg 7560
aggacgatcg acgtccgcga gcgggtcagc cgctgaggat gtgcccgtcg tggcgagtcg 7620
tcccacgcag cgcgacgcgg aagatccgat tgcgatcgtc ggagcgagtt gccgtctgcc 7680
cgggtggcgt atcgatctga gcgggttctg gacgctcctc gagggtcgc gcgacaccgt 7740
cgggcgagtc cccgccgaac gctgggatgc agcagcgtag ttgatccc accccgatgc 7800
cccggggaag acgcccgtta cgcgcgcac tttcttgagc gacgtagcct gcttcgacgc 7860
ctccttcttc ggcacgtcgc ctgcggaagc gctgcggatg gaccctgcac atcgactctt 7920
gctggaggtg tgcgtggagg cgctggagaa cgcgcgcgac gctccatcgg cgctcgtcgg 7980
tacggaacg ggagtgttca tcgggatcgg cccgtccgaa tatgagggcg cgctgcccga 8040
agcgacggcg tccgcagaga tcgacgctca tggcgggctg gggacgatgc ccagcgtcgg 8100
agcggggcga atctcgtatg cctcggggct gcgagggccg tgtgtcggcg tggatacggc 8160
ctattcgttc tcgctggttg ccgttcatct ggctgtcag agcttgcgt ccggggaatg 8220
ctccacggcc ctggctggtg gggatcgtc gatgtgtcgc ccgagcacc tcgtgtggct 8280
ctcgaagacc cggcgctggt ccaggagcgg tcgctgcaag gcattttcgg cggagggcga 8340
tgggttcgga cgaggcgaa ggtgcgccgt cgtggtcctc aagcggtcga gtggagccc 8400
cgcgacggcg gatcgatat tggcggtgat tcgaggtacc gcgatcaatc acgaggtgc 8460
gagcagcggt ctgaccgtgc cgaacgggag cttccaaaga atcgtgctga aacggggcct 8520
ggcggaacga ggctgcgcgg cgtcttcggg gggttatgtc gaggcacacg gcacgggcac 8580
gacgcttggg gaccccatcg aaatccaagc tctgaatgcg gtatacggcc tcgggcgaga 8640
tgtcggcaac cgctgctga tcgggtcggg gaagaccaac cttggccatc ctgagtatgc 8700
gtcggggatc actgggctgc tgaaggctcg cttgtccctt cagcacgggc agattcctgc 8760
gcacctccac gcgcaggcgc tgaacccccg gatctcatgg ggtgatcttc ggctgaccgt 8820
cacgcgcgcc cggacaccgt ggccggactg gaatacgcgg cgacgggcgg ggtgagctc 8880
gttcggcatg agcgggacca acgcgcacgt ggtgctggaa gaggcgcgg cggcgacgtg 8940
cacaccgccg gcgcgggagc gaccggcaga gctgctggtg ctgtcggcaa ggaccgcgtc 9000
agccctggat gcacaggcgg cgccgctgcg cgaccatctg gagacctacc cttcgcagt 9060
tctgggcgat gtggcgttca gtctggcgac gacgcgcagc gcgatggagc accgctcgc 9120
ggtggcgcg acgtcgaggg aggggctgcg ggcagccctg gacgctgcgg cgcagggaca 9180
gacgtcgccc ggtgcggtgc gcagtatcgc cgattcctca cgcggcaagc tcgctttct 9240
cttcaccgga cagggggcgc agacgctggg catgggcccgt gggctgtacg atgtatggtc 9300
cgcttccgc gaggcgttcg acctgtgcgt gaggctgttc aaccaggagc tcgaccggcc 9360
gctccgcgag gtgatgtggg ccgaaccggc cagcgtcgac gccgcgctgc tcgaccagac 9420
agccttcacc cagccggcgc tggttacctt cgaatatgcy ctcgcccgcg tgtggcggtc 9480
gtggggtgta gagccggagt tggtcgcccg ccatagcacg ggtgagctgg tggctgctc 9540
cgtggcgggc gtgttctcgc ttgaggacgc ggtgttccct gttggtgcgc gcgggcgcct 9600
gatgcaggcg ctgcccggcg gcggggcgat ggtgtcgatc gaggcgcgg aggcgatgt 9660
ggctgctgcy gtggcgccgc acgcagcgtc ggtgtcgatc gccgcggtca acgctccgga 9720
ccaggtggtc atcgcgggcg ccgggcaacc cgtgcatgcy atcgcgcg cgatggccgc 9780
gcgcggggcg cgaaccaagg cgtcccacgt ctcgcatgcy ttcactcac cgctcatggc 9840
cccgatgctg gaggcgttcg ggcgtgtggc cgagtcgggt agctaccggc ggccgtcgat 9900
cgtcctggtc agcaatctga gcgggaaggc ttgcacagac gaggtgagct cgcggggcta 9960
ttgggtgccc cacgcgcgag aggtggtgcy cttcgcggtt ggagtgaagg cgctgacgc 10020
ggccggtgcy ggcaccttcg tcgaggtcgg tccgaaatcg acgctgctcg gcctggtgcc 10080
tgctgcacg ccggacgccc ggccggcgct gctcgcacgc tcgcgcgctg ggcgtgacga 10140
gccggcgacc gtgctcgagg cgctcgggcg gctctggggc gtcgggtggc tggctcctc 10200
ggccggccct tccccctcag gggggcgggc ggtgcccgtc cccacgtacc cttggcagc 10260
cgagcgctac tggatcgaca cgaagcgga cgacgcggcg cgtggcgacc gccgtgctc 10320
gggagcgggc cagcagcagg tcgaggaggg gggcgcggtg cgcggcgggc accggcgag 10380
cgctcggtcc gaccatccgc cgcccagag cggacgcccg gagaaggctg aggcggcccg 10440

cgaccgtccg ttccggctcg agatcgatga gccaggcgtg cttgatcacc tcgtgcttcg 10500
 gggtcacggag cggcgcgccc ctggctctggg cgagggtcgag atcgccgtcg acgcgggcggg 10560
 gctcagcttc aatgatgtcc agctcgcgct gggcatgggtg cccgacgacc tgcggggaaa 10620
 gcccacacct ccgctgctgc tcggaggcga gtgcgcccggg cgcacgcctg ccgtgggcga 10680
 gggcgtgaac ggctcgtgg tggccaacc ggctcatcgcc ctttcggcgg gagcgtttgc 10740
 taccacgctc accacgtcgg ctgctgtggt gctgcctcgg cctcaggcgc tctcggcgat 10800
 cgaggcggcc gccatgcccg tcgctgacct gacggcatgg tacgcgctcg acagaatagc 10860
 ccgccttcag ccgggggagc ggggtgctgat ccattgcggcg accggcgggg tcggtctcgc 10920
 cgcggtgtag tggcgcgagc acgtgggagc cgagggtccat gcgacggccg gcacgcccga 10980
 gaaacgcgcc tacctggagt cgctgggctg gcggtatgtg agcgattccc gctcggaccg 11040
 gttcgtcgcc gacgtgcgcg cgtggacggg cgggcaggga gtagacgtcg tgctcaactc 11100
 gctctcgggc gagctgatcg acaagagttt caatctctcg cgatcgacg gccggtttgt 11160
 ggagctcggc aagcgcgact gttacgcgga taaccagctc gggctgcggc cgttctctgcg 11220
 caatctctcc ttctcgtcgg tggatctccg ggggatgatg ctcgagcggc cggcgcggtg 11280
 ccgtgcgctc ttggaggagc tcctcggcct gatcgcgga ggcgtgttca cccctcccc 11340
 catcgcgacg ctcggatcg cccgtgctgc cgatgcgttc cggagcatgg cgcaggcgca 11400
 gcatcttggg aagctcgtac tcacgctggg tgaccggag gtccagatcc gtattccaac 11460
 ccacgcaggc gccggcccgt ccaccgggga tcgggacctg ctcgacaggg tcgctcagc 11520
 tgccgcccgg gccgcgcggg cggcgctgga ggcgttctc cgtacgcagg tctcgcagg 11580
 gctgcgcacg cccgaaatca aggtcggcgc ggaggcgtg ttcaccgcgc tcggcatgga 11640
 ctcgctcatg gccgtggagc tgcgcaatcg tatcgaggcg agcctcaagc tgaagctgtc 11700
 gacgacgttc ctgtccacgt cccccaatat cgcttctgtg gcccaaaacc tgttggtatg 11760
 tctcggcaca gctctctcct tggagcgggt ggcggcggag aacctacggg caggcgtgca 11820
 aaacgacttc gtctcatcgg gcgcagatca agactgggaa atcattgccc tatgacgatc 11880
 aatcagcttc tgaacgagct cgagcaccag ggtatcaagc tggcgggcga tggggagcgc 11940
 ctccagatac agggcccccga gaacgcctcg aaccggaacc tgcctgctcg aatctccgag 12000
 cacaanaagc cgatcctgac gatgctccgt cagagactcc ccgcagaatc catcgtgccc 12060
 gccccagccg agcggcacgc tcggtttcct ctacagaca tccaagaatc ctactggctg 12120
 gggcggacag gagcgtttac ggtcccccagc gggatccacg cctatcgcg atacgactgt 12180
 acggtctcgg acgtgcccag gctgagccgc gcctttcggg aagtcgtcgc gcggcacgac 12240
 atgcttcggg cccacacgct gcccgacatg atgcagggtg tcgagcctaa agtcgacgac 12300
 gacatcgaga tcatcgatcc gcgcgggctc gaccggagca cacgggaagc gaggctcgtg 12360
 tcgttcggag atgcgatgtc gcaccgcatc tatgacaccg agcgcctccg gctctatcac 12420
 gtcgtcggcg ttccggctgga cgagcggcaa acccgctctg tgctcagtat cgtatctcatt 12480
 aacgttgacc taggcagcct cctcatcatc ttcaaggact ggctcagctt ctacgaagat 12540
 cccgagacct ctctccctgt cctggagctc tcgtaccgcg attatgtact cgcgctggag 12600
 tctcgaaga agtctgaggc gcatacaaga tcgatggatt actggaagcg gcgcatcgcc 12660
 gagctccac ctccgcccag gcttccgatg aaggccgatc catctaccct gaaggagatc 12720
 cgcttccggc acacggagca atggctgccc tcggaactct ggggtcgatt gaagcggcgt 12780
 gtcggggagc gcgggctgac cccgacgggc gtcattcttg ctgcattttc cgagggtgac 12840
 gggcgctgga gcgcgagccc ccggtttacg ctcaacataa cgctcttcaa ccggctcccc 12900
 gtccatccgc gcgtgaacga tatcaccggg gacttcacgt cgatggctct cctggacatc 12960
 gacacacctc gcgacaagag cttcgaacag cgcgctaagc gtattcaaga gcagctgtgg 13020
 gaagcgatgg atcactgcga cgtaagcggg atcgaggtcc agcgagaggc cggccgggtc 13080
 ctggggatcc aacgaggcgc attgttcccc gtgggtgctc cgagcgcgct taaccagcaa 13140
 gtcgttggtg tcacctcgtt gcagaggctc ggaactccgg tgtacaccag cacgcagact 13200
 cctcagctgc tgctggatca tcagctctac gagcacgatg gggacctcgt cctcgcgtgg 13260
 gacatcgctc acggagtgtt cccgcccagc cttctggagc acatgctcga agcgtacgtc 13320
 gtttttctcc ggcggtcac tgaggaaacca tgggggtaac aggtgctcgt ttcgcttccg 13380
 cctgcccagc tagaagcgcg ggcgagcgca aacgcgacca acgctgctg gagcgagcat 13440
 acgctgcacg gcctgttcgc ggcgcgggtc gagcagctgc ccatgcagct cgcctggtg 13500
 tcggcgcgca agacgctcac gtacgaagag ctttcgcgcc gttcgcggcg acttggcgcg 13560
 cggctgcgcg agcagggggc acgcccgaac acattggtcg cgggtggtgat ggagaaaggc 13620
 tgggagcagg ttgtcgcggt tctcgcggtg ctcgagtcag gcgcggccta cgtgccgatc 13680
 gatgccgacc taccggcgga gcgtatccac tacctcctcg atcatggtga ggtaaagctc 13740
 gtgctgacgc agccatggct ggatggcaaa ctgtcatggc cgccggggat ccagcggctg 13800
 ctgctgagcg agggcggcgt cgaaggcgac ggcgaccagc ctccgatgat gccattcag 13860
 acaccttcgg atctcgcgta tgtcatctac acctcgggat ccacagggtt gcccaggggg 13920
 gtgatgatcg atcatcgggg tgcgctcaac accatcctgg acatcaacga gcgcttcgaa 13980
 atagggcccg gagacagggt gctggcgctc tcctcgtgta gcttcgatct ctcggtctat 14040
 gatgtgttcg ggatcctggc ggcgggcggt acgatcgtgg tgccggacgc gtcgaagctc 14100
 cgcgatccgg cgcattgggc agagtgtgac gaacgagaga aggtgacggt gtggaactcg 14160
 gtgcccggcg tgatgcggat gctcgtcgag cattttgagg gtcgccccga ttcgctcgtc 14220
 aggtctctgc ggcttctcgt gctgagcggc gactggatcc cgggtggcct gcctggcgag 14280
 ctccaggcca tcaggcccgg cgtgctgggtg atcagcctgg gcggggccac cgaagcgtcg 14340

atctgggtcca tcgggtaccc cgtgaggaac gtgcacctat cgtgggagag catccctac 14400
 ggccgtccgc tgcgcaacca gacgttccac gtgctcgatg aggcgctcga accgcgccc 14460
 gtctgggttc cggggcaact ctacattggc ggggtcgggc tggcactggg ctactggcgc 14520
 gatgaagaga agacgcgcaa gagcttcctc gtgcacccc agaccgggga gcgcctctac 14580
 aagaccggcg atctggggccg ctacctggcc gatggaaaca tcgagttcat ggggcgtgag 14640
 gacaaccaaa tcaagcttcg cggataccgc gttgagctcg gggaaatcga ggaacgctc 14700
 aagtcgcac cgaacgtacg cgacgcggcg attgtgccc tcgggaacga cgcggcgaac 14760
 aagctccttc tagcctatgt ggtcccggag ggcacacgga gacgcgctgc cgagcaggac 14820
 gcgagcctca agaccgagcg gacgcgacg agagcacacg ccgccgaagc ggacggcttg 14880
 agcgacggcg agagggtgca gttcaagctc gctcgacacg gactccggag ggacctggac 14940
 ggaaagcccg tcgtcgatct gaccggcgag gatccgcggg agggggggct ggacgtctac 15000
 gcgcgtcgcc gtagcgtccg aacgttcctt gaggccccga ttccgtttgt tgagtttgg 15060
 cgattcctga gctgcttgag cagcgtggag ccgcagcgcg cgaccttcc caaattccgt 15120
 tatccatcgg cgggcagcac gtacccggcg caaacctacg cgtatgtcaa atccggccgc 15180
 atcgaggggc tggacgaggg ctctattat taccacccgt tcgagcaccg ttgtctgaag 15240
 ctctccgac acgggatcga gcgcggagcg cacgttcggc aaaacttcga cgtgttcgat 15300
 gaagcggcgt tcaacctcct gttcgtggcg aggatcgacg ccatcgagtc gctgtatgga 15360
 tcgtcgtcgc gagaattttg cctgctggag gccgatatata tggcgagct cctgatggag 15420
 caggcgccct cctgcaacat cggcgtctgt ccggtggggc aattcaattt tgaacaggtt 15480
 cggccgggtc tcgacctgcg acattcggac gtttacgtgc acggcatgct gggcgggcg 15540
 gtagaccgcg ggcagttcca ggtctgtacg ctccgtcagg attcctcacc gaggcgccgc 15600
 acgacgcgcg gcgcccctcc cggccgcgag cagcacttcg ccgatatgct tcgcgacctc 15660
 ttgaggacca aactaccgca gtacatggtg cctacagctt tcgtggagct cgatgcgct 15720
 ccgctgacgt ccaacggcaa ggtcgatcgt aagccctgc gcgagcgga ggatacctc 15780
 tcgcccggcg attcggggca cacggcgcca cgggagcct tggaggagat cctcgtcgc 15840
 gtcgtacggg aggtgctcgg gctggagggtg gtcgggctcc agcagagctt cgtcgatct 15900
 ggtgcgacat cgattcacat cgttcgcatg aggagcctgt tgcagaagag gctggatagg 15960
 gagatcgcca tcaccgagtt gttccagtag ccgaacctcg gctcgctggc gtcgggttg 16020
 cgccgagact cgagagatct agatcagcgg ccgaacatgc aggaccgagt ggaggttcg 16080
 ccgaaggcca ggagacgtag ctaagagcgc cgaacaaaac caggccgagc gggccgatga 16140
 gccgcaagcc gcgctgcgtc acctgggac tcactgacg cgtcgaggaa cgggtgagctc atggaagaac 16200
 ggggtgctgc gctgagccgt gttgttcgaa cgctgaggaa cgggtgagctc atggaagaac 16260
 aagagtcctc cgctatcgca gtcacggca tgtcggggcg ttttccgggg gcgcgggatc 16320
 tggacgaatt ctggaggaaac ctccgagacg gcacggaggc cgtgcagcgc ttctccgagc 16380
 aggagctcgc ggcgtccgga gtcgaccccg cgctgggtgt ggacctgagc tacgctcggg 16440
 cgggcagcgt gctggaagac gtcgaccggt tcgacgctgc tttcttcggc atcagccgc 16500
 gcgaggcaga gctcatggat ccgcagcacc ggatcttcat ggaatgcgcc tgggaggcgc 16560
 tggagaacgc cggatacgac ccgacggctt acgagggctc tatcggcgtg tacgcccggc 16620
 ccaacatgag ctctacttg acgtcgaaac tccacgagca ccagcgatg atgcgggtgc 16680
 ccggctggtt tcagacgttg atcggaacg acaaggatta cctcgcgacc cagctctcct 16740
 acaggctgaa tctgagaggg ccgagcatct ccgttcaaac tgcctgctcc acctcgctcg 16800
 tggcgggtca ctggcgctgc atgagcctcc tggaccgca gtgcgacatg gcgctggccg 16860
 gcgggattac cgtccggatc cccatcgag ccggctatgt atatgctgag gggggcatct 16920
 tctctcccga cggccattgc cgggccttcg acgccaaggc gaacggcacg atcatgggca 16980
 acggctgcgg cgttgctcctc ctgaagccgc tggaccgggc gctctccgat ggtgatcccg 17040
 tccgcgcggg tatccttggg tctgccacaa acaacgacg agcgaggaa atcgggttca 17100
 ctgcgcccag tgagggtggc caggcgcaag cgatcatgga ggcgctggcg ctggcaggg 17160
 tcgaggcccg gtccatccaa tacatcgaga ccacggggac cggcacgctg ctccgagacg 17220
 ccacgagac ggcggcgctg cggcggtgt tcggtcgca cgttcggcc cggaggtctt 17280
 gcgcgatcgg ctccgtgaag accggcatcg gacacctga atcgccggct ggcatcgccg 17340
 gtttgatcaa gacggctctg gcgctggagc accggcagct gccgcccagc ctgaacttcg 17400
 agtctcctaa cccatcgatc gatttcgcga gcagcccggt ctacgtcaat acctctctta 17460
 aggattgaa taccggctcg actccgcggc gggccggcgt cagctcgttc gggatcggcg 17520
 gcaccaacgc ccatgtcgtg ctggaggaag gcgccggcg gaagcttcca gcccgggcg 17580
 cgccgcgctc tgccgagctc ttctcgtctc cggccaagag cgcagcgggc ctggatgccc 17640
 cggcgccacg gctacgagat catctgcagg cgcaccaggg gatttcgttg ggcgacgctg 17700
 ccttcagcct ggcgacgacg cgcagcccca tggagcaccg gctcgcgatg ccggcgccgt 17760
 ccgcgagggc gttgcgagag gggctcgacg cagcgcgcg aggcagacc cgcggggcg 17820
 ccgtgcgtgg ccgctgctcc cagggcaacg tgccgaaggt ggtcttcgtc tttcccgcc 17880
 agggctctca gtgggtcggc atgggcccgc agctcctggc tgaggaaacc gtcttccacg 17940
 cggcgctttc ggcgtgcgac cgggcatcc aggcgaagc tgggtggctg ctgctcgccg 18000
 agctcggccg cgacgaaggg tctccacgag tcgagcgcat cgacgtggtg cagccggtg 18060
 tgttcgccc cgcgggtggca tttggggcg tgtggcggtc gtgggggtgc gcgcccagc 18120
 tcgtgatcgg ccacagcatg ggcgaggtag ccgcgcgcga tgtggccggg gcgctgtcgc 18180
 tcgaggatgc ggtggcgatc atctgcggc gcagccggct gctccggcg atcagcggtc 18240

```

agggcgagat gggcgtgacc gagctgtcgc tggccgagggc cgaggcggcg ctccgaggct 18300
acgaggatcg ggtgagcgtg gccgtgagca acagcccgcg ctcgacgggt ctctcggggc 18360
agccggcagc gatcggcgag gtgctgtcgt ccctgaacgc gaagggggtg ttctgcgcgc 18420
gggtgaaggt ggtatgtcgcc agccacagcc cgcaggtcga cccgctgcgc gaggacctct 18480
tggcagccct gggcggggcgc cggccgggtg cggctgcggg gccgatgcgc tcgacggtga 18540
cgggcggcat ggtagcgggc cggagctcgc gagcgaatta ctggatgaac aacctcaggc 18600
agccagtgcg ctctgcgcgag gtatccagg cgcagctcca aggcggccac ggtctgttcg 18660
tggagatgag cccgcacccg atcctaacga cttcggctga ggagatgcgg cgcgcggccc 18720
agcgggcggg cgcagcgggt ggctcgcctg ggcgggggga ggacgagcgc ccggcgatgc 18780
tggagcgcgt gggcacgctg tggcgcagg gctacctgt accctggggg cggctgttcc 18840
ccgcgggggg gggcgggta ccgctgccga cctatccctg gcagcgcgag cggctactga 18900
tcgaagcgcc ggccaagagc gccgcggggc atcgccggcg cgtgcgtgcg ggcggtcacc 18960
cgctccctcg tgaatgcag accctgtcaa cccagacgag cagcgggctg tgggagacga 19020
cgctggatct caagcggctg ccgtggctcg gcgaccaccg ggtgcaggga gcggtcgtgt 19080
ttccgggcgc gccgtacctg gagatggcga ttctgcgcgg ggcggaggct ttggggcgatg 19140
gcccccttga gataactgac gtggtgtcgc ccgagcgcgt ggccttcgcg ggcgacgcgg 19200
cgggtgttgt ccaggtgtgt acgacggagc agccgtcggg gcggctgcag ttccagatcg 19260
cgagccgggc gccggggcgt ggccacgcgt ccttccgggt ccacgctcgc ggcgcgttgc 19320
tcagagtggg gcgcaccgag gtcccggctg ggcttacgt ttccgctgtg cgcgcgcggc 19380
tccaggccag cataccgcc ggcgccacct acgcggagct gaccgagatg gggctgcagt 19440
acggccctgc cttccagggg attgctgagc tatggcgggg tgaaggcgag gcgctgggac 19500
gggtacgcct gcccgacgcg gccggctcgg cagcggagta tcgggttgcg cctgcgctgc 19560
tggacgcgtg cttccagatc gtccggcagc tcttcgcccc cagtggcgag gcgacgcctg 19620
gggtgcctcg ggagtgtggc tcgctgcggc tcttgacgcg gccttcgggg gactgtggtg 19680
gccatgcgcg cgtcgtgaac catgggcacc aaacccccga tcggcagggg gccgactttt 19740
gggtgtgtcga cagctcgggt gcagtgtcgc ccgaagtgtg cgggctcgtg gcgcagcgcc 19800
ttccgggagg ggtgcgcggc cgcaagaag acgattggtt cctggagctc gactgggaac 19860
ccgcagcggt cggcacagcc aaggtcaac cgggcgggtg gctgctcctc ggcggcgccg 19920
gtgggctcgg cgcgcgcttgc cgcgcgatgc tggaggccgg cggccatgcc gtcgtgcgat 19980
cggcagagaa caacacgagc gctgcgcggc tacgcgcgct cctggcaaa gcttttgacg 20040
gccaggctcc gacggcgggt gtgcacctgc gcagcctcga tgggggtggc gactcgcacc 20100
cagggtcctg ggcgcaaggc gcatggagc gcgccggag cgcgcgacgt agtcccgatg 20160
ccctcgatcc ggcgctggta cgtggctgcg acagcgtgct ctggaccgtg caggccctgg 20220
ccggcatggg ctttcgagac gccccgcgat tgtggctttt gacccgcggc gcacaggccg 20280
tcggcgccgg cgacgtctcc gtgacacagg caccgctgct ggggctgggc cgcgtcatcg 20340
ccatggagca cgcggatctg cgtgcgctc gggctgacct cgatccagcc cggcccagg 20400
gggagctcgc tgcctcgtgc gccgagctgc tggccgacga cgcgaagcg gaagtgcgct 20460
tggcgggtgg cgagcgtatg gtccgctcga tcgtccgcgc gcagcccag accggggccc 20520
ggggggaggat cgagagctgc gttccgacc acgtcaccat ccgcgcggac agcacttacc 20580
ttgtgaccgg cggctcgggt gggctcggtc tgagcgtggc cggatggctg gccgagcgcg 20640
gcgctgggtc cctgggtcgt gtgggcccgt ccggcgcggc gagcgtggag caacgggacg 20700
ccgtcgcggc gctcagggc cgcggcgcgc gcgtcacctg ggcgaaggcg gatgtcggc 20760
atccggcgca gctcagcgg atcctccgc aggttaccac gtcggggatg ccgctgcggg 20820
gcgtcgtcca tgcggccggc atcttgagc acgggctgct gatgcagcag actccgcgcg 20880
ggtttcgtaa ggtgatggcg cccaaggctc agggggcctt gcacctgcac gcgttgacgc 20940
cggaagcgcc gctttccttc ttcgtgctgt acgcttcggg agtagggctc ttgggctcgc 21000
cgggccaggg caactacgcc gcggccaaca cgttcctcga cgctctggcg caccaccgga 21060
gggcgcaggg gctgccagcg ttgagcgtgc actggggcct gttcgcggag gtgggcatgg 21120
cggccgcgca ggaagatcgc ggcgcgcggc tggctctccc cggaatgcgg agcctcacc 21180
ccgacgaggg gctgtccgct ctggcacggc tgctcgaagg cggccgcgct cagggtgggg 21240
tgatgcgggt gaacccgcgg ctgtgggtgg agctctaccc cgcggcggcg tcttcgcgaa 21300
tgttgtcgc cctgggtgac gcgcacgcgc cgagcgcggc cgggccagcc ggggacgggg 21360
acctgtctcg ccgcctcgcg gctgccgagc cgagcgcgcg gagcgcgctc ctggagcccg 21420
tcttcgcgc ccagatctgc caggtgtcgc gcttccccga gggcaagatc gagggtggacg 21480
ccccgctcac gagcctgggc atgaactcgc tgatggggct cgagctgcgc aaccgcatcg 21540
aggccatgct gggcatcacc gtaccggcaa cgctgttgtg gacctatccc acgggtggcg 21600
cgctgagcgg gcatctggcg cgggaggcat gcgaagccgc tcctgtggag tcaccgcaca 21660
ccaccgccga ctctgccgtc gagatcgagg agatgtcgca ggacgatctg acgcagttga 21720
tcgcagcaaa attcaaggcg cttacatgac tactcgcggg cctacggcac agcagaatcc 21780
gctgaaacaa gcggccatca tcattcagcg gctggaggag cggctcgcgt ggtcgcgaca 21840
ggcggagctg gaacggaccg agccgatcgc catcgtcggg atcggctgcc gcttccctgg 21900
cgggtgcggc gctccggaa cgttttggga gctgctcgac gcggagcgcg acgcgggtcca 21960
gccgctcgac atgcgctggg cgtcgtggg tgtcgtctcc gtcgaggccg tgccgcactg 22020
ggcggggctg ctccaccgag cgatagattg cttcgatgct gcgttcttcg gcatctcgcc 22080
tcgggaggcg cgatcgtcgc acccgcgaca tcgtctgttg ctggaggctc cttgggaggg 22140

```

gctcaggagac gccgggtatcc cgccccgggtc catcgacggg agccgcaccg gtgtgttcgt 22200
 cggcgctttc acggcggaact acgcgcgcac ggtcgtctcg ctgccgcgcg agggagcgaga 22260
 cgcgtacagc gccaccggca acatgctcag catcgccgcc ggacggctgt cgtacacgct 22320
 ggggtttgcag ggaccttgcc tgaccgtcga caccgctgct tcgtcatcgc tgggtggcgat 22380
 tcacctcgcc tggcgcagcc tgcgcgcagg agagagcgat ctgcgcttgg cgggagggggt 22440
 cagcgcgctc ctctccccc acatgatgga agccgcggcg cgcacgcaag cgctgtcgcc 22500
 cgatggctgt tggcggacct tcgatgcttc ggccaacggg ttcgtccgtg gcgagggtcg 22560
 tggcctggtc gtccctcaaac ggctctccga cgcgcaacgg gatggcgacc gcatctgggc 22620
 gctgatccgg ggctcggcca tcaaccatga tggccggctc accgggttga ccgcgcccaa 22680
 cgtgctggct caggagacgg tcttgcgcga ggctgtcgcg agcgcgccag tcgaagctgg 22740
 ggccgtcgat tacgtcgaga cccacggaac agggacctcg ctgggcgatc ccatcgagggt 22800
 cgaggcgctg cggcgacagg tggggccggc gcgctccgac ggacacagct gcgtgctggg 22860
 cgcggtgaag accaacatcg gccatctcga ggccgcggca ggctagcgg ccctgatcaa 22920
 ggacgcgctt tcgctgacgc acgagcgcat cccgagaaac ctcaacttcc gcacgctcaa 22980
 tccgcgggatc cggctcggag gcagcgcgct cgcgttggcg accgagccgg tccggtggcc 23040
 gcgcacggac cgcgcgcgct tcgcgggggt gagctcgttc gggatgagcg gaacgaacgc 23100
 gcatgtgggt ctggaagagg cgcgcggcggt ggagctgtgg cctgcgcgcg cggagcgctc 23160
 ggcggagctt ttggtgctgt cgggcaagag cgaggggcg ctcgatgcgc aggcggcgcg 23220
 gctgcgcgag cacctggaca tgcaccggga gctcgggctc ggggacgtgg cgctcagcct 23280
 ggcgacgacg cgcagcgcca tgagccaccg gctcgcgggt gcggtgacgt cgcgcgaggg 23340
 gctgctggcg gcgctctcgg ccgtggcgca ggggcagacg ccggcggggg cgcgcgctg 23400
 catcgcgagc tccctcgcgcg gcaagctggc gttcctgttc accggacagg gcgcgcagac 23460
 gccgggcatg ggccgggggc tttgcgcggc gtggccagcg ttcggggagg cgctcgaccg 23520
 gtgcgtggcg ctgctcgacc gggagctgga ccgcgcgctg cgcgaggtga tctgggcgga 23580
 ggccgggagc gccagctcgt tgttgcctga ccagacggcg ttcacccagc ccgcgctctt 23640
 cgcggtggag tacgcgctga cggcgctgtg gcggtcgtgg ggctagagc cggagctcct 23700
 ggttgggcat agcatcgggg agctggtggc ggctgctgtg gcgggggtgt tctcgttga 23760
 agatgggggt aggtcgtgg cgcgcgcgcg gcgctgatg caggggctct ctcggggcg 23820
 cgcgatgggt tcgctcggag cgcgggaggc ggaggtggcg gcggcggtgg cgcgcgacgc 23880
 ggctcgggtg tcgatcgcg cggtcaatgg gccggagcag gtggtgatcg cggcggtgga 23940
 gcaagcggtg caggcgatcg cggcggggtt cgcgcgcgcg ggccgcgcga ccaagcggtc 24000
 gcatgtctcg cacgcgttcc actgcgcgct gatggaaccg atgctggagg agtctgggcg 24060
 ggtggcgggc tcggtgacgt accggcgccc aagcgtttcg ctggtgagca acctgagcgg 24120
 gaaggtgggt acggacgagc tgagcgcgcc ggggtactgg gtgcggcacg tgcgggaggc 24180
 ggtgcgcttc gcggacgggg tgaaggcgct gcacgaagcc ggcccgggga cgctcgtcga 24240
 agtggggccc aagccgacgc tgcggggct gttgccagcc tgcctgcccg aggcggagcc 24300
 gacgctgctg gcgtcgttgc gcgccggcg cgaggaggct gcgggggtgc tcgaggcgct 24360
 gggcaggtcg tgggcccgcg gcggtcgggt cagctggccg ggcgtcttcc ccacggctgg 24420
 gcggcggggt ccgctgcccga cctatccgtg gcagcgccag cgttactgga cgttcgccc 24480
 ggccgaaggc ctcggagcca cggccgcgca tgcgctggcg cagtgttctt accgggtgga 24540
 ctggcccgag atgcctcgt catccgtgga ttcgcggcga gcccggtccc gcgggtgggt 24600
 ggtgctggcc gaccgggggt gagtcgggga ggcggccgcg gcggcgcttt cgtcgcagg 24660
 atgtcgtg cgcgtgctcc atgcgcccg cgaggcctcc gcggttgccc agcaggtgac 24720
 ccaggccctc ggtggccgca acgactggca gggggtgctg tactgtggg gtctggagc 24780
 cgtcgtggag gcgggggcat cggccgaaga ggtcgccaaa gtcacccatc ttgcccgggc 24840
 gccggtgctc gcgctgattc aggcgctcgg caccggggcg cgtcaccce ggctctggat 24900
 cgtgacccga ggggcctgca cgggtggcg cgagcctgac gctgccccct gtcaggcgcc 24960
 gctgtgggggt atgggcccgg tcgcggcgct agagcatccc ggctcctggg gcgggctcgt 25020
 ggacctggat ccggaggaga gcccgacgga ggtcgaggcc ctgggtggcg agctgcttcc 25080
 gcccgcccca ccggaggga acgcagcgcc ggtgtcgtg tctgcggagg ggagttactt 25140
 ggtgacgggt gggctggggc ccttggcct cctcgttgcg cgggtgttgg tggagcgcg 25200
 ggccggggcac cttgtgctga tcagccggca cggattgccc gaccgcagg aatggggccg 25260
 agatcagccg ccagagggtg cgcgcgcgat tgcgcgcat gaggcgctgg aggcgcagg 25320
 cgcgcgggtc accgtggcg tgcgagcgt ggccgatgcc gaaggcatgg cggcgctctt 25380
 ggccggccgtc gagccgcccgc tgcgggggggt agtgacgccc gcgggtctgc tcgacgacg 25440
 gctgctggcc caccaggagc ctggtcgggt cgcccgggtg ttgcgcccc aggtggagg 25500
 ggcatgggtg ctgcacacc ttaaccgcga gcagccgctg gacctcttcg tactgttct 25560
 ctcggcgtcg ggctcttctg gctcgatcgg ccagggcagc tacgcgcgag gcaatgcctt 25620
 tttggacgct ctggcggaac tccgcgaac gcaggggctc gccgccctga gcatcgctc 25680
 gggcctgtgg gcggaggggg ggtatgggtc gcaggcgag cgcggggaac acgaggcatc 25740
 ggggaatctg gcgatgccga cgagtggggc cctggcgggc atggaatggc tgcctgggtac 25800
 gcgcgcgacg cagcgcggtg tcatccagat ggattggggc catgcgggag cggcgcccg 25860
 cgacgcgagc cgaggccgct tctgggagcg gctggttaact gccacgaaag aggcctctc 25920
 ctcggccgtg ccagctgtgg agcgtggcg caacgcgtct gttgtggaga cccgctcggc 25980

gctctacgag cttgtgcgcg gcgtgggtcg cggggtgatg ggctttaccg accagggcac 26100
gctcgacgtg cgacgaggct tcgccgagca gggcctcgac tccctgatgg ccgtggagat 26160
ccgcaaaccg cttcaggggtg agctgggtat gccgctgtcg gcgacgctag cgttcgacca 26220
tccgaccgtg gagcggtggtg tgggaatactt gctgagccag gcgctggagc tgcaggaccg 26280
caccgacgtg cggagcggttc gggtgcccgc gacagaggac ccgacgcca tcgtgggtgc 26340
cgcttgcgcg ttcgccggcg gggtcgagga cctggagtcc tactggcagc tgttgaccga 26400
gggctggtg gtcagcaccg aggtgcccgc cgaccggtgg aatggggcag accggcgcg 26460
ccccggctcg ggagaggcac agagacagac ctacgtgccc aggggtggct tctgcgcg 26520
gggtggagag ttcgatcgcg cgttcttcca catctcgccc cgggaggcga tgagcctgga 26580
cccgaacag cggctgctgc tggaaagtga ctgggaggcg accgagcgcg cgggccagga 26640
cccgtcgcg ctgctcgaga gccccacggg cggtgtctgt ggccggggcc ccaacgaata 26700
tgccgagcgg gtgcaggaac tcgccgatga ggcggcgggg ctctacagcg gcaccggcaa 26760
catgctcagg gttgctggcg gacggctatc atttttctct ggctgacag ggccgacctt 26820
ggctgtggat acggcgtgct cctcgctcgt ggtggcgctg cacttcggct gccagagctt 26880
gcgacggggc gagtgcgacc aagccctggt tggcggggtc aacatgctgc tctcgccgaa 26940
gaccttcgcg ctgctctcac ggatgcacgc actttcgccc ggcggcggtt gcaagacgtt 27000
ctcgcccgac gcgacggctt acgcgcgggc cgagggctgc gccgtgggtg tgctcaagcg 27060
gctctccgac gcgcagcgcg acccgacccc catctggcg gtgatccggg gtacggcgat 27120
caatcatgat gggccgagca gcgggtgac agtggccagc ggccctgccc agggagcgct 27180
gttacgccag gcgctggcgc acgcagggtt ggttccggcc gacgtcgatt tctggtgaatg 27240
ccacgggacc gggacggcgc tggggcagcc gatcgaggtg cgtgcgctga gcgacgtgta 27300
cgggcaagcc cgccctgccc accgaccgct gatcctggga gccgccaagg ccaaccttgg 27360
gcacatggag cccgcgggcg gcctggccgg cttgctcaag gcggtgctcg cgctggggca 27420
agagcaata ccagcccagc cggagctggg cgagctcaac ccgctcttgc cgctgggaggc 27480
gctgcccgtg gcggtggccc gcgcagcggt gccgtggccc cgcacggacc gcccgcgctt 27540
cgcggggtg agctcgttcc ggatgagcgg aacgaacgcg catgtggtgc tggagagggc 27600
ggcggggtg gactgtgtgg ctgcccgcgc ggagcgctcg gcgagcttt tgggtgctgc 27660
gggcaagagc gagggggcgc tcgatcgca ggcggcgcg gccgcgagc ctgcccgcgc 27720
gcacccggag ctcgggctcg gggacgtggc gttcagcctg gcgacgacgc gcagcgcat 27780
gaaccaccgg ctcgcggtgg cggtagcgtc gcgcgagggg ctgctggcg cgcttctcgc 27840
cgtggcgacg gggcagacgc cgccgggggc ggcgcgctgc atcgcgagct cgtcgcgcg 27900
caagctggcg ttcctgttca ccggacaggg cgcgctcttc ccgggcatgg gccgggggct 27960
ctgcccggcg tggccagcgt tccgggaggg gttcgaccgg tgcgtggcg tgttcgaccg 28020
ggagctggac cgcccgctgc gcgaggtgat gttggcgagg ccggggagcg ccgagctcgt 28080
gctgctcgac cagacggcgt tcaccaagcc cgcgctcttc accgtggagt acgctcgac 28140
ggcgctgtgg cggtcgtggg gcgtagagcc ggagctggtg gctgggcata gcgccggga 28200
gctggtggcg gcgtgctggg cgggggtggt ctgctggaa gatggggtga ggctcgtggc 28260
ggcgcgcggg cggtgatgc aggggtcttc ggcggggcgc gcgatggtg cgctcgtggc 28320
ggcggaagcg gaggtggcgg cggcggtggc gccgcagcg gcgtcggtgt cgatcgcgcc 28380
ggctcaatgg ccggagcagg tggtagtcgc gggcggtgg caagcggtgc aggcgatcgc 28440
ggcggggttc gcgcgcgcgc gcgcgcgcac caagcggtcg catgtctcgc acgcgtcca 28500
ctcgccgctg atggaaccga tgctggagga gttcgggcgc gttggcgagc cgtgagcgt 28560
ccggcgccca agcgttctgc tggtagcaaa cctgagcggg aaggtgggtg cggacgagct 28620
gagcgcgccg gggtagctgg tgcggcacgt gcgggagcg gtcgcttcg cggacgggg 28680
gaaggcgctg cacgaagccg gtgcgggcac gttcgtcgaa gttggggcga agccgacgt 28740
gctcgggctg ttgccagcct gcctgcccga ggcggagcgc acgctgctgg cgtcgttcg 28800
cgccggggcg gaggaaggct cgggggtgct cgaggcgctg ggagggctgt gggccgccc 28860
cggctcggtc agctggccgg gcgtcttccc cagggtggg cgccgggtgc cgtgcccac 28920
ctatccgtgg cagcggcagc ggtactggcc cgacatcgag cctgacagcc gtcgccagc 28980
agcccgggat ccgaccgaag gctggttcta tcgctggac tggccggaga tacctcgca 29040
cctccagaaa tcagaggagg cgagcgcgcg gagctggctg gtattggcg ataagggtg 29100
agtcggcgag gcggtcgtcg cagcgctgtc gacacgtgga cttccatgcg tcgtgctcca 29160
tgccgcccga gagacatccg cgaccgccc gctggtgacc gaggctgccc gcggtcgaag 29220
cgattggcag gtatgctctt acctgtgggg tctggacgcc gtcgtcggtg cggagggcgc 29280
gatcgatgag atcggcgacg cgaccgctcg tgctaccgcg ccggtgctcg gcttggctcg 29340
gtttctgagc accgtgtctt gttcgcccc actctgggtc gtgacccggg gggcatgcat 29400
cgttggcgac gagcctgcga tcgccccctg tcaggcgggc ttatggggga tggggcggt 29460
ggcgcgctc gagcatccc cggtctgggg cgggctcgtg gacctggatc cccgagcgag 29520
cccggcccaa gccagcccga tcgacggcga gatgctcgt accgagctat tgtcgagga 29580
gaccgaggat cagctcgctt tccgcatagg gcgcccgcac gcggcacggc tgggtggcgc 29640
cccggcacag gggcaagcgg caccgggtgt gctgtctgcg gaggcgagct acctggtgac 29700
gggagggcctc ggtgggctgg gcctgatcgt ggccagtggt ctgggtggagc tgggagcgcg 29760
gcacttgggt ctgaccagcc ggcgcgggtt gcccgaccgg caggcggtgt gcgagcagca 29820
gccgcctgag atccgcgcgc ggatcgacgc ggtcgaggcg ctggaggcgc ggggtgcacg 29880
ggtgaccgtg gcagcggtgg acgtggccga cgtcgaaccg atgacagcgc tgggttctgc 29940

ggctcgagccc ccgctgagag ggggtggtgca cggcgtggc gtcagcgta tgcgtccact 30000
 ggccggagacg gacgagaccc tgctcgagtc ggtgctccgt cccaaggtgg ccgggagctg 30060
 gctgctgcac cggctgctgc acggccggcc tctcgacctg tctgctgtgt tctcgtcggg 30120
 cgcagcgggtg tggggttagcc atagccaggg tgcgtacgcg gcggccaacg ctttcctcga 30180
 cgggctcgcg catcttcggc gttcgcaatc gctgcctgcg ttgagcgctg cgtggggtct 30240
 gtggggccag ggagggcatgg cggacgcgga ggctcatgca cgtctgagcg acatcggggg 30300
 tctgcccattg tcgacgtcgg cagcgttgtc ggcgtccag cgcctggtgg agaccggcgc 30360
 ggctcagcgc acggtgaccc ggatggactg ggcgcgttc cgcgcggtgt acaccgctcg 30420
 agggcgctcg aacctgcttt cggcgctggt cgcaggcgcg gacatcatcg cgccttcccc 30480
 tccggcgga gcaacccgga actggcggtg cctgtccgtt gcggaagccc gcgtggctct 30540
 gcacgagatc gtccatgggg ccgtcgctcg ggtgctgggc ttcctcgacc cagcgcgct 30600
 cgatcctggg atggggttca atgagcaggg cctcgactcg ttgatggcgg tggagatccg 30660
 caacctctt caggctgagc tggagctgcg gcttttcgacg acgctggcct ttgatcatcc 30720
 gacgggtacag cggctgggtg agcatctgct cgtcgatgta ctgaagctgg aggatcgag 30780
 cgacaccag catgttcggg cgttggcgtc agacgagccc atcgccatcg tgggagccgc 30840
 ctgcccgttc ccgggcgggg tggaggacct ggagtcctac tggcagctat tggccgaggg 30900
 cgtgggtggtc agcggcgagg tgcggcgga ccgggtggat gcggcggaact ggtacgaccc 30960
 tgatccggag atccaggcc ggacttacgt gaccaaaggc gccttctcgc gcgatttgca 31020
 gagattggat gcgaccttct tccgcatctc gcctcgcgag gcgatgagcc tcgacccgca 31080
 gcagcgggtg ctctcgagg taagctggga agcgtcgag agcggggta tcgctccgga 31140
 tacgctgcga gatagcccca ccggggtgtt cgtgggtgcg gggcccaatg agtactacac 31200
 gcagcggctg cgaggcttca ccgacggagc ggcagggttg tacggcgga ccgggaacat 31260
 gctcagcgtt acggctggac ggctgtcgtt tttcctgggt ctgacaggcc cgacgctggc 31320
 catggatacg gcgtgctcgt catcctgggt cgcgtcgac ctcgctgccc agagcctgag 31380
 actggcgag tcgatcaag cgtgggtgg cggggtcaac gtgctgctcg cgcggagac 31440
 ctctcgctg ctctcacgga tgcgcgcgt ttcgcccagc gggcggtgca agacgttctc 31500
 ggccgacgcg gacggctacg cgcggggcg ggggtgccc gtggtggtgc tcaagcggct 31560
 gcgcatgctg cagcgccgcg gcgactccat cctggcgctg atccggggaa cgcggtgaa 31620
 ccacgacggc ccgagcagcg ggctgacctg acccaacgga cccgcccagc aagcatgct 31680
 gcgccaggcg ctctcgcaag caggcgtgtc tccggtcgac gttgatttgg tggagtgtca 31740
 cgggacaggg acggcgctgg gcgacccgat cgaggtgagc gcgctgagcg aggtgtatgg 31800
 tccaggggcg tccggggacc gaccgctggt gctggggggc gccaaaggcca acgctcgca 31860
 tctggaggcg gcatctggct tggccagcct gctcaaggcc gtgcttgccc tgcggcacga 31920
 gcagatcccg gccagcccg agctggggga gctcaaccgc cacttgccgt ggaacacgct 31980
 gccggtggcg gtgccacgta aggcggtgcc gtggggggc ggcgcacgccc cgcgtcgggc 32040
 cggcgtgagc gcgttcgggt tgagcggaa caactgcat gtcgtgctgg aggaggcacc 32100
 ggaggtggag ccggcgcccg cggcgccggc gcgaccggtg gagctggtcg tgcctatcggc 32160
 caagagcgcg gcggcgctgg acgcccggc ggcacggctc tggcgccacc tgcctcgca 32220
 cccggagctg agcctcgccg acgtggcgtt cagcctggcg acgacgcgca gccgatgga 32280
 gcacggctc gccatcgca cgacctcgcg cgaggccctg cgaggcgccg tggacggcg 32340
 ggccgagcaa aagacggcgc agggcgcggt gcgcgcaag gccgtgctct caccgggta 32400
 gctggcttct ctgttcaccg gacagggcg gcaaatgccc ggcattggggc gtgggtgtga 32460
 cgaaacgtgg cctgctgtcc gggagcggtt cgaccggtgc gtggcgctct tcgatcgga 32520
 gatcgaccag cctctgcgag aggtgatgtg ggctgcgccc ggcctcgctc agcgggcgcg 32580
 gctcgatcag accgctgacg cgcagccggc tctctttcgg ctggagtagc cgttggctgc 32640
 cctgtggcgt tcgtggggcg tggagccgca cgtactgctc ggtcatagca tcggcgagct 32700
 ggtcgccgccc tgcgtggcg gcgtgttctc gctcgaagat gcggtagagt tggtagccgc 32760
 gcgcgggcg ctgatcgagg cgtaccgc cgcggtgcc atggtagcca tcgcagcgtc 32820
 cgaggccgag gtggccgctt ccgtggcgcc ccacggccc acggtgtcga tcgcccgggt 32880
 caacggctct gacggcgctg tgatcgccgg cgcggaggta cagggtgctc cctcgggc 32940
 gacgttcgag gcgctggga tacgcacgaa gaggctcgcc gctctccatg cgttccactc 33000
 gccgctcatg gatccgatgc tgaagactt ccagcggtc gctcgacga tcgctacccg 33060
 cgcgcccagc cgcgggtgg tgcgaatgt caccggccac gtcgaggcc ccgagatcgc 33120
 cagccccag tatgggttcc ggcatgtgag aagcgccgtg cgttccggc acggggcaaa 33180
 ggctgtgcat gcccggggtg ccgccacgtt cgtcgagggt ggcccgaagc cggctcctgct 33240
 cgggctgttg ccagcgtgcc tccgggaagc ggacgggtc ctcgtgccgt cgtacggcg 33300
 ggaccgctcg gaatgcgagg tggctcctcg ggcgtcggg gcttggtagt cctggggggg 33360
 tgcgtcgac tggaggggcg tgtccccga tggcgcgcg cgcgtggctc cgtccatgta 33420
 tccatggcag cgtgagcgcc attggatgga cctcaccgc cgaagcgccg cgcctgcagg 33480
 gatcgagggt cgtggccgc tggctggtgt cgggctctgc atgcccggcg ctgtgttgca 33540
 ccacgtgctc tcgatcgga caccgcatca gcccttctc ggtgatcacc tcgtgtttgg 33600
 caaggtgggt gtgcccggcg ccttccatgt cgcggtgac ctcagcatcg ccgagagcg 33660
 ctggcccag cggcgatcg agctgacagg cgtggagttc ctgaaggcca tcgcatgga 33720
 gcccagaccg gaggtcgagc tccacggcgt gctcaccccc gaagccggcg gggatggcta 33780
 cctgttcgag ctggcgaccc tggcgcgccc ggagaccgaa cgccgatgga cgaccacgc 33840

- 10 -

ccgcggtcgg gtgcagccga cagacggcgc gcccggcgcy ttgcgcgcgc tcgaggtgct 33900
 ggagggaccgc gcgatccagc ccctcgactt cgccggattc ctgcacaggt tatcgggcgt 33960
 gcggatcgcc tggggtcgcg tttggcgatg gctgcaggac gggcgcgctc gcgacgaggg 34020
 ctcgcttgcc accctcgctg cgacctatcc gaacgcccac gacgtggcgc ccttgacccc 34080
 gatcctgctg gacaacggct ttgcggtgag cctgctgtca acccgagcgc agccggagga 34140
 cgacgggacg ccccgctgc cgttcgccgt ggaacgggtg cgggtggtggc gggcgccggc 34200
 tggaaagggtg cgggtgtggcg gcgtgcccgc gtcgcaggca ttcgggtgtct cgagcttctg 34260
 gctggtcgac gaaactggcg aggtggtcgc cgaggtggag ggatttgttt gccgcccggc 34320
 gccgcgagag gtgttccctg ggcaggagtc gggcgcgctc actgcagcct tgtaccgcct 34380
 cgactggccc gaagcgccct tgcctgatgc gcctgcggaa cggatcgagg agagctgggt 34440
 cgtggtggca gcacctggct cggagatggc cgcgcgctc gcaacacggc tcaaccgctg 34500
 cgtcctcgcc gaacccaaag gcctcgaggc gggcctcgcy ggggtgtctc ccgaggtgct 34560
 gatctgcctc tgggaggctg gagcccacga ggaagctccg gcggcgccgc agctgtggc 34620
 gaccgagggc ctctcggtgg tgcaggcgct cagggaccgc gcggtgcgcc tgtggtgggt 34680
 gacctggggc gcagtggcgc tgcaggccgg tgcagggtg caggctcgcca cagcgccggc 34740
 atggggcctc ggcgcgacag tgatgcagga gcgcccggag ctgagctgca ctctggtgga 34800
 tttggagccg gaggccgatg cagcgcgctc agctgacgtt ctgttgcggg agctcgctcg 34860
 cgctgacgac gagacacagg ttgctttccg ttcggaaaag cggcgcgtag cgcgcgctgt 34920
 caaagcgacg acccccgaag ggctcctggt ccctgacgca gactcctatc gactggaggc 34980
 tgggcagaag ggcacattgg accagctccg cctcgcgccg gcacagcgcc gggcacctgg 35040
 cccggcgag gtcgagatca aggtaacgc ctcggggctc aacttccgga ccgtcctcgc 35100
 tgtgctggga atgtatccg gcgacgcccgc gccgatgggc ggagattgtg ccggtgtcgc 35160
 cagcgcggtg gggcaggggg tgcgccacgt cgcggtcgcc gatgctgtca tgacgtcggt 35220
 gacgttgcat cgattcgta cggtcgacgc gcggtcggtg gtccggcagc ctgacaggct 35280
 gactcccgcg caggcagcta cggtgccggt cgcttctctg acggcctggc tcgctctgca 35340
 cgacctgggg aatctgcggc gcggcgagcg ggtgctgac catgctgccc ccggcggtgt 35400
 gggcatggcc gcggtgcaaa tgcgccgatg gataggggccc gagggtgttc ccacggcgag 35460
 cccgtccaag tggcgagcgc ttcaggccat gggcggtgccc gcacgcgaca tgcgcaactc 35520
 gcggacgctg gaggttgctg agacgttccg gcaggtcacc ggcggccggg gcgtggacgt 35580
 ggtgctcaac gcgctggcgc gcgagttcgt ggacgcgagc ctgtccctgc tgcgacggg 35640
 cgggcggttc ctcgagatgg gcaagaccga catacgggat cgagccgccc tccgcccgcg 35700
 gcatcccggg gtctcgctatc ggggtattcga catcctggag ctgctccggc atcgaaactc 35760
 agagatcctc gagcgctggt tgcagggtct tgctgcggga catctgcggc cattgcccgt 35820
 gcatgcttcc gcgatcacca aggcggaggc agcgtttccg ttcatggcgc aagcgccgca 35880
 tcagggcaag gtcgtgctgc tggcgccgccc cctcgagcgc ccttggcgcc cgacgggac 35940
 cgtaactgctg accggtgggc tgggagcgtt ggggtccacc gtggcccgcct ggctcgccca 36000
 gcaggcgctg ccgcacatgg tgctcacagg tccggcgggc ctggatagc cgggcgctgc 36060
 caaagccgct gcggagatcg aagcgctcgg cgctcggggt acgatcgccg cgtcggtatg 36120
 cgccgatcgg aatgcgctgg aggtctgtgct ccaggccatt ccggcgaggt ggccgttaca 36180
 gggcggtgat catgcagcgc gaggcctcga tgatggtgtg ctgtgatgag agaccaccga 36240
 ccgcttctcg cgggtgctgg caccgaagggt gactggcgcc tggaaatctg atgagctcac 36300
 ggcggggcaac gatctcgctt tcttctgctg gttctctctc atgtcggggc tcttgggctc 36360
 ggcggggcag tccaactatg cggcgcccaa caccctcttc gacgcgctgg ccgcatcgc 36420
 gcggggccgaa ggcctggcgg cgagagcct cgcggtgggg ccatggtcgg acggaggcat 36480
 ggcagcgggg ctacagcgcg cgctgcaggc gcggctcgct cggcatggga tgggagctct 36540
 gtcgcccggc cagggcaccg cgctgctcgg gcaggcgctg gctcgccggc aaacgcagct 36600
 cgggggcgat tgcctcgacg tgctgcccgc aagccaaagt tccgggagcgg cagtgcggcc 36660
 tgtgtggcgc gcgttgggtg gcgaggaggc gcgccatag gcggctgggg cgagggggc 36720
 attggccgcy cgtcttgggg cgctgcccga ggcgctgcg gccgacgagg tgcgcaagg 36780
 cgtgcaggcc gagatcgcg gcgtgctttc atggagcgcc gcgagcgccg tgcgctcga 36840
 tcggccgctg tcggacttgg gcctcgactc gctcacggcg gtcggagctg gcaactgtg 36900
 cggccagcgg gtgggtgcca cgctgcccgc gacgctggca ttcgatcacc cgacggtcga 36960
 cgcgctcacg cgctggctgc tcgataaggc cctggccgtg gccgagccga gcgtatcgt 37020
 cgcaagctc tcgcccaggg tcgcccctga cgagccatt gccatcatg gcatcggtg 37080
 ccgtttccca ggcggcggtg ccgatccgga gtcgttttgg cggctgctcg aagaggcgag 37140
 cgatgcccgt gtcgaggtgc cgcatgagc atgggacatc gacgcttctc atgatccgga 37200
 tccggatgtg gcgggcaaga tgacgacacg ctttggcggc ttcctgtccc atatcgaccg 37260
 gttcgatccg gccttcttcg gcatctcgcc gcgcgaagc acgacctgg atccgacga 37320
 gcggctgctc ctggagacga gctgggaggc gttcgagcgc gccgggattt tgcggagcg 37380
 gctgatgggg agcgataccg gcgtgttctg ggggctcttc taccaggagt acgctcgct 37440
 gcggcgccgg atcgaggcgt tcgatggcta tctaggcacc ggcaccacgg ccagcgtcg 37500
 ctggggcagg atctcttatg tgctcgggct aaaggggccg agcctgacgg tggacaccg 37560
 gtgctcctcg tcgctgggtc cgggtgcacct ggcctgccc gcgctgccc ggggagagtg 37620
 ttcggtgccg ctggcccgcg gcgtggcgct gatgctcac cggcgacgt tcgtggagtt 37680
 cagccggctg cgaggcctgg ctcccagcgg acggtgcaag agcttctcgg ccgagccga 37740

cggcgtgggg tggagcgaag gctgcgcat gctcctgctc aaaccgcttc gcgatgcgca 37800
 gcgcgatggg gatccgatcc tggcgggtgat ccgcggcacc gcggtgaacc aggatgggcy 37860
 cagcaacggg ctgacggcgc ccaacgggtc gtcgcagcaa gagtgatcc gtcggggcct 37920
 ggagcaggcg gggctggctc cgccggagct cagctacgtc gaggccacg gcaccggcac 37980
 gacgttgggg gaccccatcg aagtgcaggc cctggggcgc gtgctggcac agggcgacc 38040
 ctccggaccg ccgctcgtga tcgggtcggt gaagtccaat atcggacata cgcaggtgc 38100
 ggcgggctgt gccggtgtca tcaaggtggc gctggcgctc gaggcggggc ttatcccgag 38160
 gagcctgcat ttccgacgcg ccaatccgca cattccgtgg tcggagctcg ccgtgcaggt 38220
 ggccgccaac ccgctcgaat ggacgagaaa cggcgtggcg cgacgagccg gggtaggtc 38280
 gtttggcgct agcgggacca acgcgcacgt ggtgctggag gaggcgccag cggcgcgctt 38340
 cgccggcgcg cggcgcgctt cagcggagct tttcgtgctg tcggcgaaga gcgcgcggc 38400
 gctggacgcg caggcgcgcg ggctttcggc gcacgtcgtt gcgcaccgg agctcggcct 38460
 cggcgacctg gcgttcagcc tggcgacgac ccgcagcccg atgacgtacc ggctcgggt 38520
 ggcggcgacc tcgcgcgagg cgctgtctgc cgctcgcac acagcggcg aggggacggc 38580
 gccgcccga cgggctcgcg gccacgcttc cacaggcagc gcccacaaag tggttttcgt 38640
 ctttctctggc cagggtctcc agtggctggg catgggcca aagctcctct cggagagcct 38700
 cgctctccgc gacgcgctct cggcggtgga ccgagcgatt caggccgaag ccggctggct 38760
 gctgctcgcc gaggctcgcg ccgatgagac cacctcgcag ctccggcgca tcgacgtggt 38820
 gcagccggcg ctgttcgcga tcgaggtcgc gctgtcggcg ctgtggcggt cgtggggcgt 38880
 cgagccggat gcagtggtag gccacagcat gggcgaaagt gcggccgcgc acgtcggcgt 38940
 cgccctgtcg ctccgagatg ctgtagcgat catctgccg gcgcagcctg tgctgcggcg 39000
 gatcagcggc caaggcgaga tggcggtcgt cgagctttcc ctggccgagg ccgagggcagc 39060
 gctcctgggg tacgaagacc ggctcagcgt ggcgggtgagc aacagcccg cctcagcgtt 39120
 gctggcgggc gagccggcag cgctcgcaga ggtgctggcg atccttgcgg caaagggggt 39180
 gttctgccgt cgagtcagg tggacgtcgc cagccacagc ccacagatcg acccgctcg 39240
 cgacgagcta ttggcagcat tggcgagct cgagcccgca caagcgaccg tctcgatgcg 39300
 ctccagcggt acgagcacga tcatggcggg cccggagctc gtggcgagct actggcgga 39360
 caacgttcga cagccggtgc gcttcgcga agcgggtgcaa tcgttgatgg aagacgggtca 39420
 tgggctgttc gtggagatga gcccgcatcc gatcctgacg acatcggtcg aggagatccg 39480
 accggcgacg aagcgggagg gaggcgcggt gggctcgttg cggcgtggac aggacgagcg 39540
 cctgtccatg ttggaggcgc tgggagcgct ctgggtacac ggccaggcggt tgggctggga 39600
 gcggctgttc tcccgggcg gcgcgggct ccgtcgcgtg ccgctgccga cctatccctg 39660
 gcagcgcgag cggtagtggg tcgatcgccc gaccggcgcg gcggcgggcg gcagccgctt 39720
 tgctcatgct ggcagtcacc cgctcctggg tgaatgcag accctgtcga cccagaggag 39780
 cagcgcgctg tgggagacga cgctggatct ccccgggctc cggtggctcg gcgatcccg 39840
 ggtgcagggg gcggtcgtgt tcccgggcgc ggcgtacctg gagatggcg tttcgtcccg 39900
 ggccgaggcc ttgggtgacg gtccgctcca ggtcagcgat gttgtgctcg ccgagggcgt 39960
 ggcccttcgc gatgatacgc cggcgggcgt gcaggtcatg gcgaccgagg agcagaccag 40020
 ccgctcgcaa ttccacgttg cgagccgggt gcggggccac ggcgggtgctg cctttcgaag 40080
 ccatgccgcg ggggtgctgc gccagatcga gcgcggcgag gtcccgcgga ggctggatct 40140
 ggccgcgctt cgtgcccggc ttccaggccag cgcacccgct ggcggtacct atgcggcgct 40200
 ggccgagatg gggctcagat acggcccagc gttccagggg cttgtcagag tgtggcgggg 40260
 ggagggcgag gcgctgggac gtgtgcggt ccccgaggcc gccggctccc cagcccgctg 40320
 ccggtccac ccgcgctct tggatgctg cttccacgtg agcagcgct tcgctgaccg 40380
 cggcgaggcg acgcatggg taccggtgga aatcggtcgt ctgcggtggt tccagcgcc 40440
 gtcgggggag ctgtggtgtc atgcgcggag tgtgagccac ggaaagccaa caccgaccg 40500
 gcggagatcc gacttctggg tggtcgacag cacggcgcg atcgtcgcc agatctccg 40560
 gctcgtggcg cagcggctcg cgggaggtgt acgcccggcg gaagaagacg actggtcat 40620
 ggagccggct tgggaaccga ccgcggtccc cggtaccgag gtcattggcg gccggtggt 40680
 gctcatcggc tcggcgcgcg ggctcggcg tcgctcccac tcggcgctga cggagctgg 40740
 ccattccgtc gtccacgcga caggcgcgcg cacgagcgcc gccgggttg aggcactctt 40800
 gacggcgctc ttccagcgcc aggcggcgac gtcggtggtg cacctcgga gcttcgatga 40860
 gcgtggcggt ctccagcgcg atgccccct cgacgctgat gcgcttgagg agtcgctggt 40920
 tccctccggg gacagcgtgc tctggaccgt gcaggccgtg gccggggcg gcttccgaga 40980
 tctcctcgcg ttgtggctcg tgacacggcg cgctcaggcc atcgggcgcc gcgacgtctc 41040
 tgtggcgcaa gcgccgctcc tggggctggg ccgcttatc gccttgagg acgcccagct 41100
 tgcgtcgct cggtatcgacc tcgatccagc ggcggcgag ggagaagtc atgagctgct 41160
 cgccagctg ttggccgacg acgcccagga ggaagtcggt tttcgcgcg gtgagcgcg 41220
 cgtggcccg ctctccgaa ggtgcccgga gaccgactgc cgagagaaaa tcgagcccg 41280
 ggaagggcg ccgttccggc tggagatcga tgggtccggc gtgctcgacg acctggtgct 41340
 ccgagccacg gaggcgcgcc ctctggccc gggcgaggtc gagatcgcc tcgagggcg 41400
 ggggctcaac tttctcgacg tgatgaggc catggggatc taccctgggc ccggggacg 41460
 tccggttgcg ctggggcgcg agtgcctcg ccgaattgt gcgatggcg aaggtgtcga 41520
 gaggcttctg atcgccagc acgtcgtggc cgtcgcggc ttcagttctg gcacccacgt 41580
 caccatcgac gcccggtatc tcgcacctc ccccgcgcg ctgacggcg cgaggcagc 41640

cgcgtgcccc gtcgcattca tgacggcctg gtacgggtctc gtccatctgg ggaggctccg 41700
 ggccggcgag cgcgtgctca tccactcggc gacggggggc accgggctcg ctgctgtgca 41760
 gatcgcccg cactcggcg cggagatatt tgcgaccgct ggtacaccgg agaagcgggc 41820
 gtggctgccc gagcagggga tcgcgacgt gatggactcg cggctcgctgg acttcgcccga 41880
 gcaagctgctg gccgcgacga agggcgaggg ggtcgacgtc gtgttgaaact cgtgtctctgg 41940
 cgccgcgacg gacgcgagcc ttctgaccct cgtgccggac ggccgcttca tcgagctcgg 42000
 caagacggac atctatgcag atcgctcgtc ggggctcgtc cacttcagga agagcctgctc 42060
 ctacagcgcc gtcgatcttg cgggcttggc cgtgcgtcgg cccgagcgcg tcgcagcgct 42120
 gctggcgag gtggtggaac tgctcgacg gggagcgctg cagccgcttc cggtagagat 42180
 ctccccctc tcgcgggcgg cggacgcgtt ccggaaaatg gcgcaagcgc agcatctcgg 42240
 gaagctcgtg ctccgctgg aggaccggga cgtgcggatc cgcgttccgg gcgaatccgg 42300
 cgtcgccatc cgcgcgagc ggcctacct cgtgaccggc ggtctggggg ggctcggtct 42360
 gagcgtggct ggatggctgg ccgagcaggg ggctgggcat ttggtgctgg tgggcccgtc 42420
 cggcgcggtg agcgcgagc agcagacggc tgcgcccggc ctcgagggcg accgcccggc 42480
 tctcacggta gcgagggcag acgtcgccga tcggcgcgag atggagcgga tccctccgca 42540
 gggtaccgcg tcggggatgc cgtccgcggt gttccgcgcg gtcgttccat gcggccggaa tcctggacga 42600
 cgggctgctg atgcagaaa ccccgcgcg gttccgcgcg gtcgtggcg ccaaggtccg 42660
 aggggcttgc cactgcatg cgttgacacg cgaagcgccg ctctccttct tcgtgctgta 42720
 cgcttcggga gcaaggctct tgggctcgcc gggccagggc aactacggcg cgccaacac 42780
 gttctcgac gactggcac accaccggag ggcgcgaggg ctgccagcat tgagcatcga 42840
 ctggggcctg ttcgcgagc tgggtttggc cgccggcgag caaaatcgcg gcgcacggct 42900
 ggtcaccgcg gggacgcgga gcctcaccgc cgacgaagg ctgtggggcg tcgagcgctc 42960
 gctcgacggc gatcgacccc agggccgggt catgcccgtt gacgtgccc agtgggtgga 43020
 gttctaccg gcggcgcat ctctcgagag gttgtcgcg ctcatgacgg cacggcgct 43080
 ggcttcgggt cggctcgccg gggatcgga cctgctcgaa cggctcgcca ccgcccaggc 43140
 gggcgcgcg gcagggatgc tgcagggagt cgtgcgcg cggtctcg aggtgtcg 43200
 cctctccgaa ggcaagctcg acgtggatgc gccgtcacg agcctgggaa tggactcgt 43260
 gatggggcta gagctgcga accgcatcga ggccgtgctc ggcataacca tgccggcgac 43320
 cctgctgtgg acctacccca cgggtggcagc gctgagtgcg catctggct ctcatgtcgt 43380
 ctctacgggg gatggggaat ccgcgcgccc gccggatata gggagcgtgg ctccaacgac 43440
 ccacgaagtc gcttcgctcg acgaagacgg gttgttcg cggtgtgatg ttgattgatg 43500
 gcgcgcggga aagaggtgat tgcgtgacag accgagaagg ccagctcctg gagcgttgc 43560
 gtgaggttac tctggccctt cgcaagacgc tgaacgagcg cgataccctg gagctcgaga 43620
 agaccgagcc gatcgccatc gtggggatcg gctgccgtt ccccgggcga gcgggcactc 43680
 cggaggcggt ctgggagctg ctcgacgacg ggccgacgc gatccggcgg ctcgagggagc 43740
 gctggggcgt cgtaggtgtc gacccaggcg acgacgtacc gcgctggggc gggctgctca 43800
 ccgaggccat cgacggttcc gacgcccggt tcttcgggtat cgcccccg gaggcacgg 43860
 gcctcgaccc gcagcatcgc ctgctgctgg aggtcgctc ggagggggtt gaagcggc 43920
 gcataccgccc caggctccctc gtccggagcc gcaccggcgt gttcgtcgcc 43980
 cggagtacct ccacgccgccc gtccgacac agccgcgca agagcgggac gcgtacagca 44040
 ccaccggcaa catgctcagc atcgccgccc gacggctatc gtacacgctg gggctcgagg 44100
 gaccttgctt gaccgtcgat acggcggtgt cgtcatcgt ggtggccatt cactcgctc 44160
 gccgcgacct gcgcgctcga gagagcgatc tcgcgctggc gggaggggtc aacatgcttc 44220
 tctccccga cagatgcga gctctggcg gcacccaggc gctgtcgccc aatggccgtt 44280
 gccagacctt cgacgctcg gccaacgggt tcgtccgtgg ggagggtgc ggtctgatcg 44340
 tgctcaagcg attgagcgac gcgcggcggg atggggaccg gatctggggc ctgatccgag 44400
 gatcgcccat caatcaggac ggccggctga cggggtgac ggcgcccac gtgctcgccc 44460
 agggggcgct cttgcgagc gcgtcgcgga acgcccggct cgaggccgag gccatcggtt 44520
 acatcgagac ccacggggcg gcaacctcgc tgggcgaccc catcgagatc gaagcgctgc 44580
 cgcgtgtggg ggggcccggc cgagccgacg gagcgcgctg cgtgctgggc gcggtgaaga 44640
 ccaacctcgg ccacctggag ggcgctgccc gcgtggcggg cctgatcaag gcgacgctt 44700
 cgctacatca cgagcgcatc ccgaggaacc tcaactttcg tacgtcaat ccgcggtacc 44760
 ggatcgaggg gaccgcgtc gcgttggcga ccgaaccggg gccctggcg cggacgggct 44820
 ggacgcgctt cgcgggagtgc agctcgcttc ggatgagcgg gaccaacgcg catgtgggt 44880
 tggaggaggc gccggcggtg gagcctgagg ccgcccggc cgagcgcgca gcggagctgt 44940
 tcgtctgtc ggcaagagc gcggcgggc tggatgcgca ggcagccgg ctgcccggacc 45000
 acctggagaa gcacgtcgag cttggcctcg gcgatgtggc gttcagcctg gcgacgacg 45060
 gcagcgcat ggagcaccg ctgcggtggc ccgcgagctc gcgcgagggc ctcgagggg 45120
 cgctttcggc cgacgcgag gggcacacgc cgccggggag cgtgcgtggg cgggctcgg 45180
 gcggcagcgc gccgaagggt gtcttcgtgt tccccggc gggctcgag tgggtgggca 45240
 tgggcccga gctcatggcc gaagagccgg tcttccggg gcgctggag ggttgcgac 45300
 gggccatcga ggccgaagcg ggtggtcgc tgctcgggga gctctccgc gcagagggcg 45360
 cctcgagct cgggcgcatc gacgtggttc agccgggtgt ctctcgcat gaagtagcgc 45420
 tctctcgct gtggcggtcg tggggagtg agccgggaag ggtgggtggc cacagcatg 45480
 gcgaggttgc gggcgcgac gtggccggcg cgtgtcgtc cgaggacgcg gtcgcatca 45540

tctgccggcg	cagccggctg	ctgcccggga	tcagcgggtca	gggggagatg	gcgctggctg	45600
agctgtcgct	ggaggaggcc	gagggggcgc	tgcgtggcca	tgagggctcg	ctgagcgtgg	45660
cggtgagcaa	cagcccgcg	tcgaccgtgc	tcgcccggca	gccggcgcg	ctctcgagg	45720
tgctggcggc	gctgacggcc	aagggggtgt	tctggcgga	ggtgaagggtg	gacgtcgcca	45780
gccatagccc	gcaggtcgac	ccgctgcgcg	aagagctgat	cgcgcgctg	ggagcgatcc	45840
ggccgcgagc	ggctgcgggtg	ccgatgcgct	cgacggtgac	ggggcggggtg	atcgcggttc	45900
cggagctcgg	tgcgagctac	tgggcgga	accttcggca	gccggtgcgc	ttcgctggcg	45960
cgggcgaaagc	gctgctggag	gggtggccccg	cgctgttcat	cgagatgagc	ccgcaccgga	46020
tcctgggtgcc	gcccctggac	gagatccaga	cgggcgccga	gcaaggggggc	gctcggggtg	46080
gctcgctcgc	gcgagggcag	gacgagcgcg	cgacgctgct	ggaggcgctg	gggacgctgt	46140
ggggcgctcgg	ctatccgggtg	agctgggctc	ggctgttccc	cgcgggcggc	aggcggttc	46200
cgctggcgac	ctatccctgg	cagcacgagc	gggtgctggat	cgaggtcgag	cctgacgccc	46260
ggcgctcgc	cgagcccgac	cccaccaagg	actggttcta	ccgaacggac	tgccccgagg	46320
tgcccccgcg	cgccccgaaa	tcggagacag	ctcatgggag	ctggctgctg	ttggccgaca	46380
gggggtgggt	cggtgaggcg	gtcgctgcag	cgctgtcgac	gcgaggactt	tcctgcaccg	46440
tgcttcatgc	gtcggtgac	gcctccaccg	tcgcccagca	ggtatccgaa	gctgccagtc	46500
ggcgaaacga	ctggcaggga	gtcctctacc	tgtggggcct	cgacgcccgtc	gtcgatgctg	46560
gggcatcggc	cgacgaagtc	agcgaggcta	cccgcctgct	caccgcaccc	gtccttgggc	46620
tggttcgatt	cctgagcgct	gcgccccatc	ctcctcgctt	ctgggtgggtg	acccgcgggg	46680
catgcacggt	ggggcgcgag	ccagaggcct	ctctttgcc	agcggcgttg	tgggcgccc	46740
cgcgcgctgc	ggcgctggag	caccccgctg	cctgggggtg	cctcggtgac	ctggatcctc	46800
agaagagccc	gacggagatc	gagccccctg	tgcccagact	gcttctcgcc	gacggcgagg	46860
atcaactggc	gttcccgacg	ggtcgagggc	acgcagcacg	cctttagacc	gccccgcgg	46920
agggcgacgt	cgcaaccgata	tcgctgtccg	cgagggggag	ctacctgggtg	acgggccccg	46980
tggttgccct	tggtctgctc	gtggctcggt	ggctgggtgga	gcggggagct	cgacatctgg	47040
tgctcaccag	ccggcacggg	ctgccagagc	gacagggcgtc	ggggcgagag	cagcccgccg	47100
agggcccgcg	gcgcatcgca	gcggtcgagg	ggctggaagc	gcaggggcg	cggggtgacc	47160
tgccagcggt	ggatgtcgcc	gagggcgatc	ccatgacggc	gctgctggcc	gcatcgagc	47220
ccccgttgcg	cggggtgggtg	cacgcgcggc	gcgtcttccc	cgctcgctcac	ctggcgagga	47280
cgagcagggc	cctgctggag	tcgggtgctc	gtcccaagg	ggccgggagc	tggtgctgc	47340
accggctgct	gcgcgaccgg	cctctcgacc	tgctcgctgc	gttctcgctc	ggcgcgccg	47400
tggtgggtgg	caaaggccaa	ggcgcatacg	ccgcggccaa	tgcttctctc	gacgggctcg	47460
cgccaccatcg	ccgcgcgcac	tcgctgccc	cgcttgagcct	cgccctggggc	ttatggggcc	47520
agggagggcat	ggttgatgca	aaggctcatg	cacgtctgag	cgacatcggg	gtcctgcccc	47580
tgggcacggg	gccggccctg	tcggcgctgg	agcgccctgt	gaacaccagc	gctgtccagc	47640
gttcgggtcac	acggatggac	tgggcgcgct	tcgcccgggt	ctatgcccg	cgagggcgcc	47700
gcaacttgct	ttcggtctcg	gtcgcgagg	acgagcgcg	tgctctccc	ccggtgcccga	47760
cggaacaaccg	gatctggcg	ggcctgtccc	ttgcccagag	ccgctcagcc	ctctacgagc	47820
tcgtttcgcg	catcgctgc	cggtgtctgg	gcttctccga	cccggcgcg	ctcgacgtcg	47880
gcccagggctt	cgccgagcag	gggtctgact	ccctgatggc	tctggagatc	cgtaaccgcc	47940
ttcagcgcgga	gctggggcgaa	cggtgtctgg	cgactctggc	cttcgaccac	ccgacgggtg	48000
agcggtggt	ggcgcatctc	ctcacccagc	tgctgaagct	ggaggaccgg	agcgacaccc	48060
ggcacatccg	gtcggtggcg	gcggatgacg	acatcgccat	cgctgggtgc	gcctgcccgt	48120
ttccaggtgg	ggatgagggc	ctggagacat	actggcgga	tctggccgag	ggcatggtgg	48180
tcagcaccga	ggtgccagcc	gaccggtggc	gcgcccggga	ctggtacgac	cccgatcccg	48240
aggttccggg	ccggacctat	gtggcccaagg	gtgccttccc	ccgcgatgtg	cgagcttgg	48300
atggggcggtt	cttcgccatt	ttccctcgctg	agggcatgag	cctggaccgg	caacagcgcc	48360
tggtgctgga	ggtgagctgg	gagggcgatcg	agcgcgctgg	ccaggaccgg	atggcgctgc	48420
gcgagagcgc	cacggcgctg	ttcgtgggca	tgatcgggag	cgagcacgcc	gagcggtgc	48480
agggcctcga	cgacgacgcg	gcgttgctgt	acggcaccac	cggaacctg	ctcagcgtcg	48540
ccgctggagc	gctgtcgctc	ttcctgggtc	tgacggccc	gacgatgacg	gtggacaccg	48600
cctgctcgctc	gtcgctgggtg	gcgttgcaac	tcgctgcca	gagcctgcga	ttggggcag	48660
gcgaccaggc	cctggccggc	gggtccagcg	tgcttttgct	gccgcggtca	ttcgctcgcg	48720
cgctcgcgat	gcgtttgctt	tcgcccagatg	ggcggtgcaa	gacgttctcg	ggcgctgcag	48780
acggctttgc	gcggggccgag	ggctgcggcg	tggtgggtgct	caagcggtc	cgtagcgcg	48840
agcgcgaccg	cgaccccatc	ctggcggtgg	tcaggagcac	ggcgatcaac	cacgatggcc	48900
cgagcagcgg	gctcacgggtg	cccagcggtc	ctgcccagca	ggcggtgcta	cgccagggcg	48960
tgggcgcaagc	ggggcggtgg	ccggccgagg	tcgatttcgt	ggagtggcac	gggacgggga	49020
cagcgctggg	tgaccgcgac	gaggtgcagg	cgctggggcg	ggtgtacggg	cgggggccgc	49080
ccgcccagcg	gccgctctgg	ctggggcgctg	tcaaggccaa	cctcgggcac	ctggaggccg	49140
cgggcggtt	ggccggcgctg	ctcaagggtc	tcttggcgct	ggagcacgag	cagattccgg	49200
ctcaaccgga	gctcgacgag	ctcaaccgcg	acatcccgtg	ggcagagctg	ccagtggccg	49260
ttgtcccgag	ggcggtcccc	tgggcgcgcg	gcgcccggcc	gcgtcggtga	ggcggtgagc	49320
ctttcgccct	gagcgggacc	aacgcgcgctg	tggtgttggg	ggagggcgcc	gcggtggagc	49380
ctgtggccgc	ggcccccgag	cgcgcgagcg	agctgttcgt	cctgtcgggc	aagagcgcg	49440

cggcgctgga tgcgcaggca gcccgctgc gggaccacct ggagaagcat gtcgagcttg 49500
 gcctcggcga tgtggcgctt agcctggcga cgacgcgcag cgcgatggag caccggctgg 49560
 cggtagccgc gagctcgcgc gaggcgctgc gagggcgct ttcggccgca gcgcaggggc 49620
 acacgcccgc gggagccgtg cgtggcgggg cctcggcgcg cagcgcgccg aaggtggctt 49680
 tcgtgtttcc cggccagggc tcgcagtggg tgggcatggg ccgaaagctc atggccgaag 49740
 agccggtctt ccggcgggcg ctggagggtt gcgaccgggc catcgaggcg gaagcgggct 49800
 ggtcgtgctc cggggagctc tccgcccagc aggcgcctc gcagctcggg cgcacgcagc 49860
 tgggttcagcc ggtgctgttc gccatggaag tagcgcttcc tgcgctgtgg cgtcgtggg 49920
 gagtggagcc ggaagcggtg gtgggccaca gcatggcgga ggttgcggcg gcgcacgtgg 49980
 ccggcgcgct gtcgctcgag gacgcggtgg ccatcatctg ccggcgcgag cggctgctgc 50040
 ggcggatcag cggtcagggg gagatggcgc tggtcgagct gtcgctggag gaggccgagg 50100
 cggcgctcgc tggccatgag ggtcggctga gcgtggcggt gagcaacagc ccgcgctcga 50160
 ccgtcctcgc cggcgagccg gcggcgctct cggaggtgct ggccggcgct acggccaagg 50220
 ggggtgttctg gcggcagggt aaggtggacg tcgcccagca tagcccgag gtcgaccgcg 50280
 tgcgcgaaga gctgacgcgc gcgctgggag cgtccggcc gcgagcggtt gcggtgcccga 50340
 tgcgctcgac ggtgacgggc ggggtgacgc cgggtccgga gctcgggtgc agtactagg 50400
 cggacaacct tcggcagccg gtgcgcttct ctgcccgggc gcaagcgctg ctggagggtg 50460
 gcccccgctt gttcatcgag atgagccgc acccgatcct ggtgcccgcg ctggacgaga 50520
 tccagacggc ggccgagcaa gggggcgctg cgggtgggctc gctgcccga gggcaggacg 50580
 agcgcgcgac gctgctggag gcgctgggga cgctgtgggc gtcgggctat ccggtgagct 50640
 gggctcggct gttcccgcgc ggcggcaggc ggggtccgct gccgacctat ccctggcagc 50700
 acgagcggtg ctggatcgag gacagcgctg atgggtcgaa gccctcgtg -cggcttcggc 50760
 agcttcgcaa cggcgccacg gaccatccgc tgcctggggc tccattgctc gctcggcg 50820
 gaccggagc tcacttgtgg gagcaagcgc tgagcgacga gaggctatcc tacctttcgg 50880
 aacatagggt ccatggcgaa gccgtgttgc ccagcgcggc gtatgtagag atggcgctcg 50940
 ccgcccggct agatctctat ggcacggcga cgctggtgct ggagcagctg gcgctcgagc 51000
 gagccctcgc cgtgccctcc gaaggcgagc gcatcggtga agtggccctc agcgaagaag 51060
 gtcccggctg ggcctcattc caggtatcga gtcgtgagga ggcaggtagg agctgggtgc 51120
 ggcacgccac ggggcacgtg ttagcgggac agagctcagc ggtgggagcg ttgaaggaa 51180
 ctccgtggga gattcaacgg cgtgtccga gcgtcctgtc gtcggaggcg ctctatccg 51240
 tgcctcaaga gcacgcccgc gactatggtc gcttggcagg agacatggca tcctcaagt 51300
 tcggcacggg ggaaggtgctc gggcggttac gcttggcagg agacatggca tcctcaagt 51360
 gcgcctaccg gattcatccc gccttgttgg atgcatgttt tcagggtgct acagcgctgc 51420
 tcaccacgcc ggaatccatc gagattcgga ggcgggtgac gcatctccac gaaccggatc 51480
 tcccgcggtc cagggtcccg gtgaatcaag cggtagtgga cacttggctg tgggacggcg 51540
 cgctggagcg tggacggcgc cagagcgcg gcgtgcccgt cgacctggtg ctccggcagc 51600
 tccatgcgaa gtgggagggtc atggagcgcc tcgcgagggc gtacatcatc ggcactctcc 51660
 gcatatggaa cgtcttctgc gctgctggag agcgtcacac gatagacgag ttgctcgtca 51720
 ggcttcaaat ctctgtcgtc tacaggaagg tcatcaagcg atggatggaa cacttgtctg 51780
 cgatcggcat ccttgtaggg gacggagagc attttgtgag ctctcagccg ctgcccggagc 51840
 ctgatttggc ggcgggtgctc gaggaggccg ggaaggtgtt cgccgacctc ccagtcctat 51900
 ttgagtggtg caagtttgct ggggaacggc tcgcgagctt attgaccggt aagacgctcg 51960
 cgctcgagat cctcttccct ggtggctcgt tcgatatggc ggagcgaatc tatcgagatt 52020
 cgcccatcgc ccgttactcg aacggcatcg tgcgcggtgt cgtcgagtcg gcggcgcggg 52080
 tggtagcacc gtcgggaatg ttcagcatct tggagatcgg agcagggagc ggcgcgacca 52140
 ccgcccggct cctcccgggt ttgctgctg accggagcga gtaccatttc accgatgttt 52200
 ccttgcctct ccttgcctgc gcggagcaaa gatttcgaga ttatccattc ctgaagtatg 52260
 gcattcttga tgtcgaccag gagccagctg gccagggata cgcacatcag aggtttgagc 52320
 tcatcgtcgc ggccaatgct atccatgcga cccgcgatat aagagccacg gcgaagcgtc 52380
 tccgtgctgt gctcgcgccc ggaggccttc tgggtgctgt cgagggcaca gggcatccga 52440
 tcctgttcca tatcaccagc ggattgattg aggggtggca gaagtacgaa gatgatcttc 52500
 gtatcgacca tccgctcctg cctgctcgga cctggtgtga cgtcctgcgc cgggtaggct 52560
 ttgcccagcgc cgtgagctcg ccaggcgagc gatctccggc ggggatccct ggacagcacg 52620
 tgatcctctc gcgcgcgccc ggcatagcag gagccgcttg tgacagctcc ggtgagtcgg 52680
 cgaccgaatc gccggccgcg cgtgcagtac ggcaggaatg ggccgatggc tccgctgagc 52740
 tcgtccatcg gatggcggtg gagaggatgt acttccaccg ccggccgggc cgccaggttt 52800
 ggggtccacg tcgattgctg accggtggag gcgcgttcac gaaggcgctc gctggagatc 52860
 tgcctcgtt cgaagacacc gggcaggctc tggcagaggt tcaggggctc gcctgcccgc 52920
 agctcgaggc ttctgctttc gcgcccgggg acccgcgga agagtgggtg tacgctttcg 52980
 aatggcagcg caaagaccct ataccagagg ctccggcagc cgctcttctc tcctccgcgg 53040
 gggcttggct cgtgctgatg gaccagggcg ggacagggcg tgcgcgctca tcgctgctg 53100
 aagggcgagg cgaggcgctg gtcgcgctca tcgcggtac ggcatacgcc tgctcgcgc 53160
 cggggctgta tcaagtcgat ccggcgagc cagatggctt tcataccctg ctccgcgatg 53220
 cattcgccga ggaccggatt tgcgcgcggt tagtgcatat gtggagcctt gatcgagcgg 53280
 cagcagggga gaggcgaca gccgagtcgc ttcaggccga tcaactcctg gggagcctga 53340

gcgcgcctttc tctgggtgcag ggcgtgggtgc gccggagggtg gcgcaacatg ccgcggccttt 53400
 ggctccttgac ccgcgcctgt catgcgggtg gcgcggaggga cgcagcggcc tcggtggcgc 53460
 aggcgcgggt gtggggcctc ggtcggacgc tcgcgcctcga gcatccagag ctgcgggtgca 53520
 cgctcgtgga cgtgaacccg gcgcgcgtctc cagaggacgc agccgcactg gcggtggagc 53580
 tcggggcgag cgacagagag gaccaggctc cattgcgtc ggatggccgc tacgtggcgc 53640
 gcctcgtgcg gagctccttt tccggcaagc ctgctacgga ttgcggcatc cgggcggagc 53700
 gcagctatgt gatcaccgat ggcattgggga gagggtgggt ctgcggtcgc caatggatgg 53760
 tgatgcaggg ggcccgccat gtgggtgctc tggatcgcg cggcgcttcc gaggcagac 53820
 gggatgccct ccggtccatg gccgaggctg gcgcggaggg gcagatcgtg gagcccgacg 53880
 tggctcggcg cgacgatgtc gctcggctcc tctcgaagat cgaaccgtc atgcccgccg 53940
 ttcgggggat cgtgtacgtg gacgggacct tccaggcgga ctctcgatg ctggagctgg 54000
 atgcccgctc cttcaaggag tggatgtatc ccaagggtgct cggagcgtgg aacctgcacg 54060
 cgctgaccag ggatagatcg ctggacttct tcgtcctgta tctctcgggc acctcgcttc 54120
 tgggcttgcc aggacagggg agccgcgcgc ccggtgacgc cttcttgga gccatcgcg 54180
 atcacccggtg caaggtgggc cttacagcga tgaacatcaa ctggggattg ctctccgaag 54240
 catcatcgcc ggcgaccccg aacgacggcg gacgacggct cgaataccgg gggatggag 54300
 gcctcacgct ggagcagggg gcggcgccgc tcggcgctt gctcgacga cccagggcg 54360
 aggtagggt gatgcggctg aatctgcgcc agtgggttga gttctatccc aacggcgcc 54420
 gattggcgct gtggggcgag ctgctgaagg agcgtgaccg cgccgaccga ggcgctcga 54480
 acgcgtcgaa cctgcgcgag gcgctgcaga gcgccaggcc cgaagatcgt cagttgattc 54540
 tggagaagca cttgagcgag ctgttggggc gggggctgcg cttcccgcc gagaggatcg 54600
 agcggcacgt gccgttcagc aatctcggca tggactcgct gataggcctg gagctccgca 54660
 accgcatcga ggccgcgctc ggcatcaccg tgcggcgac cctgctatgg acctacccta 54720
 acgtagcagc tctgagcggg agcttgcctg acattctgtt tccgaatgcc gcgcgaccc 54780
 acgctccggc caccgagcgg gagaagagct tcgagaacga tgcccgagat ctcgaggctc 54840
 tgcggggcat gacggacgag cagaaggacg cgttgcctgc cgaagagctg gcgcagctcg 54900
 cgcagatcgt tggtagtaaa gggaccgagg gtagtatggc accacgaatg ccgggaagct 54960
 tgagcatgcc cttctgtcga tggacaagct tgcaaaaaag aacgcgtctt tggagcaaga 55020
 gcggaccgag ccgatcgcca tctgtaggcat tggctgccgc tccccggcg gagcgacac 55080
 tccggaggca tctggggagc tgctcgactc agggccgagc gcggtccagc cgctcgaccg 55140
 gcgctggggc ctggctcggc tccatcccag cgaggaggtg ccgcgctggg cgggactgct 55200
 caccgagggc gtggacggct tcgacgcgcg gttctttggc acctcgctc gggaggcgcg 55260
 gtcgctcgat cctcagcaac gcctgctgct ggaggtcacc tgggaaggcg tcgaggacgc 55320
 cggcatcgca cccagctccc tcgacggcag ccgcaccggg gtgttcttg gcgcatgcag 55380
 cagcgactac tcgcataccg ttgcgcaaca gcggcgcgag gacgaggaag catabgacat 55440
 caccggcaat acgctcagcg tcgcccggc agggttgcct tatacgctag ggctgcaggg 55500
 accctgcctg accgtcgaca cggcttgcct gtcgtcgctc tgggcatcc acctgctg 55560
 ccgagcctg cgcgctcgcg agagcgatct cgcgctggcg ggaggcgctc acatgctcct 55620
 ttcgtccaag acgatgataa tgctggggcg catccaggcg ctgctcgccg atggccactg 55680
 ccggacattc gacgcctcgg ccaacgggtt cgtccgtggg gagggtcgcg gtatggctgt 55740
 gctcaaacgg cttctccgacg cccagcgaca cggcgatcgg atctgggctc tgatccgggg 55800
 ttcggccatg aatcaggatg gccggtcgac aggggttagg gcacccaatg tgctcgctca 55860
 ggaggcgctc ttgcgcgagg cgctgcagag cgctcgcgtc gacgcggggg ccatcggtta 55920
 tgcgagacc cacggaacgg ggacctcgt cggcgaccgg atcgaggtcg aggcgctcg 55980
 tgccgtgttg gggccggcg gcggcgatgg gagccgctg gtgctggggc cagtgaagac 56040
 aaacctcggc caccctggagg gcgctgcagg cgtggcgggg ttgatcaagg cggcgctggc 56100
 tctgcaccac gaactgatcc cgcgaaacct ccatttccac acgctcaatc cgcggatccg 56160
 gatcgagggg accgcgctcg cgctggcgac ggagccggtg ccgtggccgc gggcgggcg 56220
 accgcgcttc gcgggggtga gcgcgttcg cctcagcggc accaacgtcc atgtcgtgct 56280
 ggaggaggcg ccggccacgg tgctcgcacc ggcgacggcg ggcgctcag cggagctttt 56340
 ggtgctgtcg gcgaagagcg ccgcgcgct ggacgcacag gcggcgggc tctcagcgca 56400
 catcgccgcg taccggagc aggggtctcg agacgtcgcg ttcagcctg tatcgacg 56460
 tagcccgatg gagcacggc tcgcggtggc ggcgacctc cgcgaggcg tgcgaaagcg 56520
 gctggaggtt gcggcgaggg ggcagacccc ggcagggcg gcgcgaggca gggcgcttc 56580
 ctgcggggc aagctcgct tctgttcgc cggcgaggcg gcgcagggtc cgggcatggg 56640
 ccgtgggttg tgggagggcg ggccggcggt ccgcgagacc ttcgaccggg gcgtcacgct 56700
 cttcgaccgg gagctccatc agccgctctg cgaggtgatg tgggcccagc cgggcagcag 56760
 catctcgctc ttgctggacc agacggcgct caccagcg cgctctttg cgctggagta 56820
 cgcgctggcc gcgctcttc ggtcgtggg cgtggagccg gagctcgctg ctggccatag 56880
 cctcgggcag ctggtggcg cctgcgtggc ggggtgtgtt tccctcgagg acgcgctg 56940
 cttggtggtc gcgcggggc ggttgatgca ggcgctggcg gccggcgcg cggtgggtg 57000
 gatcgcgcca gtcaatgggc cggagcaggt ggtgatcgcg ggcggcgaga aattcgtgca 57060
 gcagatcgcg gcggcggtcg cgcgcgggg ggcgcgaacc aaaccgctg atgtctcgca 57120
 cgcgttccac tcgcgctca tggatccgat gctggaggcg ttcggcgggg tgactgagtc 57180

ggtgacgtac cggcggcctt cgatcgcgct ggtgagcaac ctgagcggga agccctgcac 57300
 cgatgaggtg agcgcgcggg gttactgggt gcgtcacgcg cgagaggcgg tgcgcttcgc 57360
 ggacggagtg aaggcgctgc acgcggcccg tgcgggcctc ttcgtcaggg tggggccgaa 57420
 gccgacgctg ctccggcctt tgccggcctg cctgcccggat gccaggcccg tgcgtctccc 57480
 agcgtcgcgc gccgggctg acgaggctgc gagcgcgcta gaggcgctgg gtgggttctg 57540
 ggtcgtcggg ggatcgggtca cctggctcggg tgtcttccct tcgggcccggac ggccgggtacc 57600
 gctgccaaacc tatccctggc agcgcgagcg ttactggatc gaagcgcccg tcgatcgtga 57660
 ggccggacggc accggccgtg ctccggcggg gggccacccc ctctcgggtg aagtcctttc 57720
 cgtgctgacc catgccggtc tgcgcctgtg ggagacgacg ctggaccgaa agcggctgcc 57780
 gtggctcggc gagcaccggg cgcaggggga ggtcgtgtt cctggcgcgg ggtacctgga 57840
 gatggcgctg tgcctcggggg ccgagatctt gggcgatgga ccgatccagg tcacggatgt 57900
 ggtgctcatc gagacgctga ccttcgcggg cgatacggcg gtaccggctc aggtgggtgac 57960
 gaccgaggag cgaccgggac ggctgcgggt ccaggtagcg agtcgggagc cgggggaacg 58020
 tcgcgcgccc ttccggatcc acgcccgcgg cgtgctgcgc cggatccggc gcgtcgagac 58080
 cccggcgagg tcgaacctcg ccgcccctgc cgcccggctt catgcccggc tgcccgcctg 58140
 ggctatctat ggtgcgctcg ccgagatggg gcttcaatac ggcccggcgt agtcgggggtc 58200
 cggcgagctg tggcggggtg agggcgaggc gctgggcagg gtgagactgc ctgaggccgc 58260
 cggctccgcg acagcctacc agctgcctcc ggtgctgctg gacgcgctgc tccaaatgat 58320
 tgttggcgcg ttccgcgata gcgatgaggc gacgcgctg gcgccggctg aggtgggctc 58380
 ggtcgggctg ttccagcggg ctcccgggga gctatggtg catgcgcgcg tcgtgagcga 58440
 tggtaacacg gcctccagcc ggtggagcgc cgactttgag ttgatggac gtacgggcgc 58500
 ggtggtcgcc gagatctccc ggctgggtgt ggagcggtt gcgagcggtg tacgccggcg 58560
 cgacgcagac gactggttcc tgcgtgctcg cgagggtggt gggctcgggc gctcgttg 58620
 ctccggcgtg aaggccgccc gccatgtcgt cgtccacgcc gcgggggacg acacgagcac 58740
 tgcaggaatg cgcgcgctcc tggccaacgc gttcgacggc caggccccga cggccgtggt 58800
 gcacctcagc agcctcgcgc gggcgggcca gctcggcccg gggctcgggg cgagggcg 58860
 gctcgacgcg ccccgagcc cagatgtcga tgcgatgcc ctccaatcgg cgctgatcg 58920
 tgggttcgac agcgtgctct ccctgggtga agcgtggtc ggcatggacc tccgaaacgc 58980
 gccgcggctg tggctcttga ccccgggggc tcaggcgggc gccgcggcg atgtctccgt 59040
 ggtgaacg cgctgttgg ggtcggggc caccatcgcc ttggagcacg ccgagctgcg 59100
 ctgtatcagc gtcgacctg atccagccga gcctgaagg gaagccgatg ctttgcctgg 59160
 cgagctactt gcagatgat ccgaggagga ggtcgcgctg cgcggtggcg accggctcgt 59220
 tgcgcggctc gtccaccggc tgcccgcgcg tcagcgccgg gagaaggctg agccccgg 59280
 tgacaggccg ttccggctag agatcgatga acccgcgcg ctggaccaac tgcgtctccg 59340
 agccacgggg cggcgcgctc ctggctccgg cgaggctcag atctccgtcg aagcggcg 59400
 gctcgaactc atcgacatcc agctggcgtt gggcgcttgc cccaatgat tgcctggaga 59460
 agaaatcgag ccgttgggtg tcggaagcga gtgcgcggg cgcacgtcg ctgtgggca 59520
 gggcgtgaac ggccttgtg tgggccaagc ggtgatcgcc ctgcggcg gagtatctg 59580
 taccatgtc accacgtcgg ccacgctggt gttgcctcgg cctctggggc tctcggcgac 59640
 cgaggcgccc gcgatgcccc tcgcgtatct gacggcctgg tacgcccctg acaaggctcg 59700
 ccacctgcag gcgggggagc ggtgctgctg ccatgcggag gccggtggtg tcggtctttg 59760
 ccgcgtgcga tgggcgacg gcgtggggcg cgaggtgtat gcgaccgccc acacgcccga 59820
 gaaccgtgcc tacctggagt cgctgggctg gcggtacgt agcgattccc gctcggggcg 59880
 gttcgtcaca gacgtgcat catggacgga cggcgagggt gtggacgtcg tgcctgactc 59940
 gcttccgggc gagcgcacat acaagagcct catggtcctg cgcgcctgtg ctgccttctg 60000
 gaagctgggc aggcgcgacg actgcgcca cagcagcct gggctgccgc cgctcctacg 60060
 gaatttttcc ttctcgcagg tggacttgcg ggaatgatg ctcgatcaac cggcgaggat 60120
 ccgtgcgctc ctcgacgagc tgttcgggtt ggtcgcagcc ggtgccatca gccactggg 60180
 gtcgggggtg cgcgttggcg gatccctcac gccaccgccc gtcgagacct tcccgatctc 60240
 tcgcgcagcc gaggcattcc ggaggatggc gcaaggacag catctcggga agctcgtgct 60300
 cacgctggac gaccggagg tgccggatccg cgtccggccc gaatccagcg tcgcccctcg 60360
 cgcggacggc acctacctt tgaccggcg ggtgggtggc ctccggtctg gcgtggccgg 60420
 atggctggcc gagcggggcg cggggcaact ggtgctgggt ggcgctccc gtcggcgag 60480
 cgcagagcag cgagccgccc tggcgggcgt ggaggccac ggcgcgcgcg tcacgggtgg 60540
 gaaagcgga gtcgccgat ggtaacagat cgagcggggt ctcccgagg ttaccgctg 60600
 ggggatgccc ctgcgggggt tgcgtgcatg ggcaggctc gtggatgacg ggtcgtgat 60660
 gcagcagact ccggcgcggt tccgcacggg gatgggacct aaggtccagg gggccttgca 60720
 cttgcacacg ctgacacgcg aagcgcctct ttcttcttc gtgctgacg ctctgcagc 60780
 tgggcttttc ggctcgcag gccagggcaa ctatgccgca gccaacgcgt tcctcgacgc 60840
 cctttcgcag caccgaagg cgaggggcct gccggcgctg ggcggcgaga tctctcgcgg 60900
 cacgaggtg gggatggcg ttgcgcaaga aaaccgtggc gcgcggcaga tctctcgcgg 60960
 gatgcggggc atcaccccc atgagggtct gtcagctctg gcgcgcttgc tcgagggtga 61020
 tcgcgtgcag acgggggtga taccgatcac tccgcggcag tgggtggagt tctaccggc 61080
 aacagcggcc tcacggaggt tgcgcgggct ggtgaccacg cagcgcgcgg tcgctgatcg 61140

gaccgccggg gatcggggacc tgctcgaaca gcttgcgctcg gctgagccga gcgcgcggggc 61200
ggggctgctg caggacgctcg tgcgcgtgca ggtctcgcac gtgctgcgtc tccctgaaga 61260
caagatcgag gtggatgccc cgtctctgag catgggcatg gactcgctga tgagcctgga 61320
gctgcgcaac cgcacgagg ctgcgctggg cgtcgcccg cctgcagcct tggggtggac 61380
gtaccaaacg gtagcagcga taacgcgctg gctgctcgac gacgcccctc tctccgggt 61440
tggcgcggtg tcggacacgg acgaatcgac ggcgagcgcc gggtcgttcg tccacgtcct 61500
ccgctttcgt cctgtcgtca agccgcgggc tctctcttc tgttttcacg gttctggcgg 61560
ctcgcccgag ggcttccgtt cctggctcga gaagtctgag tggagcgatc tggaaatcgt 61620
ggccatgtgg cagcatcgca gcctcgctc caggagcgcg cctggtaaga agtacgtcca 61680
agaggcgcc tcgctgattc agcactatgc agacgcaccg tttcggttag tagggttcag 61740
cctgggtgtc cgggtcgtca tggggacagc cgtggagctc gccagtcgtt ccggcgacc 61800
ggctccgctg gccgtcttca cgttggggcg cagcttgatc tcttcttcag agatcacccc 61860
ggagatggag accgatataa tagccaagct cttcttcga aatgcccgcg gttctgtcg 61920
atccacccaa caagtccagg ccgatgctcg cgcagacaag gtcacacag acaccatggt 61980
ggctccggcc cccggggact cgaaggagcc gcccgtaag atcgcggtcc ctatcgtcgc 62040
catcgccggc tcggacgatg tgatcgctgc tccgagcgac gttcaggatc tacaatctcg 62100
caccacggag cgcttctata tgcactcctc tcccgagat caccgaatttc tctcgatcg 62160
agggcgcgag atcatgcaca tctcgactc gcatctcaat ccgctgctcg ccgcgaggac 62220
gacgtcgtca ggcccccgct tcgaggcaaa atgatggcag cctccctcgg gcgcgcgaga 62280
tgggttggag cagcgtgggc gctggcgcc ggcgcgaggc cgcgaggcg catgagcctt 62340
cctggacgtt tgcagtatag gagattttat gacacaggag caagcgaatc agagtggagc 62400
gaagcctgct ttcgacttca agcgttcgc gcctgggtac cgggaggacc cgttccccgc 62460
gatcgagcgc ctgagagagg caacccccat cttctactgg gatgaaggcc gctcctgggt 62520
cctcacccga taccacgacg tgtcggcggt gttccgcgac gaacgcttcg cggtcagtcc 62580
agaagagtgg gaatcgagcg cggagtactc gtcggccatt cccgagctca gcgatatgaa 62640
gaagtacgga ttgttcgggc tgcgcggga ggatcacgt cgggtccgca agctcgtcaa 62700
cccgtcgttt acgtcacgcg ccacgcacct gctgcgcgc gaaatacagc gcaccgtcga 62760
ccagctgctc gatgctcgct ccggaacaag ggagtctgac gttgtgcggg attacgcgga 62820
gggaatcccg atgcgcgca tcagcgtctt gttgaagggt ccggccgagt gtgacgagaa 62880
gttccgtcgc ttcggctcgg cgactgcgcg cgcgctcggc gtgggtttgg tgcgccaggt 62940
cgatgaggag accaagaccc tggctcgcgt cgtcacccag gggctcgcgc tgcctcatga 63000
cgtcctcgat gagcggcgca ggaacccgct cgaaaatgac gtcctgacga tgctgcttca 63060
ggccgaggcc gacggcagca ggctgagcac gaaggagctg gtcgcgctcg tgggtgcgat 63120
tatcgctgct ggacccgata ccacgatcta ccttatcgcg ttcgctgtgc tcaacctgct 63180
gcggtcgcgc gaggcgctcg agctggtgaa ggccgagccc gggctcatga ggaacgcgct 63240
cgatgaggtg ctccgcttcg acaatatcct cagaatagga actgtgcgtt tgcccaggca 63300
ggacctggag tactgcgggg catcgatcaa gaaaggggag atggtctttc tccctgatccc 63360
gagcgccctg agagatggga ctgtattctc caggccagac gtgtttgatg tgcgacggga 63420
cacgggcgcg agcctcgcgt acggtagag ccccatgtc tgccccggg tgtcccttcg 63480
tcgctcgag gcggagatcg ccgtgggcac catcttccgt aggttccccg agatgaagct 63540
gaaagaaact cccgtgtttg gataccaccc cgcgttccgg aacatcgaat cactcaacgt 63600
catcttgaag cctccaaaag ctggatagct cgcgggggta tcgcttccc aacctattc 63660
cctcatgata cagctcgcgc gcgggtgctg tctgcgcgg gtgcgattcg atccagcgga 63720
caagcccatt gtcagcgcg cgaagtcgaa tccacggccc ggagaagagc ccgtccgggt 63780
gacgtcggaa gaagtgcgg gcgcgcgccc gggagcgcaa agctcgcctg ttcgcgctca 63840
gcacgcgct cgtcatgtcc ggccctgcac ccgcgcgag gagccgccc cctgatgca 63900
ggcctcacc gagcggcagg ttctgctctc gctcgtcgc ctcgcgctcg tccctctgac 63960
cgcgcgcgc ttcggcgagc tcgcgcggcg gctgcgcag cccgaggtgc tcggcgagct 64020
cttcggcggc gtggtgctgg gcccgctcgt cgtcggcgcg ctcgctcctg ggttccatcg 64080
agtcctcttc caggatccgg cgggtcgggt cgtgctctcc ggcattctct ggataggcgc 64140
gtctgctctg ctgctcatgg cgggtatcga ggtcgatgtg agcatcctgc gcaaggaggc 64200
gcgccccggg gcgctctcgg cgctcggcgc gatcgcgccc ccgctgcgca cgccggggcc 64260
gctggtgag cgcatgaggg gcgcgttcac gtgggatctc gacgtctcgc cgacagctc 64320
tgcgcaagcc tgagcctcgg cgctgctcg tacacctcgc cgggtgctcgc tccgcccgcg 64380
gacatccggc cgcccggcg ggcagctc gagccggact cgccggatga cgaggccgac 64440
gaggccgacg aggcgctccg cccgttccgc gacgcgatcg ccgcgtactc ggaggccgtt 64500
cgggtggcgg aggcggcgca gcggccgcg ctggagagcc tctgcgggt cgcgatcgtg 64560
cggctgggca aggcgctcga caaggtccct ttcgcgcaca cgacggcccg cgtctcccag 64620
atcgccggca gactccagaa cgatgcggtc tgggtcgtatg tcgcccggcg gtacgcgagc 64680
ttcgcgcgcg cgacggagca cgcgctccgc gacgcggcgt cggccatgga ggcgctcgcg 64740
gccggcccg accgcggatc gagccgctg tccgctgccc taggggagtt tcggggggag 64800
cgggcgcgcc ttcaccccgc ggaccgtgta ccccgctccc accagcagat cctgaccgag 64860
ctgcgcgag ccgagcgggc gctcatcgca ctctacactg cgttcgcccc tgaggagtga 64920
gcctctctcg ggcgagccg agcggcgggc tgccggtgggt tccctcttcg caaccatgac 64980
cggagcccg ctccggtccgc gcagcggtca gcgcgcgctc cggcagagat cgctggagcg 65040

acaggcgacg acccgcccga ggggtgctgaa cggattgccc cagccctcat tgcggatccc 65100
 ctccagacac tcgttcagct gcttggcgct gatgcccct gggcactcgc cgaaggctcag 65160
 ctccgtcgcgc cactcggatc ggatcctgtt cgagcacgcg tccttgctcg aatactccc 65220
 gtcttgctcg atgtgtgtgc acccgccctc gcggtcgcac cgcgcgcga cgaatgctatc 65280
 gacggcgctg ccgactggca ccggcgccct gccctgcgcg ccacccgggg tttgcgcctc 65340
 cccgcctgac cgcttttcgc cgccgcacgc cgcgagcagg ctcatctccc acaccgagat 65400
 caggcccacg accagcttcc cagcaatctt ttgcatggct tccccctccc caccagacgt 65460
 cacatcagag actctccgct cggctcgtcg gttcgcacgc cggcgacggc caccagcaga 65520
 accgtccccc accagaacag ccgcatgcgg gtttctcgca acatgccccg acatccttgc 65580
 gactagcgtg cctccgctcg tgccgagatc ggctgtcctg tgcgacggca atatccttgc 65640
 atcgcccggg caggaggtac cgacacgggc gccggcgggg aggtgcccgc acgggctcga 65700
 aatgtgctgc ggcaggcgcc tccatgccc cagccgggaa cgcggcgccc ggccagcctc 65760
 ggggtgacgc cgcaaacggg agatgtctcc ggagaggcgc cgggcacagc cgagcgccgt 65820
 caccaccgtg cgcactcgtg agctccagct cctcggcata gaagagaccg tcaactccc 65880
 tccgtgtagg cgatcgtgct gatcagcgcg ttctccgctt gacgcgagtc gacccgggta 65940
 tgctgcacga caatgggaac gtccgattcg atcacgctgg catagtccgt atcgcgcggg 66000
 atcggtctcg gttcggtcag atcgttgaac cggacgtgcc gggcgccct cgctgggacg 66060
 gtcacccggg acggcccggc ggggtcgcgg tcgctgaagt agacgggtgat ggcgacctgc 66120
 gcgtcccggt ccgacgcatt caacaggcag gccgtctcat ggctcgtcat ctgcgctcg 66180
 ggtccgttgc tccggcctgg gatgtagccc tctgcgattg cccagcgct ccccccagtc 66240
 ggcttctcca tatgtctcc ctgctggctc ctctttggct gcctccctct gctgtccagg 66300
 agcgacggcc tcttctccc acgcgctcgg ggatccatgg ctgaggatcc tcgcccagcg 66360
 ctcttgccg accggcgcg cagagcccg cgggctttga aagcacgcga ccggacacgt 66420
 gatcccgcg cgacgaggg gcccccgctc tgatcccgat cgtgacatcg cgacgtccgc 66480
 cggcgccctc gcaggccggc ctgagcgttg cgcggtcatg gtcgtcctcg cgtcaccgcc 66540
 acccgccgat tcacatccca ccgcggcacg acgcttgctc aaaccgcggc gagacggccg 66600
 ggggctgtg gtaccggcca gcccgagacg gaggcccgag agggacagtg ggtcccgct 66660
 gaagcagtga ggcgatcgag ttggcagatg aaacacgttg acacgggccc acgagtcggc 66720
 cgccggatag ggctcacgct cggctctccc gcgagcatgg cgtcgcggcg ctgtggcgcc 66780
 ccgagcgaga aaatcgtgca gggcacgcgg ctgcgcggcg ggcgggatgc gcacgtcgcc 66840
 gccgacgtcg accccgacgc cgcgaccacg cggctggcgg tggacgtcgt tcacctctcg 66900
 ccgcccagac gcacgaggg cggcagcgag cgggttcgtc tctggcagcg tccgagctcc 66960
 gagtccccgt ggcaacgggt cggagtgtc gactacaacg ctgcccagcc aagaggcaag 67020
 ctggccgaga cgaccgtgcc gcatgccaac ttcgagctgc tcatcaccgt cgagaagcag 67080
 agcagccctc agtctccatc ttctgcccgc gtcacggggc cgacgtccgt cgggtaacat 67140
 cgcgctatca gcagcgtga gcccgccagc agggcccgaga gccctgcctc gatcgccctc 67200
 tccatcatac catccttgcg tactctccca gcgacggccg cgtcgaagca accgcgctgc 67260
 cggcgccggt ctacgtgcgc gacaggagag cgtcctggcg cggcctgcgc atcgtcgga 67320
 ggatcggcg agcatggaga aagaatcgag gatcgcgatc tacggcgcca tcgcagccaa 67380
 cgtggcgatc gcggcggtca agttcatcgc cgcgcggctg accggcagct cggcgatgct 67440
 ctccgagggc gtgcaactccc tcgtcgatag tgacagcggg ctctctctcc tgcctggcaa 67500
 gcaccggagc gcacgcccgc ccgacgcga gcatccgttc ggccacggca aggagctcta 67560
 tttctggacg ctgatcgtcg ccacatgat ctctgcgcg ggcggcgggg tctcgatcta 67620
 cgaagggatc ttgcacctct tgcaccccg ccagatcgag gatccgacgt ggaactacgt 67680
 cgtcctcggc gcagcggccg tcttcgaggg gacgtcgtc atcatctcga tccacgagtt 67740
 caagaagaag gacggacagg gctacctcgc ggcatgagg tccagcaagg acccgacgac 67800
 gttcacgac gtcttgagg actccgcgg gctcgcggg ctaccatcg ccttctcgg 67860
 cgtctggctc gggcaccgce tgggaaaccc ctacctgac ggcgcggcgt cgtcggcat 67920
 cggcctcgtg ctgcgcggc tgcgggtctt cctcgccagc cagagccgtg ggtcctcgt 67980
 gggggagagc gcggacagg agctcctcgc cgcgatccgc gcgctcgcca gcgcagatcc 68040
 tggcgtgtcg gcgggtgggg ggccctgac gatgcacttc ggtccgcacg aagtcctggt 68100
 cgtgctgcgc atcgagtctg acccgcgct caccggcgtc ggggtcgcgg aggcgatcga 68160
 gcgcacatcg acccggtatc ggagcgagc acccgacgtg aagcacatct acgtcgaggc 68220
 caggctcgtc caccagcgc cgagggcggt acgcgcggg gagagaccgc gcgcggcctc 68280
 cgccatctc cgcgccgccc gggctcaggt ggccctcgca gcagggcgcg cctggcgggc 68340
 aaaccgtgca gacgtcgtcc ttcgacgcga ggtacgctgg ttgcaagtgc tcacgcccga 68400
 tcgagaggtc cggcagcgcc ggagcccggg cgggcccggg gcacgaaggc gcggcgagcg 68460
 caggctcga gggggcgac gtcagagga agggcaggg gcagggggc atgctcggcg 68520
 ggcgagatga cggctggcgt cgcggcctcc cggcgccgg cgcgcttcgc gccgcgtcc 68580
 agcgcggtcg ctgcgcgat ctgcggcgcc gccggctcat cgcctccgtg tccctcgccg 68640
 gcggcgccag catggcggtc gtctcgtgt tccagctcgg gatcatcgag cgcctcgccc 68700
 atctccgct tccagggttc gattcggcca aggtgacgag ctccgatatc 68750

<210> 2

<211> 1421

- 19 -

<212> PRT

<213> Sorangium cellulosum

<400> 2

Val Ala Asp Arg Pro Ile Glu Arg Ala Ala Glu Asp Pro Ile Ala Ile
 1 5 10 15
 Val Gly Ala Ser Cys Arg Leu Pro Gly Gly Val Ile Asp Leu Ser Gly
 20 25 30
 Phe Trp Thr Leu Leu Glu Gly Ser Arg Asp Thr Val Gly Arg Val Pro
 35 40 45
 Ala Glu Arg Trp Asp Ala Ala Ala Trp Phe Asp Pro Asp Pro Asp Ala
 50 55 60
 Pro Gly Lys Thr Pro Val Thr Arg Ala Ser Phe Leu Ser Asp Val Ala
 65 70 75 80
 Cys Phe Asp Ala Ser Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Arg
 85 90 95
 Met Asp Pro Ala His Arg Leu Leu Leu Glu Val Cys Trp Glu Ala Leu
 100 105 110
 Glu Asn Ala Ala Ile Ala Pro Ser Ala Leu Val Gly Thr Glu Thr Gly
 115 120 125
 Val Phe Ile Gly Ile Gly Pro Ser Glu Tyr Glu Ala Ala Leu Pro Gln
 130 135 140
 Ala Thr Ala Ser Ala Glu Ile Asp Ala His Gly Gly Leu Gly Thr Met
 145 150 155 160
 Pro Ser Val Gly Ala Gly Arg Ile Ser Tyr Ala Leu Gly Leu Arg Gly
 165 170 175
 Pro Cys Val Ala Val Asp Thr Ala Tyr Ser Ser Ser Leu Val Ala Val
 180 185 190
 His Leu Ala Cys Gln Ser Leu Arg Ser Gly Glu Cys Ser Thr Ala Leu
 195 200 205
 Ala Gly Gly Val Ser Leu Met Leu Ser Pro Ser Thr Leu Val Trp Leu
 210 215 220
 Ser Lys Thr Arg Ala Leu Ala Arg Asp Gly Arg Cys Lys Ala Phe Ser
 225 230 235 240
 Ala Glu Ala Asp Gly Phe Gly Arg Gly Glu Gly Cys Ala Val Val Val
 245 250 255
 Leu Lys Arg Leu Ser Gly Ala Arg Ala Asp Gly Asp Arg Ile Leu Ala
 260 265 270
 Val Ile Arg Gly Ser Ala Ile Asn His Asp Gly Ala Ser Ser Gly Leu
 275 280 285
 Thr Val Pro Asn Gly Ser Ser Gln Glu Ile Val Leu Lys Arg Ala Leu
 290 295 300
 Ala Asp Ala Gly Cys Ala Ala Ser Ser Val Gly Tyr Val Glu Ala His
 305 310 315 320
 Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Ile Gln Ala Leu Asn

Ala	Val	Tyr	Gly	Leu	Gly	Arg	Asp	Val	Ala	Thr	Pro	Leu	Ile	Gly	
			340					345					350		
Ser	Val	Lys	Thr	Asn	Leu	Gly	His	Pro	Glu	Tyr	Ala	Ser	Gly	Ile	Thr
		355					360					365			
Gly	Leu	Leu	Lys	Val	Val	Leu	Ser	Leu	Gln	His	Gly	Gln	Ile	Pro	Ala
	370					375					380				
His	Leu	His	Ala	Gln	Ala	Leu	Asn	Pro	Arg	Ile	Ser	Trp	Gly	Asp	Leu
385				390						395					400
Arg	Leu	Thr	Val	Thr	Arg	Ala	Arg	Thr	Pro	Trp	Pro	Asp	Trp	Asn	Thr
				405					410					415	
Pro	Arg	Arg	Ala	Gly	Val	Ser	Ser	Phe	Gly	Met	Ser	Gly	Thr	Asn	Ala
			420					425					430		
His	Val	Val	Leu	Glu	Glu	Ala	Pro	Ala	Ala	Thr	Cys	Thr	Pro	Pro	Ala
	435						440					445			
Pro	Glu	Arg	Pro	Ala	Glu	Leu	Leu	Val	Leu	Ser	Ala	Arg	Thr	Ala	Ser
	450					455					460				
Ala	Leu	Asp	Ala	Gln	Ala	Ala	Arg	Leu	Arg	Asp	His	Leu	Glu	Thr	Tyr
465				470						475					480
Pro	Ser	Gln	Cys	Leu	Gly	Asp	Val	Ala	Phe	Ser	Leu	Ala	Thr	Thr	Arg
				485					490					495	
Ser	Ala	Met	Glu	His	Arg	Leu	Ala	Val	Ala	Ala	Thr	Ser	Arg	Glu	Gly
			500					505					510		
Leu	Arg	Ala	Ala	Leu	Asp	Ala	Ala	Ala	Gln	Gly	Gln	Thr	Ser	Pro	Gly
	515						520					525			
Ala	Val	Arg	Ser	Ile	Ala	Asp	Ser	Ser	Arg	Gly	Lys	Leu	Ala	Phe	Leu
	530					535					540				
Phe	Thr	Gly	Gln	Gly	Ala	Gln	Thr	Leu	Gly	Met	Gly	Arg	Gly	Leu	Tyr
545					550					555					560
Asp	Val	Trp	Ser	Ala	Phe	Arg	Glu	Ala	Phe	Asp	Leu	Cys	Val	Arg	Leu
				565					570					575	
Phe	Asn	Gln	Glu	Leu	Asp	Arg	Pro	Leu	Arg	Glu	Val	Met	Trp	Ala	Glu
			580					585					590		
Pro	Ala	Ser	Val	Asp	Ala	Ala	Leu	Leu	Asp	Gln	Thr	Ala	Phe	Thr	Gln
		595					600					605			
Pro	Ala	Leu	Phe	Thr	Phe	Glu	Tyr	Ala	Leu	Ala	Ala	Leu	Trp	Arg	Ser
	610					615					620				
Trp	Gly	Val	Glu	Pro	Glu	Leu	Val	Ala	Gly	His	Ser	Ile	Gly	Glu	Leu
625					630					635					640
Val	Ala	Ala	Cys	Val	Ala	Gly	Val	Phe	Ser	Leu	Glu	Asp	Ala	Val	Phe
				645					650					655	
Leu	Val	Ala	Ala	Arg	Gly	Arg	Leu	Met	Gln	Ala	Leu	Pro	Ala	Gly	Gly
				660				665					670		

- 21 -

Ala Met Val Ser Ile Glu Ala Pro Glu Ala Asp Val Ala Ala Ala Val
 675 680 685
 Ala Pro His Ala Ala Ser Val Ser Ile Ala Ala Val Asn Ala Pro Asp
 690 695 700
 Gln Val Val Ile Ala Gly Ala Gly Gln Pro Val His Ala Ile Ala Ala
 705 710 715 720
 Ala Met Ala Ala Arg Gly Ala Arg Thr Lys Ala Leu His Val Ser His
 725 730 735
 Ala Phe His Ser Pro Leu Met Ala Pro Met Leu Glu Ala Phe Gly Arg
 740 745 750
 Val Ala Glu Ser Val Ser Tyr Arg Arg Pro Ser Ile Val Leu Val Ser
 755 760 765
 Asn Leu Ser Gly Lys Ala Cys Thr Asp Glu Val Ser Ser Pro Gly Tyr
 770 775 780
 Trp Val Arg His Ala Arg Glu Val Val Arg Phe Ala Asp Gly Val Lys
 785 790 795 800
 Ala Leu His Ala Ala Gly Ala Gly Thr Phe Val Glu Val Gly Pro Lys
 805 810 815
 Ser Thr Leu Leu Gly Leu Val Pro Ala Cys Met Pro Asp Ala Arg Pro
 820 825 830
 Ala Leu Leu Ala Ser Ser Arg Ala Gly Arg Asp Glu Pro Ala Thr Val
 835 840 845
 Leu Glu Ala Leu Gly Gly Leu Trp Ala Val Gly Gly Leu Val Ser Trp
 850 855 860
 Ala Gly Leu Phe Pro Ser Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr
 865 870 875 880
 Pro Trp Gln Arg Glu Arg Tyr Trp Ile Asp Thr Lys Ala Asp Asp Ala
 885 890 895
 Ala Arg Gly Asp Arg Arg Ala Pro Gly Ala Gly His Asp Glu Val Glu
 900 905 910
 Glu Gly Gly Ala Val Arg Gly Gly Asp Arg Arg Ser Ala Arg Leu Asp
 915 920 925
 His Pro Pro Pro Glu Ser Gly Arg Arg Glu Lys Val Glu Ala Ala Gly
 930 935 940
 Asp Arg Pro Phe Arg Leu Glu Ile Asp Glu Pro Gly Val Leu Asp His
 945 950 955 960
 Leu Val Leu Arg Val Thr Glu Arg Arg Ala Pro Gly Leu Gly Glu Val
 965 970 975
 Glu Ile Ala Val Asp Ala Ala Gly Leu Ser Phe Asn Asp Val Gln Leu
 980 985 990
 Ala Leu Gly Met Val Pro Asp Asp Leu Pro Gly Lys Pro Asn Pro Pro
 995 1000 1005
 Leu Leu Leu Gly Gly Glu Cys Ala Gly Arg Ile Val Ala Val Gly Glu
 1010 1015 1020

- 22 -

Gly Val Asn Gly Leu Val Val Gly Gln Pro Val Ile Ala Leu Ser Ala
 1025 1030 1035 1040
 Gly Ala Phe Ala Thr His Val Thr Thr Ser Ala Ala Leu Val Leu Pro
 1045 1050 1055
 Arg Pro Gln Ala Leu Ser Ala Ile Glu Ala Ala Ala Met Pro Val Ala
 1060 1065 1070
 Tyr Leu Thr Ala Trp Tyr Ala Leu Asp Arg Ile Ala Arg Leu Gln Pro
 1075 1080 1085
 Gly Glu Arg Val Leu Ile His Ala Ala Thr Gly Gly Val Gly Leu Ala
 1090 1095 1100
 Ala Val Gln Trp Ala Gln His Val Gly Ala Glu Val His Ala Thr Ala
 1105 1110 1115 1120
 Gly Thr Pro Glu Lys Arg Ala Tyr Leu Glu Ser Leu Gly Val Arg Tyr
 1125 1130 1135
 Val Ser Asp Ser Arg Ser Asp Arg Phe Val Ala Asp Val Arg Ala Trp
 1140 1145 1150
 Thr Gly Gly Glu Gly Val Asp Val Val Leu Asn Ser Leu Ser Gly Glu
 1155 1160 1165
 Leu Ile Asp Lys Ser Phe Asn Leu Leu Arg Ser His Gly Arg Phe Val
 1170 1175 1180
 Glu Leu Gly Lys Arg Asp Cys Tyr Ala Asp Asn Gln Leu Gly Leu Arg
 1185 1190 1195 1200
 Pro Phe Leu Arg Asn Leu Ser Phe Ser Leu Val Asp Leu Arg Gly Met
 1205 1210 1215
 Met Leu Glu Arg Pro Ala Arg Val Arg Ala Leu Leu Glu Glu Leu Leu
 1220 1225 1230
 Gly Leu Ile Ala Ala Gly Val Phe Thr Pro Pro Pro Ile Ala Thr Leu
 1235 1240 1245
 Pro Ile Ala Arg Val Ala Asp Ala Phe Arg Ser Met Ala Gln Ala Gln
 1250 1255 1260
 His Leu Gly Lys Leu Val Leu Thr Leu Gly Asp Pro Glu Val Gln Ile
 1265 1270 1275 1280
 Arg Ile Pro Thr His Ala Gly Ala Gly Pro Ser Thr Gly Asp Arg Asp
 1285 1290 1295
 Leu Leu Asp Arg Leu Ala Ser Ala Ala Pro Ala Ala Arg Ala Ala Ala
 1300 1305 1310
 Leu Glu Ala Phe Leu Arg Thr Gln Val Ser Gln Val Leu Arg Thr Pro
 1315 1320 1325
 Glu Ile Lys Val Gly Ala Glu Ala Leu Phe Thr Arg Leu Gly Met Asp
 1330 1335 1340
 Ser Leu Met Ala Val Glu Leu Arg Asn Arg Ile Glu Ala Ser Leu Lys
 1345 1350 1355 1360
 Leu Lys Leu Ser Thr Thr Phe Leu Ser Thr Ser Pro Asn Ile Ala Leu

1365 1370 1375

Leu Ala Gln Asn Leu Leu Asp Ala Leu Ala Thr Ala Leu Ser Leu Glu
1380 1385 1390

Arg Val Ala Ala Glu Asn Leu Arg Ala Gly Val Gln Asn Asp Phe Val
1395 1400 1405

Ser Ser Gly Ala Asp Gln Asp Trp Glu Ile Ile Ala Leu
1410 1415 1420

<210> 3
<211> 1410
<212> PRT
<213> Sorangium cellulosum

<400> 3

Met Thr Ile Asn Gln Leu Leu Asn Glu Leu Glu His Gln Gly Ile Lys
1 5 10 15

Leu Ala Ala Asp Gly Glu Arg Leu Gln Ile Gln Ala Pro Lys Asn Ala
20 25 30

Leu Asn Pro Asn Leu Leu Ala Arg Ile Ser Glu His Lys Ser Thr Ile
35 40 45

Leu Thr Met Leu Arg Gln Arg Leu Pro Ala Glu Ser Ile Val Pro Ala
50 55 60

Pro Ala Glu Arg His Ala Pro Phe Pro Leu Thr Asp Ile Gln Glu Ser
65 70 75 80

Tyr Trp Leu Gly Arg Thr Gly Ala Phe Thr Val Pro Ser Gly Ile His
85 90 95

Ala Tyr Arg Glu Tyr Asp Cys Thr Asp Leu Asp Val Pro Arg Leu Ser
100 105 110

Arg Ala Phe Arg Lys Val Val Ala Arg His Asp Met Leu Arg Ala His
115 120 125

Thr Leu Pro Asp Met Met Gln Val Ile Glu Pro Lys Val Asp Ala Asp
130 135 140

Ile Glu Ile Ile Asp Leu Arg Gly Leu Asp Arg Ser Thr Arg Glu Ala
145 150 155 160

Arg Leu Val Ser Leu Arg Asp Ala Met Ser His Arg Ile Tyr Asp Thr
165 170 175

Glu Arg Pro Pro Leu Tyr His Val Val Ala Val Arg Leu Asp Glu Arg
180 185 190

Gln Thr Arg Leu Val Leu Ser Ile Asp Leu Ile Asn Val Asp Leu Gly
195 200 205

Ser Leu Ser Ile Ile Phe Lys Asp Trp Leu Ser Phe Tyr Glu Asp Pro
210 215 220

Glu Thr Ser Leu Pro Val Leu Glu Leu Ser Tyr Arg Asp Tyr Val Leu
225 230 235 240

Ala Leu Glu Ser Arg Lys Lys Ser Glu Ala His Gln Arg Ser Met Asp
245 250 255

- 24 -

Tyr Trp Lys Arg Arg Ile Ala Glu Leu Pro Pro Pro Pro Thr Leu Pro
 260 265 270
 Met Lys Ala Asp Pro Ser Thr Leu Lys Glu Ile Arg Phe Arg His Thr
 275 280 285
 Glu Gln Trp Leu Pro Ser Asp Ser Trp Gly Arg Leu Lys Arg Arg Val
 290 295 300
 Gly Glu Arg Gly Leu Thr Pro Thr Gly Val Ile Leu Ala Ala Phe Ser
 305 310 315 320
 Glu Val Ile Gly Arg Trp Ser Ala Ser Pro Arg Phe Thr Leu Asn Ile
 325 330 335
 Thr Leu Phe Asn Arg Leu Pro Val His Pro Arg Val Asn Asp Ile Thr
 340 345 350
 Gly Asp Phe Thr Ser Met Val Leu Leu Asp Ile Asp Thr Thr Arg Asp
 355 360 365
 Lys Ser Phe Glu Gln Arg Ala Lys Arg Ile Gln Glu Gln Leu Trp Glu
 370 375 380
 Ala Met Asp His Cys Asp Val Ser Gly Ile Glu Val Gln Arg Glu Ala
 385 390 395 400
 Ala Arg Val Leu Gly Ile Gln Arg Gly Ala Leu Phe Pro Val Val Leu
 405 410 415
 Thr Ser Ala Leu Asn Gln Gln Val Val Gly Val Thr Ser Leu Gln Arg
 420 425 430
 Leu Gly Thr Pro Val Tyr Thr Ser Thr Gln Thr Pro Gln Leu Leu Leu
 435 440 445
 Asp His Gln Leu Tyr Glu His Asp Gly Asp Leu Val Leu Ala Trp Asp
 450 455 460
 Ile Val Asp Gly Val Phe Pro Pro Asp Leu Leu Asp Asp Met Leu Glu
 465 470 475 480
 Ala Tyr Val Val Phe Leu Arg Arg Leu Thr Glu Glu Pro Trp Gly Glu
 485 490 495
 Gln Val Arg Cys Ser Leu Pro Pro Ala Gln Leu Glu Ala Arg Ala Ser
 500 505 510
 Ala Asn Ala Thr Asn Ala Leu Leu Ser Glu His Thr Leu His Gly Leu
 515 520 525
 Phe Ala Ala Arg Val Glu Gln Leu Pro Met Gln Leu Ala Val Val Ser
 530 535 540
 Ala Arg Lys Thr Leu Thr Tyr Glu Glu Leu Ser Arg Arg Ser Arg Arg
 545 550 555 560
 Leu Gly Ala Arg Leu Arg Glu Gln Gly Ala Arg Pro Asn Thr Leu Val
 565 570 575
 Ala Val Val Met Glu Lys Gly Trp Glu Gln Val Val Ala Val Leu Ala
 580 585 590
 Val Leu Glu Ser Gly Ala Ala Tyr Val Pro Ile Asp Ala Asp Leu Pro

- 25 -

595	600	605
Ala Glu Arg Ile His Tyr	Leu Leu Asp His Gly	Glu Val Lys Leu Val
610	615	620
Leu Thr Gln Pro Trp	Leu Asp Gly Lys Leu Ser Trp	Pro Pro Gly Ile
625	630	635
Gln Arg Leu Leu Val Ser	Glu Ala Gly Val Glu Gly Asp Gly	Asp Gln
645	650	655
Pro Pro Met Met Pro Ile	Gln Thr Pro Ser Asp Leu Ala Tyr	Val Ile
660	665	670
Tyr Thr Ser Gly Ser Thr	Gly Leu Pro Lys Gly Val Met	Ile Asp His
675	680	685
Arg Gly Ala Val Asn Thr	Ile Leu Asp Ile Asn Glu Arg Phe	Glu Ile
690	695	700
Gly Pro Gly Asp Arg Val	Leu Ala Leu Ser Ser Leu Ser Phe	Asp Leu
705	710	715
Ser Val Tyr Asp Val Phe	Gly Ile Leu Ala Ala Gly Gly Thr	Ile Val
725	730	735
Val Pro Asp Ala Ser Lys	Leu Arg Asp Pro Ala His Trp	Ala Glu Leu
740	745	750
Ile Glu Arg Glu Lys Val	Thr Val Trp Asn Ser Val Pro	Ala Leu Met
755	760	765
Arg Met Leu Val Glu His	Phe Glu Gly Arg Pro Asp	Ser Leu Ala Arg
770	775	780
Ser Leu Arg Leu Ser Leu	Leu Ser Gly Asp Trp Ile Pro	Val Gly Leu
785	790	795
Pro Gly Glu Leu Gln Ala	Ile Arg Pro Gly Val Ser Val	Ile Ser Leu
805	810	815
Gly Gly Ala Thr Glu Ala	Ser Ile Trp Ser Ile Gly Tyr Pro	Val Arg
820	825	830
Asn Val Asp Leu Ser Trp	Ala Ser Ile Pro Tyr Gly Arg	Pro Leu Arg
835	840	845
Asn Gln Thr Phe His Val	Leu Asp Glu Ala Leu Glu	Pro Arg Pro Val
850	855	860
Trp Val Pro Gly Gln Leu	Tyr Ile Gly Gly Val Gly Leu Ala	Leu Gly
865	870	875
Tyr Trp Arg Asp Glu Glu	Lys Thr Arg Lys Ser Phe Leu	Val His Pro
885	890	895
Glu Thr Gly Glu Arg Leu	Tyr Lys Thr Gly Asp Leu Gly	Arg Tyr Leu
900	905	910
Pro Asp Gly Asn Ile Glu	Phe Met Gly Arg Glu Asp Asn	Gln Ile Lys
915	920	925
Leu Arg Gly Tyr Arg Val	Glu Leu Gly Glu Ile Glu Glu	Thr Leu Lys
930	935	940

- 26 -

Ser His Pro Asn Val Arg Asp Ala Val Ile Val Pro Val Gly Asn Asp
 945 950 955 960
 Ala Ala Asn Lys Leu Leu Leu Ala Tyr Val Val Pro Glu Gly Thr Arg
 965 970 975
 Arg Arg Ala Ala Glu Gln Asp Ala Ser Leu Lys Thr Glu Arg Ile Asp
 980 985 990
 Ala Arg Ala His Ala Ala Glu Ala Asp Gly Leu Ser Asp Gly Glu Arg
 995 1000 1005
 Val Gln Phe Lys Leu Ala Arg His Gly Leu Arg Arg Asp Leu Asp Gly
 1010 1015 1020
 Lys Pro Val Val Asp Leu Thr Gly Gln Asp Pro Arg Glu Ala Gly Leu
 1025 1030 1035 1040
 Asp Val Tyr Ala Arg Arg Arg Ser Val Arg Thr Phe Leu Glu Ala Pro
 1045 1050 1055
 Ile Pro Phe Val Glu Phe Gly Arg Phe Leu Ser Cys Leu Ser Ser Val
 1060 1065 1070
 Glu Pro Asp Gly Ala Thr Leu Pro Lys Phe Arg Tyr Pro Ser Ala Gly
 1075 1080 1085
 Ser Thr Tyr Pro Val Gln Thr Tyr Ala Tyr Val Lys Ser Gly Arg Ile
 1090 1095 1100
 Glu Gly Val Asp Glu Gly Phe Tyr Tyr Tyr His Pro Phe Glu His Arg
 1105 1110 1115 1120
 Leu Leu Lys Leu Ser Asp His Gly Ile Glu Arg Gly Ala His Val Arg
 1125 1130 1135
 Gln Asn Phe Asp Val Phe Asp Glu Ala Ala Phe Asn Leu Leu Phe Val
 1140 1145 1150
 Gly Arg Ile Asp Ala Ile Glu Ser Leu Tyr Gly Ser Ser Ser Arg Glu
 1155 1160 1165
 Phe Cys Leu Leu Glu Ala Gly Tyr Met Ala Gln Leu Leu Met Glu Gln
 1170 1175 1180
 Ala Pro Ser Cys Asn Ile Gly Val Cys Pro Val Gly Gln Phe Asn Phe
 1185 1190 1195 1200
 Glu Gln Val Arg Pro Val Leu Asp Leu Arg His Ser Asp Val Tyr Val
 1205 1210 1215
 His Gly Met Leu Gly Gly Arg Val Asp Pro Arg Gln Phe Gln Val Cys
 1220 1225 1230
 Thr Leu Gly Gln Asp Ser Ser Pro Arg Arg Ala Thr Thr Arg Gly Ala
 1235 1240 1245
 Pro Pro Gly Arg Glu Gln His Phe Ala Asp Met Leu Arg Asp Phe Leu
 1250 1255 1260
 Arg Thr Lys Leu Pro Glu Tyr Met Val Pro Thr Val Phe Val Glu Leu
 1265 1270 1275 1280
 Asp Ala Leu Pro Leu Thr Ser Asn Gly Lys Val Asp Arg Lys Ala Leu
 1285 1290 1295

- 27 -

Arg Glu Arg Lys Asp Thr Ser Ser Pro Arg His Ser Gly His Thr Ala
 1300 1305 1310

Pro Arg Asp Ala Leu Glu Glu Ile Leu Val Ala Val Val Arg Glu Val
 1315 1320 1325

Leu Gly Leu Glu Val Val Gly Leu Gln Gln Ser Phe Val Asp Leu Gly
 1330 1335 1340

Ala Thr Ser Ile His Ile Val Arg Met Arg Ser Leu Leu Gln Lys Arg
 1345 1350 1355 1360

Leu Asp Arg Glu Ile Ala Ile Thr Glu Leu Phe Gln Tyr Pro Asn Leu
 1365 1370 1375

Gly Ser Leu Ala Ser Gly Leu Arg Arg Asp Ser Arg Asp Leu Asp Gln
 1380 1385 1390

Arg Pro Asn Met Gln Asp Arg Val Glu Val Arg Arg Lys Gly Arg Arg
 1395 1400 1405

Arg Ser
 1410

<210> 4
 <211> 1832
 <212> PRT
 <213> Sorangium cellulosum

<400> 4
 Met Glu Glu Gln Glu Ser Ser Ala Ile Ala Val Ile Gly Met Ser Gly
 1 5 10 15

Arg Phe Pro Gly Ala Arg Asp Leu Asp Glu Phe Trp Arg Asn Leu Arg
 20 25 30

Asp Gly Thr Glu Ala Val Gln Arg Phe Ser Glu Gln Glu Leu Ala Ala
 35 40 45

Ser Gly Val Asp Pro Ala Leu Val Leu Asp Pro Ser Tyr Val Arg Ala
 50 55 60

Gly Ser Val Leu Glu Asp Val Asp Arg Phe Asp Ala Ala Phe Phe Gly
 65 70 75 80

Ile Ser Pro Arg Glu Ala Glu Leu Met Asp Pro Gln His Arg Ile Phe
 85 90 95

Met Glu Cys Ala Trp Glu Ala Leu Glu Asn Ala Gly Tyr Asp Pro Thr
 100 105 110

Ala Tyr Glu Gly Ser Ile Gly Val Tyr Ala Gly Ala Asn Met Ser Ser
 115 120 125

Tyr Leu Thr Ser Asn Leu His Glu His Pro Ala Met Met Arg Trp Pro
 130 135 140

Gly Trp Phe Gln Thr Leu Ile Gly Asn Asp Lys Asp Tyr Leu Ala Thr
 145 150 155 160

His Val Ser Tyr Arg Leu Asn Leu Arg Gly Pro Ser Ile Ser Val Gln
 165 170 175

- 28 -

Thr Ala Cys Ser Thr Ser Leu Val Ala Val His Leu Ala Cys Met Ser
 180 185 190
 Leu Leu Asp Arg Glu Cys Asp Met Ala Leu Ala Gly Gly Ile Thr Val
 195 200 205
 Arg Ile Pro His Arg Ala Gly Tyr Val Tyr Ala Glu Gly Gly Ile Phe
 210 215 220
 Ser Pro Asp Gly His Cys Arg Ala Phe Asp Ala Lys Ala Asn Gly Thr
 225 230 235 240
 Ile Met Gly Asn Gly Cys Gly Val Val Leu Leu Lys Pro Leu Asp Arg
 245 250 255
 Ala Leu Ser Asp Gly Asp Pro Val Arg Ala Val Ile Leu Gly Ser Ala
 260 265 270
 Thr Asn Asn Asp Gly Ala Arg Lys Ile Gly Phe Thr Ala Pro Ser Glu
 275 280 285
 Val Gly Gln Ala Gln Ala Ile Met Glu Ala Leu Ala Leu Ala Gly Val
 290 295 300
 Glu Ala Arg Ser Ile Gln Tyr Ile Glu Thr His Gly Thr Gly Thr Leu
 305 310 315 320
 Leu Gly Asp Ala Ile Glu Thr Ala Ala Leu Arg Arg Val Phe Gly Arg
 325 330 335
 Asp Ala Ser Ala Arg Arg Ser Cys Ala Ile Gly Ser Val Lys Thr Gly
 340 345 350
 Ile Gly His Leu Glu Ser Ala Ala Gly Ile Ala Gly Leu Ile Lys Thr
 355 360 365
 Val Leu Ala Leu Glu His Arg Gln Leu Pro Pro Ser Leu Asn Phe Glu
 370 375 380
 Ser Pro Asn Pro Ser Ile Asp Phe Ala Ser Ser Pro Phe Tyr Val Asn
 385 390 395 400
 Thr Ser Leu Lys Asp Trp Asn Thr Gly Ser Thr Pro Arg Arg Ala Gly
 405 410 415
 Val Ser Ser Phe Gly Ile Gly Gly Thr Asn Ala His Val Val Leu Glu
 420 425 430
 Glu Ala Pro Ala Ala Lys Leu Pro Ala Ala Ala Pro Ala Arg Ser Ala
 435 440 445
 Glu Leu Phe Val Val Ser Ala Lys Ser Ala Ala Ala Leu Asp Ala Ala
 450 455 460
 Ala Ala Arg Leu Arg Asp His Leu Gln Ala His Gln Gly Ile Ser Leu
 465 470 475 480
 Gly Asp Val Ala Phe Ser Leu Ala Thr Thr Arg Ser Pro Met Glu His
 485 490 495
 Arg Leu Ala Met Ala Ala Pro Ser Arg Glu Ala Leu Arg Glu Gly Leu
 500 505 510
 Asp Ala Ala Ala Arg Gly Gln Thr Pro Pro Gly Ala Val Arg Gly Arg
 515 520 525

- 29 -

Cys Ser Pro Gly Asn Val Pro Lys Val Val Phe Val Phe Pro Gly Gln
 530 535 540
 Gly Ser Gln Trp Val Gly Met Gly Arg Gln Leu Leu Ala Glu Glu Pro
 545 550 555 560
 Val Phe His Ala Ala Leu Ser Ala Cys Asp Arg Ala Ile Gln Ala Glu
 565 570 575
 Ala Gly Trp Ser Leu Leu Ala Glu Leu Ala Ala Asp Glu Gly Ser Ser
 580 585 590
 Gln Leu Glu Arg Ile Asp Val Val Gln Pro Val Leu Phe Ala Leu Ala
 595 600 605
 Val Ala Phe Ala Ala Leu Trp Arg Ser Trp Gly Val Ala Pro Asp Val
 610 615 620
 Val Ile Gly His Ser Met Gly Glu Val Ala Ala Ala His Val Ala Gly
 625 630 635 640
 Ala Leu Ser Leu Glu Asp Ala Val Ala Ile Ile Cys Arg Arg Ser Arg
 645 650 655
 Leu Leu Arg Arg Ile Ser Gly Gln Gly Glu Met Ala Val Thr Glu Leu
 660 665 670
 Ser Leu Ala Glu Ala Glu Ala Ala Leu Arg Gly Tyr Glu Asp Arg Val
 675 680 685
 Ser Val Ala Val Ser Asn Ser Pro Arg Ser Thr Val Leu Ser Gly Glu
 690 695 700
 Pro Ala Ala Ile Gly Glu Val Leu Ser Ser Leu Asn Ala Lys Gly Val
 705 710 715 720
 Phe Cys Arg Arg Val Lys Val Asp Val Ala Ser His Ser Pro Gln Val
 725 730 735
 Asp Pro Leu Arg Glu Asp Leu Leu Ala Ala Leu Gly Gly Leu Arg Pro
 740 745 750
 Gly Ala Ala Ala Val Pro Met Arg Ser Thr Val Thr Gly Ala Met Val
 755 760 765
 Ala Gly Pro Glu Leu Gly Ala Asn Tyr Trp Met Asn Asn Leu Arg Gln
 770 775 780
 Pro Val Arg Phe Ala Glu Val Val Gln Ala Gln Leu Gln Gly Gly His
 785 790 795 800
 Gly Leu Phe Val Glu Met Ser Pro His Pro Ile Leu Thr Thr Ser Val
 805 810 815
 Glu Glu Met Arg Arg Ala Ala Gln Arg Ala Gly Ala Ala Val Gly Ser
 820 825 830
 Leu Arg Arg Gly Gln Asp Glu Arg Pro Ala Met Leu Glu Ala Leu Gly
 835 840 845
 Thr Leu Trp Ala Gln Gly Tyr Pro Val Pro Trp Gly Arg Leu Phe Pro
 850 855 860
 Ala Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln Arg Glu

- 30 -

865	870	875	880
Arg Tyr Trp Ile Glu Ala Pro Ala Lys Ser Ala Ala Gly Asp Arg Arg	885	890	895
Gly Val Arg Ala Gly Gly His Pro Leu Leu Gly Glu Met Gln Thr Leu	900	905	910
Ser Thr Gln Thr Ser Thr Arg Leu Trp Glu Thr Thr Leu Asp Leu Lys	915	920	925
Arg Leu Pro Trp Leu Gly Asp His Arg Val Gln Gly Ala Val Val Phe	930	935	940
Pro Gly Ala Ala Tyr Leu Glu Met Ala Ile Ser Ser Gly Ala Glu Ala	945	950	955
Leu Gly Asp Gly Pro Leu Gln Ile Thr Asp Val Val Leu Ala Glu Ala	965	970	975
Leu Ala Phe Ala Gly Asp Ala Ala Val Leu Val Gln Val Val Thr Thr	980	985	990
Glu Gln Pro Ser Gly Arg Leu Gln Phe Gln Ile Ala Ser Arg Ala Pro	995	1000	1005
Gly Ala Gly His Ala Ser Phe Arg Val His Ala Arg Gly Ala Leu Leu	1010	1015	1020
Arg Val Glu Arg Thr Glu Val Pro Ala Gly Leu Thr Leu Ser Ala Val	1025	1030	1035
Arg Ala Arg Leu Gln Ala Ser Ile Pro Ala Ala Ala Thr Tyr Ala Glu	1045	1050	1055
Leu Thr Glu Met Gly Leu Gln Tyr Gly Pro Ala Phe Gln Gly Ile Ala	1060	1065	1070
Glu Leu Trp Arg Gly Glu Gly Glu Ala Leu Gly Arg Val Arg Leu Pro	1075	1080	1085
Asp Ala Ala Gly Ser Ala Ala Glu Tyr Arg Leu His Pro Ala Leu Leu	1090	1095	1100
Asp Ala Cys Phe Gln Ile Val Gly Ser Leu Phe Ala Arg Ser Gly Glu	1105	1110	1115
Ala Thr Pro Trp Val Pro Val Glu Leu Gly Ser Leu Arg Leu Leu Gln	1125	1130	1135
Arg Pro Ser Gly Glu Leu Trp Cys His Ala Arg Val Val Asn His Gly	1140	1145	1150
His Gln Thr Pro Asp Arg Gln Gly Ala Asp Phe Trp Val Val Asp Ser	1155	1160	1165
Ser Gly Ala Val Val Ala Glu Val Cys Gly Leu Val Ala Gln Arg Leu	1170	1175	1180
Pro Gly Gly Val Arg Arg Arg Glu Glu Asp Asp Trp Phe Leu Glu Leu	1185	1190	1195
Glu Trp Glu Pro Ala Ala Val Gly Thr Ala Lys Val Asn Ala Gly Arg	1205	1210	1215

- 31 -

Trp Leu Leu Leu Gly Gly Gly Gly Gly Leu Gly Ala Ala Leu Arg Ala
 1220 1225 1230
 Met Leu Glu Ala Gly Gly His Ala Val Val His Ala Ala Glu Asn Asn
 1235 1240 1245
 Thr Ser Ala Ala Gly Val Arg Ala Leu Leu Ala Lys Ala Phe Asp Gly
 1250 1255 1260
 Gln Ala Pro Thr Ala Val Val His Leu Gly Ser Leu Asp Gly Gly Gly
 1265 1270 1275 1280
 Glu Leu Asp Pro Gly Leu Gly Ala Gln Gly Ala Leu Asp Ala Pro Arg
 1285 1290 1295
 Ser Ala Asp Val Ser Pro Asp Ala Leu Asp Pro Ala Leu Val Arg Gly
 1300 1305 1310
 Cys Asp Ser Val Leu Trp Thr Val Gln Ala Leu Ala Gly Met Gly Phe
 1315 1320 1325
 Arg Asp Ala Pro Arg Leu Trp Leu Leu Thr Arg Gly Ala Gln Ala Val
 1330 1335 1340
 Gly Ala Gly Asp Val Ser Val Thr Gln Ala Pro Leu Leu Gly Leu Gly
 1345 1350 1355 1360
 Arg Val Ile Ala Met Glu His Ala Asp Leu Arg Cys Ala Arg Val Asp
 1365 1370 1375
 Leu Asp Pro Ala Arg Pro Glu Gly Glu Leu Ala Ala Leu Leu Ala Glu
 1380 1385 1390
 Leu Leu Ala Asp Asp Ala Glu Ala Glu Val Ala Leu Arg Gly Gly Glu
 1395 1400 1405
 Arg Cys Val Ala Arg Ile Val Arg Arg Gln Pro Glu Thr Arg Pro Arg
 1410 1415 1420
 Gly Arg Ile Glu Ser Cys Val Pro Thr Asp Val Thr Ile Arg Ala Asp
 1425 1430 1435 1440
 Ser Thr Tyr Leu Val Thr Gly Gly Leu Gly Gly Leu Gly Leu Ser Val
 1445 1450 1455
 Ala Gly Trp Leu Ala Glu Arg Gly Ala Gly His Leu Val Leu Val Gly
 1460 1465 1470
 Arg Ser Gly Ala Ala Ser Val Glu Gln Arg Ala Ala Val Ala Ala Leu
 1475 1480 1485
 Glu Ala Arg Gly Ala Arg Val Thr Val Ala Lys Ala Asp Val Ala Asp
 1490 1495 1500
 Arg Ala Gln Leu Glu Arg Ile Leu Arg Glu Val Thr Thr Ser Gly Met
 1505 1510 1515 1520
 Pro Leu Arg Gly Val Val His Ala Ala Gly Ile Leu Asp Asp Gly Leu
 1525 1530 1535
 Leu Met Gln Gln Thr Pro Ala Arg Phe Arg Lys Val Met Ala Pro Lys
 1540 1545 1550
 Val Gln Gly Ala Leu His Leu His Ala Leu Thr Arg Glu Ala Pro Leu
 1555 1560 1565

- 32 -

Ser Phe Phe Val Leu Tyr Ala Ser Gly Val Gly Leu Leu Gly Ser Pro
 1570 1575 1580
 Gly Gln Gly Asn Tyr Ala Ala Ala Asn Thr Phe Leu Asp Ala Leu Ala
 1585 1590 1595 1600
 His His Arg Arg Ala Gln Gly Leu Pro Ala Leu Ser Val Asp Trp Gly
 1605 1610 1615
 Leu Phe Ala Glu Val Gly Met Ala Ala Ala Gln Glu Asp Arg Gly Ala
 1620 1625 1630
 Arg Leu Val Ser Arg Gly Met Arg Ser Leu Thr Pro Asp Glu Gly Leu
 1635 1640 1645
 Ser Ala Leu Ala Arg Leu Leu Glu Ser Gly Arg Ala Gln Val Gly Val
 1650 1655 1660
 Met Pro Val Asn Pro Arg Leu Trp Val Glu Leu Tyr Pro Ala Ala Ala
 1665 1670 1675 1680
 Ser Ser Arg Met Leu Ser Arg Leu Val Thr Ala His Arg Ala Ser Ala
 1685 1690 1695
 Gly Gly Pro Ala Gly Asp Gly Asp Leu Leu Arg Arg Leu Ala Ala Ala
 1700 1705 1710
 Glu Pro Ser Ala Arg Ser Ala Leu Leu Glu Pro Leu Leu Arg Ala Gln
 1715 1720 1725
 Ile Ser Gln Val Leu Arg Leu Pro Glu Gly Lys Ile Glu Val Asp Ala
 1730 1735 1740
 Pro Leu Thr Ser Leu Gly Met Asn Ser Leu Met Gly Leu Glu Leu Arg
 1745 1750 1755 1760
 Asn Arg Ile Glu Ala Met Leu Gly Ile Thr Val Pro Ala Thr Leu Leu
 1765 1770 1775
 Trp Thr Tyr Pro Thr Val Ala Ala Leu Ser Gly His Leu Ala Arg Glu
 1780 1785 1790
 Ala Cys Glu Ala Ala Pro Val Glu Ser Pro His Thr Thr Ala Asp Ser
 1795 1800 1805
 Ala Val Glu Ile Glu Glu Met Ser Gln Asp Asp Leu Thr Gln Leu Ile
 1810 1815 1820
 Ala Ala Lys Phe Lys Ala Leu Thr
 1825 1830
 <210> 5
 <211> 7257
 <212> PRT
 <213> Sorangium cellulosum
 <400> 5
 Met Thr Thr Arg Gly Pro Thr Ala Gln Gln Asn Pro Leu Lys Gln Ala
 1 5 10 15
 Ala Ile Ile Ile Gln Arg Leu Glu Glu Arg Leu Ala Gly Leu Ala Gln
 20 25 30

- 33 -

Ala Glu Leu Glu Arg Thr Glu Pro Ile Ala Ile Val Gly Ile Gly Cys
 35 40 45
 Arg Phe Pro Gly Gly Ala Asp Ala Pro Glu Ala Phe Trp Glu Leu Leu
 50 55 60
 Asp Ala Glu Arg Asp Ala Val Gln Pro Leu Asp Met Arg Trp Ala Leu
 65 70 75 80
 Val Gly Val Ala Pro Val Glu Ala Val Pro His Trp Ala Gly Leu Leu
 85 90 95
 Thr Glu Pro Ile Asp Cys Phe Asp Ala Ala Phe Phe Gly Ile Ser Pro
 100 105 110
 Arg Glu Ala Arg Ser Leu Asp Pro Gln His Arg Leu Leu Leu Glu Val
 115 120 125
 Ala Trp Glu Gly Leu Glu Asp Ala Gly Ile Pro Pro Arg Ser Ile Asp
 130 135 140
 Gly Ser Arg Thr Gly Val Phe Val Gly Ala Phe Thr Ala Asp Tyr Ala
 145 150 155 160
 Arg Thr Val Ala Arg Leu Pro Arg Glu Glu Arg Asp Ala Tyr Ser Ala
 165 170 175
 Thr Gly Asn Met Leu Ser Ile Ala Ala Gly Arg Leu Ser Tyr Thr Leu
 180 185 190
 Gly Leu Gln Gly Pro Cys Leu Thr Val Asp Thr Ala Cys Ser Ser Ser
 195 200 205
 Leu Val Ala Ile His Leu Ala Cys Arg Ser Leu Arg Ala Gly Glu Ser
 210 215 220
 Asp Leu Ala Leu Ala Gly Val Ser Ala Leu Leu Ser Pro Asp Met
 225 230 235 240
 Met Glu Ala Ala Ala Arg Thr Gln Ala Leu Ser Pro Asp Gly Arg Cys
 245 250 255
 Arg Thr Phe Asp Ala Ser Ala Asn Gly Phe Val Arg Gly Glu Gly Cys
 260 265 270
 Gly Leu Val Val Leu Lys Arg Leu Ser Asp Ala Gln Arg Asp Gly Asp
 275 280 285
 Arg Ile Trp Ala Leu Ile Arg Gly Ser Ala Ile Asn His Asp Gly Arg
 290 295 300
 Ser Thr Gly Leu Thr Ala Pro Asn Val Leu Ala Gln Glu Thr Val Leu
 305 310 315 320
 Arg Glu Ala Leu Arg Ser Ala His Val Glu Ala Gly Ala Val Asp Tyr
 325 330 335
 Val Glu Thr His Gly Thr Gly Thr Ser Leu Gly Asp Pro Ile Glu Val
 340 345 350
 Glu Ala Leu Arg Ala Thr Val Gly Pro Ala Arg Ser Asp Gly Thr Arg
 355 360 365
 Cys Val Leu Gly Ala Val Lys Thr Asn Ile Gly His Leu Glu Ala Ala
 370 375 380

- 34 -

Ala Gly Val Ala Gly Leu Ile Lys Ala Ala Leu Ser Leu Thr His Glu
 385 390 395 400
 Arg Ile Pro Arg Asn Leu Asn Phe Arg Thr Leu Asn Pro Arg Ile Arg
 405 410 415
 Leu Glu Gly Ser Ala Leu Ala Leu Ala Thr Glu Pro Val Pro Trp Pro
 420 425 430
 Arg Thr Asp Arg Pro Arg Phe Ala Gly Val Ser Ser Phe Gly Met Ser
 435 440 445
 Gly Thr Asn Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu Leu
 450 455 460
 Trp Pro Ala Ala Pro Glu Arg Ser Ala Glu Leu Leu Val Leu Ser Gly
 465 470 475 480
 Lys Ser Glu Gly Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Glu His
 485 490 495
 Leu Asp Met His Pro Glu Leu Gly Leu Gly Asp Val Ala Phe Ser Leu
 500 505 510
 Ala Thr Thr Arg Ser Ala Met Ser His Arg Leu Ala Val Ala Val Thr
 515 520 525
 Ser Arg Glu Gly Leu Leu Ala Ala Leu Ser Ala Val Ala Gln Gly Gln
 530 535 540
 Thr Pro Ala Gly Ala Ala Arg Cys Ile Ala Ser Ser Ser Arg Gly Lys
 545 550 555 560
 Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln Thr Pro Gly Met Gly
 565 570 575
 Arg Gly Leu Cys Ala Ala Trp Pro Ala Phe Arg Glu Ala Phe Asp Arg
 580 585 590
 Cys Val Ala Leu Phe Asp Arg Glu Leu Asp Arg Pro Leu Arg Glu Val
 595 600 605
 Met Trp Ala Glu Ala Gly Ser Ala Glu Ser Leu Leu Leu Asp Gln Thr
 610 615 620
 Ala Phe Thr Gln Pro Ala Leu Phe Ala Val Glu Tyr Ala Leu Thr Ala
 625 630 635 640
 Leu Trp Arg Ser Trp Gly Val Glu Pro Glu Leu Leu Val Gly His Ser
 645 650 655
 Ile Gly Glu Leu Val Ala Ala Cys Val Ala Gly Val Phe Ser Leu Glu
 660 665 670
 Asp Gly Val Arg Leu Val Ala Ala Arg Gly Arg Leu Met Gln Gly Leu
 675 680 685
 Ser Ala Gly Gly Ala Met Val Ser Leu Gly Ala Pro Glu Ala Glu Val
 690 695 700
 Ala Ala Ala Val Ala Pro His Ala Ala Ser Val Ser Ile Ala Ala Val
 705 710 715 720
 Asn Gly Pro Glu Gln Val Val Ile Ala Gly Val Glu Gln Ala Val Gln

- 35 -

725										730					735				
Ala	Ile	Ala	Ala	Gly	Phe	Ala	Ala	Arg	Gly	Ala	Arg	Thr	Lys	Arg	Leu				
			740					745					750						
His	Val	Ser	His	Ala	Phe	His	Ser	Pro	Leu	Met	Glu	Pro	Met	Leu	Glu				
		755					760					765							
Glu	Phe	Gly	Arg	Val	Ala	Ala	Ser	Val	Thr	Tyr	Arg	Arg	Pro	Ser	Val				
	770					775					780								
Ser	Leu	Val	Ser	Asn	Leu	Ser	Gly	Lys	Val	Val	Thr	Asp	Glu	Leu	Ser				
	785				790						795				800				
Ala	Pro	Gly	Tyr	Trp	Val	Arg	His	Val	Arg	Glu	Ala	Val	Arg	Phe	Ala				
				805					810					815					
Asp	Gly	Val	Lys	Ala	Leu	His	Glu	Ala	Gly	Ala	Gly	Thr	Phe	Val	Glu				
			820				825						830						
Val	Gly	Pro	Lys	Pro	Thr	Leu	Leu	Gly	Leu	Leu	Pro	Ala	Cys	Leu	Pro				
		835					840					845							
Glu	Ala	Glu	Pro	Thr	Leu	Leu	Ala	Ser	Leu	Arg	Ala	Gly	Arg	Glu	Glu				
	850					855					860								
Ala	Ala	Gly	Val	Leu	Glu	Ala	Leu	Gly	Arg	Leu	Trp	Ala	Ala	Gly	Gly				
	865				870				875					880					
Ser	Val	Ser	Trp	Pro	Gly	Val	Phe	Pro	Thr	Ala	Gly	Arg	Arg	Val	Pro				
				885					890					895					
Leu	Pro	Thr	Tyr	Pro	Trp	Gln	Arg	Gln	Arg	Tyr	Trp	Ile	Glu	Ala	Pro				
			900					905					910						
Ala	Glu	Gly	Leu	Gly	Ala	Thr	Ala	Ala	Asp	Ala	Leu	Ala	Gln	Trp	Phe				
		915					920						925						
Tyr	Arg	Val	Asp	Trp	Pro	Glu	Met	Pro	Arg	Ser	Ser	Val	Asp	Ser	Arg				
	930						935					940							
Arg	Ala	Arg	Ser	Gly	Gly	Trp	Leu	Val	Leu	Ala	Asp	Arg	Gly	Gly	Val				
	945				950						955				960				
Gly	Glu	Ala	Ala	Ala	Ala	Ala	Leu	Ser	Ser	Gln	Gly	Cys	Ser	Cys	Ala				
				965				970						975					
Val	Leu	His	Ala	Pro	Ala	Glu	Ala	Ser	Ala	Val	Ala	Glu	Gln	Val	Thr				
			980					985					990						
Gln	Ala	Leu	Gly	Gly	Arg	Asn	Asp	Trp	Gln	Gly	Val	Leu	Tyr	Leu	Trp				
		995					1000						1005						
Gly	Leu	Asp	Ala	Val	Val	Glu	Ala	Gly	Ala	Ser	Ala	Glu	Glu	Val	Ala				
	1010					1015					1020								
Lys	Val	Thr	His	Leu	Ala	Ala	Ala	Pro	Val	Leu	Ala	Leu	Ile	Gln	Ala				
	1025				1030						1035			1040					
Leu	Gly	Thr	Gly	Pro	Arg	Ser	Pro	Arg	Leu	Trp	Ile	Val	Thr	Arg	Gly				
			1045					1050					1055						
Ala	Cys	Thr	Val	Gly	Gly	Glu	Pro	Asp	Ala	Ala	Pro	Cys	Gln	Ala	Ala				
			1060					1065					1070						

- 36 -

Leu Trp Gly Met Gly Arg Val Ala Ala Leu Glu His Pro Gly Ser Trp
 1075 1080 1085
 Gly Gly Leu Val Asp Leu Asp Pro Glu Glu Ser Pro Thr Glu Val Glu
 1090 1095 1100
 Ala Leu Val Ala Glu Leu Leu Ser Pro Asp Ala Glu Asp Gln Leu Ala
 1105 1110 1115 1120
 Phe Arg Gln Gly Arg Arg Arg Ala Ala Arg Leu Val Ala Ala Pro Pro
 1125 1130 1135
 Glu Gly Asn Ala Ala Pro Val Ser Leu Ser Ala Glu Gly Ser Tyr Leu
 1140 1145 1150
 Val Thr Gly Gly Leu Gly Ala Leu Gly Leu Leu Val Ala Arg Trp Leu
 1155 1160 1165
 Val Glu Arg Gly Ala Gly His Leu Val Leu Ile Ser Arg His Gly Leu
 1170 1175 1180
 Pro Asp Arg Glu Glu Trp Gly Arg Asp Gln Pro Pro Glu Val Arg Ala
 1185 1190 1195 1200
 Arg Ile Ala Ala Ile Glu Ala Leu Glu Ala Gln Gly Ala Arg Val Thr
 1205 1210 1215
 Val Ala Ala Val Asp Val Ala Asp Ala Glu Gly Met Ala Ala Leu Leu
 1220 1225 1230
 Ala Ala Val Glu Pro Pro Leu Arg Gly Val Val His Ala Ala Gly Leu
 1235 1240 1245
 Leu Asp Asp Gly Leu Leu Ala His Gln Asp Ala Gly Arg Leu Ala Arg
 1250 1255 1260
 Val Leu Arg Pro Lys Val Glu Gly Ala Trp Val Leu His Thr Leu Thr
 1265 1270 1275 1280
 Arg Glu Gln Pro Leu Asp Leu Phe Val Leu Phe Ser Ser Ala Ser Gly
 1285 1290 1295
 Val Phe Gly Ser Ile Gly Gln Gly Ser Tyr Ala Ala Gly Asn Ala Phe
 1300 1305 1310
 Leu Asp Ala Leu Ala Asp Leu Arg Arg Thr Gln Gly Leu Ala Ala Leu
 1315 1320 1325
 Ser Ile Ala Trp Gly Leu Trp Ala Glu Gly Gly Met Gly Ser Gln Ala
 1330 1335 1340
 Gln Arg Arg Glu His Glu Ala Ser Gly Ile Trp Ala Met Pro Thr Ser
 1345 1350 1355 1360
 Arg Ala Leu Ala Ala Met Glu Trp Leu Leu Gly Thr Arg Ala Thr Gln
 1365 1370 1375
 Arg Val Val Ile Gln Met Asp Trp Ala His Ala Gly Ala Ala Pro Arg
 1380 1385 1390
 Asp Ala Ser Arg Gly Arg Phe Trp Asp Arg Leu Val Thr Ala Thr Lys
 1395 1400 1405
 Glu Ala Ser Ser Ser Ala Val Pro Ala Val Glu Arg Trp Arg Asn Ala
 1410 1415 1420

- 37 -

Ser Val Val Glu Thr Arg Ser Ala Leu Tyr Glu Leu Val Arg Gly Val
 1425 1430 1435 1440
 Val Ala Gly Val Met Gly Phe Thr Asp Gln Gly Thr Leu Asp Val Arg
 1445 1450 1455
 Arg Gly Phe Ala Glu Gln Gly Leu Asp Ser Leu Met Ala Val Glu Ile
 1460 1465 1470
 Arg Lys Arg Leu Gln Gly Glu Leu Gly Met Pro Leu Ser Ala Thr Leu
 1475 1480 1485
 Ala Phe Asp His Pro Thr Val Glu Arg Leu Val Glu Tyr Leu Leu Ser
 1490 1495 1500
 Gln Ala Leu Glu Leu Gln Asp Arg Thr Asp Val Arg Ser Val Arg Leu
 1505 1510 1515 1520
 Pro Ala Thr Glu Asp Pro Ile Ala Ile Val Gly Ala Ala Cys Arg Phe
 1525 1530 1535
 Pro Gly Gly Val Glu Asp Leu Glu Ser Tyr Trp Gln Leu Leu Thr Glu
 1540 1545 1550
 Gly Val Val Val Ser Thr Glu Val Pro Ala Asp Arg Trp Asn Gly Ala
 1555 1560 1565
 Asp Gly Arg Val Pro Gly Ser Gly Glu Ala Gln Arg Gln Thr Tyr Val
 1570 1575 1580
 Pro Arg Gly Gly Phe Leu Arg Glu Val Glu Thr Phe Asp Ala Ala Phe
 1585 1590 1595 1600
 Phe His Ile Ser Pro Arg Glu Ala Met Ser Leu Asp Pro Gln Gln Arg
 1605 1610 1615
 Leu Leu Leu Glu Val Ser Trp Glu Ala Ile Glu Arg Ala Gly Gln Asp
 1620 1625 1630
 Pro Ser Ala Leu Arg Glu Ser Pro Thr Gly Val Phe Val Gly Ala Gly
 1635 1640 1645
 Pro Asn Glu Tyr Ala Glu Arg Val Gln Glu Leu Ala Asp Glu Ala Ala
 1650 1655 1660
 Gly Leu Tyr Ser Gly Thr Gly Asn Met Leu Ser Val Ala Ala Gly Arg
 1665 1670 1675 1680
 Leu Ser Phe Phe Leu Gly Leu His Gly Pro Thr Leu Ala Val Asp Thr
 1685 1690 1695
 Ala Cys Ser Ser Ser Leu Val Ala Leu His Leu Gly Cys Gln Ser Leu
 1700 1705 1710
 Arg Arg Gly Glu Cys Asp Gln Ala Leu Val Gly Gly Val Asn Met Leu
 1715 1720 1725
 Leu Ser Pro Lys Thr Phe Ala Leu Leu Ser Arg Met His Ala Leu Ser
 1730 1735 1740
 Pro Gly Gly Arg Cys Lys Thr Phe Ser Ala Asp Ala Asp Gly Tyr Ala
 1745 1750 1755 1760
 Arg Ala Glu Gly Cys Ala Val Val Val Leu Lys Arg Leu Ser Asp Ala

- 38 -

1765	1770	1775
Gln Arg Asp Arg Asp Pro Ile Leu Ala Val Ile Arg Gly Thr Ala Ile 1780	1785	1790
Asn His Asp Gly Pro Ser Ser Gly Leu Thr Val Pro Ser Gly Pro Ala 1795	1800	1805
Gln Glu Ala Leu Leu Arg Gln Ala Leu Ala His Ala Gly Val Val Pro 1810	1815	1820
Ala Asp Val Asp Phe Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly 1825	1830	1835 1840
Asp Pro Ile Glu Val Arg Ala Leu Ser Asp Val Tyr Gly Gln Ala Arg 1845	1850	1855
Pro Ala Asp Arg Pro Leu Ile Leu Gly Ala Ala Lys Ala Asn Leu Gly 1860	1865	1870
His Met Glu Pro Ala Ala Gly Leu Ala Gly Leu Leu Lys Ala Val Leu 1875	1880	1885
Ala Leu Gly Gln Glu Gln Ile Pro Ala Gln Pro Glu Leu Gly Glu Leu 1890	1895	1900
Asn Pro Leu Leu Pro Trp Glu Ala Leu Pro Val Ala Val Ala Arg Ala 1905	1910	1915 1920
Ala Val Pro Trp Pro Arg Thr Asp Arg Pro Arg Phe Ala Gly Val Ser 1925	1930	1935
Ser Phe Gly Met Ser Gly Thr Asn Ala His Val Val Leu Glu Glu Ala 1940	1945	1950
Pro Ala Val Glu Leu Trp Pro Ala Ala Pro Glu Arg Ser Ala Glu Leu 1955	1960	1965
Leu Val Leu Ser Gly Lys Ser Glu Gly Ala Leu Asp Ala Gln Ala Ala 1970	1975	1980
Arg Leu Arg Glu His Leu Asp Met His Pro Glu Leu Gly Leu Gly Asp 1985	1990	1995 2000
Val Ala Phe Ser Leu Ala Thr Thr Arg Ser Ala Met Asn His Arg Leu 2005	2010	2015
Ala Val Ala Val Thr Ser Arg Glu Gly Leu Leu Ala Ala Leu Ser Ala 2020	2025	2030
Val Ala Gln Gly Gln Thr Pro Pro Gly Ala Ala Arg Cys Ile Ala Ser 2035	2040	2045
Ser Ser Arg Gly Lys Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln 2050	2055	2060
Thr Pro Gly Met Gly Arg Gly Leu Cys Ala Ala Trp Pro Ala Phe Arg 2065	2070	2075 2080
Glu Ala Phe Asp Arg Cys Val Ala Leu Phe Asp Arg Glu Leu Asp Arg 2085	2090	2095
Pro Leu Arg Glu Val Met Trp Ala Glu Pro Gly Ser Ala Glu Ser Leu 2100	2105	2110

- 39 -

Leu Leu Asp Gln Thr Ala Phe Thr Gln Pro Ala Leu Phe Thr Val Glu
 2115 2120 2125
 Tyr Ala Leu Thr Ala Leu Trp Arg Ser Trp Gly Val Glu Pro Glu Leu
 2130 2135 2140
 Val Ala Gly His Ser Ala Gly Glu Leu Val Ala Ala Cys Val Ala Gly
 2145 2150 2155 2160
 Val Phe Ser Leu Glu Asp Gly Val Arg Leu Val Ala Ala Arg Gly Arg
 2165 2170 2175
 Leu Met Gln Gly Leu Ser Ala Gly Gly Ala Met Val Ser Leu Gly Ala
 2180 2185 2190
 Pro Glu Ala Glu Val Ala Ala Ala Val Ala Pro His Ala Ala Ser Val
 2195 2200 2205
 Ser Ile Ala Ala Val Asn Gly Pro Glu Gln Val Val Ile Ala Gly Val
 2210 2215 2220
 Glu Gln Ala Val Gln Ala Ile Ala Ala Gly Phe Ala Ala Arg Gly Ala
 2225 2230 2235 2240
 Arg Thr Lys Arg Leu His Val Ser His Ala Ser His Ser Pro Leu Met
 2245 2250 2255
 Glu Pro Met Leu Glu Glu Phe Gly Arg Val Ala Ala Ser Val Thr Tyr
 2260 2265 2270
 Arg Arg Pro Ser Val Ser Leu Val Ser Asn Leu Ser Gly Lys Val Val
 2275 2280 2285
 Ala Asp Glu Leu Ser Ala Pro Gly Tyr Trp Val Arg His Val Arg Glu
 2290 2295 2300
 Ala Val Arg Phe Ala Asp Gly Val Lys Ala Leu His Glu Ala Gly Ala
 2305 2310 2315 2320
 Gly Thr Phe Val Glu Val Gly Pro Lys Pro Thr Leu Leu Gly Leu Leu
 2325 2330 2335
 Pro Ala Cys Leu Pro Glu Ala Glu Pro Thr Leu Leu Ala Ser Leu Arg
 2340 2345 2350
 Ala Gly Arg Glu Glu Ala Ala Gly Val Leu Glu Ala Leu Gly Arg Leu
 2355 2360 2365
 Trp Ala Ala Gly Gly Ser Val Ser Trp Pro Gly Val Phe Pro Thr Ala
 2370 2375 2380
 Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln Arg Gln Arg Tyr
 2385 2390 2395 2400
 Trp Pro Asp Ile Glu Pro Asp Ser Arg Arg His Ala Ala Ala Asp Pro
 2405 2410 2415
 Thr Gln Gly Trp Phe Tyr Arg Val Asp Trp Pro Glu Ile Pro Arg Ser
 2420 2425 2430
 Leu Gln Lys Ser Glu Glu Ala Ser Arg Gly Ser Trp Leu Val Leu Ala
 2435 2440 2445
 Asp Lys Gly Gly Val Gly Glu Ala Val Ala Ala Ala Leu Ser Thr Arg
 2450 2455 2460

- 40 -

Gly Leu Pro Cys Val Val Leu His Ala Pro Ala Glu Thr Ser Ala Thr
 2465 2470 2475 2480
 Ala Glu Leu Val Thr Glu Ala Ala Gly Gly Arg Ser Asp Trp Gln Val
 2485 2490 2495
 Val Leu Tyr Leu Trp Gly Leu Asp Ala Val Val Gly Ala Glu Ala Ser
 2500 2505 2510
 Ile Asp Glu Ile Gly Asp Ala Thr Arg Arg Ala Thr Ala Pro Val Leu
 2515 2520 2525
 Gly Leu Ala Arg Phe Leu Ser Thr Val Ser Cys Ser Pro Arg Leu Trp
 2530 2535 2540
 Val Val Thr Arg Gly Ala Cys Ile Val Gly Asp Glu Pro Ala Ile Ala
 2545 2550 2555 2560
 Pro Cys Gln Ala Ala Leu Trp Gly Met Gly Arg Val Ala Ala Leu Glu
 2565 2570 2575
 His Pro Gly Ala Trp Gly Gly Leu Val Asp Leu Asp Pro Arg Ala Ser
 2580 2585 2590
 Pro Pro Gln Ala Ser Pro Ile Asp Gly Glu Met Leu Val Thr Glu Leu
 2595 2600 2605
 Leu Ser Gln Glu Thr Glu Asp Gln Leu Ala Phe Arg His Gly Arg Arg
 2610 2615 2620
 His Ala Ala Arg Leu Val Ala Ala Pro Pro Gln Gly Gln Ala Ala Pro
 2625 2630 2635 2640
 Val Ser Leu Ser Ala Glu Ala Ser Tyr Leu Val Thr Gly Gly Leu Gly
 2645 2650 2655
 Gly Leu Gly Leu Ile Val Ala Gln Trp Leu Val Glu Leu Gly Ala Arg
 2660 2665 2670
 His Leu Val Leu Thr Ser Arg Arg Gly Leu Pro Asp Arg Gln Ala Trp
 2675 2680 2685
 Cys Glu Gln Gln Pro Pro Glu Ile Arg Ala Arg Ile Ala Ala Val Glu
 2690 2695 2700
 Ala Leu Glu Ala Arg Gly Ala Arg Val Thr Val Ala Ala Val Asp Val
 2705 2710 2715 2720
 Ala Asp Val Glu Pro Met Thr Ala Leu Val Ser Ser Val Glu Pro Pro
 2725 2730 2735
 Leu Arg Gly Val Val His Ala Ala Gly Val Ser Val Met Arg Pro Leu
 2740 2745 2750
 Ala Glu Thr Asp Glu Thr Leu Leu Glu Ser Val Leu Arg Pro Lys Val
 2755 2760 2765
 Ala Gly Ser Trp Leu Leu His Arg Leu Leu His Gly Arg Pro Leu Asp
 2770 2775 2780
 Leu Phe Val Leu Phe Ser Ser Gly Ala Ala Val Trp Gly Ser His Ser
 2785 2790 2795 2800
 Gln Gly Ala Tyr Ala Ala Ala Asn Ala Phe Leu Asp Gly Leu Ala His

- 41 -

2805	2810	2815
Leu Arg Arg Ser Gln Ser Leu Pro Ala Leu Ser Val Ala Trp Gly Leu		
2820	2825	2830
Trp Ala Glu Gly Gly Met Ala Asp Ala Glu Ala His Ala Arg Leu Ser		
2835	2840	2845
Asp Ile Gly Val Leu Pro Met Ser Thr Ser Ala Ala Leu Ser Ala Leu		
2850	2855	2860
Gln Arg Leu Val Glu Thr Gly Ala Ala Gln Arg Thr Val Thr Arg Met		
2865	2870	2875
Asp Trp Ala Arg Phe Ala Pro Val Tyr Thr Ala Arg Gly Arg Arg Asn		
2885	2890	2895
Leu Leu Ser Ala Leu Val Ala Gly Arg Asp Ile Ile Ala Pro Ser Pro		
2900	2905	2910
Pro Ala Ala Ala Thr Arg Asn Trp Arg Gly Leu Ser Val Ala Glu Ala		
2915	2920	2925
Arg Val Ala Leu His Glu Ile Val His Gly Ala Val Ala Arg Val Leu		
2930	2935	2940
Gly Phe Leu Asp Pro Ser Ala Leu Asp Pro Gly Met Gly Phe Asn Glu		
2945	2950	2955
Gln Gly Leu Asp Ser Leu Met Ala Val Glu Ile Arg Asn Leu Leu Gln		
2965	2970	2975
Ala Glu Leu Asp Val Arg Leu Ser Thr Thr Leu Ala Phe Asp His Pro		
2980	2985	2990
Thr Val Gln Arg Leu Val Glu His Leu Leu Val Asp Val Leu Lys Leu		
2995	3000	3005
Glu Asp Arg Ser Asp Thr Gln His Val Arg Ser Leu Ala Ser Asp Glu		
3010	3015	3020
Pro Ile Ala Ile Val Gly Ala Ala Cys Arg Phe Pro Gly Gly Val Glu		
3025	3030	3035
Asp Leu Glu Ser Tyr Trp Gln Leu Leu Ala Glu Gly Val Val Val Ser		
3045	3050	3055
Ala Glu Val Pro Ala Asp Arg Trp Asp Ala Ala Asp Trp Tyr Asp Pro		
3060	3065	3070
Asp Pro Glu Ile Pro Gly Arg Thr Tyr Val Thr Lys Gly Ala Phe Leu		
3075	3080	3085
Arg Asp Leu Gln Arg Leu Asp Ala Thr Phe Phe Arg Ile Ser Pro Arg		
3090	3095	3100
Glu Ala Met Ser Leu Asp Pro Gln Gln Arg Leu Leu Leu Glu Val Ser		
3105	3110	3115
Trp Glu Ala Leu Glu Ser Ala Gly Ile Ala Pro Asp Thr Leu Arg Asp		
3125	3130	3135
Ser Pro Thr Gly Val Phe Val Gly Ala Gly Pro Asn Glu Tyr Tyr Thr		
3140	3145	3150

- 42 -

Gln Arg Leu Arg Gly Phe Thr Asp Gly Ala Ala Gly Leu Tyr Gly Gly
 3155 3160 3165
 Thr Gly Asn Met Leu Ser Val Thr Ala Gly Arg Leu Ser Phe Phe Leu
 3170 3175 3180
 Gly Leu His Gly Pro Thr Leu Ala Met Asp Thr Ala Cys Ser Ser Ser
 3185 3190 3195 3200
 Leu Val Ala Leu His Leu Ala Cys Gln Ser Leu Arg Leu Gly Glu Cys
 3205 3210 3215
 Asp Gln Ala Leu Val Gly Gly Val Asn Val Leu Leu Ala Pro Glu Thr
 3220 3225 3230
 Phe Val Leu Leu Ser Arg Met Arg Ala Leu Ser Pro Asp Gly Arg Cys
 3235 3240 3245
 Lys Thr Phe Ser Ala Asp Ala Asp Gly Tyr Ala Arg Gly Glu Gly Cys
 3250 3255 3260
 Ala Val Val Val Leu Lys Arg Leu Arg Asp Ala Gln Arg Ala Gly Asp
 3265 3270 3275 3280
 Ser Ile Leu Ala Leu Ile Arg Gly Ser Ala Val Asn His Asp Gly Pro
 3285 3290 3295
 Ser Ser Gly Leu Thr Val Pro Asn Gly Pro Ala Gln Gln Ala Leu Leu
 3300 3305 3310
 Arg Gln Ala Leu Ser Gln Ala Gly Val Ser Pro Val Asp Val Asp Phe
 3315 3320 3325
 Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu Val
 3330 3335 3340
 Gln Ala Leu Ser Glu Val Tyr Gly Pro Gly Arg Ser Gly Asp Arg Pro
 3345 3350 3355 3360
 Leu Val Leu Gly Ala Ala Lys Ala Asn Val Ala His Leu Glu Ala Ala
 3365 3370 3375
 Ser Gly Leu Ala Ser Leu Leu Lys Ala Val Leu Ala Leu Arg His Glu
 3380 3385 3390
 Gln Ile Pro Ala Gln Pro Glu Leu Gly Glu Leu Asn Pro His Leu Pro
 3395 3400 3405
 Trp Asn Thr Leu Pro Val Ala Val Pro Arg Lys Ala Val Pro Trp Gly
 3410 3415 3420
 Arg Gly Ala Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly Leu Ser
 3425 3430 3435 3440
 Gly Thr Asn Val His Val Val Leu Glu Glu Ala Pro Glu Val Glu Pro
 3445 3450 3455
 Ala Pro Ala Ala Pro Ala Arg Pro Val Glu Leu Val Val Leu Ser Ala
 3460 3465 3470
 Lys Ser Ala Ala Ala Leu Asp Ala Ala Ala Arg Leu Ser Ala His
 3475 3480 3485
 Leu Ser Ala His Pro Glu Leu Ser Leu Gly Asp Val Ala Phe Ser Leu
 3490 3495 3500

- 43 -

Ala Thr Thr Arg Ser Pro Met Glu His Arg Leu Ala Ile Ala Thr Thr
 3505 3510 3515 3520
 Ser Arg Glu Ala Leu Arg Gly Ala Leu Asp Ala Ala Ala Gln Gln Lys
 3525 3530 3535
 Thr Pro Gln Gly Ala Val Arg Gly Lys Ala Val Ser Ser Arg Gly Lys
 3540 3545 3550
 Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln Met Pro Gly Met Gly
 3555 3560 3565
 Arg Gly Leu Tyr Glu Thr Trp Pro Ala Phe Arg Glu Ala Phe Asp Arg
 3570 3575 3580
 Cys Val Ala Leu Phe Asp Arg Glu Ile Asp Gln Pro Leu Arg Glu Val
 3585 3590 3595 3600
 Met Trp Ala Ala Pro Gly Leu Ala Gln Ala Ala Arg Leu Asp Gln Thr
 3605 3610 3615
 Ala Tyr Ala Gln Pro Ala Leu Phe Ala Leu Glu Tyr Ala Leu Ala Ala
 3620 3625 3630
 Leu Trp Arg Ser Trp Gly Val Glu Pro His Val Leu Leu Gly His Ser
 3635 3640 3645
 Ile Gly Glu Leu Val Ala Ala Cys Val Ala Gly Val Phe Ser Leu Glu
 3650 3655 3660
 Asp Ala Val Arg Leu Val Ala Ala Arg Gly Arg Leu Met Gln Ala Leu
 3665 3670 3675 3680
 Pro Ala Gly Gly Ala Met Val Ala Ile Ala Ala Ser Glu Ala Glu Val
 3685 3690 3695
 Ala Ala Ser Val Ala Pro His Ala Ala Thr Val Ser Ile Ala Ala Val
 3700 3705 3710
 Asn Gly Pro Asp Ala Val Val Ile Ala Gly Ala Glu Val Gln Val Leu
 3715 3720 3725
 Ala Leu Gly Ala Thr Phe Ala Ala Arg Gly Ile Arg Thr Lys Arg Leu
 3730 3735 3740
 Ala Val Ser His Ala Phe His Ser Pro Leu Met Asp Pro Met Leu Glu
 3745 3750 3755 3760
 Asp Phe Gln Arg Val Ala Ala Thr Ile Ala Tyr Arg Ala Pro Asp Arg
 3765 3770 3775
 Pro Val Val Ser Asn Val Thr Gly His Val Ala Gly Pro Glu Ile Ala
 3780 3785 3790
 Thr Pro Glu Tyr Trp Val Arg His Val Arg Ser Ala Val Arg Phe Gly
 3795 3800 3805
 Asp Gly Ala Lys Ala Leu His Ala Ala Gly Ala Ala Thr Phe Val Glu
 3810 3815 3820
 Val Gly Pro Lys Pro Val Leu Leu Gly Leu Leu Pro Ala Cys Leu Gly
 3825 3830 3835 3840
 Glu Ala Asp Ala Val Leu Val Pro Ser Leu Arg Ala Asp Arg Ser Glu

- 44 -

3845	3850	3855
Cys Glu Val Val Leu Ala Ala Leu Gly Ala Trp Tyr Ala Trp Gly Gly		
3860	3865	3870
Ala Leu Asp Trp Lys Gly Val Phe Pro Asp Gly Ala Arg Arg Val Ala		
3875	3880	3885
Leu Pro Met Tyr Pro Trp Gln Arg Glu Arg His Trp Met Asp Leu Thr		
3890	3895	3900
Pro Arg Ser Ala Ala Pro Ala Gly Ile Ala Gly Arg Trp Pro Leu Ala		
3905	3910	3915
Gly Val Gly Leu Cys Met Pro Gly Ala Val Leu His His Val Leu Ser		
3925	3930	3935
Ile Gly Pro Arg His Gln Pro Phe Leu Gly Asp His Leu Val Phe Gly		
3940	3945	3950
Lys Val Val Val Pro Gly Ala Phe His Val Ala Val Ile Leu Ser Ile		
3955	3960	3965
Ala Ala Glu Arg Trp Pro Glu Arg Ala Ile Glu Leu Thr Gly Val Glu		
3970	3975	3980
Phe Leu Lys Ala Ile Ala Met Glu Pro Asp Gln Glu Val Glu Leu His		
3985	3990	3995
Ala Val Leu Thr Pro Glu Ala Ala Gly Asp Gly Tyr Leu Phe Glu Leu		
4005	4010	4015
Ala Thr Leu Ala Ala Pro Glu Thr Glu Arg Arg Trp Thr Thr His Ala		
4020	4025	4030
Arg Gly Arg Val Gln Pro Thr Asp Gly Ala Pro Gly Ala Leu Pro Arg		
4035	4040	4045
Leu Glu Val Leu Glu Asp Arg Ala Ile Gln Pro Leu Asp Phe Ala Gly		
4050	4055	4060
Phe Leu Asp Arg Leu Ser Ala Val Arg Ile Gly Trp Gly Pro Leu Trp		
4065	4070	4075
Arg Trp Leu Gln Asp Gly Arg Val Gly Asp Glu Ala Ser Leu Ala Thr		
4085	4090	4095
Leu Val Pro Thr Tyr Pro Asn Ala His Asp Val Ala Pro Leu His Pro		
4100	4105	4110
Ile Leu Leu Asp Asn Gly Phe Ala Val Ser Leu Leu Ser Thr Arg Ser		
4115	4120	4125
Glu Pro Glu Asp Asp Gly Thr Pro Pro Leu Pro Phe Ala Val Glu Arg		
4130	4135	4140
Val Arg Trp Trp Arg Ala Pro Val Gly Arg Val Arg Cys Gly Gly Val		
4145	4150	4155
Pro Arg Ser Gln Ala Phe Gly Val Ser Ser Phe Val Leu Val Asp Glu		
4165	4170	4175
Thr Gly Glu Val Val Ala Glu Val Glu Gly Phe Val Cys Arg Arg Ala		
4180	4185	4190

- 45 -

Pro Arg Glu Val Phe Leu Arg Gln Glu Ser Gly Ala Ser Thr Ala Ala
 4195 4200 4205
 Leu Tyr Arg Leu Asp Trp Pro Glu Ala Pro Leu Pro Asp Ala Pro Ala
 4210 4215 4220
 Glu Arg Ile Glu Glu Ser Trp Val Val Val Ala Ala Pro Gly Ser Glu
 4225 4230 4235 4240
 Met Ala Ala Ala Leu Ala Thr Arg Leu Asn Arg Cys Val Leu Ala Glu
 4245 4250 4255
 Pro Lys Gly Leu Glu Ala Ala Leu Ala Gly Val Ser Pro Ala Gly Val
 4260 4265 4270
 Ile Cys Leu Trp Glu Ala Gly Ala His Glu Glu Ala Pro Ala Ala Ala
 4275 4280 4285
 Gln Arg Val Ala Thr Glu Gly Leu Ser Val Val Gln Ala Leu Arg Asp
 4290 4295 4300
 Arg Ala Val Arg Leu Trp Trp Val Thr Met Gly Ala Val Ala Val Glu
 4305 4310 4315 4320
 Ala Gly Glu Arg Val Gln Val Ala Thr Ala Pro Val Trp Gly Leu Gly
 4325 4330 4335
 Arg Thr Val Met Gln Glu Arg Pro Glu Leu Ser Cys Thr Leu Val Asp
 4340 4345 4350
 Leu Glu Pro Glu Ala Asp Ala Ala Arg Ser Ala Asp Val Leu Leu Arg
 4355 4360 4365
 Glu Leu Gly Arg Ala Asp Asp Glu Thr Gln Val Ala Phe Arg Ser Gly
 4370 4375 4380
 Lys Arg Arg Val Ala Arg Leu Val Lys Ala Thr Thr Pro Glu Gly Leu
 4385 4390 4395 4400
 Leu Val Pro Asp Ala Glu Ser Tyr Arg Leu Glu Ala Gly Gln Lys Gly
 4405 4410 4415
 Thr Leu Asp Gln Leu Arg Leu Ala Pro Ala Gln Arg Arg Ala Pro Gly
 4420 4425 4430
 Pro Gly Glu Val Glu Ile Lys Val Thr Ala Ser Gly Leu Asn Phe Arg
 4435 4440 4445
 Thr Val Leu Ala Val Leu Gly Met Tyr Pro Gly Asp Ala Gly Pro Met
 4450 4455 4460
 Gly Gly Asp Cys Ala Gly Val Ala Thr Ala Val Gly Gln Gly Val Arg
 4465 4470 4475 4480
 His Val Ala Val Gly Asp Ala Val Met Thr Leu Gly Thr Leu His Arg
 4485 4490 4495
 Phe Val Thr Val Asp Ala Arg Leu Val Val Arg Gln Pro Ala Gly Leu
 4500 4505 4510
 Thr Pro Ala Gln Ala Ala Thr Val Pro Val Ala Phe Leu Thr Ala Trp
 4515 4520 4525
 Leu Ala Leu His Asp Leu Gly Asn Leu Arg Arg Gly Glu Arg Val Leu
 4530 4535 4540

- 46 -

Ile His Ala Ala Ala Gly Gly Val Gly Met Ala Ala Val Gln Ile Ala
 4545 4550 4555 4560
 Arg Trp Ile Gly Ala Glu Val Phe Ala Thr Ala Ser Pro Ser Lys Trp
 4565 4570 4575
 Ala Ala Val Gln Ala Met Gly Val Pro Arg Thr His Ile Ala Ser Ser
 4580 4585 4590
 Arg Thr Leu Glu Phe Ala Glu Thr Phe Arg Gln Val Thr Gly Gly Arg
 4595 4600 4605
 Gly Val Asp Val Val Leu Asn Ala Leu Ala Gly Glu Phe Val Asp Ala
 4610 4615 4620
 Ser Leu Ser Leu Leu Ser Thr Gly Gly Arg Phe Leu Glu Met Gly Lys
 4625 4630 4635 4640
 Thr Asp Ile Arg Asp Arg Ala Ala Val Ala Ala Ala His Pro Gly Val
 4645 4650 4655
 Arg Tyr Arg Val Phe Asp Ile Leu Glu Leu Ala Pro Asp Arg Thr Arg
 4660 4665 4670
 Glu Ile Leu Glu Arg Val Val Glu Gly Phe Ala Ala Gly His Leu Arg
 4675 4680 4685
 Ala Leu Pro Val His Ala Phe Ala Ile Thr Lys Ala Glu Ala Ala Phe
 4690 4695 4700
 Arg Phe Met Ala Gln Ala Arg His Gln Gly Lys Val Val Leu Leu Pro
 4705 4710 4715 4720
 Ala Pro Ser Ala Ala Pro Leu Ala Pro Thr Gly Thr Val Leu Leu Thr
 4725 4730 4735
 Gly Gly Leu Gly Ala Leu Gly Leu His Val Ala Arg Trp Leu Ala Gln
 4740 4745 4750
 Gln Gly Val Pro His Met Val Leu Thr Gly Arg Arg Gly Leu Asp Thr
 4755 4760 4765
 Pro Gly Ala Ala Lys Ala Val Ala Glu Ile Glu Ala Leu Gly Ala Arg
 4770 4775 4780
 Val Thr Ile Ala Ala Ser Asp Val Ala Asp Arg Asn Ala Leu Glu Ala
 4785 4790 4795 4800
 Val Leu Gln Ala Ile Pro Ala Glu Trp Pro Leu Gln Gly Val Ile His
 4805 4810 4815
 Ala Ala Gly Ala Leu Asp Asp Gly Val Leu Asp Glu Gln Thr Thr Asp
 4820 4825 4830
 Arg Phe Ser Arg Val Leu Ala Pro Lys Val Thr Gly Ala Trp Asn Leu
 4835 4840 4845
 His Glu Leu Thr Ala Gly Asn Asp Leu Ala Phe Phe Val Leu Phe Ser
 4850 4855 4860
 Ser Met Ser Gly Leu Leu Gly Ser Ala Gly Gln Ser Asn Tyr Ala Ala
 4865 4870 4875 4880
 Ala Asn Thr Phe Leu Asp Ala Leu Ala Ala His Arg Arg Ala Glu Gly

- 47 -

4885	4890	4895
Leu Ala Ala Gln Ser Leu Ala Trp Gly Pro Trp Ser Asp Gly Gly Met 4900 4905 4910		
Ala Ala Gly Leu Ser Ala Ala Leu Gln Ala Arg Leu Ala Arg His Gly 4915 4920 4925		
Met Gly Ala Leu Ser Pro Ala Gln Gly Thr Ala Leu Leu Gly Gln Ala 4930 4935 4940		
Leu Ala Arg Pro Glu Thr Gln Leu Gly Ala Met Ser Leu Asp Val Arg 4945 4950 4955 4960		
Ala Ala Ser Gln Ala Ser Gly Ala Ala Val Pro Pro Val Trp Arg Ala 4965 4970 4975		
Leu Val Arg Ala Glu Ala Arg His Thr Ala Ala Gly Ala Gln Gly Ala 4980 4985 4990		
Leu Ala Ala Arg Leu Gly Ala Leu Pro Glu Ala Arg Arg Ala Asp Glu 4995 5000 5005		
Val Arg Lys Val Val Gln Ala Glu Ile Ala Arg Val Leu Ser Trp Ser 5010 5015 5020		
Ala Ala Ser Ala Val Pro Val Asp Arg Pro Leu Ser Asp Leu Gly Leu 5025 5030 5035 5040		
Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Val Leu Gly Gln Arg Val 5045 5050 5055		
Gly Ala Thr Leu Pro Ala Thr Leu Ala Phe Asp His Pro Thr Val Asp 5060 5065 5070		
Ala Leu Thr Arg Trp Leu Leu Asp Lys Val Leu Ala Val Ala Glu Pro 5075 5080 5085		
Ser Val Ser Ser Ala Lys Ser Ser Pro Gln Val Ala Leu Asp Glu Pro 5090 5095 5100		
Ile Ala Ile Ile Gly Ile Gly Cys Arg Phe Pro Gly Gly Val Ala Asp 5105 5110 5115 5120		
Pro Glu Ser Phe Trp Arg Leu Leu Glu Glu Gly Ser Asp Ala Val Val 5125 5130 5135		
Glu Val Pro His Glu Arg Trp Asp Ile Asp Ala Phe Tyr Asp Pro Asp 5140 5145 5150		
Pro Asp Val Arg Gly Lys Met Thr Thr Arg Phe Gly Gly Phe Leu Ser 5155 5160 5165		
Asp Ile Asp Arg Phe Asp Pro Ala Phe Phe Gly Ile Ser Pro Arg Glu 5170 5175 5180		
Ala Thr Thr Met Asp Pro Gln Gln Arg Leu Leu Leu Glu Thr Ser Trp 5185 5190 5195 5200		
Glu Ala Phe Glu Arg Ala Gly Ile Leu Pro Glu Arg Leu Met Gly Ser 5205 5210 5215		
Asp Thr Gly Val Phe Val Gly Leu Phe Tyr Gln Glu Tyr Ala Ala Leu 5220 5225 5230		

- 48 -

Ala Gly Gly Ile Glu Ala Phe Asp Gly Tyr Leu Gly Thr Gly Thr Thr
 5235 5240 5245
 Ala Ser Val Ala Ser Gly Arg Ile Ser Tyr Val Leu Gly Leu Lys Gly
 5250 5255 5260
 Pro Ser Leu Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Val
 5265 5270 5275 5280
 His Leu Ala Cys Gln Ala Leu Arg Arg Gly Glu Cys Ser Val Ala Leu
 5285 5290 5295
 Ala Gly Gly Val Ala Leu Met Leu Thr Pro Ala Thr Phe Val Glu Phe
 5300 5305 5310
 Ser Arg Leu Arg Gly Leu Ala Pro Asp Gly Arg Cys Lys Ser Phe Ser
 5315 5320 5325
 Ala Ala Ala Asp Gly Val Gly Trp Ser Glu Gly Cys Ala Met Leu Leu
 5330 5335 5340
 Leu Lys Pro Leu Arg Asp Ala Gln Arg Asp Gly Asp Pro Ile Leu Ala
 5345 5350 5355 5360
 Val Ile Arg Gly Thr Ala Val Asn Gln Asp Gly Arg Ser Asn Gly Leu
 5365 5370 5375
 Thr Ala Pro Asn Gly Ser Ser Gln Gln Glu Val Ile Arg Arg Ala Leu
 5380 5385 5390
 Glu Gln Ala Gly Leu Ala Pro Ala Asp Val Ser Tyr Val Glu Cys His
 5395 5400 5405
 Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Val Gln Ala Leu Gly
 5410 5415 5420
 Ala Val Leu Ala Gln Gly Arg Pro Ser Asp Arg Pro Leu Val Ile Gly
 5425 5430 5435 5440
 Ser Val Lys Ser Asn Ile Gly His Thr Gln Ala Ala Ala Gly Val Ala
 5445 5450 5455
 Gly Val Ile Lys Val Ala Leu Ala Leu Glu Arg Gly Leu Ile Pro Arg
 5460 5465 5470
 Ser Leu His Phe Asp Ala Pro Asn Pro His Ile Pro Trp Ser Glu Leu
 5475 5480 5485
 Ala Val Gln Val Ala Ala Lys Pro Val Glu Trp Thr Arg Asn Gly Val
 5490 5495 5500
 Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Val Ser Gly Thr Asn Ala
 5505 5510 5515 5520
 His Val Val Leu Glu Glu Ala Pro Ala Ala Ala Phe Ala Pro Ala Ala
 5525 5530 5535
 Ala Arg Ser Ala Glu Leu Phe Val Leu Ser Ala Lys Ser Ala Ala Ala
 5540 5545 5550
 Leu Asp Ala Gln Ala Ala Arg Leu Ser Ala His Val Val Ala His Pro
 5555 5560 5565
 Glu Leu Gly Leu Gly Asp Leu Ala Phe Ser Leu Ala Thr Thr Arg Ser
 5570 5575 5580

- 49 -

Pro Met Thr Tyr Arg Leu Ala Val Ala Ala Thr Ser Arg Glu Ala Leu
 5585 5590 5595 5600
 Ser Ala Ala Leu Asp Thr Ala Ala Gln Gly Gln Ala Pro Pro Ala Ala
 5605 5610 5615
 Ala Arg Gly His Ala Ser Thr Gly Ser Ala Pro Lys Val Val Phe Val
 5620 5625 5630
 Phe Pro Gly Gln Gly Ser Gln Trp Leu Gly Met Gly Gln Lys Leu Leu
 5635 5640 5645
 Ser Glu Glu Pro Val Phe Arg Asp Ala Leu Ser Ala Cys Asp Arg Ala
 5650 5655 5660
 Ile Gln Ala Glu Ala Gly Trp Ser Leu Leu Ala Glu Leu Ala Ala Asp
 5665 5670 5675 5680
 Glu Thr Thr Ser Gln Leu Gly Arg Ile Asp Val Val Gln Pro Ala Leu
 5685 5690 5695
 Phe Ala Ile Glu Val Ala Leu Ser Ala Leu Trp Arg Ser Trp Gly Val
 5700 5705 5710
 Glu Pro Asp Ala Val Val Gly His Ser Met Gly Glu Val Ala Ala Ala
 5715 5720 5725
 His Val Ala Gly Ala Leu Ser Leu Glu Asp Ala Val Ala Ile Ile Cys
 5730 5735 5740
 Arg Arg Ser Leu Leu Leu Arg Arg Ile Ser Gly Gln Gly Glu Met Ala
 5745 5750 5755 5760
 Val Val Glu Leu Ser Leu Ala Glu Ala Glu Ala Ala Leu Leu Gly Tyr
 5765 5770 5775
 Glu Asp Arg Leu Ser Val Ala Val Ser Asn Ser Pro Arg Ser Thr Val
 5780 5785 5790
 Leu Ala Gly Glu Pro Ala Ala Leu Ala Glu Val Leu Ala Ile Leu Ala
 5795 5800 5805
 Ala Lys Gly Val Phe Cys Arg Arg Val Lys Val Asp Val Ala Ser His
 5810 5815 5820
 Ser Pro Gln Ile Asp Pro Leu Arg Asp Glu Leu Leu Ala Ala Leu Gly
 5825 5830 5835 5840
 Glu Leu Glu Pro Arg Gln Ala Thr Val Ser Met Arg Ser Thr Val Thr
 5845 5850 5855
 Ser Thr Ile Met Ala Gly Pro Glu Leu Val Ala Ser Tyr Trp Ala Asp
 5860 5865 5870
 Asn Val Arg Gln Pro Val Arg Phe Ala Glu Ala Val Gln Ser Leu Met
 5875 5880 5885
 Glu Asp Gly His Gly Leu Phe Val Glu Met Ser Pro His Pro Ile Leu
 5890 5895 5900
 Thr Thr Ser Val Glu Glu Ile Arg Arg Ala Thr Lys Arg Glu Gly Val
 5905 5910 5915 5920
 Ala Val Gly Ser Leu Arg Arg Gly Gln Asp Glu Arg Leu Ser Met Leu

- 50 -

5925	5930	5935
Glu Ala Leu Gly Ala Leu Trp Val His Gly Gln Ala Val Gly Trp Glu 5940	5945	5950
Arg Leu Phe Ser Ala Gly Gly Ala Gly Leu Arg Arg Val Pro Leu Pro 5955	5960	5965
Thr Tyr Pro Trp Gln Arg Glu Arg Tyr Trp Val Asp Ala Pro Thr Gly 5970	5975	5980
Gly Ala Ala Gly Gly Ser Arg Phe Ala His Ala Gly Ser His Pro Leu 5985	5990	5995
Leu Gly Glu Met Gln Thr Leu Ser Thr Gln Arg Ser Thr Arg Val Trp 6005	6010	6015
Glu Thr Thr Leu Asp Leu Lys Arg Leu Pro Trp Leu Gly Asp His Arg 6020	6025	6030
Val Gln Gly Ala Val Val Phe Pro Gly Ala Ala Tyr Leu Glu Met Ala 6035	6040	6045
Leu Ser Ser Gly Ala Glu Ala Leu Gly Asp Gly Pro Leu Gln Val Ser 6050	6055	6060
Asp Val Val Leu Ala Glu Ala Leu Ala Phe Ala Asp Asp Thr Pro Ala 6065	6070	6075
Ala Val Gln Val Met Ala Thr Glu Glu Arg Pro Gly Arg Leu Gln Phe 6085	6090	6095
His Val Ala Ser Arg Val Pro Gly His Gly Gly Ala Ala Phe Arg Ser 6100	6105	6110
His Ala Arg Gly Val Leu Arg Gln Ile Glu Arg Ala Glu Val Pro Ala 6115	6120	6125
Arg Leu Asp Leu Ala Ala Leu Arg Ala Arg Leu Gln Ala Ser Ala Pro 6130	6135	6140
Ala Ala Ala Thr Tyr Ala Ala Leu Ala Glu Met Gly Leu Glu Tyr Gly 6145	6150	6155
Pro Ala Phe Gln Gly Leu Val Glu Leu Trp Arg Gly Glu Gly Glu Ala 6165	6170	6175
Leu Gly Arg Val Arg Leu Pro Glu Ala Ala Gly Ser Pro Ala Ala Cys 6180	6185	6190
Arg Leu His Pro Ala Leu Leu Asp Ala Cys Phe His Val Ser Ser Ala 6195	6200	6205
Phe Ala Asp Arg Gly Glu Ala Thr Pro Trp Val Pro Val Glu Ile Gly 6210	6215	6220
Ser Leu Arg Trp Phe Gln Arg Pro Ser Gly Glu Leu Trp Cys His Ala 6225	6230	6235
Arg Ser Val Ser His Gly Lys Pro Thr Pro Asp Arg Arg Ser Thr Asp 6245	6250	6255
Phe Trp Val Val Asp Ser Thr Gly Ala Ile Val Ala Glu Ile Ser Gly 6260	6265	6270

- 51 -

Leu Val Ala Gln Arg Leu Ala Gly Gly Val Arg Arg Arg Glu Glu Asp
 6275 6280 6285
 Asp Trp Phe Met Glu Pro Ala Trp Glu Pro Thr Ala Val Pro Gly Ser
 6290 6295 6300
 Glu Val Met Ala Gly Arg Trp Leu Leu Ile Gly Ser Gly Gly Gly Leu
 6305 6310 6315 6320
 Gly Ala Ala Leu His Ser Ala Leu Thr Glu Ala Gly His Ser Val Val
 6325 6330 6335
 His Ala Thr Gly Arg Gly Thr Ser Ala Ala Gly Leu Gln Ala Leu Leu
 6340 6345 6350
 Thr Ala Ser Phe Asp Gly Gln Ala Pro Thr Ser Val Val His Leu Gly
 6355 6360 6365
 Ser Leu Asp Glu Arg Gly Val Leu Asp Ala Asp Ala Pro Phe Asp Ala
 6370 6375 6380
 Asp Ala Leu Glu Glu Ser Leu Val Arg Gly Cys Asp Ser Val Leu Trp
 6385 6390 6395 6400
 Thr Val Gln Ala Val Ala Gly Ala Gly Phe Arg Asp Pro Pro Arg Leu
 6405 6410 6415
 Trp Leu Val Thr Arg Gly Ala Gln Ala Ile Gly Ala Gly Asp Val Ser
 6420 6425 6430
 Val Ala Gln Ala Pro Leu Leu Gly Leu Gly Arg Val Ile Ala Leu Glu
 6435 6440 6445
 His Ala Glu Leu Arg Cys Ala Arg Ile Asp Leu Asp Pro Ala Arg Arg
 6450 6455 6460
 Asp Gly Glu Val Asp Glu Leu Leu Ala Glu Leu Leu Ala Asp Asp Ala
 6465 6470 6475 6480
 Glu Glu Glu Val Ala Phe Arg Gly Gly Glu Arg Arg Val Ala Arg Leu
 6485 6490 6495
 Val Arg Arg Leu Pro Glu Thr Asp Cys Arg Glu Lys Ile Glu Pro Ala
 6500 6505 6510
 Glu Gly Arg Pro Phe Arg Leu Glu Ile Asp Gly Ser Gly Val Leu Asp
 6515 6520 6525
 Asp Leu Val Leu Arg Ala Thr Glu Arg Arg Pro Pro Gly Pro Gly Glu
 6530 6535 6540
 Val Glu Ile Ala Val Glu Ala Ala Gly Leu Asn Phe Leu Asp Val Met
 6545 6550 6555 6560
 Arg Ala Met Gly Ile Tyr Pro Gly Pro Gly Asp Gly Pro Val Ala Leu
 6565 6570 6575
 Gly Ala Glu Cys Ser Gly Arg Ile Val Ala Met Gly Glu Gly Val Glu
 6580 6585 6590
 Ser Leu Arg Ile Gly Gln Asp Val Val Ala Val Ala Pro Phe Ser Phe
 6595 6600 6605
 Gly Thr His Val Thr Ile Asp Ala Arg Met Leu Ala Pro Arg Pro Ala
 6610 6615 6620

- 52 -

Ala Leu Thr Ala Ala Gln Ala Ala Ala Leu Pro Val Ala Phe Met Thr
 6625 6630 6635 6640
 Ala Trp Tyr Gly Leu Val His Leu Gly Arg Leu Arg Ala Gly Glu Arg
 6645 6650 6655
 Val Leu Ile His Ser Ala Thr Gly Gly Thr Gly Leu Ala Ala Val Gln
 6660 6665 6670
 Ile Ala Arg His Leu Gly Ala Glu Ile Phe Ala Thr Ala Gly Thr Pro
 6675 6680 6685
 Glu Lys Arg Ala Trp Leu Arg Glu Gln Gly Ile Ala His Val Met Asp
 6690 6695 6700
 Ser Arg Ser Leu Asp Phe Ala Glu Gln Val Leu Ala Ala Thr Lys Gly
 6705 6710 6715 6720
 Glu Gly Val Asp Val Val Leu Asn Ser Leu Ser Gly Ala Ala Ile Asp
 6725 6730 6735
 Ala Ser Leu Ser Thr Leu Val Pro Asp Gly Arg Phe Ile Glu Leu Gly
 6740 6745 6750
 Lys Thr Asp Ile Tyr Ala Asp Arg Ser Leu Gly Leu Ala His Phe Arg
 6755 6760 6765
 Lys Ser Leu Ser Tyr Ser Ala Val Asp Leu Ala Gly Leu Ala Val Arg
 6770 6775 6780
 Arg Pro Glu Arg Val Ala Ala Leu Leu Ala Glu Val Val Asp Leu Leu
 6785 6790 6795 6800
 Ala Arg Gly Ala Leu Gln Pro Leu Pro Val Glu Ile Phe Pro Leu Ser
 6805 6810 6815
 Arg Ala Ala Asp Ala Phe Arg Lys Met Ala Gln Ala Gln His Leu Gly
 6820 6825 6830
 Lys Leu Val Leu Ala Leu Glu Asp Pro Asp Val Arg Ile Arg Val Pro
 6835 6840 6845
 Gly Glu Ser Gly Val Ala Ile Arg Ala Asp Gly Ala Tyr Leu Val Thr
 6850 6855 6860
 Gly Gly Leu Gly Gly Leu Gly Leu Ser Val Ala Gly Trp Leu Ala Glu
 6865 6870 6875 6880
 Gln Gly Ala Gly His Leu Val Leu Val Gly Arg Ser Gly Ala Val Ser
 6885 6890 6895
 Ala Glu Gln Gln Thr Ala Val Ala Ala Leu Glu Ala His Gly Ala Arg
 6900 6905 6910
 Val Thr Val Ala Arg Ala Asp Val Ala Asp Arg Ala Gln Met Glu Arg
 6915 6920 6925
 Ile Leu Arg Glu Val Thr Ala Ser Gly Met Pro Leu Arg Gly Val Val
 6930 6935 6940
 His Ala Ala Gly Ile Leu Asp Asp Gly Leu Leu Met Gln Gln Thr Pro
 6945 6950 6955 6960
 Ala Arg Phe Arg Ala Val Met Ala Pro Lys Val Arg Gly Ala Leu His

- 53 -

6965	6970	6975
Leu His Ala Leu Thr Arg Glu Ala Pro Leu Ser Phe Phe Val Leu Tyr 6980	6985	6990
Ala Ser Gly Ala Gly Leu Leu Gly Ser Pro Gly Gln Gly Asn Tyr Ala 6995	7000	7005
Ala Ala Asn Thr Phe Leu Asp Ala Leu Ala His His Arg Arg Ala Gln 7010	7015	7020
Gly Leu Pro Ala Leu Ser Ile Asp Trp Gly Leu Phe Ala Asp Val Gly 7025	7030	7035
Leu Ala Ala Gly Gln Gln Asn Arg Gly Ala Arg Leu Val Thr Arg Gly 7045	7050	7055
Thr Arg Ser Leu Thr Pro Asp Glu Gly Leu Trp Ala Leu Glu Arg Leu 7060	7065	7070
Leu Asp Gly Asp Arg Thr Gln Ala Gly Val Met Pro Phe Asp Val Arg 7075	7080	7085
Gln Trp Val Glu Phe Tyr Pro Ala Ala Ala Ser Ser Arg Arg Leu Ser 7090	7095	7100
Arg Leu Met Thr Ala Arg Arg Val Ala Ser Gly Arg Leu Ala Gly Asp 7105	7110	7115
Arg Asp Leu Leu Glu Arg Leu Ala Thr Ala Glu Ala Gly Ala Arg Ala 7125	7130	7135
Gly Met Leu Gln Glu Val Val Arg Ala Gln Val Ser Gln Val Leu Arg 7140	7145	7150
Leu Ser Glu Gly Lys Leu Asp Val Asp Ala Pro Leu Thr Ser Leu Gly 7155	7160	7165
Met Asp Ser Leu Met Gly Leu Glu Leu Arg Asn Arg Ile Glu Ala Val 7170	7175	7180
Leu Gly Ile Thr Met Pro Ala Thr Leu Leu Trp Thr Tyr Pro Thr Val 7185	7190	7195
Ala Ala Leu Ser Ala His Leu Ala Ser His Val Val Ser Thr Gly Asp 7205	7210	7215
Gly Glu Ser Ala Arg Pro Pro Asp Thr Gly Ser Val Ala Pro Thr Thr 7220	7225	7230
His Glu Val Ala Ser Leu Asp Glu Asp Gly Leu Phe Ala Leu Ile Asp 7235	7240	7245
Glu Ser Leu Ala Arg Ala Gly Lys Arg 7250	7255	

<210> 6
 <211> 3798
 <212> PRT
 <213> Sorangium cellulosum

<400> 6
 Val Thr Asp Arg Glu Gly Gln Leu Leu Glu Arg Leu Arg Glu Val Thr
 1 5 10 15

- 54 -

Leu Ala Leu Arg Lys Thr Leu Asn Glu Arg Asp Thr Leu Glu Leu Glu
 20 25 30
 Lys Thr Glu Pro Ile Ala Ile Val Gly Ile Gly Cys Arg Phe Pro Gly
 35 40 45
 Gly Ala Gly Thr Pro Glu Ala Phe Trp Glu Leu Leu Asp Asp Gly Arg
 50 55 60
 Asp Ala Ile Arg Pro Leu Glu Glu Arg Trp Ala Leu Val Gly Val Asp
 65 70 75 80
 Pro Gly Asp Asp Val Pro Arg Trp Ala Gly Leu Leu Thr Glu Ala Ile
 85 90 95
 Asp Gly Phe Asp Ala Ala Phe Phe Gly Ile Ala Pro Arg Glu Ala Arg
 100 105 110
 Ser Leu Asp Pro Gln His Arg Leu Leu Leu Glu Val Ala Trp Glu Gly
 115 120 125
 Phe Glu Asp Ala Gly Ile Pro Pro Arg Ser Leu Val Gly Ser Arg Thr
 130 135 140
 Gly Val Phe Val Gly Val Cys Ala Thr Glu Tyr Leu His Ala Ala Val
 145 150 155 160
 Ala His Gln Pro Arg Glu Glu Arg Asp Ala Tyr Ser Thr Thr Gly Asn
 165 170 175
 Met Leu Ser Ile Ala Ala Gly Arg Leu Ser Tyr Thr Leu Gly Leu Gln
 180 185 190
 Gly Pro Cys Leu Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala
 195 200 205
 Ile His Leu Ala Cys Arg Ser Leu Arg Ala Arg Glu Ser Asp Leu Ala
 210 215 220
 Leu Ala Gly Gly Val Asn Met Leu Leu Ser Pro Asp Thr Met Arg Ala
 225 230 235 240
 Leu Ala Arg Thr Gln Ala Leu Ser Pro Asn Gly Arg Cys Gln Thr Phe
 245 250 255
 Asp Ala Ser Ala Asn Gly Phe Val Arg Gly Glu Gly Cys Gly Leu Ile
 260 265 270
 Val Leu Lys Arg Leu Ser Asp Ala Arg Arg Asp Gly Asp Arg Ile Trp
 275 280 285
 Ala Leu Ile Arg Gly Ser Ala Ile Asn Gln Asp Gly Arg Ser Thr Gly
 290 295 300
 Leu Thr Ala Pro Asn Val Leu Ala Gln Gly Ala Leu Leu Arg Glu Ala
 305 310 315 320
 Leu Arg Asn Ala Gly Val Glu Ala Glu Ala Ile Gly Tyr Ile Glu Thr
 325 330 335
 His Gly Ala Ala Thr Ser Leu Gly Asp Pro Ile Glu Ile Glu Ala Leu
 340 345 350
 Arg Ala Val Val Gly Pro Ala Arg Ala Asp Gly Ala Arg Cys Val Leu

- 55 -

355					360					365					
Gly	Ala	Val	Lys	Thr	Asn	Leu	Gly	His	Leu	Glu	Gly	Ala	Ala	Gly	Val
370					375					380					
Ala	Gly	Leu	Ile	Lys	Ala	Thr	Leu	Ser	Leu	His	His	Glu	Arg	Ile	Pro
385					390					395					400
Arg	Asn	Leu	Asn	Phe	Arg	Thr	Leu	Asn	Pro	Arg	Ile	Arg	Ile	Glu	Gly
			405						410					415	
Thr	Ala	Leu	Ala	Leu	Ala	Thr	Glu	Pro	Val	Pro	Trp	Pro	Arg	Thr	Gly
		420					425						430		
Arg	Thr	Arg	Phe	Ala	Gly	Val	Ser	Ser	Phe	Gly	Met	Ser	Gly	Thr	Asn
	435						440						445		
Ala	His	Val	Val	Leu	Glu	Glu	Ala	Pro	Ala	Val	Glu	Pro	Glu	Ala	Ala
	450					455					460				
Ala	Pro	Glu	Arg	Ala	Ala	Glu	Leu	Phe	Val	Leu	Ser	Ala	Lys	Ser	Ala
465					470					475					480
Ala	Ala	Leu	Asp	Ala	Gln	Ala	Ala	Arg	Leu	Arg	Asp	His	Leu	Glu	Lys
			485						490					495	
His	Val	Glu	Leu	Gly	Leu	Gly	Asp	Val	Ala	Phe	Ser	Leu	Ala	Thr	Thr
			500					505					510		
Arg	Ser	Ala	Met	Glu	His	Arg	Leu	Ala	Val	Ala	Ala	Ser	Ser	Arg	Glu
		515					520						525		
Ala	Leu	Arg	Gly	Ala	Leu	Ser	Ala	Ala	Ala	Gln	Gly	His	Thr	Pro	Pro
	530					535					540				
Gly	Ala	Val	Arg	Gly	Arg	Ala	Ser	Gly	Gly	Ser	Ala	Pro	Lys	Val	Val
545					550					555					560
Phe	Val	Phe	Pro	Gly	Gln	Gly	Ser	Gln	Trp	Val	Gly	Met	Gly	Arg	Lys
			565						570				575		
Leu	Met	Ala	Glu	Glu	Pro	Val	Phe	Arg	Ala	Ala	Leu	Glu	Gly	Cys	Asp
			580					585					590		
Arg	Ala	Ile	Glu	Ala	Glu	Ala	Gly	Trp	Ser	Leu	Leu	Gly	Glu	Leu	Ser
		595					600					605			
Ala	Asp	Glu	Ala	Ala	Ser	Gln	Leu	Gly	Arg	Ile	Asp	Val	Val	Gln	Pro
	610					615					620				
Val	Leu	Phe	Ala	Met	Glu	Val	Ala	Leu	Ser	Ala	Leu	Trp	Arg	Ser	Trp
625					630					635					640
Gly	Val	Glu	Pro	Glu	Ala	Val	Val	Gly	His	Ser	Met	Gly	Glu	Val	Ala
			645						650				655		
Ala	Ala	His	Val	Ala	Gly	Ala	Leu	Ser	Leu	Glu	Asp	Ala	Val	Ala	Ile
			660					665					670		
Ile	Cys	Arg	Arg	Ser	Arg	Leu	Leu	Arg	Arg	Ile	Ser	Gly	Gln	Gly	Glu
		675					680					685			
Met	Ala	Leu	Val	Glu	Leu	Ser	Leu	Glu	Glu	Ala	Glu	Ala	Ala	Leu	Arg
		690				695					700				

- 56 -

Gly His Glu Gly Arg Leu Ser Val Ala Val Ser Asn Ser Pro Arg Ser
 705 710 715 720
 Thr Val Leu Ala Gly Glu Pro Ala Ala Leu Ser Glu Val Leu Ala Ala
 725 730 735
 Leu Thr Ala Lys Gly Val Phe Trp Arg Gln Val Lys Val Asp Val Ala
 740 745 750
 Ser His Ser Pro Gln Val Asp Pro Leu Arg Glu Glu Leu Ile Ala Ala
 755 760 765
 Leu Gly Ala Ile Arg Pro Arg Ala Ala Ala Val Pro Met Arg Ser Thr
 770 775 780
 Val Thr Gly Gly Val Ile Ala Gly Pro Glu Leu Gly Ala Ser Tyr Trp
 785 790 795 800
 Ala Asp Asn Leu Arg Gln Pro Val Arg Phe Ala Ala Ala Ala Gln Ala
 805 810 815
 Leu Leu Glu Gly Gly Pro Ala Leu Phe Ile Glu Met Ser Pro His Pro
 820 825 830
 Ile Leu Val Pro Pro Leu Asp Glu Ile Gln Thr Ala Ala Glu Gln Gly
 835 840 845
 Gly Ala Ala Val Gly Ser Leu Arg Arg Gly Gln Asp Glu Arg Ala Thr
 850 855 860
 Leu Leu Glu Ala Leu Gly Thr Leu Trp Ala Ser Gly Tyr Pro Val Ser
 865 870 875 880
 Trp Ala Arg Leu Phe Pro Ala Gly Gly Arg Arg Val Pro Leu Pro Thr
 885 890 895
 Tyr Pro Trp Gln His Glu Arg Cys Trp Ile Glu Val Glu Pro Asp Ala
 900 905 910
 Arg Arg Leu Ala Ala Ala Asp Pro Thr Lys Asp Trp Phe Tyr Arg Thr
 915 920 925
 Asp Trp Pro Glu Val Pro Arg Ala Ala Pro Lys Ser Glu Thr Ala His
 930 935 940
 Gly Ser Trp Leu Leu Leu Ala Asp Arg Gly Gly Val Gly Glu Ala Val
 945 950 955 960
 Ala Ala Ala Leu Ser Thr Arg Gly Leu Ser Cys Thr Val Leu His Ala
 965 970 975
 Ser Ala Asp Ala Ser Thr Val Ala Glu Gln Val Ser Glu Ala Ala Ser
 980 985 990
 Arg Arg Asn Asp Trp Gln Gly Val Leu Tyr Leu Trp Gly Leu Asp Ala
 995 1000 1005
 Val Val Asp Ala Gly Ala Ser Ala Asp Glu Val Ser Glu Ala Thr Arg
 1010 1015 1020
 Arg Ala Thr Ala Pro Val Leu Gly Leu Val Arg Phe Leu Ser Ala Ala
 1025 1030 1035 1040
 Pro His Pro Pro Arg Phe Trp Val Val Thr Arg Gly Ala Cys Thr Val
 1045 1050 1055

- 57 -

Gly Gly Glu Pro Glu Ala Ser Leu Cys Gln Ala Ala Leu Trp Gly Leu
 1060 1065 1070
 Ala Arg Val Ala Ala Leu Glu His Pro Ala Ala Trp Gly Gly Leu Val
 1075 1080 1085
 Asp Leu Asp Pro Gln Lys Ser Pro Thr Glu Ile Glu Pro Leu Val Ala
 1090 1095 1100
 Glu Leu Leu Ser Pro Asp Ala Glu Asp Gln Leu Ala Phe Arg Ser Gly
 1105 1110 1115 1120
 Arg Arg His Ala Ala Arg Leu Val Ala Ala Pro Pro Glu Gly Asp Val
 1125 1130 1135
 Ala Pro Ile Ser Leu Ser Ala Glu Gly Ser Tyr Leu Val Thr Gly Gly
 1140 1145 1150
 Leu Gly Gly Leu Gly Leu Leu Val Ala Arg Trp Leu Val Glu Arg Gly
 1155 1160 1165
 Ala Arg His Leu Val Leu Thr Ser Arg His Gly Leu Pro Glu Arg Gln
 1170 1175 1180
 Ala Ser Gly Gly Glu Gln Pro Pro Glu Ala Arg Ala Arg Ile Ala Ala
 1185 1190 1195 1200
 Val Glu Gly Leu Glu Ala Gln Gly Ala Arg Val Thr Val Ala Ala Val
 1205 1210 1215
 Asp Val Ala Glu Ala Asp Pro Met Thr Ala Leu Leu Ala Ala Ile Glu
 1220 1225 1230
 Pro Pro Leu Arg Gly Val Val His Ala Ala Gly Val Phe Pro Val Arg
 1235 1240 1245
 His Leu Ala Glu Thr Asp Glu Ala Leu Leu Glu Ser Val Leu Arg Pro
 1250 1255 1260
 Lys Val Ala Gly Ser Trp Leu Leu His Arg Leu Leu Arg Asp Arg Pro
 1265 1270 1275 1280
 Leu Asp Leu Phe Val Leu Phe Ser Ser Gly Ala Ala Val Trp Gly Gly
 1285 1290 1295
 Lys Gly Gln Gly Ala Tyr Ala Ala Ala Asn Ala Phe Leu Asp Gly Leu
 1300 1305 1310
 Ala His His Arg Arg Ala His Ser Leu Pro Ala Leu Ser Leu Ala Trp
 1315 1320 1325
 Gly Leu Trp Ala Glu Gly Gly Met Val Asp Ala Lys Ala His Ala Arg
 1330 1335 1340
 Leu Ser Asp Ile Gly Val Leu Pro Met Ala Thr Gly Pro Ala Leu Ser
 1345 1350 1355 1360
 Ala Leu Glu Arg Leu Val Asn Thr Ser Ala Val Gln Arg Ser Val Thr
 1365 1370 1375
 Arg Met Asp Trp Ala Arg Phe Ala Pro Val Tyr Ala Ala Arg Gly Arg
 1380 1385 1390
 Arg Asn Leu Leu Ser Ala Leu Val Ala Glu Asp Glu Arg Ala Ala Ser

- 58 -

1395	1400	1405
Pro Pro Val Pro Thr Ala Asn Arg Ile Trp Arg Gly Leu Ser Val Ala 1410 1415 1420		
Glu Ser Arg Ser Ala Leu Tyr Glu Leu Val Arg Gly Ile Val Ala Arg 1425 1430 1435 1440		
Val Leu Gly Phe Ser Asp Pro Gly Ala Leu Asp Val Gly Arg Gly Phe 1445 1450 1455		
Ala Glu Gln Gly Leu Asp Ser Leu Met Ala Leu Glu Ile Arg Asn Arg 1460 1465 1470		
Leu Gln Arg Glu Leu Gly Glu Arg Leu Ser Ala Thr Leu Ala Phe Asp 1475 1480 1485		
His Pro Thr Val Glu Arg Leu Val Ala His Leu Leu Thr Asp Val Leu 1490 1495 1500		
Lys Leu Glu Asp Arg Ser Asp Thr Arg His Ile Arg Ser Val Ala Ala 1505 1510 1515 1520		
Asp Asp Asp Ile Ala Ile Val Gly Ala Ala Cys Arg Phe Pro Gly Gly 1525 1530 1535		
Asp Glu Gly Leu Glu Thr Tyr Trp Arg His Leu Ala Glu Gly Met Val 1540 1545 1550		
Val Ser Thr Glu Val Pro Ala Asp Arg Trp Arg Ala Ala Asp Trp Tyr 1555 1560 1565		
Asp Pro Asp Pro Glu Val Pro Gly Arg Thr Tyr Val Ala Lys Gly Ala 1570 1575 1580		
Phe Leu Arg Asp Val Arg Ser Leu Asp Ala Ala Phe Phe Ala Ile Ser 1585 1590 1595 1600		
Pro Arg Glu Ala Met Ser Leu Asp Pro Gln Gln Arg Leu Leu Leu Glu 1605 1610 1615		
Val Ser Trp Glu Ala Ile Glu Arg Ala Gly Gln Asp Pro Met Ala Leu 1620 1625 1630		
Arg Glu Ser Ala Thr Gly Val Phe Val Gly Met Ile Gly Ser Glu His 1635 1640 1645		
Ala Glu Arg Val Gln Gly Leu Asp Asp Ala Ala Leu Leu Tyr Gly 1650 1655 1660		
Thr Thr Gly Asn Leu Leu Ser Val Ala Ala Gly Arg Leu Ser Phe Phe 1665 1670 1675 1680		
Leu Gly Leu His Gly Pro Thr Met Thr Val Asp Thr Ala Cys Ser Ser 1685 1690 1695		
Ser Leu Val Ala Leu His Leu Ala Cys Gln Ser Leu Arg Leu Gly Glu 1700 1705 1710		
Cys Asp Gln Ala Leu Ala Gly Gly Ser Ser Val Leu Leu Ser Pro Arg 1715 1720 1725		
Ser Phe Val Ala Ala Ser Arg Met Arg Leu Leu Ser Pro Asp Gly Arg 1730 1735 1740		

- 59 -

Cys Lys Thr Phe Ser Ala Ala Ala Asp Gly Phe Ala Arg Ala Glu Gly
 1745 1750 1755 1760
 Cys Ala Val Val Val Leu Lys Arg Leu Arg Asp Ala Gln Arg Asp Arg
 1765 1770 1775
 Asp Pro Ile Leu Ala Val Val Arg Ser Thr Ala Ile Asn His Asp Gly
 1780 1785 1790
 Pro Ser Ser Gly Leu Thr Val Pro Ser Gly Pro Ala Gln Gln Ala Leu
 1795 1800 1805
 Leu Arg Gln Ala Leu Ala Gln Ala Gly Val Ala Pro Ala Glu Val Asp
 1810 1815 1820
 Phe Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu
 1825 1830 1835 1840
 Val Gln Ala Leu Gly Ala Val Tyr Gly Arg Gly Arg Pro Ala Glu Arg
 1845 1850 1855
 Pro Leu Trp Leu Gly Ala Val Lys Ala Asn Leu Gly His Leu Glu Ala
 1860 1865 1870
 Ala Ala Gly Leu Ala Gly Val Leu Lys Val Leu Leu Ala Leu Glu His
 1875 1880 1885
 Glu Gln Ile Pro Ala Gln Pro Glu Leu Asp Glu Leu Asn Pro His Ile
 1890 1895 1900
 Pro Trp Ala Glu Leu Pro Val Ala Val Val Arg Arg Ala Val Pro Trp
 1905 1910 1915 1920
 Pro Arg Gly Ala Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly Leu
 1925 1930 1935
 Ser Gly Thr Asn Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu
 1940 1945 1950
 Pro Val Ala Ala Ala Pro Glu Arg Ala Ala Glu Leu Phe Val Leu Ser
 1955 1960 1965
 Ala Lys Ser Ala Ala Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Asp
 1970 1975 1980
 His Leu Glu Lys His Val Glu Leu Gly Leu Gly Asp Val Ala Phe Ser
 1985 1990 1995 2000
 Leu Ala Thr Thr Arg Ser Ala Met Glu His Arg Leu Ala Val Ala Ala
 2005 2010 2015
 Ser Ser Arg Glu Ala Leu Arg Gly Ala Leu Ser Ala Ala Ala Gln Gly
 2020 2025 2030
 His Thr Pro Pro Gly Ala Val Arg Gly Arg Ala Ser Gly Gly Ser Ala
 2035 2040 2045
 Pro Lys Val Val Phe Val Phe Pro Gly Gln Gly Ser Gln Trp Val Gly
 2050 2055 2060
 Met Gly Arg Lys Leu Met Ala Glu Glu Pro Val Phe Arg Ala Ala Leu
 2065 2070 2075 2080
 Glu Gly Cys Asp Arg Ala Ile Glu Ala Glu Ala Gly Trp Ser Leu Leu
 2085 2090 2095

- 60 -

Gly Glu Leu Ser Ala Asp Glu Ala Ala Ser Gln Leu Gly Arg Ile Asp
 2100 2105 2110
 Val Val Gln Pro Val Leu Phe Ala Met Glu Val Ala Leu Ser Ala Leu
 2115 2120 2125
 Trp Arg Ser Trp Gly Val Glu Pro Glu Ala Val Val Gly His Ser Met
 2130 2135 2140
 Gly Glu Val Ala Ala Ala His Val Ala Gly Ala Leu Ser Leu Glu Asp
 2145 2150 2155 2160
 Ala Val Ala Ile Ile Cys Arg Arg Ser Arg Leu Leu Arg Arg Ile Ser
 2165 2170 2175
 Gly Gln Gly Glu Met Ala Leu Val Glu Leu Ser Leu Glu Glu Ala Glu
 2180 2185 2190
 Ala Ala Leu Arg Gly His Glu Gly Arg Leu Ser Val Ala Val Ser Asn
 2195 2200 2205
 Ser Pro Arg Ser Thr Val Leu Ala Gly Glu Pro Ala Ala Leu Ser Glu
 2210 2215 2220
 Val Leu Ala Ala Leu Thr Ala Lys Gly Val Phe Trp Arg Gln Val Lys
 2225 2230 2235 2240
 Val Asp Val Ala Ser His Ser Pro Gln Val Asp Pro Leu Arg Glu Glu
 2245 2250 2255
 Leu Ile Ala Ala Leu Gly Ala Ile Arg Pro Arg Ala Ala Ala Val Pro
 2260 2265 2270
 Met Arg Ser Thr Val Thr Gly Gly Val Ile Ala Gly Pro Glu Leu Gly
 2275 2280 2285
 Ala Ser Tyr Trp Ala Asp Asn Leu Arg Gln Pro Val Arg Phe Ala Ala
 2290 2295 2300
 Ala Ala Gln Ala Leu Leu Glu Gly Gly Pro Ala Leu Phe Ile Glu Met
 2305 2310 2315 2320
 Ser Pro His Pro Ile Leu Val Pro Pro Leu Asp Glu Ile Gln Thr Ala
 2325 2330 2335
 Ala Glu Gln Gly Gly Ala Ala Val Gly Ser Leu Arg Arg Gly Gln Asp
 2340 2345 2350
 Glu Arg Ala Thr Leu Leu Glu Ala Leu Gly Thr Leu Trp Ala Ser Gly
 2355 2360 2365
 Tyr Pro Val Ser Trp Ala Arg Leu Phe Pro Ala Gly Gly Arg Arg Val
 2370 2375 2380
 Pro Leu Pro Thr Tyr Pro Trp Gln His Glu Arg Tyr Trp Ile Glu Asp
 2385 2390 2395 2400
 Ser Val His Gly Ser Lys Pro Ser Leu Arg Leu Arg Gln Leu Arg Asn
 2405 2410 2415
 Gly Ala Thr Asp His Pro Leu Leu Gly Ala Pro Leu Leu Val Ser Ala
 2420 2425 2430
 Arg Pro Gly Ala His Leu Trp Glu Gln Ala Leu Ser Asp Glu Arg Leu

- 61 -

2435	2440	2445
Ser Tyr Leu Ser Glu His Arg Val His Gly Glu Ala Val Leu Pro Ser		
2450	2455	2460
Ala Ala Tyr Val Glu Met Ala Leu Ala Ala Gly Val Asp Leu Tyr Gly		
2465	2470	2475 2480
Thr Ala Thr Leu Val Leu Glu Gln Leu Ala Leu Glu Arg Ala Leu Ala		
	2485	2490 2495
Val Pro Ser Glu Gly Gly Arg Ile Val Gln Val Ala Leu Ser Glu Glu		
	2500	2505 2510
Gly Pro Gly Arg Ala Ser Phe Gln Val Ser Ser Arg Glu Glu Ala Gly		
	2515	2520 2525
Arg Ser Trp Val Arg His Ala Thr Gly His Val Cys Ser Gly Gln Ser		
	2530	2535 2540
Ser Ala Val Gly Ala Leu Lys Glu Ala Pro Trp Glu Ile Gln Arg Arg		
	2545	2550 2555 2560
Cys Pro Ser Val Leu Ser Ser Glu Ala Leu Tyr Pro Leu Leu Asn Glu		
	2565	2570 2575
His Ala Leu Asp Tyr Gly Pro Cys Phe Gln Gly Val Glu Gln Val Trp		
	2580	2585 2590
Leu Gly Thr Gly Glu Val Leu Gly Arg Val Arg Leu Pro Gly Asp Met		
	2595	2600 2605
Ala Ser Ser Ser Gly Ala Tyr Arg Ile His Pro Ala Leu Leu Asp Ala		
	2610	2615 2620
Cys Phe Gln Val Leu Thr Ala Leu Leu Thr Thr Pro Glu Ser Ile Glu		
	2625	2630 2635 2640
Ile Arg Arg Arg Leu Thr Asp Leu His Glu Pro Asp Leu Pro Arg Ser		
	2645	2650 2655
Arg Ala Pro Val Asn Gln Ala Val Ser Asp Thr Trp Leu Trp Asp Ala		
	2660	2665 2670
Ala Leu Asp Gly Gly Arg Arg Gln Ser Ala Ser Val Pro Val Asp Leu		
	2675	2680 2685
Val Leu Gly Ser Phe His Ala Lys Trp Glu Val Met Glu Arg Leu Ala		
	2690	2695 2700
Gln Ala Tyr Ile Ile Gly Thr Leu Arg Ile Trp Asn Val Phe Cys Ala		
	2705	2710 2715 2720
Ala Gly Glu Arg His Thr Ile Asp Glu Leu Leu Val Arg Leu Gln Ile		
	2725	2730 2735
Ser Val Val Tyr Arg Lys Val Ile Lys Arg Trp Met Glu His Leu Val		
	2740	2745 2750
Ala Ile Gly Ile Leu Val Gly Asp Gly Glu His Phe Val Ser Ser Gln		
	2755	2760 2765
Pro Leu Pro Glu Pro Asp Leu Ala Ala Val Leu Glu Glu Ala Gly Arg		
	2770	2775 2780

- 62 -

Val Phe Ala Asp Leu Pro Val Leu Phe Glu Trp Cys Lys Phe Ala Gly
 2785 2790 2795 2800
 Glu Arg Leu Ala Asp Val Leu Thr Gly Lys Thr Leu Ala Leu Glu Ile
 2805 2810 2815
 Leu Phe Pro Gly Gly Ser Phe Asp Met Ala Glu Arg Ile Tyr Arg Asp
 2820 2825 2830
 Ser Pro Ile Ala Arg Tyr Ser Asn Gly Ile Val Arg Gly Val Val Glu
 2835 2840 2845
 Ser Ala Ala Arg Val Val Ala Pro Ser Gly Met Phe Ser Ile Leu Glu
 2850 2855 2860
 Ile Gly Ala Gly Thr Gly Ala Thr Thr Ala Ala Val Leu Pro Val Leu
 2865 2870 2875 2880
 Leu Pro Asp Arg Thr Glu Tyr His Phe Thr Asp Val Ser Pro Leu Phe
 2885 2890 2895
 Leu Ala Arg Ala Glu Gln Arg Phe Arg Asp Tyr Pro Phe Leu Lys Tyr
 2900 2905 2910
 Gly Ile Leu Asp Val Asp Gln Glu Pro Ala Gly Gln Gly Tyr Ala His
 2915 2920 2925
 Gln Arg Phe Asp Val Ile Val Ala Ala Asn Val Ile His Ala Thr Arg
 2930 2935 2940
 Asp Ile Arg Ala Thr Ala Lys Arg Leu Leu Ser Leu Leu Ala Pro Gly
 2945 2950 2955 2960
 Gly Leu Leu Val Leu Val Glu Gly Thr Gly His Pro Ile Trp Phe Asp
 2965 2970 2975
 Ile Thr Thr Gly Leu Ile Glu Gly Trp Gln Lys Tyr Glu Asp Ser Leu
 2980 2985 2990
 Arg Ile Asp His Pro Leu Leu Pro Ala Arg Thr Trp Cys Asp Val Leu
 2995 3000 3005
 Arg Arg Val Gly Phe Ala Asp Ala Val Ser Leu Pro Gly Asp Gly Ser
 3010 3015 3020
 Pro Ala Gly Ile Leu Gly Gln His Val Ile Leu Ser Arg Ala Pro Gly
 3025 3030 3035 3040
 Ile Ala Gly Ala Ala Cys Asp Ser Ser Gly Glu Ser Ala Thr Glu Ser
 3045 3050 3055
 Pro Ala Ala Arg Ala Val Arg Gln Glu Trp Ala Asp Gly Ser Ala Asp
 3060 3065 3070
 Val Val His Arg Met Ala Leu Glu Arg Met Tyr Phe His Arg Arg Pro
 3075 3080 3085
 Gly Arg Gln Val Trp Val His Gly Arg Leu Arg Thr Gly Gly Gly Ala
 3090 3095 3100
 Phe Thr Lys Ala Leu Ala Gly Asp Leu Leu Leu Phe Glu Asp Thr Gly
 3105 3110 3115 3120
 Gln Val Val Ala Glu Val Gln Gly Leu Arg Leu Pro Gln Leu Glu Ala
 3125 3130 3135

- 63 -

Ser Ala Phe Ala Pro Arg Asp Pro Arg Glu Glu Trp Leu Tyr Ala Leu
 3140 3145 3150
 Glu Trp Gln Arg Lys Asp Pro Ile Pro Glu Ala Pro Ala Ala Ala Ser
 3155 3160 3165
 Ser Ser Ser Ala Gly Ala Trp Leu Val Leu Met Asp Gln Gly Gly Thr
 3170 3175 3180
 Gly Ala Ala Leu Val Ser Leu Leu Glu Gly Arg Gly Glu Ala Cys Val
 3185 3190 3195 3200
 Arg Val Ile Ala Gly Thr Ala Tyr Ala Cys Leu Ala Pro Gly Leu Tyr
 3205 3210 3215
 Gln Val Asp Pro Ala Gln Pro Asp Gly Phe His Thr Leu Leu Arg Asp
 3220 3225 3230
 Ala Phe Gly Glu Asp Arg Ile Cys Arg Ala Val Val His Met Trp Ser
 3235 3240 3245
 Leu Asp Ala Thr Ala Ala Gly Glu Arg Ala Thr Ala Glu Ser Leu Gln
 3250 3255 3260
 Ala Asp Gln Leu Leu Gly Ser Leu Ser Ala Leu Ser Leu Val Gln Ala
 3265 3270 3275 3280
 Leu Val Arg Arg Arg Trp Arg Asn Met Pro Arg Leu Trp Leu Leu Thr
 3285 3290 3295
 Arg Ala Val His Ala Val Gly Ala Glu Asp Ala Ala Ala Ser Val Ala
 3300 3305 3310
 Gln Ala Pro Val Trp Gly Leu Gly Arg Thr Leu Ala Leu Glu His Pro
 3315 3320 3325
 Glu Leu Arg Cys Thr Leu Val Asp Val Asn Pro Ala Pro Ser Pro Glu
 3330 3335 3340
 Asp Ala Ala Ala Leu Ala Val Glu Leu Gly Ala Ser Asp Arg Glu Asp
 3345 3350 3355 3360
 Gln Val Ala Leu Arg Ser Asp Gly Arg Tyr Val Ala Arg Leu Val Arg
 3365 3370 3375
 Ser Ser Phe Ser Gly Lys Pro Ala Thr Asp Cys Gly Ile Arg Ala Asp
 3380 3385 3390
 Gly Ser Tyr Val Ile Thr Asp Gly Met Gly Arg Val Gly Leu Ser Val
 3395 3400 3405
 Ala Gln Trp Met Val Met Gln Gly Ala Arg His Val Val Leu Val Asp
 3410 3415 3420
 Arg Gly Gly Ala Ser Glu Ala Ser Arg Asp Ala Leu Arg Ser Met Ala
 3425 3430 3435 3440
 Glu Ala Gly Ala Glu Val Gln Ile Val Glu Ala Asp Val Ala Arg Arg
 3445 3450 3455
 Asp Asp Val Ala Arg Leu Leu Ser Lys Ile Glu Pro Ser Met Pro Pro
 3460 3465 3470
 Leu Arg Gly Ile Val Tyr Val Asp Gly Thr Phe Gln Gly Asp Ser Ser

- 64 -

3475 3480 3485
 Met Leu Glu Leu Asp Ala Arg Arg Phe Lys Glu Trp Met Tyr Pro Lys
 3490 3495 3500
 Val Leu Gly Ala Trp Asn Leu His Ala Leu Thr Arg Asp Arg Ser Leu
 3505 3510 3515 3520
 Asp Phe Phe Val Leu Tyr Ser Ser Gly Thr Ser Leu Leu Gly Leu Pro
 3525 3530 3535
 Gly Gln Gly Ser Arg Ala Ala Gly Asp Ala Phe Leu Asp Ala Ile Ala
 3540 3545 3550
 His His Arg Cys Lys Val Gly Leu Thr Ala Met Ser Ile Asn Trp Gly
 3555 3560 3565
 Leu Leu Ser Glu Ala Ser Ser Pro Ala Thr Pro Asn Asp Gly Gly Ala
 3570 3575 3580
 Arg Leu Glu Tyr Arg Gly Met Glu Gly Leu Thr Leu Glu Gln Gly Ala
 3585 3590 3595 3600
 Ala Ala Leu Gly Arg Leu Leu Ala Arg Pro Arg Ala Gln Val Gly Val
 3605 3610 3615
 Met Arg Leu Asn Leu Arg Gln Trp Leu Glu Phe Tyr Pro Asn Ala Ala
 3620 3625 3630
 Arg Leu Ala Leu Trp Ala Glu Leu Leu Lys Glu Arg Asp Arg Ala Asp
 3635 3640 3645
 Arg Gly Ala Ser Asn Ala Ser Asn Leu Arg Glu Ala Leu Gln Ser Ala
 3650 3655 3660
 Arg Pro Glu Asp Arg Gln Leu Ile Leu Glu Lys His Leu Ser Glu Leu
 3665 3670 3675 3680
 Leu Gly Arg Gly Leu Arg Leu Pro Pro Glu Arg Ile Glu Arg His Val
 3685 3690 3695
 Pro Phe Ser Asn Leu Gly Met Asp Ser Leu Ile Gly Leu Glu Leu Arg
 3700 3705 3710
 Asn Arg Ile Glu Ala Ala Leu Gly Ile Thr Val Pro Ala Thr Leu Leu
 3715 3720 3725
 Trp Thr Tyr Pro Asn Val Ala Ala Leu Ser Gly Ser Leu Leu Asp Ile
 3730 3735 3740
 Leu Phe Pro Asn Ala Gly Ala Thr His Ala Pro Ala Thr Glu Arg Glu
 3745 3750 3755 3760
 Lys Ser Phe Glu Asn Asp Ala Ala Asp Leu Glu Ala Leu Arg Gly Met
 3765 3770 3775
 Thr Asp Glu Gln Lys Asp Ala Leu Leu Ala Glu Lys Leu Ala Gln Leu
 3780 3785 3790
 Ala Gln Ile Val Gly Glu
 3795

<210> 7

<211> 2439

- 65 -

<212> PRT

<213> Sorangium cellulosum

<400> 7

Met Ala Thr Thr Asn Ala Gly Lys Leu Glu His Ala Leu Leu Leu Met
1 5 10 15

Asp Lys Leu Ala Lys Lys Asn Ala Ser Leu Glu Gln Glu Arg Thr Glu
20 25 30

Pro Ile Ala Ile Val Gly Ile Gly Cys Arg Phe Pro Gly Gly Ala Asp
35 40 45

Thr Pro Glu Ala Phe Trp Glu Leu Leu Asp Ser Gly Arg Asp Ala Val
50 55 60

Gln Pro Leu Asp Arg Arg Trp Ala Leu Val Gly Val His Pro Ser Glu
65 70 75 80

Glu Val Pro Arg Trp Ala Gly Leu Leu Thr Glu Ala Val Asp Gly Phe
85 90 95

Asp Ala Ala Phe Phe Gly Thr Ser Pro Arg Glu Ala Arg Ser Leu Asp
100 105 110

Pro Gln Gln Arg Leu Leu Leu Glu Val Thr Trp Glu Gly Leu Glu Asp
115 120 125

Ala Gly Ile Ala Pro Gln Ser Leu Asp Gly Ser Arg Thr Gly Val Phe
130 135 140

Leu Gly Ala Cys Ser Ser Asp Tyr Ser His Thr Val Ala Gln Gln Arg
145 150 155 160

Arg Glu Glu Gln Asp Ala Tyr Asp Ile Thr Gly Asn Thr Leu Ser Val
165 170 175

Ala Ala Gly Arg Leu Ser Tyr Thr Leu Gly Leu Gln Gly Pro Cys Leu
180 185 190

Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Ile His Leu Ala
195 200 205

Cys Arg Ser Leu Arg Ala Arg Glu Ser Asp Leu Ala Leu Ala Gly Gly
210 215 220

Val Asn Met Leu Leu Ser Ser Lys Thr Met Ile Met Leu Gly Arg Ile
225 230 235 240

Gln Ala Leu Ser Pro Asp Gly His Cys Arg Thr Phe Asp Ala Ser Ala
245 250 255

Asn Gly Phe Val Arg Gly Glu Gly Cys Gly Met Val Val Leu Lys Arg
260 265 270

Leu Ser Asp Ala Gln Arg His Gly Asp Arg Ile Trp Ala Leu Ile Arg
275 280 285

Gly Ser Ala Met Asn Gln Asp Gly Arg Ser Thr Gly Leu Met Ala Pro
290 295 300

Asn Val Leu Ala Gln Glu Ala Leu Leu Arg Glu Ala Leu Gln Ser Ala
305 310 315 320

Arg Val Asp Ala Gly Ala Ile Gly Tyr Val Glu Thr His Gly Thr Gly

Thr	Ser	Leu	Gly	Asp	Pro	Ile	Glu	Val	Glu	Ala	Leu	Arg	Ala	Val	Leu
			340					345						350	
Gly	Pro	Ala	Arg	Ala	Asp	Gly	Ser	Arg	Cys	Val	Leu	Gly	Ala	Val	Lys
		355					360					365			
Thr	Asn	Leu	Gly	His	Leu	Glu	Gly	Ala	Ala	Gly	Val	Ala	Gly	Leu	Ile
	370					375					380				
Lys	Ala	Ala	Leu	Ala	Leu	His	His	Glu	Leu	Ile	Pro	Arg	Asn	Leu	His
385					390					395					400
Phe	His	Thr	Leu	Asn	Pro	Arg	Ile	Arg	Ile	Glu	Gly	Thr	Ala	Leu	Ala
				405					410					415	
Leu	Ala	Thr	Glu	Pro	Val	Pro	Trp	Pro	Arg	Ala	Gly	Arg	Pro	Arg	Phe
			420					425					430		
Ala	Gly	Val	Ser	Ala	Phe	Gly	Leu	Ser	Gly	Thr	Asn	Val	His	Val	Val
		435					440					445			
Leu	Glu	Glu	Ala	Pro	Ala	Thr	Val	Leu	Ala	Pro	Ala	Thr	Pro	Gly	Arg
	450					455					460				
Ser	Ala	Glu	Leu	Leu	Val	Leu	Ser	Ala	Lys	Ser	Ala	Ala	Ala	Leu	Asp
465					470					475					480
Ala	Gln	Ala	Ala	Arg	Leu	Ser	Ala	His	Ile	Ala	Ala	Tyr	Pro	Glu	Gln
				485					490					495	
Gly	Leu	Gly	Asp	Val	Ala	Phe	Ser	Leu	Val	Ser	Thr	Arg	Ser	Pro	Met
			500					505					510		
Glu	His	Arg	Leu	Ala	Val	Ala	Ala	Thr	Ser	Arg	Glu	Ala	Leu	Arg	Ser
		515					520					525			
Ala	Leu	Glu	Val	Ala	Ala	Gln	Gly	Gln	Thr	Pro	Ala	Gly	Ala	Ala	Arg
	530					535					540				
Gly	Arg	Ala	Ala	Ser	Ser	Pro	Gly	Lys	Leu	Ala	Phe	Leu	Phe	Ala	Gly
545					550					555					560
Gln	Gly	Ala	Gln	Val	Pro	Gly	Met	Gly	Arg	Gly	Leu	Trp	Glu	Ala	Trp
			565						570					575	
Pro	Ala	Phe	Arg	Glu	Thr	Phe	Asp	Arg	Cys	Val	Thr	Leu	Phe	Asp	Arg
			580					585					590		
Glu	Leu	His	Gln	Pro	Leu	Cys	Glu	Val	Met	Trp	Ala	Glu	Pro	Gly	Ser
		595					600					605			
Ser	Arg	Ser	Ser	Leu	Leu	Asp	Gln	Thr	Ala	Phe	Thr	Gln	Pro	Ala	Leu
	610					615					620				
Phe	Ala	Leu	Glu	Tyr	Ala	Leu	Ala	Ala	Leu	Phe	Arg	Ser	Trp	Gly	Val
625					630					635					640
Glu	Pro	Glu	Leu	Val	Ala	Gly	His	Ser	Leu	Gly	Glu	Leu	Val	Ala	Ala
				645					650					655	
Cys	Val	Ala	Gly	Val	Phe	Ser	Leu	Glu	Asp	Ala	Val	Arg	Leu	Val	Val
			660					665					670		

- 67 -

Ala Arg Gly Arg Leu Met Gln Ala Leu Pro Ala Gly Gly Ala Met Val
 675 680 685
 Ser Ile Ala Ala Pro Glu Ala Asp Val Ala Ala Ala Val Ala Pro His
 690 695 700
 Ala Ala Leu Val Ser Ile Ala Ala Val Asn Gly Pro Glu Gln Val Val
 705 710 715 720
 Ile Ala Gly Ala Glu Lys Phe Val Gln Gln Ile Ala Ala Ala Phe Ala
 725 730 735
 Ala Arg Gly Ala Arg Thr Lys Pro Leu His Val Ser His Ala Phe His
 740 745 750
 Ser Pro Leu Met Asp Pro Met Leu Glu Ala Phe Arg Arg Val Thr Glu
 755 760 765
 Ser Val Thr Tyr Arg Arg Pro Ser Ile Ala Leu Val Ser Asn Leu Ser
 770 775 780
 Gly Lys Pro Cys Thr Asp Glu Val Ser Ala Pro Gly Tyr Trp Val Arg
 785 790 795 800
 His Ala Arg Glu Ala Val Arg Phe Ala Asp Gly Val Lys Ala Leu His
 805 810 815
 Ala Ala Gly Ala Gly Leu Phe Val Glu Val Gly Pro Lys Pro Thr Leu
 820 825 830
 Leu Gly Leu Val Pro Ala Cys Leu Pro Asp Ala Arg Pro Val Leu Leu
 835 840 845
 Pro Ala Ser Arg Ala Gly Arg Asp Glu Ala Ala Ser Ala Leu Glu Ala
 850 855 860
 Leu Gly Gly Phe Trp Val Val Gly Gly Ser Val Thr Trp Ser Gly Val
 865 870 875 880
 Phe Pro Ser Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln
 885 890 895
 Arg Glu Arg Tyr Trp Ile Glu Ala Pro Val Asp Arg Glu Ala Asp Gly
 900 905 910
 Thr Gly Arg Ala Arg Ala Gly Gly His Pro Leu Leu Gly Glu Val Phe
 915 920 925
 Ser Val Ser Thr His Ala Gly Leu Arg Leu Trp Glu Thr Thr Leu Asp
 930 935 940
 Arg Lys Arg Leu Pro Trp Leu Gly Glu His Arg Ala Gln Gly Glu Val
 945 950 955 960
 Val Phe Pro Gly Ala Gly Tyr Leu Glu Met Ala Leu Ser Ser Gly Ala
 965 970 975
 Glu Ile Leu Gly Asp Gly Pro Ile Gln Val Thr Asp Val Val Leu Ile
 980 985 990
 Glu Thr Leu Thr Phe Ala Gly Asp Thr Ala Val Pro Val Gln Val Val
 995 1000 1005
 Thr Thr Glu Glu Arg Pro Gly Arg Leu Arg Phe Gln Val Ala Ser Arg
 1010 1015 1020

- 68 -

Glu Pro Gly Glu Arg Arg Ala Pro Phe Arg Ile His Ala Arg Gly Val
 1025 1030 1035 1040
 Leu Arg Arg Ile Gly Arg Val Glu Thr Pro Ala Arg Ser Asn Leu Ala
 1045 1050 1055
 Ala Leu Arg Ala Arg Leu His Ala Ala Val Pro Ala Ala Ala Ile Tyr
 1060 1065 1070
 Gly Ala Leu Ala Glu Met Gly Leu Gln Tyr Gly Pro Ala Leu Arg Gly
 1075 1080 1085
 Leu Ala Glu Leu Trp Arg Gly Glu Gly Glu Ala Leu Gly Arg Val Arg
 1090 1095 1100
 Leu Pro Glu Ala Ala Gly Ser Ala Thr Ala Tyr Gln Leu His Pro Val
 1105 1110 1115 1120
 Leu Leu Asp Ala Cys Val Gln Met Ile Val Gly Ala Phe Ala Asp Arg
 1125 1130 1135
 Asp Glu Ala Thr Pro Trp Ala Pro Val Glu Val Gly Ser Val Arg Leu
 1140 1145 1150
 Phe Gln Arg Ser Pro Gly Glu Leu Trp Cys His Ala Arg Val Val Ser
 1155 1160 1165
 Asp Gly Gln Gln Ala Ser Ser Arg Trp Ser Ala Asp Phe Glu Leu Met
 1170 1175 1180
 Asp Gly Thr Gly Ala Val Val Ala Glu Ile Ser Arg Leu Val Val Glu
 1185 1190 1195 1200
 Arg Leu Ala Ser Gly Val Arg Arg Arg Asp Ala Asp Asp Trp Phe Leu
 1205 1210 1215
 Glu Leu Asp Trp Glu Pro Ala Ala Leu Gly Gly Pro Lys Ile Thr Ala
 1220 1225 1230
 Gly Arg Trp Leu Leu Leu Gly Glu Gly Gly Gly Leu Gly Arg Ser Leu
 1235 1240 1245
 Cys Ser Ala Leu Lys Ala Ala Gly His Val Val Val His Ala Ala Gly
 1250 1255 1260
 Asp Asp Thr Ser Thr Ala Gly Met Arg Ala Leu Leu Ala Asn Ala Phe
 1265 1270 1275 1280
 Asp Gly Gln Ala Pro Thr Ala Val Val His Leu Ser Ser Leu Asp Gly
 1285 1290 1295
 Gly Gly Gln Leu Gly Pro Gly Leu Gly Ala Gln Gly Ala Leu Asp Ala
 1300 1305 1310
 Pro Arg Ser Pro Asp Val Asp Ala Asp Ala Leu Glu Ser Ala Leu Met
 1315 1320 1325
 Arg Gly Cys Asp Ser Val Leu Ser Leu Val Gln Ala Leu Val Gly Met
 1330 1335 1340
 Asp Leu Arg Asn Ala Pro Arg Leu Trp Leu Leu Thr Arg Gly Ala Gln
 1345 1350 1355 1360
 Ala Ala Ala Ala Gly Asp Val Ser Val Val Gln Ala Pro Leu Leu Gly

- 69 -

1365	1370	1375
Leu Gly Arg Thr Ile Ala Leu Glu His Ala Glu Leu Arg Cys Ile Ser		
1380	1385	1390
Val Asp Leu Asp Pro Ala Glu Pro Glu Gly Glu Ala Asp Ala Leu Leu		
1395	1400	1405
Ala Glu Leu Leu Ala Asp Asp Ala Glu Glu Glu Val Ala Leu Arg Gly		
1410	1415	1420
Gly Asp Arg Leu Val Ala Arg Leu Val His Arg Leu Pro Asp Ala Gln		
1425	1430	1435
Arg Arg Glu Lys Val Glu Pro Ala Gly Asp Arg Pro Phe Arg Leu Glu		
1445	1450	1455
Ile Asp Glu Pro Gly Ala Leu Asp Gln Leu Val Leu Arg Ala Thr Gly		
1460	1465	1470
Arg Arg Ala Pro Gly Pro Gly Glu Val Glu Ile Ser Val Glu Ala Ala		
1475	1480	1485
Gly Leu Asp Ser Ile Asp Ile Gln Leu Ala Leu Gly Val Ala Pro Asn		
1490	1495	1500
Asp Leu Pro Gly Glu Glu Ile Glu Pro Leu Val Leu Gly Ser Glu Cys		
1505	1510	1515
Ala Gly Arg Ile Val Ala Val Gly Glu Gly Val Asn Gly Leu Val Val		
1525	1530	1535
Gly Gln Pro Val Ile Ala Leu Ala Ala Gly Val Phe Ala Thr His Val		
1540	1545	1550
Thr Thr Ser Ala Thr Leu Val Leu Pro Arg Pro Leu Gly Leu Ser Ala		
1555	1560	1565
Thr Glu Ala Ala Ala Met Pro Leu Ala Tyr Leu Thr Ala Trp Tyr Ala		
1570	1575	1580
Leu Asp Lys Val Ala His Leu Gln Ala Gly Glu Arg Val Leu Ile His		
1585	1590	1595
Ala Glu Ala Gly Gly Val Gly Leu Cys Ala Val Arg Trp Ala Gln Arg		
1605	1610	1615
Val Gly Ala Glu Val Tyr Ala Thr Ala Asp Thr Pro Glu Asn Arg Ala		
1620	1625	1630
Tyr Leu Glu Ser Leu Gly Val Arg Tyr Val Ser Asp Ser Arg Ser Gly		
1635	1640	1645
Arg Phe Val Thr Asp Val His Ala Trp Thr Asp Gly Glu Gly Val Asp		
1650	1655	1660
Val Val Leu Asp Ser Leu Ser Gly Glu Arg Ile Asp Lys Ser Leu Met		
1665	1670	1675
Val Leu Arg Ala Cys Gly Arg Leu Val Lys Leu Gly Arg Arg Asp Asp		
1685	1690	1695
Cys Ala Asp Thr Gln Pro Gly Leu Pro Pro Leu Leu Arg Asn Phe Ser		
1700	1705	1710

- 70 -

Phe Ser Gln Val Asp Leu Arg Gly Met Met Leu Asp Gln Pro Ala Arg
 1715 1720 1725
 Ile Arg Ala Leu Leu Asp Glu Leu Phe Gly Leu Val Ala Ala Gly Ala
 1730 1735 1740
 Ile Ser Pro Leu Gly Ser Gly Leu Arg Val Gly Gly Ser Leu Thr Pro
 1745 1750 1755 1760
 Pro Pro Val Glu Thr Phe Pro Ile Ser Arg Ala Ala Glu Ala Phe Arg
 1765 1770 1775
 Arg Met Ala Gln Gly Gln His Leu Gly Lys Leu Val Leu Thr Leu Asp
 1780 1785 1790
 Asp Pro Glu Val Arg Ile Arg Ala Pro Ala Glu Ser Ser Val Ala Val
 1795 1800 1805
 Arg Ala Asp Gly Thr Tyr Leu Val Thr Gly Gly Leu Gly Gly Leu Gly
 1810 1815 1820
 Leu Arg Val Ala Gly Trp Leu Ala Glu Arg Gly Ala Gly Gln Leu Val
 1825 1830 1835 1840
 Leu Val Gly Arg Ser Gly Ala Ala Ser Ala Glu Gln Arg Ala Ala Val
 1845 1850 1855
 Ala Ala Leu Glu Ala His Gly Ala Arg Val Thr Val Ala Lys Ala Asp
 1860 1865 1870
 Val Ala Asp Arg Ser Gln Ile Glu Arg Val Leu Arg Glu Val Thr Ala
 1875 1880 1885
 Ser Gly Met Pro Leu Arg Gly Val Val His Ala Ala Gly Leu Val Asp
 1890 1895 1900
 Asp Gly Leu Leu Met Gln Gln Thr Pro Ala Arg Phe Arg Thr Val Met
 1905 1910 1915 1920
 Gly Pro Lys Val Gln Gly Ala Leu His Leu His Thr Leu Thr Arg Glu
 1925 1930 1935
 Ala Pro Leu Ser Phe Phe Val Leu Tyr Ala Ser Ala Ala Gly Leu Phe
 1940 1945 1950
 Gly Ser Pro Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala Phe Leu Asp
 1955 1960 1965
 Ala Leu Ser His His Arg Arg Ala Gln Gly Leu Pro Ala Leu Ser Ile
 1970 1975 1980
 Asp Trp Gly Met Phe Thr Glu Val Gly Met Ala Val Ala Gln Glu Asn
 1985 1990 1995 2000
 Arg Gly Ala Arg Gln Ile Ser Arg Gly Met Arg Gly Ile Thr Pro Asp
 2005 2010 2015
 Glu Gly Leu Ser Ala Leu Ala Arg Leu Leu Glu Gly Asp Arg Val Gln
 2020 2025 2030
 Thr Gly Val Ile Pro Ile Thr Pro Arg Gln Trp Val Glu Phe Tyr Pro
 2035 2040 2045
 Ala Thr Ala Ala Ser Arg Arg Leu Ser Arg Leu Val Thr Thr Gln Arg
 2050 2055 2060

- 71 -

Ala Val Ala Asp Arg Thr Ala Gly Asp Arg Asp Leu Leu Glu Gln Leu
 2065 2070 2075 2080
 Ala Ser Ala Glu Pro Ser Ala Arg Ala Gly Leu Leu Gln Asp Val Val
 2085 2090 2095
 Arg Val Gln Val Ser His Val Leu Arg Leu Pro Glu Asp Lys Ile Glu
 2100 2105 2110
 Val Asp Ala Pro Leu Ser Ser Met Gly Met Asp Ser Leu Met Ser Leu
 2115 2120 2125
 Glu Leu Arg Asn Arg Ile Glu Ala Ala Leu Gly Val Ala Ala Pro Ala
 2130 2135 2140
 Ala Leu Gly Trp Thr Tyr Pro Thr Val Ala Ala Ile Thr Arg Trp Leu
 2145 2150 2155 2160
 Leu Asp Asp Ala Leu Val Val Arg Leu Gly Gly Gly Ser Asp Thr Asp
 2165 2170 2175
 Glu Ser Thr Ala Ser Ala Gly Ser Phe Val His Val Leu Arg Phe Arg
 2180 2185 2190
 Pro Val Val Lys Pro Arg Ala Arg Leu Phe Cys Phe His Gly Ser Gly
 2195 2200 2205
 Gly Ser Pro Glu Gly Phe Arg Ser Trp Ser Glu Lys Ser Glu Trp Ser
 2210 2215 2220
 Asp Leu Glu Ile Val Ala Met Trp His Asp Arg Ser Leu Ala Ser Glu
 2225 2230 2235 2240
 Asp Ala Pro Gly Lys Lys Tyr Val Gln Glu Ala Ala Ser Leu Ile Gln
 2245 2250 2255
 His Tyr Ala Asp Ala Pro Phe Ala Leu Val Gly Phe Ser Leu Gly Val
 2260 2265 2270
 Arg Phe Val Met Gly Thr Ala Val Glu Leu Ala Ser Arg Ser Gly Ala
 2275 2280 2285
 Pro Ala Pro Leu Ala Val Phe Thr Leu Gly Gly Ser Leu Ile Ser Ser
 2290 2295 2300
 Ser Glu Ile Thr Pro Glu Met Glu Thr Asp Ile Ile Ala Lys Leu Phe
 2305 2310 2315 2320
 Phe Arg Asn Ala Ala Gly Phe Val Arg Ser Thr Gln Gln Val Gln Ala
 2325 2330 2335
 Asp Ala Arg Ala Asp Lys Val Ile Thr Asp Thr Met Val Ala Pro Ala
 2340 2345 2350
 Pro Gly Asp Ser Lys Glu Pro Pro Val Lys Ile Ala Val Pro Ile Val
 2355 2360 2365
 Ala Ile Ala Gly Ser Asp Asp Val Ile Val Pro Pro Ser Asp Val Gln
 2370 2375 2380
 Asp Leu Gln Ser Arg Thr Thr Glu Arg Phe Tyr Met His Leu Leu Pro
 2385 2390 2395 2400
 Gly Asp His Glu Phe Leu Val Asp Arg Gly Arg Glu Ile Met His Ile



- 73 -

Ser Pro Glu Ala Leu Glu Leu Val Lys Ala Glu Pro Gly Leu Met Arg
 275 280 285
 Asn Ala Leu Asp Glu Val Leu Arg Phe Asp Asn Ile Leu Arg Ile Gly
 290 295 300
 Thr Val Arg Phe Ala Arg Gln Asp Leu Glu Tyr Cys Gly Ala Ser Ile
 305 310 315 320
 Lys Lys Gly Glu Met Val Phe Leu Leu Ile Pro Ser Ala Leu Arg Asp
 325 330 335
 Gly Thr Val Phe Ser Arg Pro Asp Val Phe Asp Val Arg Arg Asp Thr
 340 345 350
 Gly Ala Ser Leu Ala Tyr Gly Arg Gly Pro His Val Cys Pro Gly Val
 355 360 365
 Ser Leu Ala Arg Leu Glu Ala Glu Ile Ala Val Gly Thr Ile Phe Arg
 370 375 380
 Arg Phe Pro Glu Met Lys Leu Lys Glu Thr Pro Val Phe Gly Tyr His
 385 390 395 400
 Pro Ala Phe Arg Asn Ile Glu Ser Leu Asn Val Ile Leu Lys Pro Ser
 405 410 415
 Lys Ala Gly

<210> 9
 <211> 607
 <212> PRT
 <213> Sorangium cellulosum

<400> 9
 Ala Ser Leu Asp Ala Leu Phe Ala Arg Ala Thr Ser Ala Arg Val Leu
 1 5 10 15
 Asp Asp Gly His Gly Arg Ala Thr Glu Arg His Val Leu Ala Glu Ala
 20 25 30
 Arg Gly Ile Glu Asp Leu Arg Ala Leu Arg Glu His Leu Arg Ile Gln
 35 40 45
 Glu Gly Gly Pro Ser Phe His Cys Met Cys Leu Gly Asp Leu Thr Val
 50 55 60
 Glu Leu Leu Ala His Asp Gln Pro Leu Ala Ser Ile Ser Phe His His
 65 70 75 80
 Ala Arg Ser Leu Arg His Pro Asp Trp Thr Ser Asp Ala Met Leu Val
 85 90 95
 Asp Gly Pro Ala Leu Val Arg Trp Leu Ala Ala Arg Gly Ala Pro Gly
 100 105 110
 Pro Leu Arg Glu Tyr Glu Glu Glu Arg Glu Arg Ala Arg Thr Ala Gln
 115 120 125
 Glu Ala Arg Arg Leu Trp Leu Ala Ala Ala Pro Pro Cys Phe Ala Pro
 130 135 140

- 74 -

Asp Leu Pro Arg Phe Glu Asp Asp Ala Asn Gly Leu Pro Leu Gly Pro
 145 150 155 160
 Met Ser Pro Glu Val Ala Glu Ala Glu Arg Arg Leu Arg Ala Ser Tyr
 165 170 175
 Ala Thr Pro Glu Leu Ala Cys Ala Ala Leu Leu Ala Trp Leu Gly Thr
 180 185 190
 Gly Ala Gly Pro Trp Ser Gly Tyr Pro Ala Tyr Glu Met Leu Pro Glu
 195 200 205
 Asn Leu Leu Leu Gly Phe Gly Leu Pro Thr Ala Ile Ala Ala Ala Ser
 210 215 220
 Ala Pro Gly Thr Ser Glu Ala Ala Leu Arg Gly Ala Ala Arg Leu Phe
 225 230 235 240
 Ala Ser Trp Glu Val Val Ser Ser Lys Lys Ser Gln Leu Gly Asn Ile
 245 250 255
 Pro Glu Ala Leu Trp Glu Arg Leu Arg Thr Ile Val Arg Ala Met Gly
 260 265 270
 Asn Ala Asp Asn Leu Ser Arg Phe Glu Arg Ala Glu Ala Ile Ala Ala
 275 280 285
 Glu Val Arg Arg Leu Arg Ala Gln Pro Ala Pro Phe Ala Ala Gly Ala
 290 295 300
 Gly Leu Ala Val Ala Gly Val Ser Ser Ser Gly Arg Leu Ser Gly Leu
 305 310 315 320
 Val Thr Asp Gly Asp Ala Leu Tyr Ser Gly Asp Gly Asn Asp Ile Val
 325 330 335
 Met Phe Gln Pro Gly Arg Ile Ser Pro Val Val Leu Leu Ala Gly Thr
 340 345 350
 Asp Pro Phe Phe Glu Leu Ala Pro Pro Leu Ser Gln Met Leu Phe Val
 355 360 365
 Ala His Ala Asn Ala Gly Thr Ile Ser Lys Val Leu Thr Glu Gly Ser
 370 375 380
 Pro Leu Ile Val Met Ala Arg Asn Gln Ala Arg Pro Met Ser Leu Val
 385 390 395 400
 His Ala Arg Gly Phe Met Ala Trp Val Asn Gln Ala Met Val Pro Asp
 405 410 415
 Pro Glu Arg Gly Ala Pro Phe Val Val Gln Arg Ser Thr Ile Met Glu
 420 425 430
 Phe Glu His Pro Thr Pro Arg Cys Leu His Glu Pro Ala Gly Ser Ala
 435 440 445
 Phe Ser Leu Ala Cys Asp Glu Glu His Leu Tyr Trp Cys Glu Leu Ser
 450 455 460
 Ala Gly Arg Leu Glu Leu Trp Arg His Pro His His Arg Pro Gly Ala
 465 470 475 480
 Pro Ser Arg Phe Ala Tyr Leu Gly Glu His Pro Ile Ala Ala Thr Trp
 485 490 495

- 75 -

Tyr Pro Ser Leu Thr Leu Asn Ala Thr His Val Leu Trp Ala Asp Pro
 500 505 510
 Asp Arg Arg Ala Ile Leu Gly Val Asp Lys Arg Thr Gly Val Glu Pro
 515 520 525
 Ile Val Leu Ala Glu Thr Arg His Pro Pro Ala His Val Val Ser Glu
 530 535 540
 Asp Arg Asp Ile Phe Ala Leu Thr Gly Gln Pro Asp Ser Arg Asp Trp
 545 550 555 560
 His Val Glu His Ile Arg Ser Gly Ala Ser Thr Val Val Ala Asp Tyr
 565 570 575
 Gln Arg Gln Leu Trp Asp Arg Pro Asp Met Val Leu Asn Arg Arg Gly
 580 585 590
 Leu Phe Phe Thr Thr Asn Asp Arg Ile Leu Thr Leu Ala Arg Ser
 595 600 605

<210> 10
 <211> 423
 <212> PRT
 <213> Sorangium cellulosum

<400> 10
 Met Gly Ala Leu Ile Ser Val Ala Ala Pro Gly Cys Ala Leu Gly Gly
 1 5 10 15
 Ala Glu Glu Glu Gly Gln Pro Gly Gln Asp Ala Gly Ala Gly Ala Leu
 20 25 30
 Ala Pro Ala Arg Glu Val Met Ala Ala Glu Val Ala Ala Gly Gln Met
 35 40 45
 Pro Gly Ala Val Trp Leu Val Ala Arg Gly Asp Asp Val His Val Asp
 50 55 60
 Ala Val Gly Val Thr Glu Leu Gly Gly Ser Ala Pro Met Arg Arg Asp
 65 70 75 80
 Thr Ile Phe Arg Ile Ala Ser Met Thr Lys Ala Val Thr Ala Thr Ala
 85 90 95
 Val Met Met Leu Val Glu Glu Gly Lys Leu Asp Leu Asp Ser Pro Val
 100 105 110
 Asp Arg Trp Leu Pro Glu Leu Ala Asn Arg Lys Val Leu Ala Arg Ile
 115 120 125
 Asp Gly Pro Ile Asp Glu Thr Val Pro Ala Glu Arg Pro Ile Thr Val
 130 135 140
 Arg Asp Leu Met Thr Phe Thr Met Gly Phe Gly Ile Ser Phe Asp Ala
 145 150 155 160
 Ser Ser Pro Ile Gln Arg Ala Ile Asp Glu Leu Gly Leu Val Asn Ala
 165 170 175
 Gln Pro Val Pro Met Thr Pro His Gly Pro Asp Glu Trp Ile Arg Arg
 180 185 190

- 76 -

Leu Gly Thr Leu Pro Leu Met His Gln Pro Gly Ala Gln Trp Met Tyr
 195 200 205
 Asn Thr Gly Ser Leu Val Gln Gly Val Leu Val Gly Arg Ala Ala Asp
 210 215 220
 Gln Gly Phe Asp Ala Phe Val Arg Glu Arg Ile Leu Ala Pro Leu Gly
 225 230 235 240
 Met Arg Asp Thr Asp Phe His Val Pro Ala Asp Lys Leu Ala Arg Phe
 245 250 255
 Ala Gly Cys Gly Tyr Phe Thr Asp Glu Gln Thr Gly Glu Lys Thr Arg
 260 265 270
 Met Asp Arg Asp Gly Ala Glu Ser Ala Tyr Ala Ser Pro Pro Ala Phe
 275 280 285
 Pro Ser Gly Ala Ala Gly Leu Val Ser Thr Val Asp Asp Tyr Leu Leu
 290 295 300
 Phe Ala Arg Met Leu Met Asn Gly Gly Val His Glu Gly Arg Arg Leu
 305 310 315 320
 Leu Ser Ala Ala Ser Val Arg Glu Met Thr Ala Asp His Leu Thr Pro
 325 330 335
 Ala Gln Lys Ala Ala Ser Ser Phe Phe Pro Gly Phe Phe Glu Thr His
 340 345 350
 Gly Trp Gly Tyr Gly Met Ala Val Val Thr Ala Pro Asp Ala Val Ser
 355 360 365
 Glu Val Pro Gly Arg Tyr Gly Trp Asp Gly Gly Phe Gly Thr Ser Trp
 370 375 380
 Ile Asn Asp Pro Gly Arg Glu Leu Ile Gly Ile Val Met Thr Gln Ser
 385 390 395 400
 Ala Gly Phe Leu Phe Ser Gly Ala Leu Glu Arg Phe Trp Arg Ser Val
 405 410 415
 Tyr Val Ala Thr Glu Ser Ala
 420

<210> 11
 <211> 713
 <212> PRT
 <213> Sorangium cellulosum

<400> 11
 Met His Gly Leu Thr Glu Arg Gln Val Leu Leu Ser Leu Val Thr Leu
 1 5 10 15
 Ala Leu Ile Leu Val Thr Ala Arg Ala Ser Gly Glu Leu Ala Arg Arg
 20 25 30
 Leu Arg Gln Pro Glu Val Leu Gly Glu Leu Phe Gly Gly Val Val Leu
 35 40 45
 Gly Pro Ser Val Val Gly Ala Leu Ala Pro Gly Phe His Arg Ala Leu
 50 55 60
 Phe Gln Glu Pro Ala Val Gly Val Val Leu Ser Gly Ile Ser Trp Ile

- 77 -

65		70		75		80
Gly Ala Leu Leu Leu Leu Leu Met Ala Gly Ile Glu Val Asp Val Gly						
	85			90		95
Ile Leu Arg Lys Glu Ala Arg Pro Gly Ala Leu Ser Ala Leu Gly Ala						
	100			105		110
Ile Ala Pro Pro Leu Ala Ala Gly Ala Ala Phe Ser Ala Leu Val Leu						
	115			120		125
Asp Arg Pro Leu Pro Ser Gly Leu Phe Leu Gly Ile Val Leu Ser Val						
	130			135		140
Thr Ala Val Ser Val Ile Ala Lys Val Leu Ile Glu Arg Glu Ser Met						
	145			150		155
Arg Arg Ser Tyr Ala Gln Val Thr Leu Ala Ala Gly Val Val Ser Glu						
	165			170		175
Val Ala Ala Trp Val Leu Val Ala Met Thr Ser Ser Ser Tyr Gly Ala						
	180			185		190
Ser Pro Ala Leu Ala Val Ala Arg Ser Ala Leu Leu Ala Ser Gly Phe						
	195			200		205
Leu Leu Phe Met Val Leu Val Gly Arg Arg Leu Thr His Leu Ala Met						
	210			215		220
Arg Trp Val Ala Asp Ala Thr Arg Val Ser Lys Gly Gln Val Ser Leu						
	225			230		235
Val Leu Val Leu Thr Phe Leu Ala Ala Ala Leu Thr Gln Arg Leu Gly						
	245			250		255
Leu His Pro Leu Leu Gly Ala Phe Ala Leu Gly Val Leu Leu Asn Ser						
	260			265		270
Ala Pro Arg Thr Asn Arg Pro Leu Leu Asp Gly Val Gln Thr Leu Val						
	275			280		285
Ala Gly Leu Phe Ala Pro Val Phe Phe Val Leu Ala Gly Met Arg Val						
	290			295		300
Asp Val Ser Gln Leu Arg Thr Pro Ala Ala Trp Gly Thr Val Ala Leu						
	305			310		315
Leu Leu Ala Thr Ala Thr Ala Ala Lys Val Val Pro Ala Ala Leu Gly						
	325			330		335
Ala Arg Leu Gly Gly Leu Arg Gly Ser Glu Ala Ala Leu Val Ala Val						
	340			345		350
Gly Leu Asn Met Lys Gly Gly Thr Asp Leu Ile Val Ala Ile Val Gly						
	355			360		365
Val Glu Leu Gly Leu Leu Ser Asn Glu Ala Tyr Thr Met Tyr Ala Val						
	370			375		380
Val Ala Leu Val Thr Val Thr Ala Ser Pro Ala Leu Leu Ile Trp Leu						
	385			390		395
Glu Lys Arg Ala Pro Pro Thr Gln Glu Glu Ser Ala Arg Leu Glu Arg						
	405			410		415

- 78 -

Glu Glu Ala Ala Arg Arg Ala Tyr Ile Pro Gly Val Glu Arg Ile Leu
 420 425 430
 Val Pro Ile Val Ala His Ala Leu Pro Gly Phe Ala Thr Asp Ile Val
 435 440 445
 Glu Ser Ile Val Ala Ser Lys Arg Lys Leu Gly Glu Thr Val Asp Ile
 450 455 460
 Thr Glu Leu Ser Val Glu Gln Gln Ala Pro Gly Pro Ser Arg Ala Ala
 465 470 475 480
 Gly Glu Ala Ser Arg Gly Leu Ala Arg Leu Gly Ala Arg Leu Arg Val
 485 490 495
 Gly Ile Trp Arg Gln Arg Arg Glu Leu Arg Gly Ser Ile Gln Ala Ile
 500 505 510
 Leu Arg Ala Ser Arg Asp His Asp Leu Leu Val Ile Gly Ala Arg Ser
 515 520 525
 Pro Ala Arg Ala Arg Gly Met Ser Phe Gly Arg Leu Gln Asp Ala Ile
 530 535 540
 Val Gln Arg Ala Glu Ser Asn Val Leu Val Val Val Gly Asp Pro Pro
 545 550 555 560
 Ala Ala Glu Arg Ala Ser Ala Arg Arg Ile Leu Val Pro Ile Ile Gly
 565 570 575
 Leu Glu Tyr Ser Phe Ala Ala Ala Asp Leu Ala Ala His Val Ala Leu
 580 585 590
 Ala Trp Asp Ala Glu Leu Val Leu Leu Ser Ser Ala Gln Thr Asp Pro
 595 600 605
 Gly Ala Val Val Trp Arg Asp Arg Glu Pro Ser Arg Val Arg Ala Val
 610 615 620
 Ala Arg Ser Val Val Asp Glu Ala Val Phe Arg Gly Arg Arg Leu Gly
 625 630 635 640
 Val Arg Val Ser Ser Arg Val His Val Gly Ala His Pro Ser Asp Glu
 645 650 655
 Ile Thr Arg Glu Leu Ala Arg Ala Pro Tyr Asp Leu Leu Val Leu Gly
 660 665 670
 Cys Tyr Asp His Gly Pro Leu Gly Arg Leu Tyr Leu Gly Ser Thr Val
 675 680 685
 Glu Ser Val Val Val Arg Ser Arg Val Pro Val Ala Leu Leu Val Ala
 690 695 700
 His Gly Gly Thr Arg Glu Gln Val Arg
 705 710

<210> 12
 <211> 126
 <212> PRT
 <213> Sorangium cellulosum

<400> 12
 Met Asp Lys Pro Ile Gly Arg Thr Arg Cys Ala Ile Ala Glu Gly Tyr

- 79 -

```

      1             5             10             15
Ile Pro Gly Gly Ser Asn Gly Pro Glu Pro Gln Met Thr Ser His Glu
      20             25             30
Thr Ala Cys Leu Leu Asn Ala Ser Asp Arg Asp Ala Gln Val Ala Ile
      35             40             45
Thr Val Tyr Phe Ser Asp Arg Asp Pro Ala Gly Pro Tyr Arg Val Thr
      50             55             60
Val Pro Ala Arg Arg Thr Arg His Val Arg Phe Asn Asp Leu Thr Glu
      65             70             75             80
Pro Glu Pro Ile Pro Arg Asp Thr Asp Tyr Ala Ser Val Ile Glu Ser
      85             90             95
Asp Ala Pro Ile Val Val Gln His Thr Arg Leu Asp Ser Arg Gln Ala
      100            105            110
Glu Asn Ala Leu Leu Ser Thr Ile Ala Tyr Thr Asp Arg Glu
      115            120            125

```

<210> 13
 <211> 149
 <212> PRT
 <213> Sorangium cellulosum

```

<400> 13
Met Lys His Val Asp Thr Gly Arg Arg Phe Gly Arg Arg Ile Gly His
  1             5             10             15
Thr Leu Gly Leu Leu Ala Ser Met Ala Leu Ala Gly Cys Gly Gly Pro
      20             25             30
Ser Glu Lys Thr Val Gln Gly Thr Arg Leu Ala Pro Gly Ala Asp Ala
      35             40             45
Arg Val Thr Ala Asp Val Asp Pro Asp Ala Ala Thr Thr Arg Leu Ala
      50             55             60
Val Asp Val Val His Leu Ser Pro Pro Glu Arg Leu Glu Ala Gly Ser
      65             70             75             80
Glu Arg Phe Val Val Trp Gln Arg Pro Ser Pro Glu Ser Pro Trp Arg
      85             90             95
Arg Val Gly Val Leu Asp Tyr Asn Ala Asp Ser Arg Arg Gly Lys Leu
      100            105            110
Ala Glu Thr Thr Val Pro Tyr Ala Asn Phe Glu Leu Leu Ile Thr Ala
      115            120            125
Glu Lys Gln Ser Ser Pro Gln Ser Pro Ser Ser Ala Ala Val Ile Gly
      130            135            140
Pro Thr Ser Val Gly
145

```

<210> 14
 <211> 184
 <212> PRT
 <213> Sorangium cellulosum

- 80 -

<400> 14

Val Thr Ser Glu Glu Val Pro Gly Ala Ala Leu Gly Ala Gln Ser Ser
 1 5 10 15
 Leu Val Arg Ala Gln His Ala Ala Arg His Val Arg Pro Cys Thr Arg
 20 25 30
 Ala Glu Glu Pro Pro Ala Leu Met His Gly Leu Thr Glu Arg Gln Val
 35 40 45
 Leu Leu Ser Leu Val Ala Leu Ala Leu Val Leu Leu Thr Ala Arg Ala
 50 55 60
 Phe Gly Glu Leu Ala Arg Arg Leu Arg Gln Pro Glu Val Leu Gly Glu
 65 70 75 80
 Leu Phe Gly Gly Val Val Leu Gly Pro Ser Val Val Gly Ala Leu Ala
 85 90 95
 Pro Gly Phe His Arg Val Leu Phe Gln Asp Pro Ala Val Gly Val Val
 100 105 110
 Leu Ser Gly Ile Ser Trp Ile Gly Ala Leu Val Leu Leu Leu Met Ala
 115 120 125
 Gly Ile Glu Val Asp Val Ser Ile Leu Arg Lys Glu Ala Arg Pro Gly
 130 135 140
 Ala Leu Ser Ala Leu Gly Ala Ile Ala Pro Pro Leu Arg Thr Pro Gly
 145 150 155 160
 Pro Leu Val Gln Arg Met Gln Gly Ala Phe Thr Trp Asp Leu Asp Val
 165 170 175
 Ser Pro Arg Arg Ser Ala Gln Ala
 180

<210> 15

<211> 143

<212> PRT

<213> Sorangium cellulosum

<400> 15

Val Asn Ala Pro Cys Met Arg Cys Thr Ser Gly Pro Gly Val Arg Ser
 1 5 10 15
 Gly Gly Ala Ile Ala Pro Ser Ala Glu Ser Ala Pro Gly Arg Ala Ser
 20 25 30
 Leu Arg Arg Met Leu Thr Ser Thr Ser Ile Pro Ala Met Ser Ser Arg
 35 40 45
 Thr Ser Ala Pro Ile Gln Glu Met Pro Glu Ser Thr Thr Pro Thr Ala
 50 55 60
 Gly Ser Trp Lys Arg Thr Arg Trp Asn Pro Gly Ala Ser Ala Pro Thr
 65 70 75 80
 Thr Asp Gly Pro Ser Thr Thr Pro Pro Lys Ser Ser Pro Ser Thr Ser
 85 90 95
 Gly Trp Arg Ser Arg Arg Ala Ser Ser Pro Lys Ala Arg Ala Val Arg
 100 105 110

- 81 -

Arg Thr Ser Ala Arg Ala Thr Ser Glu Ser Arg Thr Cys Arg Ser Val
 115 120 125

Arg Pro Cys Ile Arg Ala Gly Gly Ser Ser Ala Arg Val Gln Gly Arg
 130 135 140

Thr
 145

<210> 16
 <211> 185
 <212> PRT
 <213> Sorangium cellulosum

<400> 16
 Val Leu Ala Pro Pro Ala Asp Ile Arg Pro Pro Ala Ala Ala Gln Leu
 1 5 10 15

Glu Pro Asp Ser Pro Asp Asp Glu Ala Asp Glu Ala Asp Glu Ala Leu
 20 25 30

Arg Pro Phe Arg Asp Ala Ile Ala Ala Tyr Ser Glu Ala Val Arg Trp
 35 40 45

Ala Glu Ala Ala Gln Arg Pro Arg Leu Glu Ser Leu Val Arg Leu Ala
 50 55 60

Ile Val Arg Leu Gly Lys Ala Leu Asp Lys Val Pro Phe Ala His Thr
 65 70 75 80

Thr Ala Gly Val Ser Gln Ile Ala Gly Arg Leu Gln Asn Asp Ala Val
 85 90 95

Trp Phe Asp Val Ala Ala Arg Tyr Ala Ser Phe Arg Ala Ala Thr Glu
 100 105 110

His Ala Leu Arg Asp Ala Ala Ser Ala Met Glu Ala Leu Ala Ala Gly
 115 120 125

Pro Tyr Arg Gly Ser Ser Arg Val Ser Ala Ala Val Gly Glu Phe Arg
 130 135 140

Gly Glu Ala Ala Arg Leu His Pro Ala Asp Arg Val Pro Ala Ser Asp
 145 150 155 160

Gln Gln Ile Leu Thr Ala Leu Arg Ala Ala Glu Arg Ala Leu Ile Ala
 165 170 175

Leu Tyr Thr Ala Phe Ala Arg Glu Glu
 180 185

<210> 17
 <211> 146
 <212> PRT
 <213> Sorangium cellulosum

<400> 17
 Met Ala Asp Ala Ala Ser Arg Ser Ala Cys Ser Val Ala Ala Arg Lys
 1 5 10 15

Leu Ala Tyr Arg Ala Ala Thr Ser Asn Gln Thr Ala Ser Phe Trp Ser
 20 25 30

- 82 -

Leu Pro Ala Ile Trp Glu Thr Pro Ala Val Val Cys Ala Lys Gly Thr
 35 40 45

Leu Ser Ser Ala Leu Pro Ser Arg Thr Ile Ala Ser Arg Thr Arg Leu
 50 55 60

Ser Ser Arg Gly Arg Cys Ala Ala Ser Ala His Arg Thr Ala Ser Glu
 65 70 75 80

Tyr Ala Ala Ile Ala Ser Arg Asn Gly Arg Ser Ala Ser Ser Ala Ser
 85 90 95

Ser Ala Ser Ser Ser Gly Glu Ser Gly Ser Ser Trp Ala Ala Ala Gly
 100 105 110

Gly Arg Met Ser Ala Gly Gly Ala Ser Thr Gly Glu Val Tyr Glu Gln
 115 120 125

Ala Pro Arg Leu Arg Leu Ala Gln Ser Val Ala Ala Arg Arg Arg Asp
 130 135 140

Pro Thr
 145

<210> 18
 <211> 288
 <212> PRT
 <213> Sorangium cellulosum

<400> 18
 Val Thr Val Ser Ser Met Pro Arg Ser Trp Ser Ser Arg Val Arg Thr
 1 5 10 15

Val Val Thr Ala Leu Gly Cys Ala Arg Arg Leu Ser Gly Ser Ile Ser
 20 25 30

Arg Leu Arg Arg His Pro Glu Ala Gly Arg Ala Pro Arg Ser Arg Leu
 35 40 45

Arg Ala Trp Arg Arg Leu Pro Gln His Ile Ser Ser Pro Trp Arg His
 50 55 60

Leu Pro Pro Gly Ala Arg Val Gly Thr Ser Cys Pro Ala Asp Arg Arg
 65 70 75 80

Ile Leu Pro Ser His Arg Thr Ala Asp Leu Gly Thr Ser Gly Gly Thr
 85 90 95

Leu Val Ala Arg Met Ser Gly His Val Ala Arg Asn Pro His Ala Ala
 100 105 110

Val Leu Val Gly Asp Gly Ser Ala Arg Gly Arg Arg Arg Leu Ser Asn
 115 120 125

Arg Arg Ala Glu Arg Arg Val Ser Asp Val Thr Cys Arg Glu Gly Gly
 130 135 140

Glu Ala Met Gln Lys Ile Ala Gly Lys Leu Val Val Gly Leu Ile Ser
 145 150 155 160

Val Ser Gly Met Ser Leu Leu Ala Ala Cys Gly Gly Glu Lys Arg Ser
 165 170 175

- 83 -

Gly Gly Glu Ala Gln Thr Pro Gly Gly Ala Gln Gly Glu Ala Pro Val
 180 185 190
 Pro Val Gly Ser Ala Val Asp Ser Ile Val Ala Ala Arg Cys Asp Arg
 195 200 205
 Glu Ala Arg Cys Asn Asn Ile Gly Gln Asp Arg Glu Tyr Ser Ser Lys
 210 215 220
 Asp Ala Cys Ser Asn Lys Ile Arg Ser Glu Trp Arg Asp Glu Leu Thr
 225 230 235 240
 Phe Gly Glu Cys Pro Gly Gly Ile Asp Ala Lys Gln Leu Asn Glu Cys
 245 250 255
 Leu Glu Gly Ile Arg Asn Glu Gly Cys Gly Asn Pro Phe Asp Thr Leu
 260 265 270
 Gly Arg Val Val Ala Cys Arg Ser Ser Asp Leu Cys Arg Asp Ala Arg
 275 280 285

<210> 19
 <211> 288
 <212> PRT
 <213> Sorangium cellulosum

<400> 19
 Val Thr Val Ser Ser Met Pro Arg Ser Trp Ser Ser Arg Val Arg Thr
 1 5 10 15
 Val Val Thr Ala Leu Gly Cys Ala Arg Arg Leu Ser Gly Ser Ile Ser
 20 25 30
 Arg Leu Arg Arg His Pro Glu Ala Gly Arg Ala Pro Arg Ser Arg Leu
 35 40 45
 Arg Ala Trp Arg Arg Leu Pro Gln His Ile Ser Ser Pro Trp Arg His
 50 55 60
 Leu Pro Pro Gly Ala Arg Val Gly Thr Ser Cys Pro Ala Asp Arg Arg
 65 70 75 80
 Ile Leu Pro Ser His Arg Thr Ala Asp Leu Gly Thr Ser Gly Gly Thr
 85 90 95
 Leu Val Ala Arg Met Ser Gly His Val Ala Arg Asn Pro His Ala Ala
 100 105 110
 Val Leu Val Gly Asp Gly Ser Ala Arg Gly Arg Arg Arg Leu Ser Asn
 115 120 125
 Arg Arg Ala Glu Arg Arg Val Ser Asp Val Thr Cys Arg Glu Gly Gly
 130 135 140
 Glu Ala Met Gln Lys Ile Ala Gly Lys Leu Val Val Gly Leu Ile Ser
 145 150 155 160
 Val Ser Gly Met Ser Leu Leu Ala Ala Cys Gly Gly Glu Lys Arg Ser
 165 170 175
 Gly Gly Glu Ala Gln Thr Pro Gly Gly Ala Gln Gly Glu Ala Pro Val

- 84 -

	180		185		190
Pro Val Gly Ser Ala Val Asp Ser Ile Val Ala Ala Arg Cys Asp Arg	195	200	205		
Glu Ala Arg Cys Asn Asn Ile Gly Gln Asp Arg Glu Tyr Ser Ser Lys	210	215	220		
Asp Ala Cys Ser Asn Lys Ile Arg Ser Glu Trp Arg Asp Glu Leu Thr	225	230	235	240	
Phe Gly Glu Cys Pro Gly Gly Ile Asp Ala Lys Gln Leu Asn Glu Cys	245	250	255		
Leu Glu Gly Ile Arg Asn Glu Gly Cys Gly Asn Pro Phe Asp Thr Leu	260	265	270		
Gly Arg Val Val Ala Cys Arg Ser Ser Asp Leu Cys Arg Asp Ala Arg	275	280	285		

<210> 20
 <211> 155
 <212> PRT
 <213> Sorangium cellulosum

<400> 20
 Met Asp Pro Arg Ala Arg Arg Glu Lys Arg Pro Ser Leu Leu Asp Ser
 1 5 10 15
 Arg Gly Arg Gln Pro Lys Arg Ser Gln Gln Gly Gly His Met Glu Lys
 20 25 30
 Pro Ile Gly Arg Thr Arg Trp Ala Ile Ala Glu Gly Tyr Ile Pro Gly
 35 40 45
 Arg Ser Asn Gly Pro Glu Pro Gln Met Thr Ser His Glu Thr Ala Cys
 50 55 60
 Leu Leu Asn Ala Ser Asp Arg Asp Ala Gln Val Ala Ile Thr Val Tyr
 65 70 75 80
 Phe Ser Asp Arg Asp Pro Ala Gly Pro Tyr Arg Val Thr Val Pro Ala
 85 90 95
 Arg Arg Thr Arg His Val Arg Phe Asn Asp Leu Thr Glu Pro Glu Pro
 100 105 110
 Ile Pro Arg Asp Thr Asp Tyr Ala Ser Val Ile Glu Ser Asp Val Pro
 115 120 125
 Ile Val Val Gln His Thr Arg Leu Asp Ser Arg Gln Ala Glu Asn Ala
 130 135 140
 Leu Ile Ser Thr Ile Ala Tyr Thr Asp Arg Glu
 145 150 155

<210> 21
 <211> 156
 <212> PRT
 <213> Sorangium cellulosum

- 85 -

<400> 21

Val Arg Arg Ser Arg Trp Gln Met Lys His Val Asp Thr Gly Arg Arg
 1 5 10 15
 Val Gly Arg Arg Ile Gly Leu Thr Leu Gly Leu Leu Ala Ser Met Ala
 20 25 30
 Leu Ala Gly Cys Gly Gly Pro Ser Glu Lys Ile Val Gln Gly Thr Arg
 35 40 45
 Leu Ala Pro Gly Ala Asp Ala His Val Ala Ala Asp Val Asp Pro Asp
 50 55 60
 Ala Ala Thr Thr Arg Leu Ala Val Asp Val Val His Leu Ser Pro Pro
 65 70 75 80
 Glu Arg Ile Glu Ala Gly Ser Glu Arg Phe Val Val Trp Gln Arg Pro
 85 90 95
 Ser Ser Glu Ser Pro Trp Gln Arg Val Gly Val Leu Asp Tyr Asn Ala
 100 105 110
 Ala Ser Arg Arg Gly Lys Leu Ala Glu Thr Thr Val Pro His Ala Asn
 115 120 125
 Phe Glu Leu Leu Ile Thr Val Glu Lys Gln Ser Ser Pro Gln Ser Pro
 130 135 140
 Ser Ser Ala Ala Val Ile Gly Pro Thr Ser Val Gly
 145 150 155

<210> 22

<211> 305

<212> PRT

<213> Sorangium cellulosum

<400> 22

Met Glu Lys Glu Ser Arg Ile Ala Ile Tyr Gly Ala Ile Ala Ala Asn
 1 5 10 15
 Val Ala Ile Ala Ala Val Lys Phe Ile Ala Ala Ala Val Thr Gly Ser
 20 25 30
 Ser Ala Met Leu Ser Glu Gly Val His Ser Leu Val Asp Thr Ala Asp
 35 40 45
 Gly Leu Leu Leu Leu Leu Gly Lys His Arg Ser Ala Arg Pro Pro Asp
 50 55 60
 Ala Glu His Pro Phe Gly His Gly Lys Glu Leu Tyr Phe Trp Thr Leu
 65 70 75 80
 Ile Val Ala Ile Met Ile Phe Ala Ala Gly Gly Gly Val Ser Ile Tyr
 85 90 95
 Glu Gly Ile Leu His Leu Leu His Pro Arg Gln Ile Glu Asp Pro Thr
 100 105 110
 Trp Asn Tyr Val Val Leu Gly Ala Ala Ala Val Phe Glu Gly Thr Ser
 115 120 125
 Leu Ile Ile Ser Ile His Glu Phe Lys Lys Lys Asp Gly Gln Gly Tyr
 130 135 140

- 86 -

Leu Ala Ala Met Arg Ser Ser Lys Asp Pro Thr Thr Phe Thr Ile Val
 145 150 155 160
 Leu Glu Asp Ser Ala Ala Leu Ala Gly Leu Thr Ile Ala Phe Leu Gly
 165 170 175
 Val Trp Leu Gly His Arg Leu Gly Asn Pro Tyr Leu Asp Gly Ala Ala
 180 185 190
 Ser Ile Gly Ile Gly Leu Val Leu Ala Ala Val Ala Val Phe Leu Ala
 195 200 205
 Ser Gln Ser Arg Gly Leu Leu Val Gly Glu Ser Ala Asp Arg Glu Leu
 210 215 220
 Leu Ala Ala Ile Arg Ala Leu Ala Ser Ala Asp Pro Gly Val Ser Ala
 225 230 235 240
 Val Gly Arg Pro Leu Thr Met His Phe Gly Pro His Glu Val Leu Val
 245 250 255
 Val Leu Arg Ile Glu Phe Asp Ala Ala Leu Thr Ala Ser Gly Val Ala
 260 265 270
 Glu Ala Ile Glu Arg Ile Glu Thr Arg Ile Arg Ser Glu Arg Pro Asp
 275 280 285
 Val Lys His Ile Tyr Val Glu Ala Arg Ser Leu His Gln Arg Ala Arg
 290 295 300
 Ala
 305

<210> 23
 <211> 135
 <212> PRT
 <213> Sorangium cellulosum

<400> 23
 Val Gln Thr Ser Ser Phe Asp Ala Arg Tyr Ala Gly Cys Lys Ser Ser
 1 5 10 15
 Arg Arg Ile Ala Arg Ser Gly Ser Ala Gly Ala Arg Ala Gly Arg Ala
 20 25 30
 His Glu Gly Ala Ala Ser Ala Gly Phe Glu Gly Gly Asp Val Met Arg
 35 40 45
 Lys Ala Arg Ala His Gly Ala Met Leu Gly Gly Arg Asp Asp Gly Trp
 50 55 60
 Arg Arg Gly Leu Pro Gly Ala Gly Ala Leu Arg Ala Ala Leu Gln Arg
 65 70 75 80
 Gly Arg Ser Arg Asp Leu Ala Arg Arg Arg Leu Ile Ala Ser Val Ser
 85 90 95
 Leu Ala Gly Gly Ala Ser Met Ala Val Val Ser Leu Phe Gln Leu Gly
 100 105 110
 Ile Ile Glu Arg Leu Pro Asp Pro Pro Leu Pro Gly Phe Asp Ser Ala
 115 120 125

- 87 -

Lys Val Thr Ser Ser Asp Ile
130 135

<210> 24
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: universal
reverse primer

<400> 24
ggaaacagct atgaccatg 19

<210> 25
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: universal
forward primer

<400> 25
gtaaaacgac ggccagt 17

<210> 26
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
NH24 end "B"

<400> 26
gtgactggcg cctggaatct gcatgagc 28

<210> 27
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer NH2
end "A"

<400> 27
agcgggagct tgctagacat tctgtttc 28

<210> 28
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer NH2
end "B"

<400> 28
gacgcgcctc gggcagcgcc ccaa 24

<210> 29

- 88 -

<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
pEP015-NH6 end "B"

<400> 29
caccgaagcg tcgatctggt ccatc

25

<210> 30
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
pEP015H2.7 end "A"

<400> 30
cggtcagatc gacgacgggc ttcc

25

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/52, C07K 14/535, C07D 493/00		A3	(11) International Publication Number: WO 99/66028
			(43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: PCT/EP99/04171		[US/US]; 413 Vuncannon Drive, Fuquay-Varina, NC 27526 (US).	
(22) International Filing Date: 16 June 1999 (16.06.99)		(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).	
(30) Priority Data: 09/099,504 18 June 1998 (18.06.98) US 60/101,631 24 September 1998 (24.09.98) US 60/118,906 5 February 1999 (05.02.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except AT US): NOVAR-TIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VER-WALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SCHUPP, Thomas [CH/CH]; Fröschmattweg 5, CH-4313 Möhlin (CH). LIGON, James, Madison [US/US]; 3616 South Pointe Drive, Apex, NC 27502 (US). MOLNAR, Istvan [HU/US]; 4004 Branchwood Drive, Durham, NC 27705 (US). ZIRKLE, Ross [US/US]; 6532 Wynbrook Way, Raleigh, NC 27612 (US). GÖRLACH, Jörn [DE/US]; 3907 King Charles Road, Durham, NC 27707 (US). CYR, Devon			
(88) Date of publication of the international search report: 29 June 2000 (29.06.00)			
(54) Title: GENES FOR THE BIOSYNTHESIS OF EPOTHILONES			
(57) Abstract			
<p>Nucleic acid molecules are isolated from <i>Sorangium cellulosum</i> that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/04171

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/52 C07K14/535 C07D493/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 22461 A (BIOTECHNOLOG FORSCHUNG GMBH ;GERTH KLAUS (DE); HOEFLE GERHARD (DE)) 28 May 1998 (1998-05-28) the whole document	1-10
Y	SCHUPP T. ET AL.: "A Sorangium cellulosum (myxobacterium) gene cluster for the biosynthesis of the macrolide antibiotic soraphen A: cloning, characterization and homology to polyketide synthase genes from actinomycetes" J. BACTERIOL., vol. 177, no. 13, 1995, pages 3673-3679, XP000893003 the whole document	1-10

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

17 April 2000

Date of mailing of the international search report

03/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/04171

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	MOLNAR I. ET AL.: "The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from <i>Sorangium cellulosum</i> So ce90" CHEM. BIOL., vol. 7, 2000, pages 97-109, XP000904734 the whole document	1-93
T	TANG LI, ET AL.: "Cloning and heterologous expression of the epothilone gene cluster." SCIENCE, vol. 287, 28 January 2000 (2000-01-28), pages 640-642, XP002135841 the whole document	1-93

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/04171

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9822461 A	28-05-1998	AU 5483798 A	10-06-1998
		CN 1237970 A	08-12-1999
		CZ 9901750 A	15-09-1999
		EP 0941227 A	15-09-1999
		NO 992338 A	14-05-1999
		PL 333435 A	06-12-1999

